

# COUNTRY REPORTS

Collected and Edited by Ma'n H. Zarwati

## Australia

Don Chalmers

Researchers in genomics are exploring novel ways to interact directly with prospective participants without utilizing physicians, hospitals, or biobanks as intermediaries. Many researchers are interested in using the internet to directly recruit and enroll research participants in genomic studies by posting information online about active or proposed studies. This direct-to-participant (DTP) approach could take place under three main scenarios:

- A researcher in your country wants to conduct DTP genomic research with participants in your country
- A researcher in your country wants to conduct DTP genomic research with participants in another country
- A researcher from outside your country wants to conduct DTP genomic research with participants in your country

There is uncertainty about whether DTP recruitment, enrollment, and research are lawful under these scenarios.

### Part I — DTP-Specific Questions

1. As far as you know, is DTP genomic research a topic of interest to researchers or other stakeholders in your country?  
[Multiple choice]

- a. There has been little, if any, discussion of the issue as of now

b. There has been discussion among researchers, but little discussion among policy makers

c. There has been discussion among both researchers and policy makers

d. I am not sure — or other answer

1.1 In Australia, genomic research would require ethics approval like any other human research. DTP research would also attract the general requirements for approving human research, including minimizing risk and ensuring consent (Chapter 2.1-2.3 *National Statement*). In addition, there are specific requirements for Genomic Research in the *National Statement* in Chapter 3.3. Any proposed DTP genomic research would need to comply with the specific requirements of Chapter 3.3 to be satisfactorily addressed for ethical approval.

1.2 The National Health and Medical Research Council has the issue of Direct to Consumer Genetic Testing under consideration and has published three relevant information documents.<sup>1</sup>

1.3 The Commonwealth Australia Government, Department of Health has issued guidance for the Provision of Direct-to-Consumer Genetic Tests: Guiding Principles for Providers.<sup>2</sup>

The Australian Genomics Health Alliance (AGHA) published a news page on Understanding Direct-to-Consumer Genetic Testing, with information on clinical-grade testing.<sup>3</sup>

2. Assume that a researcher in your country wants to conduct DTP genomic research with participants in your country and that such research is subject to IRB/REC review. Please

describe the conditions for IRB/REC approval, if it could be approved at all.

The researcher would require ethics approval, with the following comments.

The equivalent IRB/REC approval in Australia is granted by our Human Research Ethics Committees (HREC). The conditions for approval of all human research are set out in the National Statement on Ethical Conduct in Human Research 2007 (updated 2018) (hereafter the “*National Statement*”).<sup>4</sup>

In addition to the general requirements for approving human research, including minimizing risk and ensuring consent (Chapter 2.1-2.3 *National Statement*), there are specific requirements for Genomic Research in Chapter 3.3. Any application for ethical approval of the proposed DTP genomic research would need the specific requirements of Chapter 3.3 to be satisfactorily addressed.

Our *National Statement* is intended to be consistent with the international human rights instruments ratified by Australia and provides our national guidelines for researchers, HRECs and others conducting ethical review of research and emphasizes institutional responsibilities for the quality, safety, and ethical acceptability of their research. The *National Statement* must be read with the *Australian Code for the Responsible Conduct of Research*, 2018 (the “*Research Code*”), which also applies to responsible and ethical research practice, and responsibilities of institutions and researchers in areas, such as data and record management, publication of findings, authorship, conflict of interest, supervision of students and allegations of research misconduct.

Don Chalmers, A.O., F.A.A.L., F.A.H.M.S., is Distinguished Professor of Law at University of Tasmania, Australia.

**3. Assume that a researcher in your country wants to conduct DTP genomic research in another country. Please describe the conditions that must be satisfied for IRB/REC approval in your country, if it could be approved at all. Would your IRB/REC also require approval from a research ethics review body in the other country?**

Under Chapter 4.8.1 *National Statement* any research “conducted overseas by researchers from Australian institutions must comply with this National Statement.” The researcher in Australia may apply for HREC approval in Australia for research in another country under the terms of Chapter 4.8, provided the research has merit, demonstrates respect for the laws and customs of the host country, and has all required local ethics approvals. These are in addition to the general requirements for ethics approval, including minimizing risk and ensuring consent in Chapter 2 of the *National Statement*. There is an over-riding requirement to respect “beliefs, customs and cultural heritage, and local laws” of all participants in other countries.<sup>5</sup>

The Australian HREC would require approval from the research ethics review body in the other country, where there is one.<sup>6</sup> Where there are no “ethics approval processes” in the overseas country, research participants must be “accorded no less respect than [the] *National Statement* requires,”<sup>7</sup> as well as these specific elements for Research generally in Chapter 3.1 and Genomic Research, in particular, as set out in Chapter 3.3.<sup>8</sup> As far as is necessary to satisfy the requirements of paragraphs 1.10 to 1.13, the design and conduct of the research should reflect continuing consultation with the local participant population and the communities to which they belong.<sup>9</sup> The Australian researcher conducting DTP genomic research in another country must also comply with the *Australian Code for*

*the Responsible Conduct of Research*, 2018.<sup>10</sup>

**4. Assume that a researcher from outside your country wants to conduct DTP genomic research in your country.**

- a. Would it be lawful for the researcher to do so without HREC approval in either the researcher’s country or your country? [Yes/No]  
 Yes  
 No  
 Not sure or other
- b. Would it be lawful for the researcher to do so if the research were approved by an IRB/REC in the researcher’s own country, but was not submitted for approval in your country? [Yes/No]  
 Yes  
 No  
 Not sure or other
- c. Would the external researcher be required to have a collaborator in your country? [Yes/No]  
 Yes  
 No  
 Not sure or other
- d. Would it matter whether the external researcher is based at a commercial, governmental, or academic entity? [Yes/No]  
 Yes  
 No  
 Not sure or other

Essentially, as stated above at 3, the overseas researcher would require approval for the research in Australia and be required to comply with the National Statement and the *Australian Code for the Responsible Conduct of Research*. The researcher from outside Australia may apply for recognition of the “outside” ethics approval and an Australian HREC can decide whether the approval for research proposal meets the requirements of

the National Statement. The overseas researcher may also apply directly to the relevant HREC provided specific requirements of Chapter 4.8 *National Statement* — People in Other Countries are met, dealing with international/overseas research and international researchers doing research in this country.

There are also specific requirements for dealing with the importation and exportation of human biospecimens in laboratory-based research in *National Statement* Chapter 3.2: provided there is the required ethical approval of an Australian HREC or an equivalent ethical approval process in the overseas country of the researcher. The overseas researcher would also have to respect the general obligation to and rights of the research participants imposed by Australian law.

**5. As far as you know, what are the perceived benefits and risks that could occur if a researcher from another country conducted IRB/REC-approved genomic research on samples or data obtained from your country? Please consider the perspectives of the public, research participants, socially-defined groups (e.g., indigenous or minority populations), researchers, and other professional or government entities.**

As a general observation, Australia does not differentiate between local and overseas researchers. It is the quality of the peer reviewed research, the expertise and skill of the researcher and team, and the ethical acceptability of the project that are the prime considerations. Generally, the perceived benefits and risks that could occur, if a researcher from another country conducted approved genomic research on samples or data obtained from Australia, are no different from research approved and conducted by an Australian researcher. The *National Statement* does not differentiate between overseas and locally based researchers. Both

require HREC approval for research conducted in this country.

All human research requires approval. Specific issues with specific research participants, such as socially-defined groups, including as examples indigenous or minority populations, would be critical components of the research design and ethical approval processes. There are specific requirements for dealing with the importation and exportation of human biospecimens in laboratory-based research in *National Statement* Chapter 3 and with research on people in other countries in Chapter 4.8 *National Statement*. People in Other Countries. In addition, Australia has a specific specialist National Centre for Indigenous Genomics (NCIG) centred at the Australian National University (ncig.anu.edu.au/).

## Part II — General Questions

### 6. Does your country have biohazard committees, data protection boards, export permit authorities, or other entities that regulate the exporting of biospecimens or the transferring of data across borders for research? If so, do these requirements apply to individual citizens as well as research and medical institutions?

Yes to both questions, Australia has these regulatory systems and these apply to individuals as well as institutions, with the following specific comments.

#### 6.1 Australia has Biohazard Committees

As a general comment, the overall regulatory framework for food, agriculture, water resources and the application of biotechnology in Australia is set out on the Australian Government's Department of Agriculture website.<sup>11</sup>

There are a range of co-operating government departments that oversee biohazards. Principally, Biosecurity Australia (within the Australian Government Department of Agriculture,

Fisheries and Forestry) provides quarantine assessments and policy advice to protect the agricultural sector. The Australian Quarantine and Inspection Service (AQIS) manages border quarantine controls. In research, the importation and exportation of human biospecimens in laboratory-based research in *National Statement* Chapter 3.4, with the research itself, are subject to the legal biohazard regime. The Commonwealth *Gene Technology Act 2000* establishes the national regulatory framework for genetically modified organisms (GMOs). The *Therapeutic Goods Act, 1989* deals with exportation of human blood, organs and derived substances, without the relevant Government approvals.<sup>12</sup>

#### 6.2 Data Protection — Privacy

Australian privacy principles (APPs) in the *Privacy Act 1988* (Cth) deal with data protection and are comparable to the EU *General Data Protection Regulation* (GDPR). All Government agencies, all private sector and not-for-profit organisations (over \$3 million turnover), all private health service providers and some small businesses must comply with the APPs in dealing with personal information.<sup>13</sup>

### 7. Does your country have laws, policies, or guidelines dealing with genetic or genomic research or genetic or genomic privacy that would apply to international DTP research? Do your national laws on these issues apply outside of your country when residents or citizens of your country enroll in a DTP study conducted abroad?

Yes, there are guidelines.

The *National Statement* and the *Australian Code for the Responsible Conduct of Research, 2018* apply. In addition to the general requirements of minimizing risk and ensuring consent (Chapter 2.1-2.3 *National Statement*), there are specific requirements and guidelines dealing with genetic/genomic research and privacy for Genomic Research set out in Chapter 3.3. With respect to genetic/genomic

privacy there is specific guidance in Chapter 3.3.58— 3.3.61. As noted above, Chapter 4.8 *National Statement* — People in Other Countries deals with international DTP research and the requirement to apply the same standards to such international research as applies to genetic/genomic research and privacy in this country.

### 8. Does your country have laws, policies, guidelines, or cultural expectations regarding the return of individual or aggregate research results? [Multiple choice]

- The law requires the return of individual results unless the participant expressly declines to have results returned
- The law is silent on return of results; the expectation is that individual results will be returned unless the participant expressly declines to have the results returned
- The law is silent on return of results; aggregate results are typically returned, but individual results are not returned unless expressly stated in the research protocol
- I am not sure — or other answer

In Australia, the return of results is a requirement of our *National Statement* in Chapter 3.3.26 where researchers are required to *consider* whether to return results of research, and in so doing, researchers should distinguish between individual and overall research results, how these results will be provided to participants, how the return of results will be managed, and the risks of the return of individual research results and overall research results.

### 9. Does your country have laws, policies, or guidelines regarding “direct-to-consumer” genetic testing (e.g., 23andMe) and, if so, what do they provide? [Multiple choice]

- a. Yes. Direct-to-consumer genetic testing is illegal
- b. Yes. Direct-to-consumer genetic testing is legal**
- c. No. Direct-to-consumer genetic testing is not an issue
- d. I am not sure — or other answer

See response 1.2 above. Australian laws apply to DTC genetic tests provided by *Australian* companies or laboratories that are classified as Class 3 in vitro diagnostic devices by our Therapeutic Goods Administration (TGA). Since 2010 all these tests undergo TGA regulatory scrutiny on risks. Commercial medical device manufacturers require a conformity assessment certificate from the TGA. Since 2017, Australian “in-house” developed DTC tests require accreditation by the National Association of Testing Authorities, Australia (NATA) and accreditation by our National Pathology Accreditation Advisory Council (NPAAC) may be required.

However, there is a critical distinction between “direct-to-consumer” genetic tests in Australia and those available internationally and accessed directly by an individual. The strict Australian regulation and quality standards for DTC genetic testing conducted in Australia do not apply to or regulate the quality of internet-based DTC genetic tests conducted overseas. Our TGA and other regulators have no authority to prevent access to DTC genetic tests conducted overseas.

There has been some academic discussion.<sup>14</sup>

### Part III — Looking to the Future

**10. How, if at all, do you anticipate that your country’s laws, policies, or guidelines will change in the next 5-10 years in response to international DTP genomic research? [Multiple choice]**

- a. I do not think they will change at all**
- b. I think they will restrict international DTP research
- c. I think they will allow international DTP research

d. I am not sure — or other answer

Noting that Australia currently has NHMRC guidelines and information papers on DTP research and the Commonwealth of Australia Government supports and promotes international research collaborations, I do not foresee restrictions in this research direction. I would refer again to the Response to Question 1.

On the other hand, on-line access to direct-to-consumer (DTC) genetic testing needs to be researched to identify challenges for Australia. DTC test results may be confusing to consumers and may be referred to doctors to interpret. Public trust in NATA and NPAAC accredited genetic tests must be protected. In Australia, our Therapeutic Goods Administration oversees regulation of the genetic testing sector. There is still significant pharmacogenomic research to be done investigating individual genetic response to certain drugs. Our Australian Competition and Consumer Commission (ACCC) has been auditing DTC tests and issued advice about misleading claims on one test available through a national chemist chain.<sup>15</sup>

#### Note

The author has no conflicts to disclose.

#### References

1. National Health Medical Research Council, Australian Government, Direct-to-Consumer Genetic Testing: A Statement from the National Health and Medical Research Council, NHMRC REF#G9, December 2014, available at <<https://nhmrc.gov.au/about-us/publications/direct-consumer-genetic-testing-statement>> (last visited October 10, 2019); National Health Medical Research Council, Australian Government, Understanding Direct-to-Consumer Genetic DNA Testing: An Information Resource for Consumers, NHMRC REF# G8, December 2014, available at <<https://nhmrc.gov.au/sites/default/files/documents/reports/direct-consumer-genetic-testing.pdf>> (last visited October 10, 2019); National Health Medical Research Council, Australian Government, Discussing Direct-to-Consumer Genetic DNA Testing with Patients: A Short Guide for Health Professionals, NHMRC REF#G7, December 2013, available at <<https://nhmrc.gov.au/sites/default/files/documents/>

attachments/Discussing%20direct-to-consumer-genetic-dna-testing.pdf> (last visited October 10, 2019).

2. National Pathology Accreditation Advisory Council (NPAAC), Department of Health, Australian Government, The Provision of Direct to Consumer Genetic Tests: Guiding Principles for Providers, 2014, available at <<http://www.health.gov.au/internet/main/publishing.nsf/Content/health-npaac-path-bestpractice>> (last visited October 10, 2019).
3. T. Boughtwood, “Understanding Direct-to-Consumer Genetic Testing,” Australian Genomics Health Alliance, April 12, 2018, available at <<https://www.http://www.australiangenomics.org.au/understanding-direct-to-consumer-genetic-testing/>> (last visited December 10, 2019).
4. National Health and Medical Research Council, Australian Research Council, Universities Australia, Australian Government, *National Statement on Ethical Conduct in Human Research 2007* (Updated 2018) (Canberra: Commonwealth of Australia, 2018).
5. *Id.* at 82.
6. *Id.* at 80.
7. *Id.*
8. *Id.*
9. *Id.*
10. National Health and Medical Research Council, Australian Research Council, Australian Government, *Australian Code for the Responsible Conduct of Research* (Canberra: Commonwealth of Australia, 2018).
11. Department of Agriculture, Australian Government, Regulatory framework in Australia, available at <<http://www.agriculture.gov.au/ag-farm-food/biotechnology/framework>> (last visited October 10, 2019).
12. *Therapeutic Goods Act 1989* (Cth) (Austl.).
13. C. Critchley et al., “Public Reaction to Direct-to-Consumer Online Genetic Tests: Comparing Attitudes, Trust and Intentions Across Commercial and Conventional Providers,” *Public Understanding of Science* 24, no. 6 (2014): 731-750.
14. J. Tiller and P. Lacaze, “Regulation of Internet-based Genetic Testing: Challenges for Australia and Other Jurisdictions,” *Frontiers in Public Health* 6, no. 24 (2018): 1-6; K. Harvey and B. Diug, “Short Note on Retail Genetics,” *Australian Prescriber* 40, no. 3 (2017): 86-87, available at <<https://www.nps.org.au/australian-prescriber/articles/retail-genetics>> (last visited October 10, 2019); National Pathology Accreditation Advisory Council (NPAAC), Department of Health, Australian Government, The Provision of Direct to Consumer Genetic Tests: Guiding Principles for Providers, 2014, available at <[SYMPOSIUM 2: REGULATION OF INTERNATIONAL DIRECT-TO-PARTICIPANT GENOMIC RESEARCH • WINTER 2019](http://www.health.gov.au/internet/main/publishing.nsf/Content/health-</a></li>
</ol>
</div>
<div data-bbox=)

npaac-path-bestpractice> (last visited October 10, 2019).

15. National Pathology Accreditation Advisory Council (NPAAC), Department of Health, Australian Government, *supra* note 14.

## Brazil

*Sueli G. Dallari and  
Marina de Neiva Borba*

Researchers in genomics are exploring novel ways to interact directly with prospective participants without utilizing physicians, hospitals, or biobanks as intermediaries. Many researchers are interested in using the internet to directly recruit and enroll research participants in genomic studies by posting information online about active or proposed studies. This direct-to-participant (DTP) approach could take place under three main scenarios:

- A researcher in your country wants to conduct DTP genomic research with participants in your country
- A researcher in your country wants to conduct DTP genomic research with participants in another country
- A researcher from outside your country wants to conduct DTP genomic research with participants in your country

There is uncertainty about whether DTP recruitment, enrollment, and research are lawful under these scenarios.

### Part I — DTP-Specific Questions

- 1. As far as you know, is DTP genomic research a topic of interest to researchers or other stakeholders in your country?**  
[Multiple choice]

- a. There has been little, if any, discussion of the issue as of now**
- b. There has been discussion among researchers, but little discussion among policy makers
- c. There has been discussion among both researchers and policy makers
- d. I am not sure — or other answer

In Brazil, the ethical review system of research protocols involving the participation of human beings, including genetic and genomic studies, is regulated by the Conselho Nacional de Saúde (CNS), which is a collegial, deliberative, and permanent board of the Sistema Único de Saúde (SUS), a department of the Health Ministry that has the mission of supervising and monitoring public health policies, pursuant to article 1, paragraph 2, of the Law no. 8,142 dated December 28, 1990.<sup>1</sup>

This system of ethical analysis started in 1996 by the Resolution of the Conselho Nacional de Saúde (CNS) n. 196,<sup>2</sup> which created a network of ethical appreciation of research projects composed of two independent institutional committees: the Comitê de Ética em Pesquisa (CEP) with local level assignments, and the Comissão Nacional de Ética em Pesquisa (CONEP) with specific ethical review assignments of related projects (such as human genetics, indigenous populations, biobanks, and international cooperation).<sup>3</sup>

Therefore, the CEP/CONEP system develops “a cooperative work that aims, in particular, to protect the research participants of Brazil” so that when they proceed to the ethical review of these protocols, their members become co-responsible for ensuring such protection, according to items VII and VII.1 of the Resolution of the Conselho Nacional de Saúde (CNS) n. 466, dated December 12, 2012.<sup>4</sup>

As far as we know, there has been little, if any, discussion of DTP genomic research. However, the CONEP has the task of resolving omissions related to the ethical aspects of research involving the participation of human beings, including genetic and genomic studies, because of the relevance of the protection of Brazilian participants.

- 2. Assume that a researcher in your country wants to conduct DTP genomic research with participants in your country and that such research is subject to IRB/REC review. Please describe the conditions for IRB/REC approval, if it could be approved at all.**

For CEP/CONEP system approval, DTP genomic research should be subject to the conditions of Resolution of the Conselho Nacional de Saúde (CNS) n. 466, dated December 12, 2012,<sup>5</sup> which requires that the researcher responsible for the research be affiliated with a public or private institution legitimately registered<sup>6</sup> according to items II.8 and II.16. If the researcher is not regularly linked to one institution, the research project could not be registered in Plataforma Brasil,<sup>7</sup> which is a national and unified electronic database of research records involving human beings in the CEP/CONEP system, according to item VI.<sup>8</sup>

In addition, genetic or genomic research should be subject to the conditions of Resolution of the Conselho Nacional de Saúde (CNS) n. 340, dated July 8, 2004,<sup>9</sup> which requires, among other requirements, the protection of the data of the research participants (items III.2 and III.11), genetic counseling when applicable (item III.5), the guarantee of access to genetic data, as well as the right to withdraw them from the database at any time (item III.8).

If the research involves the storage or use of human biological material, the research should also be subject

*Sueli G. Dallari, M.Sc., Ph.D., is a Professor and Lawyer, Libera docens in Health Law, University of Sao Paulo, Brazil. Marina de Neiva Borba, M.Sc., Ph.D., is a Lawyer, Postdoctoral Fellow in Public Health, and Member of the Health Law Research Center, University of Sao Paulo, Brazil*

to the conditions of Resolution of the Conselho Nacional de Saúde (CNS) n. 441, dated May 12, 2011,<sup>10</sup> which requires, for example, the regulation of the depositary institution and its approval by the CEP and, where applicable, by CONEP (item 3.I). Such regulation should provide for the definition of those responsible for the safekeeping and use of the material, the guarantee of secrecy and confidentiality and the possibility of contacting donors to obtain specific consent for use in a new research project (item 3.III). It is important to clarify that it is mandatory for the storage of human genetic data to be made by an appropriate institution responsible for data protection (item III.14 of Resolution CNS 340).<sup>11</sup>

**3. Assume that a researcher in your country wants to conduct DTP genomic research in another country. Please describe the conditions that must be satisfied for IRB/REC approval in your country, if it could be approved at all. Would your IRB/REC also require approval from a research ethics review body in the other country?**

For CEP/CONEP system approval, international DTP genomic research shall be subject to the conditions above and also those of the Resolution of the National Health Council (CNS) n. 292, dated July 8, 1999,<sup>12</sup> which requires the identification of the Brazilian researcher and the national institution co-responsible (item II.1), the indication of responsibilities, rights and obligations of the parties involved (item II.2), the description of the risks and benefits of the research (item IV), the approval document of the Research Ethics Committee of the country in which the research will be carried out (item VII.1), and the detail of the financial resources (item VII.3), among other requirements.

The Brazilian researcher and the national institution should also be subject to the laws and regulations on the shipment of biological material abroad and on industrial property

and technology transfer (item V): Law 9.279, dated May 14, 1996 that regulates rights and obligations related to industrial property, Decree 2.553, dated April 16, 1998 that regulates it; Law 9.610, dated February 19, 1998 on copyright; and also Resolution of the Agência Nacional de Vigilância Sanitária (ANVISA) n. 20, dated April 10, 2014 on sanitary regulations for the transport of human biological material.

Therefore, according to current Brazilian legislation, REC approval from other countries is mandatory for approval of international DTP genetic or genomic research by CEP/CONEP system.

**4. Assume that a researcher from outside your country wants to conduct DTP genomic research in your country.**

- a. Would it be lawful for the researcher to do so without IRB/REC approval in either the researcher's country or your country? [Yes/No]  
 Yes  
 No  
 Not sure or other

The Resolution of the Conselho Nacional de Saúde (CNS) n. 292,<sup>13</sup> dated July 8, 1999, requires both approval by the Research Ethics Committee of the proposing country of the research for them to be approved by the Comitê de Ética em Pesquisa (CEP) and by the Comissão Nacional de Ética em Pesquisa (CONEP) in Brazil, according to items VII.1 and VIII.

- b. Would it be lawful for the researcher to do so if the research were approved by an IRB/REC in the researcher's own country, but was not submitted for approval in your country? [Yes/No]  
 Yes  
 No  
 Not sure or other

As explained above, the Resolution of the Conselho Nacional de

Saúde (CNS) n. 292, dated July 8, 1999, requires both approval by the Research Ethics Committee of the proposing country of the research and then be approved by the Comitê de Ética em Pesquisa (CEP) and by the Comissão Nacional de Ética em Pesquisa (CONEP) in Brazil, according to items VII.1 and VIII.<sup>14</sup>

- c. Would the external researcher be required to have a collaborator in your country? [Yes/No]  
 Yes  
 No  
 Not sure or other

The item II.1 of the resolution of the Conselho Nacional de Saúde (CNS) n. 292, dated July 8, 1999, requires the participation of a Brazilian researcher to conduct research in Brazil even if the project has the coordination in another country.<sup>15</sup> Thus, it is mandatory to have the participation of a Brazilian researcher for approval by the Comitê de Ética em Pesquisa (CEP) and by the Comissão Nacional de Ética em Pesquisa (CONEP) in Brazil.

- d. Would it matter whether the external researcher is based at a commercial, governmental, or academic entity? [Yes/No]  
 Yes  
 No  
 Not sure or other

The Resolution of the Conselho Nacional de Saúde (CNS) n. 292,<sup>16</sup> does not make any demands regarding the international institution in which the external researcher is linked. But the participation of a Brazilian researcher for approval by the Comitê de Ética em Pesquisa (CEP) and by the Comissão Nacional de Ética em Pesquisa (CONEP) is mandatory in Brazil.

**5. As far as you know, what are the perceived benefits and risks that could occur if a researcher from another country conducted IRB/REC-approved genomic research on samples or data obtained from your country?**

**Please consider the perspectives of the public, research participants, socially-defined groups (e.g., indigenous or minority populations), researchers, and other professional or government entities.**

The primary purpose of genetic research is the scientific knowledge that could alleviate suffering and improve the health of participants. From the perspective of researchers and professional or governmental entities, genomic research can produce new information that should be published in order to share and transfer technology.

On the other hand, the risks associated with genomic research include social damage (such as discrimination and stigmatization of research participants and their future generations), psychological damage (such as depression, anxiety, anger, or fear) and financial/economic damage (such as no access to the labor market or health insurance). In addition, from the perspective of researchers, professional, or governmental entities, these researches may produce administrative, civil, and criminal liability for the harm caused to participants, as well as economic expenses with genetic counseling and clinical follow-up of these subjects.

## Part II — General Questions

**6. Does your country have biohazard committees, data protection boards, export permit authorities, or other entities that regulate the exporting of biospecimens or the transferring of data across borders for research? If so, do these requirements apply to individual citizens as well as research and medical institutions?**

In Brazil, the board responsible for regulating all these issues is the Conselho Nacional de Saúde (CNS), which is a collegial, deliberative and permanent board of the Sistema Único de Saúde (SUS), which is part

of the Health Ministry. In addition, genetic or genomic research must be approved by the Comissão Nacional de Ética em Pesquisa (CONEP), according to Resolution of the Conselho Nacional de Saúde (CNS) n. 340, dated July 8, 2004.<sup>17</sup> It is important to emphasize that only Brazilian researchers approved by CONEP are allowed to perform these procedures. No information or any kind of samples could be sent outside the country without its final approval.

According to Resolution of the Agência Nacional de Vigilância Sanitária (ANVISA) n. 20, dated April 10, 2014 (8), researchers from other countries are not allowed to send information or any kind of samples outside Brazil since they will not get the approval of the Agência Nacional de Vigilância Sanitária (ANVISA), a government agency linked to the Ministry of Health, part of the Brazilian National Health System (SUS) as the coordinator of the Brazilian Health Regulatory System (SNVS) present throughout the national territory.

**7. Does your country have laws, policies, or guidelines dealing with genetic or genomic research or genetic or genomic privacy that would apply to international DTP research? Do your national laws on these issues apply outside of your country when residents or citizens of your country enroll in a DTP study conducted abroad?**

Brazil does have laws, policies, and guidelines dealing with genetic or genomic research and genetic or genomic privacy that are applied to international DTP research. As explained above, the board responsible for regulating the ethical review procedures of such protocols is the Conselho Nacional de Saúde (CNS). Furthermore, this research has to be approved by the Comissão Nacional de Ética em Pesquisa (CONEP). Finally, data or samples should only could be sent to other countries after the approval of the Agência Nacional de Vigilância Sanitária (ANVISA).

In relation to genomic research involving human beings, national or international, the National Health Council issued Resolutions 466,<sup>18</sup> 340,<sup>19</sup> and 292,<sup>20</sup> which require data protection mechanisms in order to avoid stigmatization and discrimination of individuals, families or groups in such research.

However, these Resolutions are not clear when residents or citizens of our country are enrolled in a DTP study conducted outside Brazil.

**8. Does your country have laws, policies, guidelines, or cultural expectations regarding the return of individual or aggregate research results? [Multiple choice]**

- a. The law requires the return of individual results unless the participant expressly declines to have results returned
- b. The law is silent on return of results; the expectation is that individual results will be returned unless the participant expressly declines to have the results returned
- c. The law is silent on return of results; aggregate results are typically returned, but individual results are not returned unless expressly stated in the research protocol
- d. I am not sure — or other answer

In Brazil, the Guidelines for Ethical Analysis of Human Genetic Research Projects determine in the Informed Consent Form (TCLE) that all participants will be informed of all the results of exams and tests performed, but they have the option of not knowing this information, according to item V.1 of the Resolution of the Conselho Nacional de Saúde (CNS) n. 340, dated in July 8, 2004.<sup>21</sup>

**9. Does your country have laws, policies, or guidelines regarding “direct-to-consumer” genetic testing (e.g., 23andMe) and,**

**if so, what do they provide?**  
**[Multiple choice]**

- a. Yes. Direct-to-consumer genetic testing is illegal
- b. Yes. Direct-to-consumer genetic testing is legal
- c. No. Direct-to-consumer genetic testing is not an issue
- d. I am not sure — or other answer

The Agência Nacional de Vigilância Sanitária (ANVISA) expressly prohibits the supply of products intended to “perform genetic tests to determine the presence or predict susceptibility to disease or physiological condition” to lay users, who are individuals without technical training or formal scientific basis for use of these products, according to article 15 item III and article 3, item XLI of the Resolution n. 36, dated August 26, 2015.<sup>22</sup>

**Part III — Looking to the Future**

**10. How, if at all, do you anticipate that your country’s laws, policies, or guidelines will change in the next 5-10 years in response to international DTP genomic research? [Multiple choice]**

- a. I do not think they will change at all
- b. I think they will restrict international DTP research
- c. I think they will allow international DTP research
- d. I am not sure — or other answer**

I am not sure if my country’s laws, policies, or guidelines will change in the next years in response to international DTP genomic research due to the importance of participant protection in research in Brazil.

**Note**

The authors have no conflicts to disclose.

**References**

1. Lei No. 8.142, de 28 Dezembro de 1990, COLLEIS REP. FED. BRASIL, 6: 3583, Dezembro 1990 (Braz.) art. 1, para. 2.

2. Brazil, Resolution of the Conselho Nacional de Saúde (CNS) n. 196, dated in October 10, 1996, *available at* <<http://conselho.saude.gov.br/resolucoes/1996/Reso196.doc>> (last visited October 11, 2019);
3. Brazil, Resolution of the Conselho Nacional de Saúde (CNS) n. 196, dated in October 10, 1996, *available at* <<http://conselho.saude.gov.br/resolucoes/1996/Reso196.doc>> (last visited October 11, 2019); Brazil, Resolution of the Conselho Nacional de Saúde (CNS) n. 466, dated in December 12, 2012, *available at* <<http://conselho.saude.gov.br/resolucoes/2012/Reso466.pdf>> (last visited October 11, 2019).
4. Brazil, Resolution of the Conselho Nacional de Saúde (CNS) n. 466, dated in December 12, 2012, *available at* <<http://conselho.saude.gov.br/resolucoes/2012/Reso466.pdf>> (last visited October 11, 2019), items VII and VII.1.
5. *Id.*
6. *Id.*
7. Brazil, Operating Standard of the Conselho Nacional de Saúde (CNS) n. 1, dated in 2013, p. 8, *available at* <<http://plataformabrasil.saude.gov.br/login.jsf>> (last visited October 11, 2019).
8. Brazil, Resolution of the Conselho Nacional de Saúde (CNS) n. 466, *supra* note 4.
9. Brazil, Resolution of the Conselho Nacional de Saúde (CNS) n. 340, dated in July 8, 2004, *available at* <<http://conselho.saude.gov.br/resolucoes/2004/Reso340.doc>> (last visited October 11, 2019).
10. Brazil, Resolution of the Conselho Nacional de Saúde (CNS) n. 441, dated in May 12, 2011, *available at* <<http://conselho.saude.gov.br/resolucoes/2011/Reso441.pdf>> (last visited October 11, 2019).
11. Brazil, Resolution of the Conselho Nacional de Saúde (CNS) n. 340, dated in July 8, 2004, *available at* <<http://conselho.saude.gov.br/resolucoes/2004/Reso340.doc>> (last visited October 11, 2019).
12. Brazil, Resolution of the Conselho Nacional de Saúde (CNS) n. 292, dated in July 8, 1999, *available at* <<http://conselho.saude.gov.br/resolucoes/1999/Reso292.doc>> (last visited October 11, 2019).
13. *Id.*
14. *Id.*
15. *Id.*
16. *Id.*
17. Brazil, Resolution of the Conselho Nacional de Saúde (CNS) n. 340, *supra* note 9.
18. Brazil, Resolution of the Conselho Nacional de Saúde (CNS) n. 466, *supra* note 4.
19. Brazil, Resolution of the Conselho Nacional de Saúde (CNS) n. 340, *supra* note 9.
20. Brazil, Resolution of the Conselho Nacional de Saúde (CNS) n. 292, *supra* note 12.
21. Brazil, Resolution of the Conselho Nacional de Saúde (CNS) n. 340, *supra* note 9.
22. Brazil, Resolution of the Agência Nacional de Vigilância Sanitária (ANVISA) n. 36, dated in August 26, 2015, *available at* <[http://portal.anvisa.gov.br/documents/10181/2979365/RDC\\_36\\_2015\\_COMP.pdf/5ab916c1-108f-43d9-80b9-39984434c8aa](http://portal.anvisa.gov.br/documents/10181/2979365/RDC_36_2015_COMP.pdf/5ab916c1-108f-43d9-80b9-39984434c8aa)> (last visited October 11, 2019).

## Canada

*Miriam Pinkesz and  
Yann Joly*

Researchers in genomics are exploring novel ways to interact directly with prospective participants without utilizing physicians, hospitals, or biobanks as intermediaries. Many researchers are interested in using the internet to directly recruit and enroll research participants in genomic studies by posting information online about active or proposed studies. This direct-to-participant (DTP) approach could take place under three main scenarios:

- A researcher in your country wants to conduct DTP genomic research with participants in your country
- A researcher in your country wants to conduct DTP genomic research with participants in another country
- A researcher from outside your country wants to conduct DTP genomic research with participants in your country

There is uncertainty about whether DTP recruitment, enrollment, and research are lawful under these scenarios.

### Part I — DTP-Specific Questions

- 1. As far as you know, is DTP genomic research a topic of interest to researchers or other**



**stakeholders in your country?**  
[Multiple choice]

- a. There has been little, if any, discussion of the issue as of now
- b. There has been discussion among researchers, but little discussion among policy makers**
- c. There has been discussion among both researchers and policy makers
- d. I am not sure — or other answer

However, a notable exception in the policymaking community is the Privacy Commissioner of Canada and a few consumer associations that have issued two information briefs on the topic.<sup>1</sup>

**2. Assume that a researcher in your country wants to conduct DTP genomic research with participants in your country and that such research is subject to IRB/REC review. Please describe the conditions for IRB/REC approval, if it could be approved at all.**

The preconditions for DTP genomic research to receive research ethics board (REB) approval either stem from provincial statutes,<sup>2</sup> private institutional policies,<sup>3</sup> or the *Tri-Council Policy Statement: Ethical Conduct for Research Involving Humans* (TCPS2<sup>4</sup>), Canada's leading research ethics policy. The applicable ethical rules depend on the funding source of the research, the institution under whose auspices the research is conducted (i.e., whether it is private or public, and federal or provincial), and whether the research engages federal or provincial powers. The TCPS2 specifically applies to institutions eligible to receive or are receiving funding from The Canadian Institutes of Health Research, the Natural Sciences and Engineer-

ing Research Council of Canada, and the Social Sciences and Humanities Research Council of Canada. Nevertheless, the TCPS2 is the most widely used Canadian ethics policy,<sup>5</sup> and has been extensively adopted by various agencies and institutions across Canada, both public and private.<sup>6</sup> Where DTP genomic research is undertaken by private institutions not receiving funding from the aforesaid agencies, the TCPS2 does not apply, but the researchers remain subject to independent REB approval and relevant federal or provincial laws.<sup>7</sup> The chief areas demanding regulatory and ethical compliance are: consent, privacy, incidental findings, secondary uses, data linkage, biobanking, genetic research, and research involving First Nations communities. Research projects are required to have procedures pertaining to each of these categories, which will be subject to independent REB review.<sup>8</sup>

*Free and Informed Consent*

The foremost legal and ethical requirement for DTP genomic research is free and informed consent. This is legislated through Canadian jurisprudence,<sup>9</sup> provincial legislation,<sup>10</sup> and the TCPS2. Chapter 3 of the TCPS2 lays out the consent requirements for participation in research. An essential factor for researchers to determine prior to obtaining consent, is whether the potential benefits of the research outweigh the potential risks.<sup>11</sup> According to the TCPS2, the benefits must outweigh the risks, which pertain to the participants, the group they represent, or society as a whole. Once the risk-benefit determination is made, participants should be provided with the necessary information to make an informed decision as to whether the benefits of participating in the research are indeed worth the foreseeable risks. Specifically, participants' consent must be: (1) documented;<sup>12</sup> (2) obtained prior to collection of research data;<sup>13</sup> (3) given voluntarily; and (4) able to be withdrawn at any

time, including withdrawal of data or biospecimens.<sup>14</sup>

Over the years, the concept of "documented consent" has grown to include electronic consent, which is particularly practical in international DTP genomic research. Québec is unique among the provinces to specifically allow electronic consent for medical treatment and research in the *Civil Code of Québec*, stating that consent "may be given otherwise than in writing if justified in the circumstances in the opinion of a research ethics committee."<sup>15</sup> On the other hand, federal and provincial common law largely regulate electronic consent through privacy and commercial law.<sup>16</sup> Nevertheless, provincial legislation dealing with electronic consent generally accept it as legally valid so long as: (1) the integrity of the electronic document is ensured;<sup>17</sup> (2) there is a link between the individual and the electronic consent;<sup>18</sup> (3) accessibility for future reference of the document is ensured; and (4) the retention of electronic consent is secured.<sup>19</sup> Furthermore, the TCPS2 permits electronic consent, and even more informal variations, such as oral consent, as long as it is recorded by the researcher.<sup>20</sup>

Voluntary consent refers to consent that is free from undue influence, coercion, and incentives for participation in research.<sup>21</sup> In the DTP research context, this translates into the need for researchers to take special care in the recruitment and informed consent process. Incentives,<sup>22</sup> monetary or otherwise, may compromise voluntariness where they are significantly large and attractive.<sup>23</sup> Therefore, researchers must be sensitive to the economic and social conditions of those in the pool of prospective participants, and have the onus of justifying to the REB their adoption of a particular model.<sup>24</sup> Additionally, an important element of voluntary consent is a participant's ability to freely withdraw consent, which encompasses withdrawal of data or biospecimens. As such, in cases of

**Miriam Pinkesz, B.C.L./L.L.B.**, is a Research Assistant, at Centre of Genomics and Policy, Faculty of Medicine, Department of Human Genetics, McGill University, Montréal, QC, Canada. **Yann Joly, Ph.D.**, Associate Professor, Research Director, Centre of Genomics and Policy, Faculty of Medicine, Department of Human Genetics, McGill University, Montréal, QC, Canada.

DTP genomic research, where data or biospecimens are often unable to be withdrawn (due to anonymization of data that is subsequently added to a large data pool), researchers must provide prospective participants full disclosure of this fact in the consent process.<sup>25</sup>

Consent must also be informed, meaning that researchers must provide full disclosure to participants of various information relevant to making an enlightened decision to participate in the research, such as foreseeable risks.<sup>26</sup> Special disclosures relevant to genomic research must additionally be provided, such as the measures employed to protect privacy, the intended uses of biospecimens, and the potential for commercialization and possible financial gain for researchers and sponsors.<sup>27</sup>

Importantly, the TCPS2 mandates that consent is an ongoing process, as researchers have a continuing duty to provide participants with information relevant to their consent.<sup>28</sup> As such, DTP genomic research projects must account for the continuing nature of consent, regardless of the international or cross-border aspect of the project. Additionally, the ethics policy lists exceptions to the general rule of informed consent, yet such departure from the rule requires independent REB approval.<sup>29</sup>

#### *Privacy*

Researchers involved in DTP genomic studies must safeguard participant data and ensure that participant confidentiality is maintained.<sup>30</sup> The duty of confidentiality applies to data obtained directly from participants as well as data obtained from other researchers or institutions. Further, measures to protect privacy as well as foreseeable disclosures should be provided to the REB and participants during the consent process.<sup>31</sup> Participant information, including biospecimens, must also be safeguarded through the lifecycle of the information, and measures to achieve protection should be provided to the REB.<sup>32</sup>

#### *Incidental Findings*

Ethics guidelines mandate that researchers must disclose any mate-

rial incidental findings discovered in the course of research.<sup>33</sup> This is particularly prevalent in genomic research, and therefore the TCPS2 advises that in such research, investigators should develop a plan indicating how incidental findings will be disclosed to research participants and submit it to the REB.<sup>34</sup> However, where disclosing incidental findings would be impracticable<sup>35</sup> or impossible, as may often be the case in international genomic research,<sup>36</sup> the researcher may request an exemption.<sup>37</sup>

#### *Secondary Uses*

Typically, participant consent to secondary uses of identifiable information should be obtained prior to research. However, where consent was not obtained, researchers must satisfy the REB that identifiable information will only be used where it is essential to the research, it will unlikely adversely affect the participant, and it is impossible or impractical to seek consent from the participant.<sup>38</sup> However, in the case of secondary uses of non-identifiable information, as is typically common practice in genomic research, participant consent is not required, although independent REB review is still necessary.<sup>39</sup> In such cases, the onus is on the researcher to satisfy the REB that the information to be used is non-identifiable. In the instance of DTP genomic research, this may translate into a situation where coded genomic data is used for secondary purposes, and the researcher does not have access to the key. In this case, renewed consent is not required, but it would be necessary where the researcher has access to the key.<sup>40</sup>

#### *Data Linkage*

The TCPS2 requires prior REB approval for researchers to engage in data linkage.<sup>41</sup>

#### *Biobanking*

Aside from the consent requirements to collect and store biospecimens,<sup>42</sup> the TCPS2 mandates special rules for biobanking. Specifically, institutions and researchers must ensure that their facilities, equipment, policies, and procedures to store biospeci-

mens are in accordance with applicable standards.<sup>43</sup> Additionally, they are required to establish appropriate physical, administrative, and technical safeguards to protect biospecimens and participant information.<sup>44</sup> Effective measures typically include ensuring the security of facilities and specific data handling procedures, record keeping, and access rules.<sup>45</sup>

#### *Genetic Research*

The TCPS2's guidelines pertaining to genetic research mirror the aforementioned rules regarding consent, privacy, incidental findings, and secondary uses.<sup>46</sup> However, particular to genomic research, the TCPS2 requires that researchers develop a plan for managing information that may be revealed through the research in their research proposal, and submit the plan to the REB, and advise prospective participants of the plan.<sup>47</sup> This particularly concerns the prospect of incidental findings and other sensitive information, which raise disclosure considerations.<sup>48</sup> Therefore, the guidelines require that where researchers plan to share findings with participants, they give participants the opportunity to make informed choices concerning whether they wish to receive such information, and whether this information will be shared with biological relatives or others.<sup>49</sup>

#### *Research Involving First Nations Communities*

Research involving First Nations demands certain sensitivities and special requirements, such as community engagement,<sup>50</sup> respect for governing authorities and community customs,<sup>51</sup> and rights and proprietary interests of individuals and communities in biospecimens or data used in research.<sup>52</sup> In DTP genomic research, special consideration would have to be made of the particular community, and may therefore require researchers to adapt certain procedures and policies accordingly.

### **3. Assume that a researcher in your country wants to conduct DTP genomic research**

**in another country. Please describe the conditions that must be satisfied for IRB/REC approval in your country, if it could be approved at all. Would your IRB/REC also require approval from a research ethics review body in the other country?**

The general rule is that the ethics standards of the institution under whose auspices the researcher works, such as the TCPS2, apply to the research irrespective of the location where the project is undertaken.<sup>53</sup> Therefore, the ultimate responsibility with regard to review and approval of a research project is the researcher's institution. As per the TCPS2, research conducted under the auspices of a Canadian institution in a foreign jurisdiction requires prior ethics review by the Canadian institution's independent REB, as well as the REB or other responsible review body at the research site.<sup>54</sup> In the instance of a private researcher not bound by the TCPS2, the prime requirement would be to abide by the legal rules of the jurisdiction where participant recruitment is taking place as well as the responsible institution's ethical standards. As such, where either of these demand independent REB review, it would be required.

**4. Assume that a researcher from outside your country wants to conduct DTP genomic research in your country.**

- a. Would it be lawful for the researcher to do so without IRB/REC approval in either the researcher's country or your country? [Yes/No]  
 Yes  
 No  
 Not sure or other
- b. Would it be lawful for the researcher to do so if the research were approved by an IRB/REC in the researcher's own country, but was not sub-

mitted for approval in your country? [Yes/No]  
 Yes  
 No  
 Not sure or other

However, Canadian REB approval is required where one of the following applies: (1) the research is conducted under the auspices of a Canadian institution subject to the TCPS2; (2) the source of funding for the research comes from, or is administered through a Canadian institution; or (3) at least one of the research collaborators is affiliated with a Canadian institution.<sup>55</sup> It should be noted that where the above conditions are not met, access to research sites and research participants is to be determined on a case-by-case basis. It is the researcher's responsibility to determine whether the research is subject to Canadian REB approval.<sup>56</sup> Regardless of whether Canadian REB approval is required, any research conducted in Canada is subject to the applicable federal and provincial laws and regulations.<sup>57</sup>

- c. Would the external researcher be required to have a collaborator in your country? [Yes/No]  
 Yes  
 No  
 Not sure or other
- d. Would it matter whether the external researcher is based at a commercial, governmental, or academic entity? [Yes/No]  
 Yes  
 No  
 Not sure or other

The ethical rules pertaining to REB review and approval typically remain the same irrespective of the type of institution in question, although legal requirements may vary.<sup>58</sup> However, where the TCPS2 policy applies, certain disclosures may have to be provided related to the researcher's host institution, especially where commercialization and possible conflict of interest may arise.<sup>59</sup>

**5. As far as you know, what are the perceived benefits and risks that could occur if a researcher from another country conducted IRB/REC-approved genomic research on samples or data obtained from your country? Please consider the perspectives of the public, research participants, socially-defined groups (e.g., indigenous or minority populations), researchers, and other professional or government entities.**

The benefits and risks relevant to DTP genomic research conducted in Canada by foreign researchers vary according to the stakeholder in question and the perspective adopted. For example, from a legal point of view, risks predominately relate to the potential lack of adequate privacy protection in foreign jurisdictions. Data transfer to, and sharing among foreign jurisdictions typically require researchers to establish appropriate contractual or other safeguards, as well as ensuring that the foreign country's laws provide satisfactory legal protections.<sup>60</sup> Additionally, researchers have to ensure that the appropriate privacy standards are met, as provincial privacy rules vary according to the province where the research is undertaken.<sup>61</sup> Furthermore, transborder data transfer presents challenges in terms of enforcing privacy related obligations, or for Canadian privacy authorities to monitor compliance.<sup>62</sup> Another privacy-related risk is that, upon entry into a foreign jurisdiction, the information may be subject to compulsory disclosure under the foreign law, such as in the case of government and law enforcement surveillance.<sup>63</sup> Aside from posing potential ethical and legal risks, data sharing may also be viewed negatively by DTP research participants.

A further possible challenge arises with regard to Canadian research participants' right to withdraw consent and thereby terminate the use of biological material and associated genetic data.<sup>64</sup> Such a requirement is fairly complex in the context

of national research projects, as the need to re-identify anonymized data in order to identify the information required to be withdrawn presents challenges of its own.<sup>65</sup> As such, the international context may prove even more challenging.

An additional legal factor that foreign researchers conducting DTP research may overlook, therefore giving rise to some challenges, is that Québec has particular linguistic and legal norms. Importantly, French is the official language of the province,<sup>66</sup> and therefore, participants in Québec have the right to receive instruction and information regarding the research in French.<sup>67</sup> This translates to the need to ensure that consent forms and other relevant information are available to participants in French.<sup>68</sup> Where researchers face language barriers, recruitment in Québec may be problematic.

Additionally, foreign researchers may not be aware of the current state of Canada's *Genetic Non-Discrimination Act*<sup>69</sup> (GNDA), which has recently been deemed unconstitutional by the Québec Court of Appeal, and whose status may soon change. As it relates to DTP genomic research, the GNDA prohibits anyone providing goods or a service or entering a contract or agreement with an individual to collect, use or disclose the results of a genetic test without the individual's written consent.<sup>70</sup> There is an exception made for health care practitioners and researchers.<sup>71</sup> In December 2018, the Québec Court of Appeal concluded that the GNDA is *ultra vires*.<sup>72</sup> The decision was subsequently appealed to the Supreme Court of Canada, where it may be invalidated. As such, DTP researchers will have to keep abreast of these developments to ensure legal compliance.

Finally, international data sharing is complex as important inconsistencies are present among jurisdictions, such as differences in terminology, data linkage processes, and mechanisms governing access to data, among others.<sup>73</sup> These can create the risk of operational obstacles rendering data sharing internationally more difficult.<sup>74</sup> Other concerns

include, a possible lack of trust on the part of participants, potential cultural, legal, and ethical or professional standard dissonance. For example, the TCPS2 mandates certain rules where genomic research involves Canadian First Nations participants.<sup>75</sup> Special instruction for such research arose due to the fact that research involving Aboriginal communities in Canada was predominantly carried out by non-Aboriginal researchers, and the research did not particularly benefit the community.<sup>76</sup> As such, First Nations communities often regard research originating outside their communities with a degree of mistrust.<sup>77</sup> This mistrust may be exacerbated in the case of foreign researchers who may lack knowledge of Canadian Aboriginal history, their socio-economic condition, and relevant customs.

Although the list of risks may appear overwhelming at first, the benefits of international DTP research cannot be overlooked. It is widely accepted that international collaboration in genomic research can facilitate genomic advancements.<sup>78</sup> For example, international collaborative access to, and use of the genomic data is essential to the goal of achieving rapid translation of research results into clinical knowledge.<sup>79</sup> More specific to genomic research conducted in Canada, are the benefits associated with such research among the country's genetically isolated populations, such as those in Newfoundland<sup>80</sup> and Saguenay-Lac St-Jean.<sup>81</sup> Such research is anticipated to accelerate the identification of genetic factors implicated in common diseases, as a significant limiting factor to statistical power in genomic research has been identified as genetic and environmental heterogeneity.<sup>82</sup> On the other hand, Canada's metropolitan cities, such as Montréal and Toronto, provide a unique environment for researchers to access a wide range of heterogeneous participants, which is useful in other types of genomic research.

## Part II — General Questions

### 6. Does your country have biohazard committees, data protection boards, export permit authorities, or other entities that regulate the exporting of biospecimens or the transferring of data across borders for research? If so, do these requirements apply to individual citizens as well as research and medical institutions?

The *Personal Information Protection and Electronic Documents Act* (PIPEDA) regulates the exportation of data and biospecimens in the commercial context.<sup>83</sup> The application of PIPEDA to DTP genomic research is rather indirect, as the Act shifts the burden onto the institution transferring the data or biospecimens through the accountability principle.<sup>84</sup> More specifically, the institution transferring data must ensure that the data will have comparable protection mechanisms in the foreign jurisdiction.<sup>85</sup> In the case of international DTP genomic research, foreign researchers must ensure that the transfer of personal health information, such as biospecimens, will not compromise the privacy of the data. Importantly, PIPEDA applies to private sector institutions that collect, use, or disclose personal information, such as health information, in the course of commercial activities.<sup>86</sup> As such, it does not apply to individuals, such as researchers working in their own capacity. Additionally, provincial privacy legislation may also apply to the transfer of biospecimens and data, sometimes, with stricter rules regarding transport.<sup>87</sup>

Aside from privacy legislation, the transportation of biospecimens is regulated through Transport Canada (TGD Regulations),<sup>88</sup> the *Human Pathogens and Toxins Act* (HPTA),<sup>89</sup> and the Canadian Biosafety Standard.<sup>90</sup> These specifically apply to human specimens containing pathogens or toxins as opposed to data. According to the TGD Regulations, biospecimens known, or reasonably believed to contain a pathogen are

subject to special rules and require a permit.<sup>91</sup> This may prove rather challenging for genomic researchers, as it is difficult to assess whether biospecimens collected from research participants, especially a wide array of participants in the DTP context, contain an infectious substance as defined by the TGD Regulations.<sup>92</sup> Nonetheless, the Regulations stress that human biospecimens are exempted from these requirements where there is no reason to believe that they contain an infectious substance.<sup>93</sup> This exemption applies to specimens collected as part of a routine screening test (even where testing for an infectious substance), but not for diagnosis of an infectious disease.<sup>94</sup> Therefore, because DTP genomic researchers will likely not collect biospecimens for diagnosis of an infectious disease, they may likely benefit from the exemptions.<sup>95</sup> The HPTA applies to individuals possessing, handling, using, storing, importing, or exporting a human pathogen or toxin.<sup>96</sup> As such, the Act concerns individual researchers as opposed to the institution under which the research is conducted. On the other hand, the TGD Regulations apply to anyone handling (shipping, transporting, and receiving) dangerous goods by road, rail, air, or water,<sup>97</sup> therefore encompassing both individuals and organizations (natural and legal persons).

**7. Does your country have laws, policies, or guidelines dealing with genetic or genomic research or genetic or genomic privacy that would apply to international DTP research? Do your national laws on these issues apply outside of your country when residents or citizens of your country enroll in a DTP study conducted abroad?**

Although the TCPS2 specifically addresses genetic privacy,<sup>98</sup> federal and provincial laws largely legislate this area indirectly through more general privacy laws. Genomic privacy will typically be addressed incidentally through PIPEDA, which applies to private sector institutions that col-

lect, use, or disclose personal information, such as health information, in the course of commercial activities.<sup>99</sup> When it comes to protecting personal information held by public bodies, the federal *Privacy Act*<sup>100</sup> applies.<sup>101</sup> Additionally, where provincial privacy laws are deemed substantively similar to PIPEDA, they apply in its place in the province.<sup>102</sup>

Canadian laws and policies relating to genomic privacy may apply internationally under certain circumstances, namely where commercial cross-border transfer of information occurs (from Canada to a foreign destination), or where the research has a real and substantial connection to Canada. In terms of ethics policies, the TCPS2 applies to international DTP genomic research where the institution conducting the research is eligible to receive, or receives funding from noted federal agencies.<sup>103</sup>

Although PIPEDA will generally not apply outside Canada, where data or specimens collected from Canadian participants are transferred to another jurisdiction, PIPEDA will regulate the commercial cross-border data transfer, collection, and use.<sup>104</sup> Specifically, PIPEDA states that individual organizations are responsible for providing a comparable level of protection in the foreign jurisdiction, otherwise known as the aforementioned accountability principle.<sup>105</sup> As such, the institution transferring data must ensure that the data will have comparable protection mechanisms in the foreign jurisdiction.<sup>106</sup> In the case of international DTP genomic research, foreign researchers must therefore ensure that the transfer of personal health information will not compromise the privacy of the data.

Further, the Privacy Commissioner of Canada may have jurisdiction over a researcher's institution outside Canada, thus extending the scope of Canadian privacy law<sup>107</sup> internationally. Where this is the case, PIPEDA or the *Privacy Act* can be applied outside Canada. The Privacy Commissioner's jurisdiction is determined through the "real and substantial connection test" delineated by jurisprudence.<sup>108</sup> According to the test, DTP research may fall under the Privacy Commis-

sioner's authority where a real and substantial link exists between Canada and the foreign institution's operation.<sup>109</sup> The research would be considered within the scope of Canadian privacy law where sufficient indicia of a real and substantial connection to Canada exist, such as, the target or subject of research and commercial activity are Canadian participants, and "active involvement and participation" with Canadian participants or Canadian stakeholders are present.<sup>110</sup>

**8. Does your country have laws, policies, guidelines, or cultural expectations regarding the return of individual or aggregate research results? [Multiple choice]**

- a. The law requires the return of individual results unless the participant expressly declines to have results returned
- b. The law is silent on return of results; the expectation is that individual results will be returned unless the participant expressly declines to have the results returned**
- c. The law is silent on return of results; aggregate results are typically returned, but individual results are not returned unless expressly stated in the research protocol
- d. I am not sure — or other answer

According to the TCPS2, researchers have an obligation to disclose any material incidental finding in the course of research.<sup>111</sup> Typically, researchers are expected to develop a plan for how incidental findings will be disclosed to research participants, especially in genomic and genetic research.<sup>112</sup> Generally, the Canadian perspective on the matter is that results should be returned where they meet the following criteria:<sup>113</sup> scientific and clinical validity, significant health implications, actionability, research results confirmed by an accredited clinical diagnostic laboratory, and independent REB approval was obtained.

**9. Does your country have laws, policies, or guidelines regarding “direct-to-consumer” genetic testing (e.g., 23andMe) and, if so, what do they provide? [Multiple choice]**

- Yes. Direct-to-consumer genetic testing is illegal
- Yes. Direct-to-consumer genetic testing is legal**
- No. Direct-to-consumer genetic testing is not an issue
- I am not sure — or other answer

Canada does not have any specific law or policy applicable to direct-to-consumer genetic testing. However, it is predominantly governed indirectly through federal and provincial privacy, health, and consumer protection laws,<sup>114</sup> and most prominently, Canada’s *Medical Devices Regulations*,<sup>115</sup> where genetic test kits are deemed a class I medical device.

**Part III — Looking to the Future**

**10. How, if at all, do you anticipate that your country’s laws, policies, or guidelines will change in the next 5-10 years in response to international DTP genomic research? [Multiple choice]**

- I do not think they will change at all
- I think they will restrict international DTP research
- I think they will allow international DTP research**
- I am not sure — or other answer

**Note**

The author has no conflicts to disclose.

**References**

- Privacy Commissioner of Canada, “Direct-to-Consumer Genetic Testing and Privacy,” available at <[https://www.priv.gc.ca/en/privacy-topics/health-genetic-and-other-body-information/02\\_05\\_d\\_69\\_gen/](https://www.priv.gc.ca/en/privacy-topics/health-genetic-and-other-body-information/02_05_d_69_gen/)> (last visited July 29, 2019); Canadian Medical Association, “Direct-to-Consumer Genetic Testing,” CMA POLICY (May 2017), available at <<https://policy-base.cma.ca/en/viewer?file=%2fdo>

- documents%2fPolicypdf%2fPD17-05.pdf#phrase=false> (last visited October 15, 2019).
- See e.g. *Healthcare (Consent) and Care Facility (Admission) Act*, RSBC 1996, c 181 [*Healthcare (Consent) and Care Facility (Admission) Act*]; *An Act respecting clinical and research activities relating to assisted procreation*, CQLR, c A-5.01, s 8; Art 20-21 *Civil Code of Québec*, RLRQ c CCQ-1991 [CCQ]; *Health Information Act*, SNWT 2014, c 2, s 68.
- Private institutions that receive accreditation from Human Research Accreditation Canada are subject to its REB standards, which includes the TCPS2. Human Research Accreditation Canada, “Normative Documents,” available at <<https://www.hracanada.org/find/normative-documents/>> (last visited July 29, 2019).
- Canadian Institutes of Health Research, Natural Sciences and Engineering Research Council of Canada, and Social Sciences and Humanities Research Council of Canada, *Tri-Council Policy Statement: Ethical Conduct for Research Involving Humans*, December 2014, art 2.1 [TCPS2].
- Government of Canada, Panel on Research Ethics, “TCPS2-Introduction,” available at <<http://www.pre.ethics.gc.ca/eng/policy-politique/initiatives/tcps2-eptc2/introduction/>> (last visited July 29, 2019).
- In the case of private institutions, many have either explicitly adopted the TCPS2, or have adopted policies to supplement it. See, McGill Research and Innovation, “Forms and Guidelines,” available at <<https://mcgill.ca/research/research/compliance/human/reb-i-ii-iii/forms-and-guidelines>> (last visited July 29, 2019).
- S.V. Zimmerman, “TCPS 2: Background and Selected Highlights Selected Highlights,” Panel on Research Ethics webinar for EHIL, presented May 2011, available at <<http://www.ehealthinformation.ca/wp-content/uploads/2014/08/zimmerman.pdf>> (last visited July 29, 2019).
- Of note that the chief source relied upon to explain the following ethical rules are found in the TCPS2. Although not every REB will employ it, the TCPS2 can be said to represent Canada’s normative ethical standards.
- Reibl v. Hughes* [1977] OJ No 2289, 78 DLR (3d) 35; *Hopp v. Lepp*, [1980] 2 SCR 192; *Kita v. Braig* [1992], 17 BCAC 55; *Edwardson v. St Joseph’s Healthcare Hamilton*, [2012] OJ No 5032, 2012 ONCA 719.
- See e.g. *Consent to Treatment and Healthcare Directives Act*, RSPEI 1996, c 10, s 6(7); Art 10-11 CCQ, *supra* note 2; *Healthcare (Consent) and Care Facility (Admission) Act*, *supra* note 2; *Medical Consent of Minors Act*, SNB 1976, c M-6.1; *Hospitals Act*,

- RSNS 1989, c 208; *Healthcare Consent Act*, 1996, SO 1996, c 2, Sch A.
- TCPS2, *supra* note 4, Chapter 2 § B.
- Id.* art 3.12.
- Id.* art 3.5.
- Id.* art 3.1. Additionally, the TCPS2 provides for certain rules in cases where the research participant lacks capacity to consent to research (TCPS2 art 3.9) taking into consideration the participant’s best interests and trying to involve the participant as much as possible in the process (TCPS2 art 3.9- application).
- Art 24 CCQ, *supra* note 2.
- Aside from Québec, Alberta’s *Health Information Act* addresses electronic consent in the context of medical treatment. *Alta Reg 70/2001* s 6. Federally, the *Secure Electronic Signature Regulations* recognize the validity of electronic signatures in the context of evidence, and establish the presumption that, absent of evidence to the contrary, a signature is presumed to be of the person identified in the digital signature certificate. *Secure Electronic Signature Regulations*, SOR/2005-30, § 5.
- This refers to ensuring that the document or information contained therein was not altered and was maintained in its entirety. E. Kirby, M.H. Zawati, and B.M. Knoppers, “Electronic Consent to Health Research in Canada,” *Canadian Bar Review* 91, no. 2 (2013): 419-435, at 425.
- This is typically established through an electronic signature. *An Act to establish a legal framework for information technology*, RSQ, c C-1.1, 2001.
- Personal Health Information Protection Act*, 2004, RSO 2004, c 3, Sch A; *Electronic Commerce Act*, 2000, RSO 2000, c 17; CCQ, *supra* note 2; *Freedom of Information and Protection of Privacy Act*, RSBC 1996, c 165; *Freedom of Information and Protection of Privacy Regulation*, RSBCReg 323/93; *Electronic Transaction Act*, RSBC 2001, c 10; *Health Information Act*, RSA 2000, c H-5; *Health Information Regulation*, Alta Reg 70/2001; *Electronic Transaction Act*, RSA 2001, c E-5.5; *Freedom of Information and Protection of Privacy Act*, SNS 1993, c 5; *Freedom of Information and Protection of Privacy Regulations*, NS Reg 105/94; *Electronic Commerce Act*, SNS 2000, c 26. See Kirby, *supra* note 17, at 423-425.
- TCPS2, *supra* note 4, art 3.12-application.
- Id.* art 3.1-application.
- The TCPS2 notes that incentives differ from reimbursements and compensation for injury. See TCPS2, *supra* note 4, art 3.2[j].
- Id.* art 3.1-application.
- Id.*
- Id.* art 3.2-application.
- Id.* art 3.2.

27. *Id.* art 12.2.  
 28. *Id.* art 3.3.  
 29. The exceptions to informed consent still require REB approval, and any alteration to the normal consent requirements should only be permitted to the extent necessary. The exceptions are: (1) the research only involves minimal risk to participants; (2) the alteration to consent is unlikely to adversely affect the welfare of participants; (3) it is impossible or impracticable to either carry out the research or address the research question if prior consent is sought; (4) alteration to consent is defined; (5) debriefing is provided, offering participants the opportunity to refuse consent or withdraw consent; and (6) cases of medical emergency. TCPS2, *supra* note 4, art 3.7-3.8.  
 30. *Id.* art 5.1.  
 31. *Id.* art 5.2.  
 32. *Id.* art 5.3.  
 33. *Id.* art 3.4.  
 34. *Id.* art 3.4-application.  
 35. *I.e.*, causing undue hardship that jeopardizes the research.  
 36. Due to large quantities of data that are possibly de-identified or anonymized. TCPS2, *supra* note 4.  
 37. *Id.* art 5.5A.  
 38. *Id.* art 5.5B.  
 39. *Id.* art 5.5B-application.  
 40. *Id.* art 5.7.  
 41. *Id.* art 5.7.  
 42. See above, “Consent” and “Secondary Uses.”  
 43. TCPS2, *supra* note 4, art 12.5(a).  
 44. *Id.* art 12.5(b).  
 45. *Id.* art 12.5-application.  
 46. *Id.* art 13.1.  
 47. *Id.* art 13.2.  
 48. *Id.* art 13.2-application. Importantly, this rule was developed because genetic research may reveal particularly sensitive information that can have implications for biological relatives, and may also affect eligibility for employment and insurance.  
 49. *Id.* art 13.3.  
 50. *Id.* art 9.1.  
 51. *Id.* art 9.3 and 9.8.  
 52. *Id.* art 9.19.  
 53. *Id.* art 8.1.  
 54. *Id.* art 8.3(b).  
 55. Government of Canada, Panel on Research Ethics, *Scope*, available at <<http://www.pre.ethics.gc.ca/eng/policy-politique/interpretations/scope-portee/>> (last visited July 29, 2019).  
 56. *Id.*  
 57. Such as, privacy laws, informed consent, capacity, etc.  
 58. For example, privacy laws differ based on whether the organization under whose auspices the research is conducted is a public institution or a private one.  
 59. TCPS2, *supra* note 4, art 3.2 and 12.2.  
 60. A. Thorogood, “Canada: Will Privacy Rules Continue to Favour Open Science?” *Human Genetics* 137, no. 8 (2018): 595-602, at 598.  
 61. For example, the province of Québec generally legislates stricter rules in terms of private sector law. For instance, data custodians (in our case, researchers) must take all reasonable steps to ensure that the data will not be used for unrelated purposes without prior consent of the concerned individuals (*Act respecting the Protection of personal information in the private sector*, CQLR c P-39.1 s 17). Additionally, Québec law requires that where personal information is collected from an individual and a file is subsequently created from the information, the person concerned be notified of the place where the file is kept and of the access and rectification rights (*Act respecting the Protection of personal information in the private sector*, CQLR c P-39.1 s 8(3)). Further, British Columbia and Nova Scotia have data residency requirements, prohibiting the transfer of personal information held by public sector institutions outside the province (*Freedom of Information and Protection of Privacy Act*, RSBC 1996 c 165 s 33.2; *Personal Information International Disclosure Protection Act* SNS 2006 c 3 s 5(1)). The variation in legal requirements therefore have to be considered by foreign researchers prior to commencing DTP genomic research in Canada.  
 62. Thorogood et al., “Protecting the Privacy of Canadians’ Health Information in the Cloud,” *Canadian Journal of Learning and Technology* 14 (2016): 173-213, at 191.  
 63. *Id.* at 194.  
 64. *McInerney v. MacDonald* [1992] 2 SCR 138.  
 65. K.M. Saulnier, “Locating Biobanks in the Canadian Privacy Maze,” *Journal of Law, Medicine & Ethics* 44, no. 1 (2016):7-19, at 10.  
 66. *Charter of the French language*, CQLR, c C-II, § 1.  
 67. *Id.* § 6.  
 68. This requirement is further established by the TCPS2, which requires that consent forms be provided in “plain language” for participants to understand. In Québec, this may mean that consent forms should also be provided in French. TCPS2, *supra* note 4, art 3.2.  
 69. *Genetic Non-Discrimination Act*, SC 2017, c 3.  
 70. *Id.* § 5.  
 71. *Id.* § 6.  
 72. *Reference Re Genetic Non-Discrimination Act*, 2018 QCCA 2193.  
 73. See E. Kirby, et al., *Data Access and Sharing by Researchers in Genomics: Policy Brief*, March 2018, available at <[http://www.genomequebec.com/DATA/PUBLICATION/35\\_en-v-Data\\_Access\\_and\\_Sharing\\_by\\_Researchers\\_in\\_Genomics\\_-\\_Policy\\_Brief.pdf](http://www.genomequebec.com/DATA/PUBLICATION/35_en-v-Data_Access_and_Sharing_by_Researchers_in_Genomics_-_Policy_Brief.pdf)> (last visited October 15, 2019).  
 74. *Id.*  
 75. See TCPS2, *supra* note 4, chapter 9.  
 76. *Id.*  
 77. *Id.*  
 78. The benefits of international collaboration are widely accepted, as numerous publically funded data sharing platforms have been established, such as, CanDig (2018), Care4Rare SOLVE (2018), and the Canadian Open Neuroscience Platform (2018). See Thorogood, *supra* note 60.  
 79. B.M. Knoppers, M.H. Abdul-Rahman, and K. Bédard, “Genomic Databases and International Collaboration,” *King’s Law Journal* 18, no. 2 (2007): 291-311.  
 80. See generally, P. Rahman et al., “The Newfoundland Population: A Unique Resource for Genetic Investigation of Complex Diseases,” *Human Molecular Genetics* 12, no. 2 (2003): 167-172.  
 81. See generally, P. Hamet et al., “Quantitative Founder-Effect Analysis of French Canadian Families Identifies Specific Loci Contributing to Metabolic Phenotypes of Hypertension,” *American Journal of Human Genetics* 76, no. 5 (2005): 815-832.  
 82. *Id.*; A.M. Glazier, J.H. Nadeau, and T.J. Aitman, “Finding Genes that Underlie Complex Traits,” *Science* 298, no. 5602 (2002): 2345-2349.  
 83. Office of the Privacy Commissioner of Canada, “Questions and Answers regarding the application of PIPEDA, Alberta and British Columbia’s *Personal Information Protection Acts*,” available at <[https://www.priv.gc.ca/en/privacy-topics/privacy-laws-in-canada/the-personal-information-protection-and-electronic-documents-act-pipeda/r\\_o\\_p/02\\_05\\_d\\_26/](https://www.priv.gc.ca/en/privacy-topics/privacy-laws-in-canada/the-personal-information-protection-and-electronic-documents-act-pipeda/r_o_p/02_05_d_26/)> (last visited July 29, 2019).  
 84. *Personal Information Protection and Electronic Documents Act* (SC 2000, c 5) schedule 1 Section 5 art 4.1 [PIPEDA].  
 85. Saulnier, *supra* note 65, at 12.  
 86. Office of the Privacy Commissioner of Canada, *PIPEDA in brief*, available at <[https://www.priv.gc.ca/en/privacy-topics/privacy-laws-in-canada/the-personal-information-protection-and-electronic-documents-act-pipeda/pipeda\\_brief/](https://www.priv.gc.ca/en/privacy-topics/privacy-laws-in-canada/the-personal-information-protection-and-electronic-documents-act-pipeda/pipeda_brief/)> (last visited July 29, 2019).  
 87. For example, Québec generally legislates stricter rules in terms of privacy, and the provinces of British Columbia and Nova Scotia have data residency requirements. Please refer to note 61.  
 88. *Transportation of Dangerous Goods Regulations* (SOR/2001-286) [TDG Regulations].  
 89. *Human Pathogens and Toxins Act* (SC 2009, c 24) [HPITA].  
 90. Government of Canada, *Canadian Biosafety Standard (CBS) Second Edition*, available at <<https://www.canada.ca/en/public-health/services/canadian-biosafety-standards-guidelines/second-edition.html#2a>> (last visited July 29, 2019).

91. Transport Canada, Government of Canada, "Shipping Infectious Substances," available at <<http://www.tc.gc.ca/eng/tdg/page-1296.html>> (last visited July 29, 2019); *TDG Regulations*, *supra* note 59, § 1.4.
92. An infectious substance is defined as a substance known or reasonably believed to contain viable micro-organisms that are known or reasonably believed to cause disease in humans or animals. *TDG Regulations*, *supra* note 88, § 1.4.
93. *Id.* § 1.42.
94. Transport Canada, *supra* note 91.
95. *Id.* Furthermore, Transport Canada advises professionals to consider the medical history, symptoms, endemic local conditions, and individual circumstances of the participant to help assess whether a specimen is regulated.
96. *HPTA*, *supra* note 89, § 6 & 7.
97. Canadian Centre for Occupational Health and Safety, Government of Canada, "Transportation of Dangerous Goods (TDG) — Overview," available at <[https://www.ccohs.ca/oshanswers/legisl/tdg/tdg\\_overview.html](https://www.ccohs.ca/oshanswers/legisl/tdg/tdg_overview.html)> (last visited July 29, 2019).
98. TCPS2, *supra* note 4, chapter 5.
99. Office of the Privacy Commissioner of Canada, *supra* note 86.
100. *Privacy Act*, RSC 1985, c P-21.
101. *Id.* § 2.
102. Office of the Privacy Commissioner of Canada, "Provincial legislation deemed substantially similar to PIPEDA," available at <[https://www.priv.gc.ca/en/privacy-topics/privacy-laws-in-canada/the-personal-information-protection-and-electronic-documents-act-pipeda/r\\_o\\_p/provincial-legislation-deemed-substantially-similar-to-pipeda/](https://www.priv.gc.ca/en/privacy-topics/privacy-laws-in-canada/the-personal-information-protection-and-electronic-documents-act-pipeda/r_o_p/provincial-legislation-deemed-substantially-similar-to-pipeda/)> (last visited July 29, 2019).
103. Government of Canada, *supra* note 5.
104. Office of the Privacy Commissioner of Canada, "Questions and Answers regarding the application of PIPEDA, Alberta and British Columbia's Personal Information Protection Acts," available at <[https://www.priv.gc.ca/en/privacy-topics/privacy-laws-in-canada/the-personal-information-protection-and-electronic-documents-act-pipeda/r\\_o\\_p/02\\_05\\_d\\_26/](https://www.priv.gc.ca/en/privacy-topics/privacy-laws-in-canada/the-personal-information-protection-and-electronic-documents-act-pipeda/r_o_p/02_05_d_26/)> (last visited July 29, 2019).
105. *Id.*; Thorogood, *supra* note 62, at 193.
106. Saulnier, *supra* note 65, at 12.
107. *PIPEDA*, in the case of commercial activity.
108. Thorogood, *supra* note 62, at 194; *Lawson v. Accusearch Inc (c.o.b. Abika.com)* [2007] FCJ No 164 [*Lawson*].
109. *Lawson*, *supra* note 108.
110. See Office of the Privacy Commissioner of Canada, Website that generates revenue by republishing Canadian court decisions and allowing them to be indexed by search engines contravened PIPEDA, available at <[actions-and-decisions/investigations-into-businesses/2015/pipeda-2015-002/> \(last visited July 29, 2019\). These criteria were extracted from the \*PIPEDA\* Report Findings as they relate to international commercial entities holding data relevant to Canadians. Indeed, such a determination would be assessed on a case by case basis, yet indicia of a link with Canada can help determine the relevance of Canadian privacy law beforehand.](https://www.priv.gc.ca/en/opc-</a></p>
</div>
<div data-bbox=)

111. TCPS2, *supra* note 4, art 3.4.
112. *Id.* at 32.
113. K. Sénécal, "Statement of Principles on the Return of Research Results and Incidental Findings," *Genome* 57, no. 7 (2014): 541-548; B.M. Knoppers, M.H. Zawati and K. Sénécal, "Return of Genetic Testing Results in the Era of Whole-Genome Sequencing," *Nature reviews, Genetics* 16, no. 9 (2015): 553-559.
114. *PIPEDA*, *supra* note 84; (AB) *Personal Information Protection Act*, S.A. 2003, c. P-6.5; (BC) *Personal Information Protection Act*, SBC 2003, c 63; (QC) *Act respecting the protection of personal information in the private sphere*, CQLR c P-39.1.
115. *Medical Devices Regulations* (SOR/98-282). For example, where the genetic test is performed in Canada, it would be classified as a Class III in vitro diagnostic device as per the *Medical Devices Regulation*. Health Canada, Government of Canada, "Guidance for the risk-based classification system for in vitro diagnostic devices (IVDDs)," available at <<https://www.canada.ca/en/health-canada/services/drugs-health-products/medical-devices/application-information/guidance-documents/guidance-document-guidance-risk-based-classification-system-vitro.html>> (last visited July 29, 2019).

## China

Haidan Chen

Researchers in genomics are exploring novel ways to interact directly with prospective participants without utilizing physicians, hospitals, or biobanks as intermediaries. Many researchers are interested in using the internet to directly recruit and enroll research participants in genomic studies by posting information online about active or proposed studies. This direct-to-participant (DTP) approach could take place under three main scenarios:

- A researcher in your country wants to conduct DTP genomic research with participants in your country
- A researcher in your country wants to conduct DTP genomic research with participants in another country
- A researcher from outside your country wants to conduct DTP genomic research with participants in your country

There is uncertainty about whether DTP recruitment, enrollment, and research are lawful under these scenarios.

### Part I — DTP-Specific Questions

#### 1. As far as you know, is DTP genomic research a topic of interest to researchers or other stakeholders in your country? [Multiple choice]

- a. There has been little, if any, discussion of the issue as of now
- b. There has been discussion among researchers, but little discussion among policy makers**
- c. There has been discussion among both researchers and policy makers
- d. I am not sure — or other answer



Currently, there is not much DTP genomic research in China. Some “Direct-to-Consumer” (DTC) genetic testing companies have conducted DTP genomic research with participants mainly from China, while some DTC genetic testing companies plan to do so. The majority of geneticists, clinicians, and bioethicists in China oppose DTC genetic testing. There are no regulations and regulatory agencies specific to DTP genomic research and DTC genetic testing in China. There has been discussion among researchers, but I am not sure whether policy makers discuss it. It’s more likely that there has been little discussion among policy makers.

**2. Assume that a researcher in your country wants to conduct DTP genomic research with participants in your country and that such research is subject to IRB/REC review. Please describe the conditions for IRB/REC approval, if it could be approved at all.**

DTP genomic research is subject to IRB/REC review, complying with the Ethics Review Measures for Biomedical Research Involving Human Subjects (Ethics Review Measures), which was issued by the National Health and Family Planning Commission in 2016. The general conditions for IRB/REC approval are listed in the Ethics Review Measures, and similar to the international standards, which include: scientific research protocols, fair selection of research subjects, rational risk-benefit ratio, standard informed consent form, respecting the rights of research subjects, abiding by the norms of research integrity, etc. Each IRB/REC usually requires further conditions for each specific research projects to be approved.

**3. Assume that a researcher in your country wants to conduct DTP genomic research**

**in another country. Please describe the conditions that must be satisfied for IRB/REC approval in your country, if it could be approved at all. Would your IRB/REC also require approval from a research ethics review body in the other country?**

If a DTP genomic research project is initiated by a researcher in China, only after IRB/REC approval in China can the project be launched. The general conditions for IRB/REC approval, which are similar to the international standards, are listed in the Ethics Review Measures, which include: scientific research protocols, fair selection of research subjects, rational risk-benefit ratio, standard informed consent form, respecting the rights of research subjects, abiding by the norms of research integrity, etc. Each IRB/REC usually requires further conditions for each specific research project to be approved.

Our IRB/RECs also require approval from a research ethics review body in the other country.

**4. Assume that a researcher from outside your country wants to conduct DTP genomic research in your country.**

a. Would it be lawful for the researcher to do so without IRB/REC approval in either the researcher’s country or your country? [Yes/No]

- Yes  
 No  
 Not sure or other

b. Would it be lawful for the researcher to do so if the research were approved by an IRB/REC in the researcher’s own country, but was not submitted for approval in your country? [Yes/No]

- Yes  
 No  
 Not sure or other

c. Would the external researcher be required to have a collaborator in your country? [Yes/No]

- Yes  
 No  
 Not sure or other

d. Would it matter whether the external researcher is based at a commercial, governmental, or academic entity? [Yes/No]

- Yes  
 No  
 Not sure or other

Assuming that a researcher from outside China wants to conduct DTP genomic research in China, he/she has to collaborate with a Chinese partner, their cooperation needs to comply with the Ordinance on the Administration of Human Genetic Resources (New Ordinance), which came into effect on July 1, 2019, Article 22 (6), and to pass the ethical review of the two cooperating parties’ respective countries (regions).

Generally speaking, research projects based at an academic entity are more easily accepted and approved by the HGRA.

**5. As far as you know, what are the perceived benefits and risks that could occur if a researcher from another country conducted IRB/REC-approved genomic research on samples or data obtained from your country? Please consider the perspectives of the public, research participants, socially-defined groups (e.g., indigenous or minority populations), researchers, and other professional or government entities.**

**Haidan Chen, Ph.D.**, is an Associate Professor of the College of Humanities and Development Studies, China Agricultural University (CAU).

*Benefits:*

- **For public good:** the advancement of scientific research, the improvement of global health, new biomarker discovery, research and development of new drugs, etc.
- **For researchers:** more and better publications, career promotion, intellectual property rights, international collaboration and exchanges, etc.
- **For research participants:** the return of individual and/or aggregate research results, etc.

*Risks:*

- unfair benefit sharing
- samples and data abuse
- privacy disclosure
- genetic discrimination
- biosafety, bioweapon, etc.

**Part II — General Questions**

**6. Does your country have biohazard committees, data protection boards, export permit authorities, or other entities that regulate the exporting of biospecimens or the transferring of data across borders for research? If so, do these requirements apply to individual citizens as well as research and medical institutions?**

Before July 1, 2019, the Human Genetic Resources Administration of China (HGRAC) and Chinese Customs regulated the exporting of biospecimens or the transferring of data across borders for research. After July 1, 2019, I'm not sure whether any entities will replace the HGRAC to play the role, as the New Ordinance does not specify which entities will regulate the exporting of biospecimens or the transferring of data across borders for research, but in general, the administrative department of science and technology under the State Council will regulate China's human genetic resources.

China does not have biohazard committees.

Yes, these requirements apply to individual citizens as well as research and medical institutions.

**7. Does your country have laws, policies, or guidelines dealing with genetic or genomic research or genetic or genomic privacy that would apply to international DTP research? Do your national laws on these issues apply outside of your country when residents or citizens of your country enroll in a DTP study conducted abroad?**

Yes, the New Ordinance will replace the Interim Measures for the Administration of Human Genetic Resources (Interim Measures) and the Administrative Licensing Service Guide for the Review and Approval of the Collection, Preservation, Trade, and Export of Human Genetic Resources (Service Guide) to deal with genetic or genomic research or genetic or genomic privacy that would apply to international DTP research. In theory, the New Ordinance applies outside of China when residents or citizens of China enroll in a DTP study conducted abroad, but in practice, it depends on specific conditions. For example, when residents or citizens of China pay for DTC genetic testing provided by 23andMe, and enroll in a DTP study conducted by 23andMe, it's difficult for the New Ordinance to deal with these issues.

**8. Does your country have laws, policies, guidelines, or cultural expectations regarding the return of individual or aggregate research results? [Multiple choice]**

- a. The law requires the return of individual results unless the participant expressly declines to have results returned
- b. The law is silent on return of results; the expectation is that individual results will be returned unless the participant expressly declines to have the results returned

- a. The law requires the return of individual results unless the participant expressly declines to have the results returned
- c. The law is silent on return of results; aggregate results are typically returned, but individual results are not returned unless expressly stated in the research protocol

d. I am not sure — or other answer

China does not have laws, policies, or guidelines regarding the return of individual or aggregate research results. Most Chinese research participants usually expect for both individual and aggregate research results. IRB/RECs in China expect that individual results will be returned unless the participant expressly declines to have the results returned. Researchers in China expect that aggregate results are typically returned, but individual results are not returned unless expressly stated in the research protocol.

**9. Does your country have laws, policies, or guidelines regarding “direct-to-consumer” genetic testing (e.g., 23andMe) and, if so, what do they provide? [Multiple choice]**

- a. Yes. Direct-to-consumer genetic testing is illegal
- b. Yes. Direct-to-consumer genetic testing is legal
- c. No. Direct-to-consumer genetic testing is not an issue
- d. I am not sure — or other answer

China does not have laws, policies, or guidelines regarding “direct-to-consumer” genetic testing (e.g., 23andMe). There are companies offering “direct-to-consumer” genetic testing, though many people oppose it.

**Part III — Looking to the Future**

**10. How, if at all, do you anticipate that your country's laws, policies, or guidelines will change in**

**the next 5-10 years in response to international DTP genomic research? [Multiple choice]**

- a. I do not think they will change at all
- b. I think they will restrict international DTP research**
- c. I think they will allow international DTP research
- d. I am not sure — or other answer

DTP genomic research has more risks for research participants. Some scholars posit that if genomic research is related to health issues, it should collaborate with clinicians and genetic counselors to explain the results of genomic research, and provide health guidance for research participants in their diagnoses and treatments.

**Note**

The author has no conflicts to disclose.

**Appendix**

**Decree of the State Council of the People's Republic of China No. 717**

Issued on May 28, 2019

Came into effect on July 1, 2019

6 chapters, 47 articles in total

*Article 7* Foreign organizations, individuals, and institutions established or actually controlled by them shall not collect or preserve human genetic resources in China, nor shall they provide human genetic resources abroad.

*Article 8* Collection, preservation, utilization, and external provision of China's human genetic resources shall not endanger public health, national security and social public interests.

*Article 9* Collection, preservation, utilization, and external provision of China's human genetic resources shall conform to ethical principles and conduct ethical review in accordance with relevant provisions of the State.

Collection, preservation, utilization, and external provision of China's human genetic resources shall respect the privacy rights of human genetic resources' providers, obtain their

prior informed consent and protect their legitimate rights and interests.

Collection, preservation, utilization, and external provision of China's human genetic resources shall comply with the technical specifications formulated by the administrative department of science and technology under the State Council.

*Article 22* The use of China's human genetic resources in international scientific research cooperation shall meet the following conditions and be jointly applied by the two partners for approval by the administrative department of science and technology under the State Council:

- 1). There is no harm to China's public health, national security and social public interests;
- 2). Two cooperating parties are Chinese and foreign entities with legal personality, and have the basis and capability to carry out relevant work;
- 3). The purpose and content of the cooperative research are clear, legitimate and the time limit is reasonable;
- 4). The cooperative research program is reasonable;
- 5). The sources of the human genetic resources to be used are legitimate, and the types, quantities and research content are in conformity with each other;
- 6). To pass the ethical review of the two cooperating parties' respective countries (regions);
- 7). The research results have clear attribution, and reasonable and clear benefit distribution plan.

In order to obtain the market license of related drugs and medical devices in China, international cooperation in clinical trials at clinical institutions using China's human genetic resources without taking human genetic resources materials out of China does not require approval. However, before clinical trials are carried out, two cooperating parties shall put on file of the types, quantities and

uses of human genetic resources at the administrative department of science and technology under the State Council. The administrative departments of science and technology under the State Council, the administrative departments of science and technology under the people's governments of provinces, autonomous regions and municipalities directly under the Central Government shall strengthen supervision over the matters on file.

*Article 23* In the process of using China's human genetic resources to carry out international scientific research cooperation, if major matters such as cooperating parties, research purposes, research content and cooperation duration have changed, the examination and approval procedures for such changes shall be handled.

*Article 24* The use of China's human genetic resources in international scientific research cooperation shall ensure the full and substantial participation of Chinese organizations and their researchers in the whole process of cooperation. All records, data and information in the process of research shall be fully open to Chinese organizations and backups shall be provided to Chinese organizations.

Where a patent application is made for the achievements of international scientific research cooperation based on China's human genetic resources, it shall be jointly filed by both parties, and the patent right shall be shared by both parties. The right to use, transfer and benefit-sharing of other scientific and technological achievements produced by the study are agreed upon by both parties through cooperation agreements; if the agreement is not agreed upon, both parties have the right to use it, but the transfer to the third party must be agreed by both parties, and the benefits obtained shall be shared according to the contribution of both parties.

*Article 27* Where international scientific research cooperation is carried out by utilizing China's human genetic resources, or if it is necessary to transport, mail, or carry human genetic resources out of the country

due to other special circumstances, the following conditions shall be met and the exit certificate of human genetic resources materials issued by the administrative department of science and technology under the State Council shall be obtained:

- 1). There is no harm to China's public health, national security and social public interests;
- 2). Having the status of a legal person;
- 3). Having clear overseas partners and reasonable outbound uses;
- 4). The collection of human genetic resources materials is lawful or comes from lawful storage organizations;
- 5). To pass ethical review.

If international scientific research cooperation using China's human genetic resources needs to transport, mail, or carry China's human genetic resources materials out of the country, it can submit an application on its own, and can also specify the exit plan in the application for carrying out international scientific research cooperation, and submit it along with all the other application for examination and approval by the administrative department of science and technology under the State Council.

If the human genetic resources materials are transported, mailed or carried out of the country, the customs formalities shall be handled on the basis of the exit certificate of the human genetic resources materials.

*Article 28* The provision or open use of information of human genetic resources to foreign organizations, individuals and institutions established or actually controlled by them shall not endanger China's public health, national security and social public interests; if it may affect China's public health, national security and social public interests, it shall pass the security review organized by the administrative department of science and technology under the State Council.

If the information of human genetic resources is provided to or used openly

by foreign organizations, individuals and institutions established or actually controlled by them, it shall be put on file at the administrative department of science and technology under the State Council for the record, and a backup of the information shall be submitted to this department.

The information of human genetic resources produced by international scientific research cooperation using China's human genetic resources can be used by both parties.

*Article 41* If foreign organizations, individuals, and institutions established or actually controlled by them violate the provisions of these ordinances, collect and preserve China's human genetic resources within the territory of China, utilize China's human genetic resources to carry out scientific research, or provide overseas China's human genetic resources, the administrative department of science and technology under the State Council shall order to stop the illegal acts, confiscate human genetic resources illegally collected and preserved and illegal gains, impose a fine of not less than 1 million yuan but not more than 10 million yuan, and impose a fine of not less than 5 times but not more than 10 times the illegal gains if the illegal gains exceed 1 million yuan.

*Article 43* If the circumstances are particularly serious, it is permanently forbidden to engage in the collection, preservation, utilization, and external provision of China's human genetic resources.

## Denmark

*Mette Hartlev*

Researchers in genomics are exploring novel ways to interact directly with prospective participants without utilizing physicians, hospitals, or biobanks as intermediaries. Many researchers are interested in using the internet to directly recruit and enroll research participants in genomic studies by posting information online about active or proposed studies. This direct-to-participant (DTP) approach could take place under three main scenarios:

- A researcher in your country wants to conduct DTP genomic research with participants in your country
- A researcher in your country wants to conduct DTP genomic research with participants in another country
- A researcher from outside your country wants to conduct DTP genomic research with participants in your country

There is uncertainty about whether DTP recruitment, enrollment, and research are lawful under these scenarios.

### Part I – DTP-Specific Questions

1. **As far as you know, is DTP genomic research a topic of interest to researchers or other stakeholders in your country?**  
[Multiple choice]
  - a. **There has been little, if any, discussion of the issue as of now** – to my knowledge this issue has not attracted interest or concern among researchers or politicians. It may be explained by the fact that

**Mette Hartlev, Ph.D., LL.D., Professor,**  
*Faculty of Law, University of Copenhagen, Denmark.*

genomic research in Denmark to a large degree takes place based on tissue samples from clinical or research biobanks, where the law allows for an exemption from the normal informed consent requirement (see answer to next question). The online advertisement and recruitment of research participants is not uncommon. There is a special website developed by a private person, where announcements for research participants can be advertised.<sup>1</sup>

- b. There has been discussion among researchers, but little discussion among policy makers
- c. There has been discussion among both researchers and policy makers
- d. I am not sure — or other answer

**2. Assume that a researcher in your country wants to conduct DTP genomic research with participants in your country and that such research is subject to IRB/REC review. Please describe the conditions for IRB/REC approval, if it could be approved at all.**

It is necessary to distinguish between situations where the research project requires direct involvement of research participants, and situations where the project can rely exclusively on tissue samples stored in a biobank. In both situations, the research project needs REC approval according to the *Act on Research Ethics Review of Health Research Projects*,<sup>2</sup> and the REC will assess the scientific quality of the project and of the possible advantages and risks. In regard to informed consent, this is only mandatory where the research participant is directly involved. If the project is based exclusively on tissue samples stored in a clinical or a research biobank, section 10 of the *Act* provides for derogation from informed consent requirements, and the REC may

decide to make an exception if the project does not pose any health risks and if under the given conditions the project does not in other ways put a strain on the tissue donor. The assessment will also take into consideration whether it would be impossible or disproportionately difficult to obtain consent or proxy consent.

**3. Assume that a researcher in your country wants to conduct DTP genomic research in another country. Please describe the conditions that must be satisfied for IRB/REC approval in your country, if it could be approved at all. Would your IRB/REC also require approval from a research ethics review body in the other country?**

The *Act on Research Ethics Review of Health Research* only applies to research activities taking place in Denmark. If recruitment takes place in Denmark, but the genetic analyses are made outside Danish jurisdiction (no research activity in Denmark), the Danish RECs do not have competence to assess and authorize the project.

**4. Assume that a researcher from outside your country wants to conduct DTP genomic research in your country.**

- a. Would it be lawful for the researcher to do so without IRB/REC approval in either the researcher's country or your country? [Yes/No]

It will always require an approval from a Danish REC to conduct a research project in Denmark. An approval from an REC in the researcher's own country does not give the researcher authorization to perform research activities in Denmark.

- Yes
- No
- Not sure or other

- b. Would it be lawful for the researcher to do so if the

research were approved by an IRB/REC in the researcher's own country, but was not submitted for approval in your country? [Yes/No]

- Yes
- No
- Not sure or other

- c. Would the external researcher be required to have a collaborator in your country? [Yes/No]

- Yes
- No
- Not sure or other

It is not a requirement according to the *Act on Research Ethics Review of Health Research Projects*, but in practice it is often necessary to collaborate with a researcher in Denmark; e.g. to get access to biobank samples.

- d. Would it matter whether the external researcher is based at a commercial, governmental, or academic entity? [Yes/No]

- Yes
- No
- Not sure or other

**5. As far as you know, what are the perceived benefits and risks that could occur if a researcher from another country conducted IRB/REC-approved genomic research on samples or data obtained from your country? Please consider the perspectives of the public, research participants, socially-defined groups (e.g., indigenous or minority populations), researchers, and other professional or government entities.**

It is my impression that the general public and most politicians are skeptical towards transfer of tissue samples for genetic analyses in other countries. E.g. in the *Danish National Strategy for Personalised Medicine* it is specifically stated that genetic analyses should be performed in the public sector and the vision is to keep

all analyses on Danish ground. In contrast, the researchers profit from international collaboration, and a vast number of tissue samples have been subject to NGS analyses at research institutions or companies abroad. To my knowledge, there has not been discussions regarding indigenous populations (although we have an indigenous population in Greenland).

## Part II — General Questions

- 6. Does your country have biohazard committees, data protection boards, export permit authorities, or other entities that regulate the exporting of biospecimens or the transferring of data across borders for research? If so, do these requirements apply to individual citizens as well as research and medical institutions?**

The *Danish Data Protection Act* supplements the general regulation in the EU *General Data Protection Regulation* (GDPR). This Act applies to processing of tissue samples, and the Act specifically addresses transfer of tissue samples to other countries for research purposes in section 10, according to which authorization from the Danish Data Protection Authority is needed for transfer of tissue samples to other countries both within the EU and outside the EU. This provision only applies to transfer of tissue samples for scientific purposes. Transfer of data for research and transfer of tissue samples for purposes other than research purposes will follow the GDPR provisions regarding disclosure of data to other countries within or outside the EU.

- 7. Does your country have laws, policies, or guidelines dealing with genetic or genomic research or genetic or genomic privacy that would apply to international DTP research? Do your national laws on these issues apply outside of your country when residents or citi-**

### **zens of your country enroll in a DTP study conducted abroad?**

The National Committee for Health Research Ethics has adopted guidelines<sup>3</sup> for genetic research which will apply to international DTP taking place in Denmark (and thus under the jurisdiction of Danish legislation). These guidelines do not apply if Danish residents are enrolled in a DTP study conducted abroad.

- 8. Does your country have laws, policies, guidelines, or cultural expectations regarding the return of individual or aggregate research results? [Multiple choice]**
- a. The law requires the return of individual results unless the participant expressly declines to have results returned**

The Ministry of Health has issued an Executive Order on Information and Consent to Participants in Health Research Projects.<sup>4</sup> Section 15 of the Executive Order provides that the investigator must inform the research participant if important information about the health of the research participant is found. Only in the exceptional situations where the research participant has clearly opted out of receiving such findings is the investigator not permitted to inform the research participant. Such an opt-out is only valid if it is an informed opt-out based on current and relevant insight, cf. the standard of good information practice. In addition, section 16.3 of the Executive Order also makes it mandatory for researchers — if practically feasible — to inform research participants (if they consent) about the general results of the project and of the possible consequences for the individual participant. In regards to genetic research, the National Committee on Health Research Ethics has adopted special guidelines<sup>5</sup> making it mandatory to return certain secondary findings to participants, who — due to the options of having an exemption from the consent requirement — have not provided an explicit

consent for biobank research involving comprehensive genetic analyses.

- b. The law is silent on return of results; the expectation is that individual results will be returned unless the participant expressly declines to have the results returned
- c. The law is silent on return of results; aggregate results are typically returned, but individual results are not returned unless expressly stated in the research protocol
- d. I am not sure — or other answer
- 9. Does your country have laws, policies, or guidelines regarding “direct-to-consumer” genetic testing (e.g., 23andMe) and, if so, what do they provide? [Multiple choice]**

- a. Yes. Direct-to-consumer genetic testing is illegal
- b. Yes. Direct-to-consumer genetic testing is legal
- c. No. Direct-to-consumer genetic testing is not an issue** — Direct to consumer genetic testing has not attracted much concern, and it is not specifically addressed in law.
- d. I am not sure — or other answer

## Part III — Looking to the Future

- 10. How, if at all, do you anticipate that your country’s laws, policies, or guidelines will change in the next 5-10 years in response to international DTP genomic research? [Multiple choice]**

- a. I do not think they will change at all
- b. I think they will restrict international DTP research
- c. I think they will allow international DTP research
- d. I am not sure — or other answer**

It is difficult to assess. In general, Danish society is quite positive towards research and trusts both researchers and the public to protect personal data and tissue samples. However, in connection with the recent establishment of a National Genome Centre, there was extensive public debate regarding the use of genetic data for research purposes, and politicians responded to this concern and adopted stricter rules on informed consent and opt-out solutions in regards to genetic data stored in the National Genome Centre. This could indicate that future policies may be stricter than the current regulation. However, given the general positive attitude to research and international collaboration, future policies could just as well be more permissive.

#### Note

The author has no conflicts to disclose.

#### References

1. "Forsøgsperson," available at <<http://forsogsperson.dk>> (last visited July 30, 2019).
2. Act on Research Ethics Review of Health Research Projects, Consolidated Act no.1083 of September 15, 2017. The Act is available in English, available at <<http://en.nvk.dk/rules-and-guidelines/act-on-research-ethics-review-of-health-research-projects>> (last visited October 17, 2019).
3. National Committee on Health Research Ethics, "Guidelines on Genomics Research," adopted June 1, 2018, available at <<http://en.nvk.dk/~media/NVK-EN/General-guidelines/Guidelines-on-Genomics-Research.pdf>> (last visited October 17, 2019).
4. Executive Order no. 498 of May 13, 2018 on Information and Consent to Participate in Health Research Projects as well as Notification and Monitoring of Health Research Projects (Danish title: Bekendtgørelse om information og samtykke til deltagelse i sundhedsvidenskabelige forskningsprojekter samt om anmeldelse af og tilsyn med sundhedsvidenskabelige forskningsprojekter).
5. National Committee on Health Research Ethics, "Guidelines on Genomics Research," *supra* note 2.

## Estonia

### Liis Leitsalu

Researchers in genomics are exploring novel ways to interact directly with prospective participants without utilizing physicians, hospitals, or biobanks as intermediaries. Many researchers are interested in using the internet to directly recruit and enroll research participants in genomic studies by posting information online about active or proposed studies. This direct-to-participant (DTP) approach could take place under three main scenarios:

- A researcher in your country wants to conduct DTP genomic research with participants in your country
- A researcher in your country wants to conduct DTP genomic research with participants in another country
- A researcher from outside your country wants to conduct DTP genomic research with participants in your country

There is uncertainty about whether DTP recruitment, enrollment, and research are lawful under these scenarios.

#### Part I — DTP-Specific Questions

1. **As far as you know, is DTP genomic research a topic of interest to researchers or other stakeholders in your country?**  
[Multiple choice]
  - a. There has been little, if any, discussion of the issue as of now
  - b. There has been discussion among researchers, but little discussion among policy makers

- c. There has been discussion among both researchers and policy makers
- d. I am not sure — or other answer

There have been DTP research projects involving online recruitment of participants with genotype data available. However, these projects were limited to data (i.e., no sample collection), and recruitment was in Estonian, thereby limiting participation to Estonian-speaking individuals. To my knowledge, no international projects have been conducted where the regional REC would have been contacted.

2. **Assume that a researcher in your country wants to conduct DTP genomic research with participants in your country and that such research is subject to IRB/REC review. Please describe the conditions for IRB/REC approval, if it could be approved at all.**

Yes, such a DTP genomic research project could get REC approval. One would have to comply with the *Oviedo Convention on Human Rights and Biomedicine* and the basic requirements for protection of persons undergoing research.<sup>1</sup> The concerns or conditions needing to be described and fulfilled involve mainly informed consent and data handling.<sup>2</sup> Conditions that could make it more difficult to get an approval include the potential for incidental findings without a specific plan on how to provide the necessary support and counseling, or involvement of potentially vulnerable research participants when the involvement has not been justified.

3. **Assume that a researcher in your country wants to conduct DTP genomic research in another country. Please describe the conditions that must be satisfied for IRB/REC**

Liis Leitsalu, Ph.D, is a Researcher at the Estonian Genome Center, Institute of Genomics, University of Tartu, Estonia.

**approval in your country, if it could be approved at all. Would your IRB/REC also require approval from a research ethics review body in the other country?**

The same conditions apply as mentioned in the previous answer. However, the local REC would recommend contacting and applying for approval from regional RECs of countries involved to make sure their national requirements are met. In several European countries, a useful starting point would be the help-desk service offered by BBMRI-ERIC, a European research infrastructure in biobanking.<sup>3</sup> As part of this service, law, ethics, and biobank experts of various countries in Europe share expertise, help with identifying the relevant ELSI issues, and navigating through the ethical and legal landscapes of the countries concerned.

**4. Assume that a researcher from outside your country wants to conduct DTP genomic research in your country.**

- a. Would it be lawful for the researcher to do so without IRB/REC approval in either the researcher's country or your country? [Yes/No]
- Yes  
 No  
 **Not sure or other**

The Estonian *Personal Data Protection Act* mentions regional ethics committees as an alternative to the Estonian Data Protection Inspectorate that would evaluate whether the handling of personal data complies with the requirements.<sup>4</sup> However, this is in the context of research conducted on personal data without informed consent from research participants. Although the need for a multidisciplinary review of the scientific merit and ethical acceptability of a research project is listed in the *Oviedo Convention on Human Rights and Biomedicine*, it has not been specified who/where that competent

body is.<sup>5</sup> Therefore, if a research project involves informed consent, there is no specific regulatory need for REC approval in Estonia. However, while REC approval may not be required, it is part of ethical research practice.

- b. Would it be lawful for the researcher to do so if the research were approved by an IRB/REC in the researcher's own country, but was not submitted for approval in your country? [Yes/No]
- Yes  
 No  
 **Not sure or other**

The requirements are likely to differ depending on what specific countries are involved. For instance, there are only certain non-EU countries listed as having an adequate level of data protection as determined by the European Commission.<sup>6</sup>

- c. Would the external researcher be required to have a collaborator in your country? [Yes/No]
- Yes  
 **No**  
 Not sure or other

A local partnering researcher is not a requirement, but the documentation submitted for the Estonian REC approval is accepted only in Estonian. This means that including a translated research protocol and other materials in Estonian as well as other in languages planned is necessary.

- d. Would it matter whether the external researcher is based at a commercial, governmental, or academic entity? [Yes/No]
- Yes  
 **No**  
 Not sure or other

Besides a small fee that is collected for the REC application process from commercial entities, with potential for profit, it should not matter.

**5. As far as you know, what are the perceived benefits and risks that**

**could occur if a researcher from another country conducted IRB/REC-approved genomic research on samples or data obtained from your country? Please consider the perspectives of the public, research participants, socially-defined groups (e.g., indigenous or minority populations), researchers, and other professional or government entities.**

International projects have great potential in the areas where sample size is a crucial factor, such as in cases of rare diseases. The informed consent, however, needs to include all the necessary information. For instance, factors such as sample or data transfer abroad or whether research is conducted by a for-profit organization may affect participants' willingness to contribute to a project.<sup>7</sup>

From the research participants' perspective, participation in a research project that has not been REC reviewed locally may leave them more vulnerable. When the local REC is not familiar with the project, the potential to provide advice regarding participants' rights in this particular project is compromised.

**Part II — General Questions**

**6. Does your country have biohazard committees, data protection boards, export permit authorities, or other entities that regulate the exporting of biospecimens or the transferring of data across borders for research? If so, do these requirements apply to individual citizens as well as research and medical institutions?**

The national supervisory authority for processing of personal data is the Estonian Data Protection Inspectorate that, among other roles, acts as a commissioner and preliminary court; an auditor and a licenser; and a law enforcement agency.<sup>8</sup>



The *Estonian Human Genes Research Act* regulates the sample transfer of population biobank participants, which includes over 150,000 individuals' samples or 15% of the adult population.<sup>9</sup> As per HGRA, sample transfer abroad must be approved by the senate of the University of Tartu. Before March 15, 2019, approval from the Government of Estonia was required.

**7. Does your country have laws, policies, or guidelines dealing with genetic or genomic research or genetic or genomic privacy that would apply to international DTP research? Do your national laws on these issues apply outside of your country when residents or citizens of your country enroll in a DTP study conducted abroad?**

Regarding protection of persons undergoing research, one would have to consider the *Oviedo Convention on Human Rights and Biomedicine*.<sup>10</sup> Regarding personal data handling of Europeans, the *General Data Protection Regulation* needs to be considered.<sup>11</sup>

**8. Does your country have laws, policies, guidelines, or cultural expectations regarding the return of individual or aggregate research results? [Multiple choice]**

- The law requires the return of individual results unless the participant expressly declines to have results returned
- The law is silent on return of results; the expectation is that individual results will be returned unless the participant expressly declines to have the results returned
- The law is silent on return of results; aggregate results are typically returned, but individual results are not returned

unless expressly stated in the research protocol

**d. I am not sure — or other answer**

The cultural expectations are in favor of receiving genetic test results. Surveys carried out repeatedly have shown that approximately 75% of the adult population is interested in genetic testing in general.<sup>12</sup>

According to the Estonian HGRA, population biobank participants have the right to know, as well as the right not to know what data the population biobank has collected.<sup>13</sup> However, besides mentioning the right to counseling, it is not specified how participants should receive results or what type of results. Return of results has currently been offered on a project basis.<sup>14</sup> Additionally, the GDPR Article 20 covers the right to data portability.<sup>15</sup> In the context of genetic research, it would mean that the research participants providing samples for research also have the right to obtain raw genetic data generated.

**9. Does your country have laws, policies, or guidelines regarding “direct-to-consumer” genetic testing (e.g., 23andMe) and, if so, what do they provide? [Multiple choice]**

- Yes. Direct-to-consumer genetic testing is illegal
- Yes. Direct-to-consumer genetic testing is legal
- No. Direct-to-consumer genetic testing is not an issue

**d. I am not sure — or other answer**

The Estonian Health Board, the competent authority in the field of medical devices in Estonia refers to genetic testing as in vitro medical devices.<sup>16</sup> The Estonian legislation regulating medical devices mentions the need for referral and genetic counseling when considering genetic testing.<sup>17</sup> Additionally, the Estonian HGRA mentions genetic testing, but not in the sense as the clinical genetic testing

referred to by the *Estonian Medical Devices Act*. Rather, the HGRA refers to genetic research in the context of the Estonian population biobank and involving the data and samples of biobank participants specifically.<sup>18</sup> The lack of regulations and need for guidelines has been raised.<sup>19</sup> As of now, however, there are no specific regulations or guidelines on direct-to-consumer genetic testing.

**Part III — Looking to the Future**

**10. How, if at all, do you anticipate that your country's laws, policies, or guidelines will change in the next 5-10 years in response to international DTP genomic research? [Multiple choice]**

- I do not think they will change at all
- I think they will restrict international DTP research
- I think they will allow international DTP research
- I am not sure — or other answer

It seems unlikely that the regulations will change in the near future considering the recent European data protection reform and new version of the Estonian *Data Protection Regulation* that went into force in January 2019.<sup>20</sup>

**Note**

The author has no conflicts to disclose.

**References**

- Convention for the Protection of Human Rights and Dignity of the Human Being with regard to the Application of Biology and Medicine: Convention on Human Rights and Biomedicine, Apr. 4, 1997, C.E.T.S. No. 164; “Inimõiguste Ja Biomeditsiini Konventsioon: Inimõiguste Ja Inimväärikuse Kaitse Bioloogia ja Arstiteaduse Rakendamisel,” *Riigi Teat*, 1997, available at <<https://www.riigiteataja.ee/akt/78570>> (last visited October 22, 2019).
- Tartu Ülikooli Inimuuringute Eetika Komitee, *Tartu Ülikool*, available at <<https://www.ut.ee/et/teadus/eetikakomitee>> (last visited October 22, 2019).
- BBMRI-ERIC, *ELSI Helpdesk*, available at <<http://www.bbMRI-eric.eu/>>

- BBMRI-ERIC/elsi-helpdesk/> (last visited October 22, 2019).
4. Personal Data Protection Act, *Riigi Teat*, 2018, available at <<https://www.riigiteataja.ee/en/eli/523012019001/consolide>> (last visited October 22, 2019).
  5. Convention for the Protection of Human Rights and Dignity of the Human Being with Regard to the Application of Biology and Medicine: Convention on Human Rights and Biomedicine, Apr. 4, 1997, C.E.T.S. No. 164; “Inimõiguste Ja Biomeditsiini Konventsioon: Inimõiguste Ja Inimväärkuse Kaitse Biologia Ja Arstiteaduse rakendamisel,” *Riigi Teat*, 1997, available at <<https://www.riigiteataja.ee/akt/78570>> (last visited October 22, 2019).
  6. “Adequacy Decisions: How the EU Determines if a Non-EU Country has an Adequate Level of Data Protection,” *Eur. Comm*, available at <[https://ec.europa.eu/info/law/law-topic/data-protection/international-dimension-data-protection/adequacy-decisions\\_en](https://ec.europa.eu/info/law/law-topic/data-protection/international-dimension-data-protection/adequacy-decisions_en)> (last visited October 22, 2019).
  7. S.B. Trinidad, S.M. Fullerton, Bares JM, et al., “Genomic Research and Wide Data Sharing: Views of Prospective Participants,” *Genetics in Medicine* 12, no. 8 (2010): 486-495, at 486.
  8. Estonian Data Protection Inspectorate, available at: <https://www.aki.ee/en/inspectorate>.
  9. Inimgeeniuringute seadus. *Riigi Teat*, available at <<https://www.riigiteataja.ee/akt/72581?leiaKehtiv>> (last visited October 22, 2019); Human Genes Research Act, *Riigi Teat*, available at <<https://www.riigiteataja.ee/en/eli/531102013003/consolide>> (last visited October 22, 2019).
  10. Convention for the Protection of Human Rights and Dignity of the Human Being with regard to the Application of Biology and Medicine: Convention on Human Rights and Biomedicine, Apr. 4, 1997, C.E.T.S. No. 164.
  11. Regulation (EU) 2016/679 of the European Parliament and of the Council of 27 April 2016 on the Protection of Natural Persons with Regard to the Processing of Personal Data and on the Free Movement of Such Data, and Repealing Directive 95/46/EC (General Data Protection Regulation), 2016 O.J. (L 119), 1.
  12. L. Leitsalu, “Communicating Genomic Research Results to Population-Based Biobank Participants,” PhD Dissertation, University of Tartu, 2016.
  13. Human Genes Research Act, *Riigi Teat*, available at <<https://www.riigiteataja.ee/en/eli/531102013003/consolide>> (last visited October 22, 2019).
  14. L. Leitsalu, H. Alavere, S. Jacquemont, et al., “Reporting Incidental Findings of Genomic Disorder-Associated Copy Number Variants to Unselected Biobank Participants,” *Personalized Medicine* 13, no. 4 (2016): 303-314; M. Alver, M. Palover, A. Saar, et al., “Recall by Geno-
- type and Cascade Screening for Familial Hypercholesterolemia in a Population-Based Biobank from Estonia,” *Genetics in Medicine* 21, no. 5 (2019): 1173-1180.
15. Regulation (EU) 2016/679 of the European Parliament and of the Council of 27 April 2016 on the Protection of Natural Persons with Regard to the Processing of Personal Data and on the Free Movement of Such Data, and Repealing Directive 95/46/EC (General Data Protection Regulation), 2016 O.J. (L 119), 1.
  16. Geenitesti, *Terviseamet*, available at <<https://www.terviseamet.ee/et/meditsiini-seadmed/meditsiiniseadmed/kodanikule/geenitesti>> (last visited October 22, 2019).
  17. Medical Devices Act, *Riigi Teat*, available at <<https://www.riigiteataja.ee/en/eli/ee/509012015001/consolide/current>> (last visited October 22, 2019); Regulation (EU) 2017/746 of the European Parliament and of the Council of 5 April 2017 on In Vitro Diagnostic Medical Devices and Repealing Directive 98/79/EC and Commission Decision 2010/227/EU, 2017 O.J. (L 117), 1.
  18. Human Genes Research Act, *Riigi Teat*, available at <<https://www.riigiteataja.ee/en/eli/531102013003/consolide>> (last visited October 22, 2019).
  19. K. Pormeister, “Tarbijale Suunatud Geenitesti Eesti Oigusruumis,” *Juridica* 4 (2016): 263-270.
  20. Personal Data Protection Act, *Riigi Teat*, 2018, available at <<https://www.riigiteataja.ee/en/eli/523012019001/consolide>> (last visited October 22, 2019); Regulation (EU) 2016/679 of the European Parliament and of the Council of 27 April 2016 on the Protection of Natural Persons with Regard to the Processing of Personal Data and on the Free Movement of Such Data, and Repealing Directive 95/46/EC (General Data Protection Regulation), 2016 O.J. (L 119), 1.

## Finland

### Sirpa Soini

Researchers in genomics are exploring novel ways to interact directly with prospective participants without utilizing physicians, hospitals, or biobanks as intermediaries. Many researchers are interested in using the internet to directly recruit and enroll research participants in genomic

**Sirpa Soini, LL.M.**, is Biobank Director, Finnish Institute for Health and Welfare (THL) and Vice-Chair of Medical Research Ethics Committee, Helsinki University Hospital.

studies by posting information online about active or proposed studies. This direct-to-participant (DTP) approach could take place under three main scenarios:

- A researcher in your country wants to conduct DTP genomic research with participants in your country
- A researcher in your country wants to conduct DTP genomic research with participants in another country
- A researcher from outside your country wants to conduct DTP genomic research with participants in your country

There is uncertainty about whether DTP recruitment, enrollment, and research are lawful under these scenarios.

### Part I — DTP-Specific Questions

1. As far as you know, is DTP genomic research a topic of interest to researchers or other stakeholders in your country? [Multiple choice]
  - a. There has been little, if any, discussion of the issue as of now
  - b. There has been discussion among researchers, but little discussion among policy makers
  - c. There has been discussion among both researchers and policy makers
  - d. I am not sure — or other answer

DTP genomics research seems like a new topic in our country. DTP for other than explicitly genomic research occurs, but usually the commissioning party has a local clinical collaborator for medical research.

Nevertheless, we know that many Finns have sent their samples abroad for commercial direct-to-consumer

genetic testing (DTC-GT) and have also provided consent for future research. These overseas companies advertise their services in Finland, but their primary message does not relate to research.

**2. Assume that a researcher in your country wants to conduct DTP genomic research with participants in your country and that such research is subject to IRB/REC review. Please describe the conditions for IRB/REC approval, if it could be approved at all.**

For the purposes of this report, in my opinion, DTP genomic research may be divided into three different categories:

1. *Interventional study setup*: the participant is asked for a blood (or saliva) sample for genomic analyses to be used in medical research *not including* use of medicinal products or devices.
2. *Clinical trial*: the participant is invited for a pre-trial phase to potentially participate in a clinical trial based on his/her genomic information (certain genetic subgroups of a disease; pharmacogenetic factors; where genomic information is used as inclusion or exclusion criteria).
3. *Study setup where genetic information is already known* (case depending, confirmatory test with a new blood (or saliva sample) may be needed and then falls under no. 1). The participant has the genetic data in their possession or can allow its use from some other source. This approach may be rather limited at the moment. Interventional studies and clinical trials (1 and 2 above) which have medical research purpose must be evaluated by an ethics committee. This is stipulated by the *Medical Research Act*.<sup>1</sup>

“**Medical research**” is defined in the *Medical Research Act* as research involving *intervention in the integrity of a person, human embryo or human fetus for the purpose of increasing knowledge of health, the causes, symptoms, diagnosis, treatment and prevention of diseases or the nature of diseases in general*. In Finland, we interpret this provision so that, for instance, pure registry-based research does not fall under the *Medical Research Act*, even if the research aim is medical. Statutory ethics committees evaluate only interventional medical research protocols.

Genomics research, as such, is not currently subject to any specific regulation, but belongs to the general medical research and/or data protection legislation. As a matter of fact, laws do not take direct position on the recruitment procedure, but it must be described to the ethics committee, if it is *medical research*. Recruitment materials must be adequate and informative, and they are assessed and approved by the ethics committees.

The *Medical Research Act* §10(a) states that all clinical trials on medicinal products shall be planned, conducted, and reported on observing the principles of good clinical research practice. We have extensive EU-regulation on clinical trials on medicinal products and devices that have directly applicable legislation in the EU Member states.

The *Medical Research Act* §5 states that *medical research* may be undertaken only under the responsibility of a medical doctor or dentist with the adequate professional and scientific qualifications. If it is a question of research other than a clinical drug trial, a person other than a medical doctor or dentist may be responsible for the research, provided that the person has the professional and scientific qualifications required for the research concerned.

**3. Assume that a researcher in your country wants to conduct DTP genomic research in another country. Please describe the conditions that must be satisfied for IRB/REC**

**approval in your country, if it could be approved at all. Would your IRB/REC also require approval from a research ethics review body in the other country?**

Laws do not limit genomic research in other countries. If the research participants are recruited in the Finnish territory for “*medical research*” (see definition in point 2), but genomic analysis and/or the research are to be conducted abroad, then the standard evaluation procedure, as described in point 2, applies.

Studies abroad are not covered by the *Medical Research Act* if participants are not recruited in Finland. Based on my long experience on Finnish ethics committees, foreign protocols are rarely submitted if Finnish participants are not involved. However, researchers and clinicians engaging in studies abroad may have to submit a research permission from their own employing organization, which may then demand various information and confirmation. This is not statutory, but is rather a hospital or institution policy.

**4. Assume that a researcher from outside your country wants to conduct DTP genomic research in your country.**

- a. Would it be lawful for the researcher to do so without IRB/REC approval in either the researcher’s country or your country? [Yes/No]
  - Yes, if no intervention (other than saliva kit or existing data)**
  - No, if it is “medical research”**
  - Not sure or other

If the study is conducted in Finland, then the Finnish laws apply. The study setup defines the need for REC approval. Only “*medical research*” is subject to ethics approval (see definition in point 2). IRB approval may be part of institutional policy, but is not currently required by law.

b. Would it be lawful for the researcher to do so if the research were approved by an IRB/REC in the researcher's own country, but was not submitted for approval in your country? [Yes/No]

**Yes.** Please see my answers in point 2; the study setup defines the need for REC approval. Only "medical research" is subject to ethics approval, so for other research it is lawful.

**No.** If "medical research" is conducted in Finland, then local REC is needed. Currently we do not apply reciprocity or acknowledge other REC approvals.

Not sure or other

c. Would the external researcher be required to have a collaborator in your country? [Yes/No]

**Yes,** if there is health intervention

No

**Not sure or other**

The answer to this question depends on the research setup. Under the *Medical Research Act §5*, medical research must be overseen by a medical doctor or dentist with the adequate professional and scientific qualifications. Medical doctors must be licensed in Finland by the National Supervisory Authority for Welfare and Health. If it is a question of research other than a clinical drug trial, a person other than a medical doctor or dentist may be responsible for the research, provided that the person has the professional and scientific qualifications required for the research concerned. A collaborator is thus needed for *medical research*. See definition in point 2.

For other than *medical research* a collaborator is not legally required.

d. Would it matter whether the external researcher is based at a commercial, governmental, or academic entity? [Yes/No]

Yes

**No,** as long as the research protocol falls within the definition of scientific research as defined by Recital 159 of the GDPR (EU *General Data Protection Regulation*) (see appendix).<sup>2</sup>

Not sure or other

**5. As far as you know, what are the perceived benefits and risks that could occur if a researcher from another country conducted IRB/REC-approved genomic research on samples or data obtained from your country? Please consider the perspectives of the public, research participants, socially-defined groups (e.g., indigenous or minority populations), researchers, and other professional or government entities.**

#### *Perspectives*

##### **PUBLIC**

Finland is generally very encouraging of health research. Finland wants to attract international researchers; also for genomic studies, by providing a high quality infrastructure for research. We have lots of experience with international research collaboration and data sharing going back decades. Finland, of course, hopes that research will also benefit our country. Therefore, there has recently been public discussion about the benefits of international research and public questions like "are we selling our data to big global companies." It is thus important to be as open and transparent as possible to maintain the trust of the people.

If there would suddenly be interests from abroad and direct contacting Finnish people without any involvement of Finnish researchers or institutions, the public perception might be very different. In my opinion, the nature of the research, beneficiaries, and researcher or commissioning party affect the public perception and acceptability.

##### **RESEARCH PARTICIPANTS**

Finnish people are relatively highly educated and eager to participate in research particularly if they suffer from certain health conditions. Finns are also very willing to send their samples to US-based DTC-GT (like 23andMe) and ancestry companies, and they share their ancestry data in social media. I would anticipate that a research group with an appealing plan would be able to draw participants. Communication with patient organizations might be a good way to develop recruitment procedures and good practices.

##### **SOCIALLY-DEFINED GROUPS**

To my knowledge, genomics research with socially-defined groups has not raised any special concerns in Finland. This is maybe because our society is based on the Nordic welfare model and we have universal access to health and social services. Discrimination based on genomic information is not a big issue as such. Actually, we would need more genomic studies for new ethnic groups immigrating to Finland to be able to better understand and treat their genomic diseases. The research agenda should benefit these groups to be acceptable for instance by increasing new knowledge to be used in health care. Here again, collaboration with local experts might be useful as a socially acceptable way to plan genomic studies.

##### **RESEARCHERS**

Finnish researchers are very global and willing to collaborate with foreign researchers. Clinicians and researchers might find it peculiar if their patients were asked to participate in genomic studies without collaboration and local expertise. It would be good to develop good practices to ensure that results are published and recognized to benefit society and the healthcare system.

##### **OTHER PROFESSIONAL ENTITIES**

As long as the patients are involved, the Finnish Medical Society and societies of various medical specialties are likely to be interested in recruiting patients to DTP studies.

## GOVERNMENT ENTITIES

Even though the use of genomic information has not been too sensitive an issue in Finland, the government wants to have more control to prevent unmanageable dissemination of Finnish genomic data globally. It is currently drafting new legislation relevant to biobanks, secondary use of health data, use of genomic data, and medical research. The aim of the new legislation is to enable research while protecting privacy and increasing transparency. However, DTP that is not regarded as *medical research* is likely to remain outside their scope (for definition, see point 2).

## Part II — General Questions

**6. Does your country have biohazard committees, data protection boards, export permit authorities, or other entities that regulate the exporting of biospecimens or the transferring of data across borders for research? If so, do these requirements apply to individual citizens as well as research and medical institutions?**

We do not have specific committees to monitor ordinary sample transport (import or export) for normal research purposes. Instead, transport of biohazardous samples<sup>3</sup> or tissues, cells and blood meant for *in vivo* human use (transplantation or procedures in licensed tissue establishments) are covered by special legislation and procedures.<sup>4</sup>

As for cross-border data transfer, Finland is an EU Member State and must follow EU legislation, such as GDPR (*General Data Protection Regulation*).<sup>5</sup> GDPR Chapter V, articles 44 — 50, set the legal grounds for non-EU-data transfers. Data transfers within the EU internal market do not usually require specific safeguards or consultation with the authorities. The same applies also for non-EU-transfers, if the legal grounds of the GDPR are met. The *Finnish Data Protection Act (1050/2018)* complements the GDPR and establishes and

mandates the national data protection authority.

**7. Does your country have laws, policies, or guidelines dealing with genetic or genomic research or genetic or genomic privacy that would apply to international DTP research? Do your national laws on these issues apply outside of your country when residents or citizens of your country enroll in a DTP study conducted abroad?**

Current laws do not limit genomic research in other countries, but for example, GDPR imposes requirements for data processing and data transfers to protect the rights of research participants. GDPR is applied as long as personal data of EU citizens are processed even outside the EU if the data controller collects the data in the EU. Finnish laws do not apply abroad, and people are at liberty to give consent for DTP research as long as it is not regarded as “medical research” (see point 2 above).

**8. Does your country have laws, policies, guidelines, or cultural expectations regarding the return of individual or aggregate research results? [Multiple choice]**

- The law requires the return of individual results unless the participant expressly declines to have results returned
- The law is silent on return of results; the expectation is that individual results will be returned unless the participant expressly declines to have the results returned
- The law is silent on return of results; aggregate results are typically returned, but individual results are not returned unless expressly stated in the research protocol
- I am not sure — **or other answer**

Only the *Finnish Biobank Act §39*<sup>6</sup> contains legal rules on returning results and is applied if the sample donor asks for health-related information determined from his or her sample. There is confusion as how to interpret this paragraph and if it covers raw genomic data. In addition, the sample donors may express their wish to be informed about clinically actionable research findings in the consent process. The biobank community is currently on its own initiative piloting ways and the feasibility of returning certain well-established genomic information to sample donors. There are still open questions to tackle, such as validation of results and need for counseling, integration of health care, and costs. The new Genome Centre is expected to develop procedures and give guidance in this matter.

**9. Does your country have laws, policies, or guidelines regarding “direct-to-consumer” genetic testing (e.g., 23andMe) and, if so, what do they provide? [Multiple choice]**

- Yes. Direct-to-consumer genetic testing is illegal
- Yes. Direct-to-consumer genetic testing is legal**
- No. Direct-to-consumer genetic testing is not an issue
- I am not sure — or other answer

Currently, direct-to-consumer genetic testing is legal in Finland.<sup>7</sup> The authorities are not able to establish whether these companies are part of the private health-care provision or not, and should as such be licensed and authorized based on the *Act on Private Health Care Providers (152/1990*, not translated in English). Mostly DTC-GT-companies are seen to operate outside of the regulatory healthcare systems, and belong instead to the realms of regulation for consumer goods and services.

DTC-tests have been subject to EU IVD-directive (98/79/EC), to be replaced by a new EU IVD-regulation that becomes applicable on May 26,

2022.<sup>8</sup> The impact on DTC-activities remains to be seen.

Thus, we do not currently have laws or policies, but the new Genome Centre (see below) is expected to give guidance, *inter alia*, on the quality and reliability of the services of DTC-companies.

### Part III – Looking to the Future

#### 10. How, if at all, do you anticipate that your country's laws, policies, or guidelines will change in the next 5-10 years in response to international DTP genomic research? [Multiple choice]

- a. I do not think they will change at all
- b. I think they will restrict international DTP research
- c. I think they will allow international DTP research

#### d. I am not sure — or other answer

Finland is currently drafting legislation to establish a Genome Centre and to regulate the use of genomic information, national genomics reference data base and genetic tests.<sup>9</sup> The aim is to enhance the use of genomic data in health care, while also to protect privacy of people living in Finland. There have been concerns about the uncontrollable dissemination of people's genomic data because they do not understand what they consent to and where the data ends up. However, this new legislation is not likely to limit the autonomy of people to participate in DTP research, but rather give guidance. The real content of the draft law is uncertain. It was submitted for public consultation in May 2019. The next version is expected first in the Spring 2019 due to the magnitude of critical statements that require more attention.

#### Note

The author has no conflicts to disclose.

#### Appendix

The *Medical Research Act* §10(d) sets the following conditions to be

assessed by an ethics committee for a clinical trial on medicinal products, but mostly the same is applied to other medical research as well:

1. Appropriateness of the trial and its planning;
2. Appropriateness of the assessment of its benefit and risks and justifiability of any conclusions regarding them;
3. The research plan;
4. Suitability of the researcher and staff;
5. The researcher's information package containing clinical and other information on the medicinal product or products used in the trial that is of significance when testing those medicinal products on people;
6. Quality of the premises and equipment to be used in the trial;
7. Sufficiency and coverage of the written information given to obtain the informed written consent and the procedure for obtaining the consent, and grounds for trials to be carried out on persons not able to give their consent;
8. The grounds on which damages possibly caused by the trial are compensated and insurance policies and other arrangements for covering a compensation payable on account of damages or death;
9. Amount of the fee or remuneration to be paid to researchers and research subjects or the criteria for determining it and procedures possibly related to the matter, as well as the main content of the agreement to be concluded between the commissioning party and the research site; and
10. Detailed procedures relating to choosing the research subjects.

Recital 159 of the GDPR (EU *General Data Protection Regulation*):

Where personal data are processed for scientific research purposes, this Regulation should also apply to that processing. For the purposes of this Regulation, the processing of personal data for scientific research purposes should be interpreted in a broad manner including for example technological development and demonstration, fundamental research, applied research and privately funded research. In addition, it should take into account the Union's objective under Article 179(1) TFEU of achieving a European Research Area. Scientific research purposes should also include studies conducted in the public interest in the area of public health. To meet the specificities of processing personal data for scientific research purposes, specific conditions should apply in particular as regards the publication or otherwise disclosure of personal data in the context of scientific research purposes. If the result of scientific research in particular in the health context gives reason for further measures in the interest of the data subject, the general rules of this Regulation should apply in view of those measures.

#### The Genome Centre

The Genome Centre would serve as a national authority for genomics and provide guidance on the genetic testing services. The *Genome Act* would require that raw data resulting from genomic studies (either from clinical genetics or biobanks) be stored in the Genome Centre. This Act is expected to pass through in the Parliament in the fall 2019 and come into force as of January 1, 2020.

The *Genome Act* may have some impact on doing international genomic research in Finland. For instance, researchers may be obliged to follow certain quality criteria and submit genomic raw data with supporting

metadata after the end of their research to the Genome Centre. It is yet unclear to which kind of research the new *Genome Act* will be applied. The obligation to store the data in the Genome Centre does not affect the ownership of the data.

The researchers may use the national genomic and other data bases for research. The new Act on the secondary use of social and health data (552/2019, in force as of May 1, 2019, not translated yet in English) will provide a single platform to access Finnish data in the future. One central idea is that the sensitive data of the Finns will not leave the country, but the access to data is offered via a data secure remote desktop.

The *Medical Research Act* (488/1999) is twenty years old and was drafted to reflect the needs at the time to establish RECs and other procedures and criteria for clinical research with intervention. The *Medical Research Act* will be revised in 2019. It will be split in two separate acts, of which one focuses on clinical drug trials, and the other for other medical research. Based on the drafts, the basic notion that medical research concern interventional studies seems to remain in the new act as well.

#### References

1. Medical Research Act (488/1999), available at <[https://www.finlex.fi/fi/laki/kaannokset/1999/en19990488\\_20100794.pdf](https://www.finlex.fi/fi/laki/kaannokset/1999/en19990488_20100794.pdf)> (last visited October 22, 2019).
2. Regulation (EU) 2016/679 of the European Parliament and of the Council of April 27, 2016 on the protection of natural persons with regard to the processing of personal data and on the free movement of such data, and repealing Directive 95/46/EC (General Data Protection Regulation), 2016 O.J. (L 119) 1.
3. Act on Transport on Dangerous Goods (719/1994), available at <[https://www.finlex.fi/fi/laki/kaannokset/1994/en19940719\\_20090388.pdf](https://www.finlex.fi/fi/laki/kaannokset/1994/en19940719_20090388.pdf)> (last visited October 22, 2019).
4. Act of the Medical Use of Human Organs and Tissues (101/2001), available at <[https://www.finlex.fi/fi/laki/kaannokset/2001/en20010101\\_20130277.pdf](https://www.finlex.fi/fi/laki/kaannokset/2001/en20010101_20130277.pdf)> (last visited October 22, 2019).
5. Regulation (EU) 2016/679, of the European Parliament and of the Council of April 27, 2016 on the protection of natural persons with regard to the processing of personal data and on the free movement of such data, and repealing

- Directive 95/46/EC (General Data Protection Regulation), 2016 O.J. (L 119) 1.
6. Biobank Act (688/2012), available at <[https://www.finlex.fi/fi/laki/kaannokset/2012/en20120688\\_20120688.pdf](https://www.finlex.fi/fi/laki/kaannokset/2012/en20120688_20120688.pdf)> (last visited October 22, 2019).
7. L. Kalokairinou, H.C. Howard, S. Slokenberga, et al., "Legislation of Direct-to-Consumer Genetic Testing in Europe: A Fragmented Regulatory Landscape," *Journal of Community Genetics* 9, no. 2 (2018): 117-132, at 117.
8. Regulation (EU) 2017/746 of the European Parliament and of the Council of April 5, 2017 on in vitro diagnostic medical devices and repealing Directive 98/79/EC and Commission Decision 2010/227/EU, 2017 O.J. (L 117), 1.
9. Ministry of Social Affairs and Health, *Genomikeskus Genome Center*, available at <<http://www.genomikeskus.fi/en/frontpage.html>> (last visited August 2, 2019).

## France

*Emmanuelle Rial-Sebbag*

Researchers in genomics are exploring novel ways to interact directly with prospective participants without utilizing physicians, hospitals, or biobanks as intermediaries. Many researchers are interested in using the internet to directly recruit and enroll research participants in genomic studies by posting information online about active or proposed studies. This direct-to-participant (DTP) approach could take place under three main scenarios:

- A researcher in your country wants to conduct DTP genomic research with participants in your country
- A researcher in your country wants to conduct DTP genomic research with participants in another country
- A researcher from outside your country wants to conduct DTP genomic research with participants in your country

**Emmanuelle Rial-Sebbag, Ph.D.**, is Director of Research, INSERM, Université de Toulouse – Université Paul Sabatier – Toulouse III.

There is uncertainty about whether DTP recruitment, enrollment, and research are lawful under these scenarios.

### Part I — DTP-Specific Questions

1. **As far as you know, is DTP genomic research a topic of interest to researchers or other stakeholders in your country? [Multiple choice]**
  - a. There has been little, if any, discussion of the issue as of now
  - b. There has been discussion among researchers, but little discussion among policy makers
  - c. There has been discussion among both researchers and policy makers
  - d. I am not sure — or other answer
2. **Assume that a researcher in your country wants to conduct DTP genomic research with participants in your country and that such research is subject to IRB/REC review. Please describe the conditions for IRB/REC approval, if it could be approved at all.**

According to French law, it is lawful to recruit for DTP genomic research in France. The *Public Health Code* (PHC) implementing the *Law relating to Research implicating human persons* outlines the conditions for IRB approval which are part of the common procedure (no specific provisions regarding DTP) with a mandatory prior approval of the Comité de Protection des Personnes (CPP).<sup>1</sup> The CPP, which is a regional body, will be in charge of assessing the respect of the conditions posed by law with regards to the methodology of the research and the informed consent documentation. The researcher will also have to conform to a meth-

odology of reference elaborated by the French Data Protection Authority to process the genetic data.<sup>2</sup> Genetic information collection for research falls under the scope of these methodologies except those whose primary or secondary purpose is the identification or re-identification of persons by their genetic characteristics.

**3. Assume that a researcher in your country wants to conduct DTP genomic research in another country. Please describe the conditions that must be satisfied for IRB/REC approval in your country, if it could be approved at all. Would your IRB/REC also require approval from a research ethics review body in the other country?**

If participants are recruited and are contributing from abroad, French law does not apply. In that case, the French researcher will be part of an international protocol and will be covered under the required approval from the country of origin of the participants.

If a French researcher is recruiting abroad and imports biological material for the needs of their own research, the recruitment phase will not need specific IRB/REC approval. However, an importation authorization will be needed (PHC, article L 1245-5-1) from the ANSM (National Authority for the Safety of Drugs and Health Products) where consent from foreign participants will be needed and will be verified. Additionally, the collection of biological samples will have to be declared to the French Ministry of Research comply with the legal requirements for using biological samples in France (PHC article L 1243.3), explaining the research program and with all necessary information related to validity of the informed consent.

**4. Assume that a researcher from outside your country wants to conduct DTP genomic research in your country.**

- a. Would it be lawful for the researcher to do so without IRB/REC approval in either the researcher's country or your country? [Yes/No]  
 Yes  
 No  
 **Not sure or other**

To date, this participation is not covered by law if there is no French investigator involved in the research. We can assume that this participation would be voluntary and would not require an approval from a French ethics committee as the law is of territorial application. In the latter case, if the samples and/or the data are collected in France, see answer 2.

- b. Would it be lawful for the researcher to do so if the research were approved by an IRB/REC in the researcher's own country, but was not submitted for approval in your country? [Yes/No]  
 Yes  
 No  
 **Not sure or other**

- c. Would the external researcher be required to have a collaborator in your country? [Yes/No]  
 Yes  
 No  
 **Not sure or other**

This would not be an obligation but a condition to conduct the study. The French researcher would only be able to contribute if he/she recruits and the sample collection is in France.

- d. Would it matter whether the external researcher is based at a commercial, governmental, or academic entity? [Yes/No]  
 Yes  
 No  
 **Not sure or other**

**5. As far as you know, what are the perceived benefits and risks that could occur if a researcher from**

**another country conducted IRB/REC-approved genomic research on samples or data obtained from your country? Please consider the perspectives of the public, research participants, socially-defined groups (e.g., indigenous or minority populations), researchers, and other professional or government entities.**

To date, these issues are not clearly debated in France. From a legal perspective, the answers on the risks and the ways they should be assessed are based on the application of French law in different situations and notably whether interventions on human participants will be conducted on French territory. From a broader perspective, the inclusion of participants from different countries should be necessary for the scientific objectives of particular research (rare diseases or large genetic protocols) but they should always respect the principles of non-discrimination and non-stigmatization.

**Part II – General Questions**

**6. Does your country have biohazard committees, data protection boards, export permit authorities, or other entities that regulate the exporting of biospecimens or the transferring of data across borders for research? If so, do these requirements apply to individual citizens as well as research and medical institutions?**

France has a stringent legal framework for conducting genetic research to be approved by the CPP when research involves humans, so to say interventional research, research with minimal risks and non-interventional research and the ANSM (only for interventional research). For genetic data, the CNIL (through the methodology of reference) is competent. This framework applies only when the recruitment and interventions are



performed in France. To date, only protocols for research on human persons (as defined by the PHC article L1121-1) are covered under French law. As of now, the free participation of individuals in research projects is outside the scope of the law and has not been yet addressed by our institutions.

**7. Does your country have laws, policies, or guidelines dealing with genetic or genomic research or genetic or genomic privacy that would apply to international DTP research? Do your national laws on these issues apply outside of your country when residents or citizens of your country enroll in a DTP study conducted abroad?**

Yes, genomic research is strictly regulated under French law, first concerning the use of genetic testing in the medical setting (diagnosis, treatment, prevention). The law also applies for research conducted under the *Research Implying Human Persons Act* included in the HPC. Notably, French law requires written informed consent either for medical or research activities when genetic information is sought (*Civil Code* article 16-10 and article PHC article L1122-1-1). However, an opt-out system is permitted when biological samples already gathered for other purposes are used for genetic research (PHC Article L1131-1-1). This framework is only applied when the research is performed in the French territories and does not apply to research to be performed abroad. As for genetic data, the law on informatics and freedom (article 63) also requires informed consent in writing that includes the same exception. The French law on informatics and freedom has possible extra-territoriality in its control over data processing as stated in the *General Data Protection Regulation*, but it is still unclear if the requirement of article 63 could be part of this control as it is a French exception.

**8. Does your country have laws, policies, guidelines, or cultural**

**expectations regarding the return of individual or aggregate research results? [Multiple choice]**

- The law requires the return of individual results unless the participant expressly declines to have results returned
- The law is silent on return of results; the expectation is that individual results will be returned unless the participant expressly declines to have the results returned
- The law is silent on return of results; aggregate results are typically returned, but individual results are not returned unless expressly stated in the research protocol
- I am not sure — **or other answer**

The law requires the return of individual results unless the participant expressly declines to have results returned (PHC, Article L1122-1).

Global results can also be returned (PHC, Article L1122-1).

**9. Does your country have laws, policies, or guidelines regarding “direct-to-consumer” genetic testing (e.g., 23andMe) and, if so, what do they provide? [Multiple choice]**

- Yes. Direct-to-consumer genetic testing is illegal**
- Yes. Direct-to-consumer genetic testing is legal
- No. Direct-to-consumer genetic testing is not an issue
- I am not sure — or other answer

Under the *Penal Code* it is illegal to personally seek genetic information (when it is done directly by an individual and out of health or the research legal framework): article 226-28-1: In fact, for a person, to request the examination of his genetic characteristics or those of a third party or the identification of a person by his

genetic fingerprints outside the conditions provided for by law is punishable by a fine of 3 750 €.

**Part III — Looking to the Future**

**10. How, if at all, do you anticipate that your country’s laws, policies, or guidelines will change in the next 5-10 years in response to international DTP genomic research? [Multiple choice]**

- I do not think they will change at all
- I think they will restrict international DTP research
- I think they will allow international DTP research
- I am not sure — or other answer**

This issue should first be discussed at the French national level as it is not currently the case. Direct-to-participant genomic research will increase in the next few years, and our institutions will have to make decisions and adapt our legal framework. I think France will act under the umbrella of the EU law as for the genomic data but will be much more restrictive as for the use of human specimens. Thus, the consequence could be a lack of harmonization between use of data and use of biospecimens.

**Note**

The author has no conflicts to disclose.

**References**

- Code de la santé publique [Public Health Code] art L 1121-1 (Fr.).
- Commission nationale de l’informatique et des libertés (CNIL), “Recherches dans le Domaine de la Santé : La CNIL Adopte de Nouvelles Mesures de Simplification,” *available at* <<https://www.cnil.fr/fr/recherches-dans-le-domaine-de-la-sante-la-cnil-adopte-de-nouvelles-mesures-de-simplification>> (last visited July 29, 2019).

## Germany

Nils Hoppe

Researchers in genomics are exploring novel ways to interact directly with prospective participants without utilizing physicians, hospitals, or biobanks as intermediaries. Many researchers are interested in using the internet to directly recruit and enroll research participants in genomic studies by posting information online about active or proposed studies. This direct-to-participant (DTP) approach could take place under three main scenarios:

- A researcher in your country wants to conduct DTP genomic research with participants in your country
- A researcher in your country wants to conduct DTP genomic research with participants in another country
- A researcher from outside your country wants to conduct DTP genomic research with participants in your country

There is uncertainty about whether DTP recruitment, enrollment, and research are lawful under these scenarios.

### Part I — DTP-Specific Questions

**1. As far as you know, is DTP genomic research a topic of interest to researchers or other stakeholders in your country?**  
[Multiple choice]

- a. There has been little, if any, discussion of the issue as of now
- b. There has been discussion among researchers, but little discussion among policy makers

**c. There has been discussion among both researchers and policy makers**

d. I am not sure — or other answer

There is a lively debate among stakeholders, driven in part by the very narrow scope of the law on genetic diagnosis, but also because of the increasing availability (and affordability) of DTC genetic testing offerings online. The FDA prohibition imposed on 23andMe in 2013 has catalyzed this debate. The German parliament (Bundestag) regularly seeks expert scientific and legal/ethical opinion on this issue through the mechanism of technology impact assessments, the last one being from April 4, 2019 on prenatal diagnostics (19/9059) which outlines increasing demands to find an EU approach to direct-to-consumer offerings in the sphere of genetics and genomics.

There has been a significant increase in stakeholder debate about commercial DTP genomic research and related issues in Germany since the *German Genetic Diagnostics Act* entered into force on 1 February 2010.<sup>1</sup> The *Act* puts restrictions on the personnel who are entitled to perform genetic tests on individuals and imposes further restrictions on the use of genetic and genomic analyses in the context of insurance provision and in employment. Prior to entering into force, there was widespread public consultancy on the issues covered by the *Act*. The stringent provisions of the GenDG encompass all genetic and genomic analyses for medical purposes but are expressly not applicable where genetic and genomic analyses are performed for research purposes only.

**2. Assume that a researcher in your country wants to conduct DTP genomic research with participants in your country and that such research is sub-**

**ject to IRB/REC review. Please describe the conditions for IRB/REC approval, if it could be approved at all.**

IRB/REC approval in Germany is only required in a limited range of contexts. These are institutional, professional, and statutory in nature. This results in a wide range of different types of IRB/REC, constituted on the basis of different instruments with widely diverging normative clout. Whilst the most important 52 regional and federal IRB/REC have formed a working group to standardize protocols and processes, there is a great deal of fragmentation and the exact answer to the question depends on a number of variables.

#### *Institutional*

Where research takes place in a research university or a similar non-university establishment (e.g., Max Planck Centre), these institutions generally require their researchers to seek approval from an internal IRB/REC. This is the most common scenario for genomics and genetics research with healthy volunteers, where neither a hospital nor a physician is involved. The approval of such an internal IRB/REC is usually a prerequisite stipulated by third party funders of research, with funds only being released upon provision of the approval.

#### *Professional*

If the researcher is a registered medical doctor (or a psychiatrist, dentist, or other regulated medical professional), they are required to seek approval from their regional medical council's IRB/REC (§ 15 MBO (German General Medical Council's professional standards instrument; binding for all members of the profession)). This is the case even if the research does not take place in a medical setting (the condition attaches purely to the professional status of the person).

Nils Hoppe, LL.B., Dr. iur., is Professor for Ethics and Law in the Life Sciences and Director of the Centre for Ethics and Law in the Life Sciences, as well as Dean of Research at the Faculty for Humanities and Social Sciences at Leibniz University in Hannover, Germany.

*Statutory*

Where the research aims at the development of a pharmaceutical product (§40 and §42 AMG (*Medicinal Products Act*))<sup>2</sup> or a medical device (§20 and §22 MPG (*Medical Devices Act*)),<sup>3</sup> the involvement of an IRB/REC is required by law. The relevant IRB/REC is the one established in the federal state where the research is taking place, though there has been an increase in commercial provision of IRB/REC approval.

Overall, DTP genomic research would not likely be subject to IRB/REC approval.

**3. Assume that a researcher in your country wants to conduct DTP genomic research in another country. Please describe the conditions that must be satisfied for IRB/REC approval in your country, if it could be approved at all. Would your IRB/REC also require approval from a research ethics review body in the other country?**

The fragmented nature of the IRB/REC landscape in Germany outlined above is relevant to this question. In an entirely non-medical setting, where:

- the researchers are not physicians,
- the research includes no element that is *medical* to the extent that the GenDG becomes applicable,
- the research institution does not have a bylaw requirement to consult an internal IRB/REC, and
- the research is not aimed at developing a pharmaceutical product or a medical device,

the research may not have to be approved by a German IRB/REC. Where an institutional IRB/REC is relevant, the conditions will be the same as outlined above (no. 2), and it will in all likelihood seek to not make

a difference between Germany and other EU Member States as long as a comparable level of research subject protection is ensured.

**4. Assume that a researcher from outside your country wants to conduct DTP genomic research in your country.**

- Would it be lawful for the researcher to do so without IRB/REC approval in either the researcher's country or your country? [Yes/No]  
 Yes  
 No  
 Not sure or other

The permissibility of conducting this research without home IRB/REC approval is a matter for the home jurisdiction of the researcher - there is no statutory requirement in German law that home approval must be obtained. Under the conditions outlined above, there is no legal requirement to obtain IRB/REC approval in Germany either.

It is worth briefly outlining that there is more than one category of external researcher in this setting: a researcher from another EU member state, from an EEC or associated state, or from a third country. Different principles apply to each in different constellations but, in general, researchers from another member state (and where the same rules apply, also those from EEC or associated states) are not treated differently to German researchers. For the rest of the answer, I am assuming a third country researcher.

If the research involves merely recruiting participants in Germany and where the sample collection is non-invasive (just saliva), the regulatory question is reduced to an issue of data protection law. Where this is the case, there will only be a substantive legal problem if the third country is a state that is not covered by the EU-GDPR.

NB: If the research forms part of a clinical trial geographically located in Germany, there is also a statutory requirement to seek German IRB/

REC approval.<sup>5</sup> Where the research is not related to a clinical trial, and is not commercial, there is no IRB/REC that is relevant in Germany and there is no legal requirement to hold an approval from another IRB/REC.

- Would it be lawful for the researcher to do so if the research were approved by an IRB/REC in the researcher's own country, but was not submitted for approval in your country? [Yes/No]  
 Yes  
 No  
 Not sure or other

Substantially as above — where there is no domestic requirement for IRB/REC approval, the existence of a foreign approval is irrelevant as well. In essence, the home approval of the research makes no normative difference in Germany.

- Would the external researcher be required to have a collaborator in your country? [Yes/No]  
 Yes  
 No  
 Not sure or other

In the assumed scenario, there is no need for a collaborator in Germany (though the provisions of the EU-GDPR will in all likelihood apply as the data are collected and processed from EU citizens). This means that the protection of the personal data, as well as the appropriate data subject rights, would have to be guaranteed at the same standard as within the EU.

- Would it matter whether the external researcher is based at a commercial, governmental, or academic entity? [Yes/No]  
 Yes  
 No  
 Not sure or other

It matters in relation to the provisions of the EU-GDPR and whether the proposed work is deemed to fall under the research exemptions of the Regulation: publicly funded research

attracts a number of possible exemptions from the requirements of data protection law. Where the researcher is affiliated with a commercial entity, these exemptions may not be available, and the research would have to follow stricter regulation.

5. **As far as you know, what are the perceived benefits and risks that could occur if a researcher from another country conducted IRB/REC-approved genomic research on samples or data obtained from your country? Please consider the perspectives of the public, research participants, socially-defined groups (e.g., indigenous or minority populations), researchers, and other professional or government entities.**

The German public is very sensitive in relation to data protection and informational self-determination. It is likely that there is a perceived risk that very personal and sensitive data are obtained and used in a way which is incommensurable with the data subjects' wishes. This will, in particular, be the case where the data are taken outside of the EU. The legislature mirrors this public perception in the weight and rigor given to the legislative framework on data protection and data subject rights (including its wide territorial scope). There is no visible indigenous or minority viewpoint over and beyond that of the rare disease community (which is well described elsewhere) that I am aware of.

The question of benefits is more difficult to answer in that DTP Genomic Research (where the results are shared with the participants) provides access to information which, under normal (i.e., physician or hospital-based) conditions would not be available (and certainly not be available without intensive interpretation). The overwhelming benefit would likely be more knowledge about one's own genetic makeup. Whether this is more than offset by the social and medical risks associated with receiving this knowledge outside of a medical set-

ting is subject to intense stakeholder debate in Germany.

## Part II – General Questions

6. **Does your country have biohazard committees, data protection boards, export permit authorities, or other entities that regulate the exporting of biospecimens or the transferring of data across borders for research? If so, do these requirements apply to individual citizens as well as research and medical institutions?**

The export of biospecimens from Germany is regulated according to the *Accord Européen Relatif au Transport International des Marchandises Dangereuses par Route* (ADR). Biospecimens are categorized according to the risk they pose (Category A – WHO risk group RG 4 and culture derived from RG 3; Category B – RG 2 and RG 3; exempt human biospecimens).<sup>6</sup> The decisive aspect is the level of infectious potential that the specimen exhibits. Category A must be sent by way of specially designated and licensed couriers. Category B and the exempt specimens may be sent by ordinary mail if packaged appropriately. Unless exempt, commercial entities and research institutes that regularly send hazardous specimens are required to nominate a hazardous goods officer.<sup>7</sup> The officer is responsible for ensuring institutional compliance with the appropriate regulations.

In relation to data protection, each federal state has a designated data protection official (usually attached to the local government structure). They enforce the requirements of data protection law against public institutions as well as non-public institutions which process data automatically, but expressly not in cases where the data are transferred for exclusively personal or family reasons.<sup>8</sup>

These provisions apply to institutions (including commercial entities), but not to private individuals.

7. **Does your country have laws, policies, or guidelines dealing with genetic or genomic research or genetic or genomic privacy that would apply to international DTP research? Do your national laws on these issues apply outside of your country when residents or citizens of your country enroll in a DTP study conducted abroad?**

The provisions of the EU-GDPR, including those specifically in relation to genetic privacy (as a special category of personal data protection, see e.g. Art. 4(13), 9, and Recital 34 EU-GDPR),<sup>9</sup> apply to entities based in third countries which obtain and process data of German/EU citizens.

In terms of criminal law, §§ 5, 6, and 7 of the German *Criminal Code* (StGB) provide that some criminal offences against a German citizen abroad can be prosecuted under German law.<sup>10</sup> There is a great deal of uncertainty whether this might also include offenses committed against an individual's privacy or informational self-determination.

8. **Does your country have laws, policies, guidelines, or cultural expectations regarding the return of individual or aggregate research results? [Multiple choice]**

- The law requires the return of individual results unless the participant expressly declines to have results returned
- The law is silent on return of results; the expectation is that individual results will be returned unless the participant expressly declines to have the results returned
- The law is silent on return of results; aggregate results are typically returned, but individual results are not returned unless expressly stated in the research protocol

d. I am not sure — **or other answer**

The law in relation to informational self-determination<sup>11</sup> provides that individuals have a *prima facie* entitlement to know results that constitute their personal data (i.e., individual results or incidental findings). It is generally accepted that this right to know one's own information also includes the right *not* to know the same information. Current jurisprudence, based on constitutional principles, therefore provides that information ought to be provided unless the individual has asked not to be informed. Most informed consent procedures now contain an appropriate section where individuals can opt in or out of the return of individual results. The guidelines issued by professional bodies, for example in the context of biobanking, provide sample consent procedures in line with the jurisprudence. In terms of the cultural expectation, it is safe to say that this is linked to the jurisprudence: the judgment which gave rise to the right of informational self-determination concerned public disquiet about the amount of information gathered in the 1980s German census. Since then, the public perception has been strongly in favor of individuals having unfettered access to their individual information, as well as strong control rights in that information. This is now increasingly reflected in the provisions of the EU-GDPR (which was decisively driven and shaped by a German Green MEP).

**9. Does your country have laws, policies, or guidelines regarding “direct-to-consumer” genetic testing (e.g., 23andMe) and, if so, what do they provide? [Multiple choice]**

- a. Yes. Direct-to-consumer genetic testing is illegal
- b. Yes. Direct-to-consumer genetic testing is legal
- c. No. Direct-to-consumer genetic testing is not an issue

d. I am not sure — **or other answer**

As outlined above, where DTC testing concerns a diagnostic aspect which amounts to medical genetic testing, the provisions of the GenDG come into effect. There is then a statutory requirement that all communication with the participant be in person, and carried out by a registered geneticist (i.e., a specially trained physician).<sup>12</sup> There are specific statutory requirements in relation to information giving and consent taking,<sup>13</sup> as well as how the feedback of genetic results is to take place.<sup>14</sup> In addition, paternity testing is only permissible in very limited circumstances.<sup>15</sup>

**Part III — Looking to the Future**

**10. How, if at all, do you anticipate that your country's laws, policies, or guidelines will change in the next 5-10 years in response to international DTP genomic research? [Multiple choice]**

- a. I do not think they will change at all
- b. I think they will restrict international DTP research
- c. I think they will allow international DTP research**
- d. I am not sure — or other answer

It is difficult to envisage a regulatory regime capable of effectively governing a cross-border activity that involves private individuals, exempt specimens that can be sent by ordinary post, and the processing of data in the context of globalized networks. The German federal government regularly provides funding for large-scale research projects that address the issues of stakeholder engagement and public communication of science in this field, and it is much more likely that the current discussion in Germany will focus on ensuring individuals' health literacy and appreciation of how data and samples are used, and to facilitate a use of data and samples which is in line with individuals' legitimate expectations. If a policy change

does take place, it is likely that this will be at the EU level rather than the individual member state level.<sup>16</sup>

**Note**

The author has no conflicts to disclose.

**References**

1. Gesetz über genetische Untersuchungen bei Menschen [GenDG] [German Genetic Diagnostics Act], July 31, 2009, BUNDESGESETZBLATT, Teil I at 2529.
2. Gesetz über den Verkehr mit Arzneimitteln [AMG] [Medicinal Products Act], Dec. 12, 2005, BUNDESGESETZBLATT, Teil I at 3394, §§ 40, 42.
3. Gesetz über Medizinprodukte [MPG] [Medical Devices Act], Aug. 7, 2002, BUNDESGESETZBLATT, Teil I at 3146, §§ 20, 22.
4. Based on the German IRB/REC Working Group recommendations, *available at* <[https://www.ak-med-ethik-komm.de/index.php?option=com\\_content&view=article&id=147&Itemid=153&lang=d](https://www.ak-med-ethik-komm.de/index.php?option=com_content&view=article&id=147&Itemid=153&lang=d)> (last visited October 23, 2019).
5. Gesetz über den Verkehr mit Arzneimitteln [AMG] [Medicinal Products Act], Dec. 12, 2005, BGBl. I at 3394, §§40, 42; Gesetz über Medizinprodukte [MPG] [Medical Devices Act], Aug. 7, 2002, BGBl. I at 3146, §§ 20, 22.
6. United Nations Economic Commission for Europe [UNECE], *European Agreement concerning the International Carriage of Dangerous Goods by Road*, ECE/TRANS/275, Vol. I and II, *available at* <<http://www.unece.org/trans/danger/publi/adr/adr2019/19contentse.html>> (last visited October 23, 2019).
7. Gesetz über die Beförderung gefährlicher Güter [GGBefG], Aug. 6, 1975, BUNDESGESETZBLATT, Teil I at 2121, § 3(1) No. 14; Verordnung über die Bestellung von Gefahrgutbeauftragten in Unternehmen [GbV], Mar. 11, BUNDESGESETZBLATT, Teil I at 304, § 3.
8. Bundesdatenschutzgesetz [BDSG], Jun. 30, 2017, BUNDESGESETZBLATT, Teil I at 2097, §1.
9. Regulation (EU) 2016/679 of the European Parliament and of the Council of 27 April 2016 on the protection of natural persons with regard to the processing of personal data and on the free movement of such data, and repealing Directive 95/46/EC (General Data Protection Regulation). EUR-Lex Access to Eur. Union law, *available at* <<https://eur-lex.europa.eu/eli/reg/2016/679/2016-05-04>> (last visited October 23, 2019).
10. STRAFGESETZBUCH [StGB] [Criminal Code], §§ 5, 6 and 7, *translation available at* <[https://www.gesetze-im-internet.de/englisch\\_stgb/index.html](https://www.gesetze-im-internet.de/englisch_stgb/index.html)> (last visited October 23, 2019).
11. BVerfG, 1 BvR 209, 269, 362, 420, 440, 484/83, Dec. 15, 1983, *available*

at <[https://www.bundesverfassungsgericht.de/SharedDocs/Entscheidungen/EN/1983/12/rs19831215\\_1bvr020983en.html](https://www.bundesverfassungsgericht.de/SharedDocs/Entscheidungen/EN/1983/12/rs19831215_1bvr020983en.html)> (last visited October 23, 2019); GRUNDGESETZ [GG] [BASIC LAW], § 1(1) *translation available at* <[https://www.gesetze-im-internet.de/englisch\\_gg/](https://www.gesetze-im-internet.de/englisch_gg/)> (last visited October 23, 2019).

12. Gesetz über genetische Untersuchungen bei Menschen [GenDG] [German Genetic Diagnostics Act], July 31, 2009, BGBl. I at 2529, § 7.
13. *Id.*, § 8, 9.
14. *Id.*, § 11.
15. *Id.*, § 17.
13. Technikfolgenabschätzung (TA) Aktueller Stand und Entwicklungen der Pränataldiagnostik, DEUTSCHER BUNDESTAG: Drucksache 19/9059, available at <<http://dip21.bundestag.de/dip21/btd/19/090/1909059.pdf>> (last visited October 23, 2019).

## Greece

### *Tina Garani-Papadatos and Panagiotis Vidalis*

Researchers in genomics are exploring novel ways to interact directly with prospective participants without utilizing physicians, hospitals, or biobanks as intermediaries. Many researchers are interested in using the internet to directly recruit and enroll research participants in genomic studies by posting information online about active or proposed studies. This direct-to-participant (DTP) approach could take place under three main scenarios:

- A researcher in your country wants to conduct DTP genomic research with participants in your country
- A researcher in your country wants to conduct DTP genomic research with participants in another country
- A researcher from outside your country wants to conduct DTP genomic research with participants in your country

There is uncertainty about whether DTP recruitment, enrollment, and research are lawful under these scenarios.

#### Part I — DTP-Specific Questions

##### 1. As far as you know, is DTP genomic research a topic of interest to researchers or other stakeholders in your country? [Multiple choice]

- a. There has been little, if any, discussion of the issue as of now
- b. There has been discussion among researchers, but little discussion among policy makers
- c. There has been discussion among both researchers and policy makers
- d. I am not sure — or other answer

##### 2. Assume that a researcher in your country wants to conduct DTP genomic research with participants in your country and that such research is subject to IRB/REC review. Please describe the conditions for IRB/REC approval, if it could be approved at all.

In Greece, all research proposals submitted in universities or public research institutes need to obtain approval by the competent RECs. Members of RECs are scientists from the institutional personnel and external independent members with expertise in law and ethics. The PI needs to submit the research protocol and all relevant information (details about funding, institutional support, CVs of the research team, etc.) and to fill out a questionnaire on ethical issues to be addressed. The committee examines all the above documents and sends a decision comprising requirements and relevant recommendations,

within 15 days (if delayed, approval is presumed). The PI needs to present a compliance report, which would be subject to further examination by the committee. If that report is satisfactory, the required ethics approval is provided by the REC. The PI has a right to object to one or more requirements; in that case, the REC sends a question to the Hellenic National Bioethics Commission, and revisits the problem, taking into account the answer received.

##### 3. Assume that a researcher in your country wants to conduct DTP genomic research in another country. Please describe the conditions that must be satisfied for IRB/REC approval in your country, if it could be approved at all. Would your IRB/REC also require approval from a research ethics review body in the other country?

If no part of the research is to be performed in a Greek university or public research institute, RECs in Greece have no competence whatsoever, even if the researcher is a Greek citizen.

##### 4. Assume that a researcher from outside your country wants to conduct DTP genomic research in your country.

- a. Would it be lawful for the researcher to do so without IRB/REC approval in either the researcher's country or your country? [Yes/No]  
 Yes  
 **No; Approval from the Host Institution of the researchers' country would be required.**  
 Not sure or other
- b. Would it be lawful for the researcher to do so if the

**Tina Garani-Papadatos, Ph.D.**, is a Professor, Dept. of Public Health Policy, National School of Public Health, University of West Attica, Greece. **Panagiotis Vidalis, Ph.D.**, is a Senior Scientist, Legal Advisor, Hellenic Bioethics Commission, Greece.

research were approved by an IRB/REC in the researcher's own country, but was not submitted for approval in your country? [Yes/No]

Yes

No

**Not sure or other. It is unclear whether a researcher would be able to conduct research in Greece without any local approval or authorization of any kind.**

c. Would the external researcher be required to have a collaborator in your country? [Yes/No]

Yes

No

Not sure or other

d. Would it matter whether the external researcher is based at a commercial, governmental, or academic entity? [Yes/No]

Yes

No

Not sure or other

**5. As far as you know, what are the perceived benefits and risks that could occur if a researcher from another country conducted IRB/REC-approved genomic research on samples or data obtained from your country? Please consider the perspectives of the public, research participants, socially-defined groups (e.g., indigenous or minority populations), researchers, and other professional or government entities.**

Benefits could occur if that research leads eventually to the identification of genomic profiles related to groups of the Greek population for healthcare purposes. Such population detailed profiles may be of interest for designing public health strategies, taking into account other locally important relevant data (nutrition, life-style). Participation of Greek researchers

(geneticists, sociologists, etc.), knowing the basic genetic, medical, demographic, and other parameters of the Greek population would increase that possibility.

Risks are definitely those of intentional or not personal data flow, without conditions of adequate protection, according to the EU legal standards (*General Data Protection Regulation* [GDPR].)

## Part II — General Questions

**6. Does your country have biohazard committees, data protection boards, export permit authorities, or other entities that regulate the exporting of biospecimens or the transferring of data across borders for research? If so, do these requirements apply to individual citizens as well as research and medical institutions?**

There are specific regulations for the exporting of biological samples used for clinical (diagnostic) purposes, which is subject to licensing by the Medical Association. No regulation on biohazard control exists for the exporting of samples to be used in research, however the transfer must comply with IATA regulations on safety.

Yet, data protection legislation is fully applicable, concerning the data transferring — see below). Data Protection Boards: Greece, as a member of the EU, was bound by *Directive 95/46/EC adopted in 1995 regulating the processing of personal data within the European Union*. Based on that Directive, Law 2472/97 was enacted in Greece, providing, among other things, for the establishment of the Hellenic Data Protection Authority, which is competent for the data protection in the country (including transferring of data across borders). Since May 25, 2018, Greece is bound by the GDPR 679/2016 and the DPA is acting in this framework. The requirements of the GDPR apply to individual citizens as well as research and medical institutions.

On September 6, 2018 Greece signed the European Declaration on Cross-border Access to the Genomic Database (European “1+Million Genomes Initiative”).<sup>1</sup>

**7. Does your country have laws, policies, or guidelines dealing with genetic or genomic research or genetic or genomic privacy that would apply to international DTP research? Do your national laws on these issues apply outside of your country when residents or citizens of your country enroll in a DTP study conducted abroad?**

*Existing laws in relevance:*

- The *Oviedo Convention* (ratified by l. 2619/1998). Greece has neither signed nor ratified the *Additional Protocol to the Convention on Human Rights and Biomedicine concerning genetic testing for health purposes* CETS n°: 203 which, in Article #7 stipulates that “a genetic test for health purposes may only be performed under individualized medical supervision and that exceptions to the general rule may be allowed by a Party, subject to appropriate measures being provided, taking into account the way the test will be carried out, to give effect to the other provisions of the Protocol.” This provision is taking into serious consideration the fact that commercial offers for genetic tests outside any health system is increasing and provides directions to Member States (MS). Although Greece has not ratified the Protocol, it would not enact any contrary legislation or policies.
- The GDPR of the EU is applicable outside of the country in case Greek citizens are involved in a study related to personal data processing conducted abroad (particularly in non- EU countries).<sup>2</sup>

*Guidelines:*

- The Hellenic National Bioethics Commission has issued several opinions in relevance.
- 8. Does your country have laws, policies, guidelines, or cultural expectations regarding the return of individual or aggregate research results? [Multiple choice]**
- a. The law requires the return of individual results unless the participant expressly declines to have results returned
  - b. The law is silent on return of results; the expectation is that individual results will be returned unless the participant expressly declines to have the results returned
  - c. **The law is silent on return of results; aggregate results are typically returned, but individual results are not returned unless expressly stated in the research protocol. Research protocols have to make provisions in accordance with the existing framework guiding research, both with regard to research ethics rules as well as research integrity.**
  - d. I am not sure — or other answer
- 9. Does your country have laws, policies, or guidelines regarding “direct-to-consumer” genetic testing (e.g., 23andMe) and, if so, what do they provide? [Multiple choice]**
- a. Yes. Direct-to-consumer genetic testing is illegal
  - b. Yes. Direct-to-consumer genetic testing is legal
  - c. **No. Direct-to-consumer genetic testing is not an issue**
  - d. I am not sure — or other answer

- **Direct-to-Consumer Genetic Testing<sup>3</sup>**

In general, the Hellenic Bioethics Commission supports the right to autonomy and the right to access information concerning a person's health, including genetic information. However, it is considered vital to maintain the balance between free access to health information and protection of vulnerable people undergoing inappropriate or excessive genetic testing. The Commission recommended drafting of explicit legislation which would include: (a) recognition of the specialty of clinical genetics, (b) quality accreditation/certification, (c) rules of procedure for genetic centers offering DTC genetic testing, and (d) use of biologic material or genetic data generated by DTC genetic testing for research purposes, with the subject's informed consent. No such law has been enacted yet.

### Part III — Looking to the Future

**10. How, if at all, do you anticipate that your country's laws, policies, or guidelines will change in the next 5-10 years in response to international DTP genomic research? [Multiple choice]**

- a. I do not think they will change at all
- b. I think they will restrict international DTP research
- c. I think they will allow international DTP research
- d. I am not sure — **or other answer**

The Hellenic National Bioethics Commission has repeatedly underlined the need for specific legal regulation of issues pertaining to genetic testing and genetic data protection. The Parliament and governmental policymakers (regardless of political orientation) have shown interest in undertaking initiatives, but so far they have not prioritized the topic. As already mentioned, Greece has neither signed nor ratified the *Additional Protocol on genetic testing*. It is possible that the emergence of a flourishing mar-

ket of genetic services (public and private) in the country will promote specific regulation in the next years. Given that Greece has signed the Declaration on a European Genomic Database, research may be facilitated. Still, however, it will have to comply with the strict provisions of the GDPR with regard to data processing and protection of the individual.

#### Note

The authors have no conflicts to disclose.

#### References

1. DirectorateGeneral for Communications Networks, Content and Technology, “EU Countries will Cooperate in Linking Genomic Databases across Borders.” *European Commission*, April 10, 2019, available at <<https://ec.europa.eu/digital-single-market/en/news/eu-countries-will-cooperate-linking-genomic-databases-across-borders>> (last visited October 23, 2019).
2. Hellenic National Bioethics Commission, “Big Data in Health,” OPINION, translated by V. Antoniou, November 9, 2017, available at <[http://www.bioethics.gr/images/pdf/GNOMES/OPINION\\_Big\\_Data\\_FINAL\\_EN.pdf](http://www.bioethics.gr/images/pdf/GNOMES/OPINION_Big_Data_FINAL_EN.pdf)> (last visited October 23, 2019); Hellenic National Bioethics Commission, “Incidental Findings in Research and Clinical Practice,” OPINION, translated by Matina Chatzigianni, June 26, 2015, available at <[http://www.bioethics.gr/images/pdf/GNOMES/OPINION\\_Incidental\\_Findings\\_FINAL\\_.pdf](http://www.bioethics.gr/images/pdf/GNOMES/OPINION_Incidental_Findings_FINAL_.pdf)> (last visited October 23, 2019); Hellenic National Bioethics Commission, “Direct-to-Consumer Genetic Testing,” OPINION, March 30, 2012, available at <[http://www.bioethics.gr/images/pdf/ENGLISH/OPINIONS\\_REPORTS/Opinion\\_DTC\\_genetic\\_tests-Final-EN.pdf](http://www.bioethics.gr/images/pdf/ENGLISH/OPINIONS_REPORTS/Opinion_DTC_genetic_tests-Final-EN.pdf)> (last visited October 23, 2019); Hellenic National Bioethics Commission, “The Use of Genetic Data in Private Insurance,” OPINION, January 11, 2008, available at <[http://www.bioethics.gr/images/pdf/ENGLISH/OPINIONS\\_REPORTS/ins\\_opinion\\_eng.pdf](http://www.bioethics.gr/images/pdf/ENGLISH/OPINIONS_REPORTS/ins_opinion_eng.pdf)> (last visited October 23, 2019); Hellenic National Bioethics Commission, “Bank of Biological Material of Human Origin (Biobanks) in Biomedical Research,” RECOMMENDATION, translated by C. Xanthopoulou, June 30, 2006, available at <[http://www.bioethics.gr/images/pdf/ENGLISH/OPINIONS\\_REPORTS/biobanks\\_recom\\_eng.pdf](http://www.bioethics.gr/images/pdf/ENGLISH/OPINIONS_REPORTS/biobanks_recom_eng.pdf)> (last visited October 23, 2019); Hellenic National Bioethics Commission, “The Collection and Use of Genetic Data,” RECOMMENDATION, March 23, 2001, available at <[http://www.bioethics.gr/images/pdf/ENGLISH/OPINIONS\\_REPORTS/](http://www.bioethics.gr/images/pdf/ENGLISH/OPINIONS_REPORTS/)



recom\_genetic\_data\_eng.pdf> (last visited October 23, 2019).

3. See Hellenic National Bioethics Commission, "Direct-to-Consumer Genetic Testing," *supra* note 2.

## India

*Krishna Ravi Srinivas*

Researchers in genomics are exploring novel ways to interact directly with prospective participants without utilizing physicians, hospitals, or biobanks as intermediaries. Many researchers are interested in using the internet to directly recruit and enroll research participants in genomic studies by posting information online about active or proposed studies. This direct-to-participant (DTP) approach could take place under three main scenarios:

- A researcher in your country wants to conduct DTP genomic research with participants in your country
- A researcher in your country wants to conduct DTP genomic research with participants in another country
- A researcher from outside your country wants to conduct DTP genomic research with participants in your country

There is uncertainty about whether DTP recruitment, enrollment, and research are lawful under these scenarios.

### Part I — DTP-Specific Questions

1. **As far as you know, is DTP genomic research a topic of interest to researchers or other stakeholders in your country?**  
[Multiple choice]

- a. **There has been little, if any, discussion of the issue as of now**
- b. There has been discussion among researchers, but little discussion among policy makers
- c. There has been discussion among both researchers and policy makers
- d. I am not sure — or other answer

2. **Assume that a researcher in your country wants to conduct DTP genomic research with participants in your country and that such research is subject to IRB/REC review. Please describe the conditions for IRB/REC approval, if it could be approved at all.**

It is not possible unless this is part of a project approved by an IRB. IRB approval is possible provided the research project is conducted by an institution that has been authorized to conduct research.

3. **Assume that a researcher in your country wants to conduct DTP genomic research in another country. Please describe the conditions that must be satisfied for IRB/REC approval in your country, if it could be approved at all. Would your IRB/REC also require approval from a research ethics review body in the other country?**

The research project should be approved by both institutions and their respective IRBs. Indian Council for Medical Research guidelines would be applicable and so are the guidelines of the respective institutions.

4. **Assume that a researcher from outside your country wants to**

### conduct DTP genomic research in your country.

- a. Would it be lawful for the researcher to do so without IRB/REC approval in either the researcher's country or your country? [Yes/No]  
 Yes  
 **No**  
 Not sure or other

- b. Would it be lawful for the researcher to do so if the research were approved by an IRB/REC in the researcher's own country, but was not submitted for approval in your country? [Yes/No]  
 Yes  
 **No**  
 Not sure or other

- c. Would the external researcher be required to have a collaborator in your country? [Yes/No]  
 **Yes**  
 No  
 Not sure or other

- d. Would it matter whether the external researcher is based at a commercial, governmental, or academic entity? [Yes/No]  
 **Yes**, but it depends on type of research and what is the objective of the research.  
 No  
 Not sure or other

5. **As far as you know, what are the perceived benefits and risks that could occur if a researcher from another country conducted IRB/REC-approved genomic research on samples or data obtained from your country? Please consider the perspectives of the public, research participants, socially-defined groups (e.g., indigenous or minority**

*Krishna Ravi Srinivas, Ph.D., is a Consultant at Research and Information Systems for Developing Countries (RIS) in New Delhi, India.*

populations), researchers, and other professional or government entities.

**Benefits:** Contribution to scientific knowledge, potential to find solutions, scope for collaboration, capacity building, and learning.

**Risks:** Biopiracy, unauthorized uses and gains from them, misappropriation, deriving value without benefit sharing and compensation, claiming intellectual property rights based on materials or data collected.

## Part II — General Questions

6. Does your country have biohazard committees, data protection boards, export permit authorities, or other entities that regulate the exporting of biospecimens or the transferring of data across borders for research?

If so, do these requirements apply to individual citizens as well as research and medical institutions?

Yes.

7. Does your country have laws, policies, or guidelines dealing with genetic or genomic research or genetic or genomic privacy that would apply to international DTP research?

Do your national laws on these issues apply outside of your country when residents or citizens of your country enroll in a DTP study conducted abroad?

No.

8. Does your country have laws, policies, guidelines, or cultural expectations regarding the return of individual or aggregate research results? [Multiple choice]

a. The law requires the return of individual results unless the

participant expressly declines to have results returned

- b. The law is silent on return of results; the expectation is that individual results will be returned unless the participant expressly declines to have the results returned
- c. The law is silent on return of results; aggregate results are typically returned, but individual results are not returned unless expressly stated in the research protocol
- d. I am not sure — or other answer

9. Does your country have laws, policies, or guidelines regarding “direct-to-consumer” genetic testing (e.g., 23andMe) and, if so, what do they provide? [Multiple choice]

- a. Yes. Direct-to-consumer genetic testing is illegal
- b. Yes. Direct-to-consumer genetic testing is legal
- c. No. Direct-to-consumer genetic testing is not an issue
- d. I am not sure — or other answer

## Part III — Looking to the Future

10. How, if at all, do you anticipate that your country’s laws, policies, or guidelines will change in the next 5-10 years in response to international DTP genomic research? [Multiple choice]

- a. I do not think they will change at all
- b. I think they will restrict international DTP research
- c. I think they will allow international DTP research
- d. I am not sure — or other answer

Please note the following points:

- 1. Under the New Drugs and Clinical Trial rules of 2019 ICMR ethical guidelines are compulsory for any biomedical

and health research including Direct to Participant Research.

- 2. ICMR guidelines cover genetics and genomics research and are applicable for any research, whether it is commercial or non-commercial.
- 3. For collaborative projects, the Health Ministry’s Screening Committee (HMSC) clearance is necessary.<sup>1</sup>
- 4. Transfer of biological samples under a material transfer agreement or memorandum of understanding is subject to the ICMR guidelines and guidelines cover all types of biological samples
- 5. Direct to Consumer Genetic Testing is available in India with at least 20 companies offering them for different purposes. While some offer general services, few offer specialized services for testing for certain diseases such as cancer.
- 6. The ICMR guidelines were revised in 2017 and they have to be read in conjunction with other relevant laws and regulations such as Drugs and Cosmetics Act, New Drugs and Clinical Trial Rules 2019.

### Note

The author has no conflicts to disclose.

### References

- 1. International Health Division, Indian Council of Medical Research, *Guidelines for International Collaboration / Research Projects in Health Research; MoUs & HMSC Procedure*, available at <<https://www.icmr.nic.in/content/guidelines>> (last visited October 23, 2019).

## Israel

*Gil Siegal*

Researchers in genomics are exploring novel ways to interact directly with prospective participants without utilizing physicians, hospitals, or biobanks as intermediaries. Many researchers are interested in using the internet to directly recruit and enroll research participants in genomic studies by posting information online about active or proposed studies. This direct-to-participant (DTP) approach could take place under three main scenarios:

- A researcher in your country wants to conduct DTP genomic research with participants in your country
- A researcher in your country wants to conduct DTP genomic research with participants in another country
- A researcher from outside your country wants to conduct DTP genomic research with participants in your country

There is uncertainty about whether DTP recruitment, enrollment, and research are lawful under these scenarios.

### Part I — DTP-Specific Questions

**1. As far as you know, is DTP genomic research a topic of interest to researchers or other stakeholders in your country?**  
[Multiple choice]

- a. There has been little, if any, discussion of the issue as of now
- b. There has been discussion among researchers, but little discussion among policy makers

- c. There has been discussion among both researchers and policy makers
- d. I am not sure — or other answer

**2. Assume that a researcher in your country wants to conduct DTP genomic research with participants in your country and that such research is subject to IRB/REC review. Please describe the conditions for IRB/REC approval, if it could be approved at all.**

To date, the legal framework of Human Subjects Research (HSR) in Israel has been set only by regulations issued by the Ministry of Health (MOH) in 1980, lacking comprehensive legislation by the Knesset, the Israeli parliament (a bill sponsored by the MOH has been in preparation for over 20 years). The *Genetic Information Law, 5761-2000*, contains several clauses dealing with consent to genetic research.<sup>1</sup> According to the *Public Health Regulations (Clinical Trials in Human Subjects)* of 1980, all research involving human genetic material requires special approval from the National Committee for Research in Humans. The Committee reviews every aspect of the research proposal based on national and international genetic research standards, such as the *Helsinki Declaration* of 1964 and its subsequent amendments. Thus, the merits of the research, protecting the autonomy and the well-being of participants and the right to terminate participation are assessed.

Pertinent to our query, the method of recruitment is part of the evaluation procedure. The researchers will have to explain how they intend to enroll participants (approaching patients, designated clinics, open recruitment via traditional or social media) and the risks each method entails (mostly confidentiality, but also discrimination, vulnerable groups, the use of

enticement). The review includes the informed consent process and documents, including clarity, accessibility (literacy level), as well as material aspects such as research objectives, breadth of use of samples and/or genetic information, data protection, and data sharing. Failure to apply for the Committee's approval can theoretically expose the researcher to disciplinary measures. Such measures, however, have been used thus far very scarcely, mostly in cases of clinical trials where participants were exposed to physical harm (such as unauthorized biopsies) and not in the genetic sphere.

**3. Assume that a researcher in your country wants to conduct DTP genomic research in another country. Please describe the conditions that must be satisfied for IRB/REC approval in your country, if it could be approved at all. Would your IRB/REC also require approval from a research ethics review body in the other country?**

The working paradigm in Israel is that each jurisdiction is responsible to implement its laws, rules and regulation. Therefore, the Israeli IRB will **not** evaluate such proposals.

**4. Assume that a researcher from outside your country wants to conduct DTP genomic research in your country.**

- a. Would it be lawful for the researcher to do so without IRB/REC approval in either the researcher's country or your country? [Yes/No]

An outside researcher cannot do research in Israel absent the Committee's approval. So, in Israel it would be unlawful.

**Gil Siegal, M.D., LL.B., S.J.D.**, is the Director of the Center for Health Law, Bioethics and Health Policy at Ono Academic College, Israel, a Member of the Israel National Bioethics and the Human Subject Research committees and Professor of Law at the University of Virginia

- Yes  
 No  
 **Not sure or other**

b. Would it be lawful for the researcher to do so if the research were approved by an IRB/REC in the researcher's own country, but was not submitted for approval in your country? [Yes/No]

- Yes  
 **No**  
 Not sure or other

Of note, this matter is a subject of repeated discussion, whereas international pharma companies, conducting multi-site/multinational studies urge Israel to relax its current practice and specifically allow reliance on another-country's approval (either directly or indirectly by requesting that documents/protocol be identical in all sites, irrespective of domestic legal/ethical concerns). Part of the impetus behind such prodding is the intention of pharma companies to make use of the combination of medical/clinical data and genetic and medical laboratory results collected for care. Apparently, Israel's record keeping represents a valuable database for pharmaceutical research and development, and hence the need to relax regulation in order to allow more and better research. The common official response, shared by most jurisdictions in the world, relates to state sovereignty and rejection of "outsourcing oversight of human subject research".

c. Would the external researcher be required to have a collaborator in your country? [Yes/No]  
 **Yes** — collaboration or a local CRO, and be approved by domestic IRB  
 No  
 Not sure or other

d. Would it matter whether the external researcher is based at a commercial, governmental, or academic entity? [Yes/No]  
 Yes  
 **No**

Not sure or other

**5. As far as you know, what are the perceived benefits and risks that could occur if a researcher from another country conducted IRB/REC-approved genomic research on samples or data obtained from your country? Please consider the perspectives of the public, research participants, socially-defined groups (e.g., indigenous or minority populations), researchers, and other professional or government entities.**

The ability to propel scientific initiatives is dependent on adequate resources — workforce, infrastructure, and funding. The prospect of allowing researchers from other countries to conduct research on domestic patients/participants can be an important way to amplify scientific progress, pool resources, and divert attention to overlooked areas in genomics (such as in cases of diseases that attract low attention in one community but are important in others). The risks are derived from the subject matter — genetic and genomic information. The concerns attached to information risks include privacy, confidentiality, genetic discrimination, and the like. However, in regimes with national health insurance schemes, these risks carry a far lesser weight, and can be adequately addressed.

## Part II — General Questions

**6. Does your country have biohazard committees, data protection boards, export permit authorities, or other entities that regulate the exporting of biospecimens or the transferring of data across borders for research? If so, do these requirements apply to individual citizens as well as research and medical institutions?**

Israel does not have dedicated committees (biohazard, data protection) to address export of genetic material for research. Several international courier companies operate in Israel with import/export permits, including the transfer of biological samples.

**7. Does your country have laws, policies, or guidelines dealing with genetic or genomic research or genetic or genomic privacy that would apply to international DTP research? Do your national laws on these issues apply outside of your country when residents or citizens of your country enroll in a DTP study conducted abroad?**

Some aspects of international genomic research have been framed into regulation issues by the MOH in 2014.<sup>2</sup> These regulations require that only coded/anonymized material can be transferred/shared with overseas research projects while the code remains solely in Israel. To share/transfer samples, researchers must ensure that sufficient biological material remains in Israel, and present a written commitment from both the non-Israeli researcher and laboratory that they will comply with local and international standards and will follow the national IRB guidelines in respect to confidentiality and privacy.

**8. Does your country have laws, policies, guidelines, or cultural expectations regarding the return of individual or aggregate research results? [Multiple choice]**

- The law requires the return of individual results unless the participant expressly declines to have results returned
- The law is silent on return of results; the expectation is that individual results will be returned unless the participant expressly declines to have the results returned,

c. **The law is silent on return of results;** aggregate results are typically returned [**not necessarily**], but **individual results are not returned unless expressly stated in the research protocol.** The national IRB does expect, and so conditions its approval, that researchers demonstrate their ability to report back to participants/patients if actionable results emerge from the study, at the expense of the researcher.

d. I am not sure — or other answer

9. **Does your country have laws, policies, or guidelines regarding “direct-to-consumer” genetic testing (e.g., 23andMe) and, if so, what do they provide? [Multiple choice]**

a. **Yes. Direct-to-consumer genetic testing is illegal,** especially because of the fear from unauthorized paternity tests, that by law can only be performed following a court order. However, the private action of sending one’s own sample abroad is not illegal as the regulatory framework applies only to the professional sector — clinicians, genetic counsellors, researchers, and laboratories.

b. Yes. Direct-to-consumer genetic testing is legal

c. No. Direct-to-consumer genetic testing is not an issue

d. I am not sure — or other answer

### Part III — Looking to the Future

10. **How, if at all, do you anticipate that your country’s laws, policies, or guidelines will change in the next 5-10 years in response to international DTP genomic research? [Multiple choice]**

a. **I do not think they will change at all**

b. I think they will restrict international DTP research

c. I think they will allow international DTP research

d. **I am not sure — or other answer**

The response of the Israeli regulators will depend on demonstrable benefits. Israel is known for its innovative spirit (“Start-Up Nation”), including of medical innovation, and such a stance is bound to impact regulation.<sup>3</sup> The ability to collect biological samples has been around for quite a while, with discernible outcomes such as deCode, 23andMe and the UK Biobank. Parochial concerns or “protecting the genomic asset” of a community seems at odds with the concerted action needed to achieve major breakthroughs in genetics and genomics. The collective engagement can be achieved once the proper mechanisms of benefit sharing, equitable access to tests and treatments, and adequate safeguards against discrimination/breach of privacy are all in place. Albeit a restrictive policy, many Israelis use overseas companies such as MyHeritage or 23andMe simply by using third parties and the internet. Thus, the tide has been noticed, and regulatory action will follow.

#### Note

The author has no conflicts to disclose.

#### References

1. Genetic Information Law, 5761-2000, (Isr.), § 13, available at <<https://www.jewishvirtuallibrary.org/jsource/Health/GeneticInformationLaw.pdf>> (last visited October 25, 2019).
2. Ministry of Health: Clinical Trials Department, “Procedure for Medical Experiments in Humans 5775-2014, at 80, available at <[http://research.telhai.ac.il/sites/default/filesfiles/%D7%A0%D7%95%D7%94%D7%9C%20%D7%9C%D7%A0%D7%99%D7%A1%D7%95%D7%99%D7%99%D7%9D%20%D7%A8%D7%A4%D7%95%D7%90%D7%99%D7%99%D7%9D%20%D7%91%D7%91%D7%A0%D7%99%20%D7%90%D7%93%D7%9D\\_%D7%AA%D7%A9%D7%A2%D7%93%20\(1\).pdf](http://research.telhai.ac.il/sites/default/filesfiles/%D7%A0%D7%95%D7%94%D7%9C%20%D7%9C%D7%A0%D7%99%D7%A1%D7%95%D7%99%D7%99%D7%9D%20%D7%A8%D7%A4%D7%95%D7%90%D7%99%D7%99%D7%9D%20%D7%91%D7%91%D7%A0%D7%99%20%D7%90%D7%93%D7%9D_%D7%AA%D7%A9%D7%A2%D7%93%20(1).pdf)> (in Hebrew only) (last visited October 25, 2019).

3. G. Siegal, “Genomic Databases and Biobanks in Israel,” *Journal of Law, Medicine and Ethics* 43, no. 4 (2015): 766-775.

## Italy

*Stefania Negri*

Researchers in genomics are exploring novel ways to interact directly with prospective participants without utilizing physicians, hospitals, or biobanks as intermediaries. Many researchers are interested in using the internet to directly recruit and enroll research participants in genomic studies by posting information online about active or proposed studies. This direct-to-participant (DTP) approach could take place under three main scenarios:

- A researcher in your country wants to conduct DTP genomic research with participants in your country
- A researcher in your country wants to conduct DTP genomic research with participants in another country
- A researcher from outside your country wants to conduct DTP genomic research with participants in your country

There is uncertainty about whether DTP recruitment, enrollment, and research are lawful under these scenarios.

### Part I — DTP-Specific Questions

1. **As far as you know, is DTP genomic research a topic of interest to researchers or other stakeholders in your country? [Multiple choice]**

- a. There has been little, if any, discussion of the issue as of now

*Stefania Negri, Ph.D., is an Associate Professor of International Law, Department of Legal Sciences, University of Salerno.*

- b. There has been discussion among researchers, but little discussion among policy makers
- c. There has been discussion among both researchers and policy makers**
- d. I am not sure — or other answer

Genomic research is a subject of discussion among Italian researchers and policy makers and within institutional bodies, although the discussion is not particularly focused on DTP genomic research.

The major institutions that have issued documents and opinions on genetics and genomics are the Italian Committee for Bioethics,<sup>1</sup> the Italian Committee for Biosecurity, Biotechnology and Life Sciences,<sup>2</sup> and the Joint Group CNB-CNBBSV.<sup>3</sup>

The permanent conference for the relations between the State, the Regions, and the Autonomous Provinces of Trento and Bolzano adopted an agreement approving the national *Plan for Innovation of the Health System Based on "Omic" Sciences*.<sup>4</sup>

The Italian Society of Human Genetics (Società Italiana di Genetica Umana, SIGU) has issued recommendations and guidelines.<sup>5</sup> In October 2006, SIGU and the Smith Kline Foundation published the *Guidelines for Clinical Protocols in Genetic Research. Recommendations for the Drafting and Assessment of Clinical Research Protocols in Genetics*.<sup>6</sup>

Although the Guidelines formulate several recommendations, they do not mention DTP genetic or genomic research.

- 2. Assume that a researcher in your country wants to conduct DTP genomic research with participants in your country and that such research is subject to IRB/REC review. Please describe the conditions for IRB/REC approval, if it could be approved at all.**

Protocols for genetic or genomic research must be approved by ethics committees.

The basic regulation for ethics committees is Legislative decree no. 211/2003,<sup>7</sup> as amended by Legislative decree no. 52 of May 14, 2019.<sup>8</sup>

Legislative decree no. 211/2003 transposed Directive 2001/20/EC of 4 April 2001 into the Italian legal order, but it should be kept in mind that the Directive will be replaced by Regulation (EU) 536/2014 (entered into force on 16 June 2014), once it will be declared applicable by the European Medicines Agency.<sup>9</sup>

In general terms, Article 6, paragraph 2 of Legislative decree n. 211/2003 contains a list of elements and conditions to be taken into account by ethics committees to formulate their opinions on proposed research protocols.

The *Guidelines for Clinical Protocols in Genetic Research* list the specific information that a protocol should contain. According to the Guidelines, any collection of human blood and/or other tissue samples for research involving genetic testing must be under the control and supervision of the ethics committee, which evaluates the protocol and the consent document according to the same general criteria used for any biomedical research protocol. These documents should contain information on the release of individual results and on the collection, storage, and use of collected biological samples and data.

In particular, the protocol should describe: methods of collection, level of identification, storage time, uses for which the samples can be employed, guarantee of safe conservation, possibility for the subject to request the destruction of the sample, possibility that the samples will be shipped to other laboratories; times, methods, security measures for processing and storing the data collected or generated in the research area, the possibility that the data will be provided to other laboratories and, if abroad, the guarantee that these will guarantee the same standards of security in the protection of confidentiality; availability of the interested party to have his/her data/samples used for further purposes; that the subject can have access to their results upon request, even if they are not useful for their

health; and whether anyone else can obtain individual results.<sup>10</sup>

- 3. Assume that a researcher in your country wants to conduct DTP genomic research in another country. Please describe the conditions that must be satisfied for IRB/REC approval in your country, if it could be approved at all. Would your IRB/REC also require approval from a research ethics review body in the other country?**

According to article 7, paragraph 1 of Legislative decree no. 211/2003, multicenter clinical trials conducted either in Italy alone, or in Italy and in third countries, must be issued an opinion by the ethics committee of the Italian institution to which the coordinator or PI for Italy is a member. This opinion must be received within thirty days from the date of receipt of the application submitted by the trial promoter and the trial must not start on any site before the opinion is issued.

According to article 8, paragraph 2, the application referred to above must, in the case of multicenter trials, also be simultaneously submitted to the relevant ethics committees for the other (Italian or foreign) research centers or institutions.

- 4. Assume that a researcher from outside your country wants to conduct DTP genomic research in your country.**

- a. Would it be lawful for the researcher to do so without IRB/REC approval in either the researcher's country or your country? [Yes/No]
- \_\_\_ Yes
- No
- \_\_\_ Not sure or other
- b. Would it be lawful for the researcher to do so if the research were approved by an IRB/REC in the researcher's

own country, but was not submitted for approval in your country? [Yes/No]

Yes

No

Not sure or other

c. Would the external researcher be required to have a collaborator in your country? [Yes/No]

**Yes.** Once Regulation (EU) 536/2014 will be applicable, Article 74 will require that the sponsor of a clinical trial who is not established in the Union shall ensure that a natural or legal person is established in the Union as its legal representative.

No

Not sure or other

d. Would it matter whether the external researcher is based at a commercial, governmental, or academic entity? [Yes/No]

Yes

No

Not sure or other

5. **As far as you know, what are the perceived benefits and risks that could occur if a researcher from another country conducted IRB/REC-approved genomic research on samples or data obtained from your country? Please consider the perspectives of the public, research participants, socially-defined groups (e.g., indigenous or minority populations), researchers, and other professional or government entities.**

The major perceived risks would regard compliance with informed consent requirements and the protection of personal data, especially if the foreign country is a non-EU Member State which is not compelled to respect European-wide agreed standards.

## Part II — General Questions

6. **Does your country have biohazard committees, data protection boards, export permit authorities, or other entities that regulate the exporting of biospecimens or the transferring of data across borders for research? If so, do these requirements apply to individual citizens as well as research and medical institutions?**

Data protection is regulated under the *Italian Personal Data Protection Code (Codice in Materia di Protezione dei Dati Personali)*<sup>11</sup> and EU Regulation 2016/679 (*General Data Protection Regulation, GDPR*).<sup>12</sup>

The Code was amended by Legislative decree no. 101/2018 in order to make it consistent with the GDPR.<sup>13</sup> This decree made use of flexibility afforded by the GDPR to Member States with respect to processing activities based on legal obligations or for purposes of public interest (Article 6(1), letters c) and e)); processing of biometric, genetic and health-related data (Article 9(4) and Article 36(5)); processing activities covered by Chapter IX of the GDPR (including research). As a result, while several provisions of the Code were left in place, as they were found not to be in conflict or overlap with the GDPR, other provisions were amended or repealed, and new sections were added. Among the repealed provisions were Sections 43–45 regulating the transfer of genetic data and samples to third countries (including towards non-EU countries under specific conditions), permissible transfers and prohibited transfers.

The Italian Data Protection Authority<sup>14</sup> issued a number of decisions on Biometrics & Genetic Data,<sup>15</sup> most notably general authorizations for the processing of genetic data, which allowed the treatment and transfer of such data under specific conditions and security measures until May 24, 2018, the date of entry into force of the GDPR.<sup>16</sup> These authorizations applied to a broad

range of persons and institutions: health care practitioners; public and private health care bodies; medical genetics laboratories; natural and legal persons, research bodies and/or institutions, associations and other public or private bodies; psychologists, technical consultants and their assistants; pharmacists, etc.

With regard to transfer of personal data to non-EU countries, the Authority also issued several authorizations for cross-border data flows towards third countries.

The Authority has recently adopted a decision indicating which provisions of its general authorizations are consistent with the GDPR.<sup>17</sup> In section 4, concerning the prescriptions for the treatment of genetic data under general authorization no. 8/2016, sub-section 4.11.4 on communication and dissemination of data, the Authority states that genetic data and biological samples collected for scientific research and statistical purposes may be communicated or transferred to research institutions and bodies, associations and other public and private research bodies, exclusively in the context of joint projects. Genetic data and biological samples may be communicated or transferred to third subjects not participating in joint projects limited to information without identification data, for scientific purposes directly related to those for which they were originally collected and clearly determined in writing in the request for data and/or samples. In this case, the requesting party undertakes not to process the data and/or use the samples for purposes other than those indicated in the request and not to communicate them or transfer them further to third parties.

7. **Does your country have laws, policies, or guidelines dealing with genetic or genomic research or genetic or genomic privacy that would apply to international DTP research? Do your national laws on these issues apply outside of your country when residents or citi-**

### zens of your country enroll in a DTP study conducted abroad?

As far as privacy is concerned, the Italian *Personal Data Protection Code*, the EU Clinical Trials Regulation and the GDPR would apply.

### 8. Does your country have laws, policies, guidelines, or cultural expectations regarding the return of individual or aggregate research results? [Multiple choice]

- The law requires the return of individual results unless the participant expressly declines to have results returned
- The law is silent on return of results; the expectation is that individual results will be returned unless the participant expressly declines to have the results returned
- The law is silent on return of results; aggregate results are typically returned, but individual results are not returned unless expressly stated in the research protocol
- I am not sure — or other answer

In the opinion issued by the Italian Committee for Bioethics on *Managing “Incidental Findings” in Genomic Investigations with New Technology Platforms*,<sup>18</sup> the issue of return of information to donors of biological samples for research purposes is partly addressed. The Committee observes that, in case of research involving the collection of a large number of samples, it is unrealistic to re-contact the donors to update them on the results, which could hardly have a clinical value of individual interest. The NBC recommends, however, that it should always be specified in the informed consent form whether there is this possibility and, if so, the choice of the information that one wishes to receive is left to the interested party. The Committee states that it is morally compulsory

to guarantee, if requested, a return of the results of clinical relevance to patients suffering from rare diseases still lacking a certain diagnosis, who have entered into research protocols and donated their samples in the hope of accelerating their knowledge of the causes of their illness.

In the *Guidelines* it is recommended that in drafting or assessing clinical research protocols in genetics it should be borne in mind that: individual genetic results must be disclosed to the patient who requests them regardless of their possible clinical utility; individual genetic results should not be given to others if they are not of immediate clinical utility; individual results that may be useful for the health of the subject must be provided to his doctor; the investigators participating in the research should receive a report containing the global results.<sup>19</sup>

### 9. Does your country have laws, policies, or guidelines regarding “direct-to-consumer” genetic testing (e.g., 23andMe) and, if so, what do they provide? [Multiple choice]

- Yes. Direct-to-consumer genetic testing is illegal
- Yes. Direct-to-consumer genetic testing is legal
- No. Direct-to-consumer genetic testing is not an issue
- Direct-to-consumer genetic testing is legal in compliance with EU law on IVDD but there is no specific organic legislation**

Genetic tests are currently regulated as *in vitro* diagnostic devices under Legislative decree n. 332/2000<sup>20</sup> transposing Directive 98/79/EC of October 27, 1998. As of 2022, the new Regulation (EU) 2017/746 of April 5, 2017 on *in vitro* diagnostic medical devices will apply.

Italy has not enacted any specific/organic legislation on DTC genetic tests. In 2017, the Ministry of Health issued *New Guidelines for Advertising of Medical Devices, in Vitro Diagnos-*

*tic Medical Devices and Medical-Surgical Devices*.<sup>21</sup>

The opinion issued by the Joint Group CNB-CNBBSV on *Genetic Susceptibility Testing and Personalized Medicine*<sup>22</sup> refers to DTC genetic testing. It does not take any position on the issue of legality, although it states that the offer of DTC diagnostic tests frequently disregards both the professional genetic counselling required by international and national regulations, as well as bioethical considerations such as the protection of confidentiality, privacy, the familiar dimension of genetics, the right “not to know” and the protection against discrimination and stigmatization.<sup>23</sup>

According to the Joint Group, the decision to place genetic tests within the generic category of “in vitro diagnostic medical devices” should be reviewed and a separate category should be envisaged.<sup>24</sup> The opinion also contains recommendations to promote the proper and responsible use of DTC genetic tests.<sup>25</sup>

### Part III — Looking to the Future

### 10. How, if at all, do you anticipate that your country’s laws, policies, or guidelines will change in the next 5-10 years in response to international DTP genomic research? [Multiple choice]

- I do not think they will change at all
- I think they will restrict international DTP research
- I think they will allow international DTP research
- I am not sure**

### Note

The author has no conflicts to disclose.

### References

- Comitato Nazionale di Bioetica (CNB), “Opinions & Responses,” available at <<http://bioetica.governo.it/en/opinions/opinions-responses/>> (last visited October 23, 2019).
- Comitato Nazionale per la Biosicurezza, le Biotecnologie e le Scienze della Vita (CNBBSV), *Pareri* (Opinions), available at <<http://cnbbsv.palazzochigi.it/it/>>



- documenti/pareri/> (last visited October 23, 2019).
3. Comitato Nazionale di Bioetica (CNB), “ICB-CNBSV Joint Group,” *available at* <<http://bioetica.governo.it/en/opinions/icb-cnbsv-joint-group/>>.
  4. Ministero della Salute, *Piano per l'innovazione del Sistema Sanitario Basato Sulle Scienze Omiche* (Plan for innovation of the health system based on omics sciences) Annex A, sub A, para. 8.b, *available at* <[http://www.salute.gov.it/imgs/C\\_17\\_notizie\\_3270\\_lista-File\\_itemName\\_0\\_file.pdf](http://www.salute.gov.it/imgs/C_17_notizie_3270_lista-File_itemName_0_file.pdf)> (last visited October 23, 2019); see also Intesa 5 giugno 2003, n. 176/CSR, G.U. Jan. 17, 2018, n. 13 (It.). In execution of the Plan, the Istituto Superiore di Sanità instituted a working group on genomics known as *Table for genomics* (Tavolo per la genomica). On July 11, 2018 an “Inter-institutional Coordination” was set up at the Directorate-General for Health Prevention of the Ministry of Health, with the task of implementing the Plan.
  5. Società Italiana di Genetica Umana (SIGU), *Linee Guida* (Guidelines), *available at* <<https://www.sigu.net/show/documenti/5/1/linee%20guida>> (last visited October 23, 2019).
  6. Fondazione Smith Kline (FSK), *Linee Guida per i protocolli clinici di ricerca genetica. Raccomandazioni per la realizzazione e la valutazione dei protocolli di ricerca clinica in campo genetico* (Guidelines for clinical protocols of genetic research. Recommendations for the implementation and evaluation of genetic clinical research protocols), *available at* <<http://www.fsk.it/gruppi-di-lavoro-fsk/i-gruppi-conclusi/linee-guida-in-genetica-umana#gdl-documenti>> (last visited October 23, 2019).
  7. Decreto Legislativo 24 giugno 2003, n. 211, G.U. Aug. 9, 2003, n. 184 (It.). After the reorganization of the Ethics Committees in 2006 (Decreto Ministeriale 12 maggio 2006, G.U. Aug. 22, 2006, n. 194 (It.)), the Law n. 189 of November 8, 2012 (Legge 8 novembre 2012, n. 189, G.U. Oct. 10, 2012, n. 263 (It.)) established that, by June 30, 2013, each Region should arrange to reorganize the Ethics Committees of its territory. The latest revision of the system was regulated by Law no. 3 of January 11, 2018, so-called Law Lorenzin, and implementing Legislative decree no. 52 of May 14, 2019 (Legge, 11 gennaio 2018, n. 3, G.U. Jan. 31, 2018, n. 25 (It.)).
  8. Decreto Legislativo 14 maggio 2019, n. 52, G.U. June 12, 2019, n. 136 (It.).
  9. Regulation (EU) 536/2014 of the European Parliament and of the Council of April 16, 2014 on clinical trials on medicinal products for human use, and repealing Directive 2001/20/EC, 2014 O.J. (L 158), 1.
  10. Fondazione Smith Kline (FSK), *supra* note 6. See especially the chapter “Check list for drafting and assessment of a genetic research protocol and the informed consent.”
  11. Decreto Legislativo 30 giugno 2003, n. 196, G.U. Jul. 30, 2003, n. 174 (It.).
  12. Decreto Legislativo 10 agosto 2018, n. 101, G.U. Sep. 4, 2018, n. 205 (It.).
  13. Regulation (EU) 2016/679 of the European Parliament and of the Council of April 27, 2016 on the protection of natural persons with regard to the processing of personal data and on the free movement of such data, and repealing Directive 95/46/EC (General Data Protection Regulation), 2016 O.J. (L 119), 1.
  14. The Garante per la protezione dei dati personali (<<https://www.garanteprivacy.it/web/guest/home>>) is an independent administrative authority established by Law no. 675 of December 31, 1996 (Legge 31 dicembre 1996, n. 675, G.U. Jan. 8, 1997, n. 5 (It.)) and regulated by the Personal Data Protection Code. Legislative decree no. 101/2018 (D.Lgs. 101/2018) established that the Authority would be responsible for monitoring the application of the GDPR.
  15. Garante per la protezione dei dati personali, *Main Decisions by the Italian Data Protection Authority*, *available at* <[https://www.garanteprivacy.it/web/guest/home\\_en/main-decisions](https://www.garanteprivacy.it/web/guest/home_en/main-decisions)> (last visited October 23, 2019).
  16. See General authorizations for the processing of genetic data nos. 8/2012, 8/2014 and 8/2016.
  17. Provvedimento che individua le prescrizioni contenute nelle Autorizzazioni generali nn. 1/2016, 3/2016, 6/2016, 8/2016 e 9/2016 che risultano compatibili con il Regolamento e con il d.lgs. n. 101/2018 di adeguamento del Codice - 13 dicembre 2018; Registro dei provvedimenti n. 497 del 13 dicembre 2018.
  18. Comitato Nazionale di Bioetica (CNB), “Managing ‘Incidental Findings’ in genomic investigations with new technology platforms,” *available at* <<http://bioetica.governo.it/en/opinions/opinions-responses/managing-incidentalfindings-in-genomic-investigations-with-new-technology-platforms/>> (last visited October 23, 2019).
  19. FSK, *supra* note 6, at 69.
  20. Decreto legislativo 8 settembre 2000, n. 332, G.U. Nov. 17, 2000, n. 189 (It.).
  21. Ministero della Salute, Nuove Linee guida del 28 marzo 2013, in merito alla pubblicità sanitaria concernente i dispositivi medici, dispositivi medico-diagnostici in vitro e presidi medico-chirurgici (New Guidelines for health advertising of medical devices, in vitro diagnostic medical devices and medical-surgical devices) (Dec. 20, 2017), *available at* <[http://www.salute.gov.it/portale/ministro/p4\\_8\\_0.jsp?lingua=italiano&label=servizionline&idMat=D-M&idAmb=PUB&idSrv=A01&flag=P](http://www.salute.gov.it/portale/ministro/p4_8_0.jsp?lingua=italiano&label=servizionline&idMat=D-M&idAmb=PUB&idSrv=A01&flag=P)> (last visited October 23, 2019).
  22. NBC-NBBLSC, “Test genetici di suscettibilità e medicina personalizzata,” (Genetic Susceptibility Testing and Personalised Medicine), July 14, 2010, *available at* <[http://cnbsv.palazzochigi.it/media/1562/3-gm\\_genetic-susceptibility-testing-and-personalised-medicine.pdf](http://cnbsv.palazzochigi.it/media/1562/3-gm_genetic-susceptibility-testing-and-personalised-medicine.pdf)> (last visited October 23, 2019).
  23. *Id.* at 6.
  24. *Id.* at 31-33.
  25. *Id.* at 43-45.

## Japan

Ryoko Hatanaka

Researchers in genomics are exploring novel ways to interact directly with prospective participants without utilizing physicians, hospitals, or biobanks as intermediaries. Many researchers are interested in using the internet to directly recruit and enroll research participants in genomic studies by posting information online about active or proposed studies. This direct-to-participant (DTP) approach could take place under three main scenarios:

- A researcher in your country wants to conduct DTP genomic research with participants in your country
- A researcher in your country wants to conduct DTP genomic research with participants in another country
- A researcher from outside your country wants to conduct DTP genomic research with participants in your country

There is uncertainty about whether DTP recruitment, enrollment, and research are lawful under these scenarios.

### Part I — DTP-Specific Questions

#### 1. As far as you know, is DTP genomic research a topic of interest to researchers or other

Ryoko Hatanaka is a Visiting Researcher, University of Hong Kong Sau Po Center for Aging; Honorable Visiting Fellow, University of Tokyo.

**stakeholders in your country?**  
[Multiple choice]

- a. There has been little, if any, discussion of the issue as of now
- b. There has been discussion among researchers, but little discussion among policy makers**
- c. There has been discussion among both researchers and policy makers
- d. I am not sure — or other answer

Japan already has some ongoing cases of DTP genomic research. Otherwise I cannot find any discussion among policy makers.

**2. Assume that a researcher in your country wants to conduct DTP genomic research with participants in your country and that such research is subject to IRB/REC review. Please describe the conditions for IRB/REC approval, if it could be approved at all.**

An IRB will generally consider the following principles:

1. Respect for human dignity
2. Informed consent
3. Protection of personal information
4. Conduct of socially useful research that contributes to human intellectual base, health, and welfare
5. Prioritization of individual's human rights security over scientific or social interests
6. Preparation and compliance of research plans based on this guideline and ensuring research appropriateness through prior examination and approval by the Ethics Review Board from an independent standpoint
7. Ensuring transparency of research through on-site inspection of research implementation status by third

parties and publication of research results

8. Promotion of public and social understanding through enlightenment activities on human genome and gene analysis research, and dialogue with the public based on the research content

*Case 1:* From 2016, in collaboration with the University of Tokyo Institute of Medical Science and Research, DeNA Science sells a genetic testing tool (MYCODE) on the Internet, where participants who have obtained consent to participate in the research will be surveyed on the Internet. They are conducting research linked with the questionnaire results and genetic analysis.<sup>1</sup>

*Case 2:* DTP genetic research targeting on bipolar disorder diagnosed patients and their family is ongoing by RIKEN Center for Brain Science.<sup>2</sup> This research purposed on defined mechanism of bipolar disorder.

*Case 3:* In 2018, collaborative research started by six Hospitals of National Hospital Organization about genomic analysis study targeting on chemical sensitivity of 800 participants as DTP.<sup>3</sup>

**3. Assume that a researcher in your country wants to conduct DTP genomic research in another country. Please describe the conditions that must be satisfied for IRB/REC approval in your country, if it could be approved at all. Would your IRB/REC also require approval from a research ethics review body in the other country?**

IRBs/RECs in Japan will review the conditions in both countries and will adopt of the stricter of the two.

**4. Assume that a researcher from outside your country wants to**

**conduct DTP genomic research in your country.**

- a. Would it be lawful for the researcher to do so without IRB/REC approval in either the researcher's country or your country? [Yes/No]  
\_\_\_ Yes  
**X No**  
\_\_\_ Not sure or other

No, a researcher from the other country should get IRB/REC approval in Japan.

There is no law about conducting DTP genomic research in another country.

1. When a research institute in Japan conducts joint research with an overseas research institute, it is required that the researcher in the partner country will act as joint researcher subject to Japanese rules for treating samples.
2. When an organization conducting research in Japan conducts collaborative research with an overseas research institute, in principle, such research should be conducted in accordance with this guideline while complying with the laws and guidelines set forth in the partner country in which the joint research is conducted.

However, in the case where the standards in the other country are stricter than this guideline, research should be conducted according to the standards in the partner country.

- b. Would it be lawful for the researcher to do so if the research were approved by an IRB/REC in the researcher's own country, but was not submitted for approval in your country? [Yes/No]  
**X Yes**  
\_\_\_ No

Not sure or other

The researcher should get the IRB/REC approval in Japan, but under some conditions the researcher can submit only their own country's approval.

- c. Would the external researcher be required to have a collaborator in your country? [Yes/No]
- Yes  
 No  
 Not sure or other

A collaborator can be a foreign country organization.

- d. Would it matter whether the external researcher is based at a commercial, governmental, or academic entity? [Yes/No]
- Yes  
 No  
 Not sure or other

It does not matter. Japanese guidelines presume the external researcher is based at a commercial, governmental, or academic entity.<sup>4</sup>

5. **As far as you know, what are the perceived benefits and risks that could occur if a researcher from another country conducted IRB/REC-approved genomic research on samples or data obtained from your country? Please consider the perspectives of the public, research participants, socially-defined groups (e.g., indigenous or minority populations), researchers, and other professional or government entities.**

#### *Benefits*

- Overseas researchers spread the contents of research. However, if used by overseas researchers who do not know Japanese specific problems, environment, living factors, etc., there is a possibility that the content of the research may not be sufficient.

- Participants can join research that cannot be done in Japan.

#### *Risks*

- It is difficult to conduct on-site investigations of research in the case of an overseas research leader.

Ethical Guidelines require on-site investigation of research:

“The head of the organization conducting the research receives regular reports once a year or more from the research director on the state of implementation of the research, and carries out regular on-site surveys by outside experts once a year or more.”<sup>5</sup>

- In the case of research by overseas researchers, it is more difficult to see how information is used and how research data is managed, compared with the provision of data to domestic researchers.
- Especially in Japan, guidelines and research plans are available only in Japanese, which often makes it difficult for overseas researchers to understand.

#### **Part II – General Questions**

6. **Does your country have biohazard committees, data protection boards, export permit authorities, or other entities that regulate the exporting of biospecimens or the transferring of data across borders for research? If so, do these requirements apply to individual citizens as well as research and medical institutions?**

Yes, the University of Tokyo and some of the larger universities have Life Science Research Ethics and Safety committees to review biohazards, the ethics of animal testing, and the export of biospecimens, among other things.

Individual citizens are not subject to such oversight.

7. **Does your country have laws, policies, or guidelines dealing with genetic or genomic research or genetic or genomic privacy that would apply to international DTP research? Do your national laws on these issues apply outside of your country when residents or citizens of your country enroll in a DTP study conducted abroad?**

There are no statutes applicable to DTP research. Self-guidelines have been established by the Ministry of Economic, Trade and Industry (METI), as well as industry groups.

8. **Does your country have laws, policies, guidelines, or cultural expectations regarding the return of individual or aggregate research results? [Multiple choice]**

- The law requires the return of individual results unless the participant expressly declines to have results returned
- The law is silent on return of results; the expectation is that individual results will be returned unless the participant expressly declines to have the results returned
- The law is silent on return of results; aggregate results are typically returned, but individual results are not returned unless expressly stated in the research protocol
- I am not sure — or **other answer**

In principle, the results of genome research are not generally returned.

However, in February 2013, the “Ethical Guidelines on Human Genome and Genetic Analysis Research” were revised, and provide that, if a provider of genetic information wishes to have their research results returned, the researcher should do so. If the

researcher opts not to return the results, the reasons or conditions for this must be indicated.<sup>6</sup>

In the guidelines, the return of genetic information is considered to be a “principle.” However, in many research projects it has become customary to not do so based on the conditions separately written in the guidelines.

However, some genome banks have decided to return results because the results of genetic information analysis may be useful not only for research but also for the health of each participant. For example, informed consent in the Tohoku Medical Megabank Project describes the circulation of genetic information as follows:

In deciding on whether to return results, the following four conditions will be carefully considered:

1. The information has accuracy and certainty as information for evaluating a health condition
2. The information shows important facts for everyone’s health
3. There is no risk that the proper implementation of research work will be seriously hindered by distributing the information.
4. If there is a significant impact on life and health, then there is an effective treatment.

**9. Does your country have laws, policies, or guidelines regarding “direct-to-consumer” genetic testing (e.g., 23andMe) and, if so, what do they provide? [Multiple choice]**

- a. Yes. Direct-to-consumer genetic testing is illegal
- b. Yes. Direct-to-consumer genetic testing is legal**
- c. No. Direct-to-consumer genetic testing is not an issue
- d. I am not sure — or other answer

There is no legislation concerning DTP genetic testing. However, there are self-guidelines established by Ministry of Economy, Trade and

Industry (METI)<sup>7</sup> and industry groups,<sup>8</sup> as well as other guidelines established by the Japanese Association of Medical Sciences.<sup>9</sup>

### Part III — Looking to the Future

**10. How, if at all, do you anticipate that your country’s laws, policies, or guidelines will change in the next 5-10 years in response to international DTP genomic research? [Multiple choice]**

- a. I do not think they will change at all
- b. I think they will restrict international DTP research
- c. I think they will allow international DTP research**
- d. I am not sure — or other answer

In Japan, there is currently no law that prohibits them. It is believed that the implementation of international DTP genomic research itself will expand. In this case, the need for norms is pressing.

#### Note

The author has no conflicts to disclose.

#### References

1. MYCODE, available at <[https://mycode.jp/survey/research.html?src=information\\_20160831](https://mycode.jp/survey/research.html?src=information_20160831)> (last visited October 24, 2019) (in Japanese only).
2. RIKEN Center for Brain Science, available at <[http://www.brain.riken.go.jp/labs/mdmd/genome\\_research.html#topics4](http://www.brain.riken.go.jp/labs/mdmd/genome_research.html#topics4)> (last visited October 24, 2019) (in Japanese only).
3. National Hospital Organization, available at <<https://www.ehs-mcs-jp.com/>> (in Japanese only) (last visited October 24, 2019).
4. Ministry of Health, Labour and Welfare (MHLW), “Ethical Guideline of Human Genome and Genomic Analysis Study,” available at <<https://www.mhlw.go.jp/general/seido/kousei/i-kenkyu/genome/0504sisin.html>> (last visited October 24, 2019), s. 4(2) (in Japanese only).
5. MYCODE, *supra* note 1.
6. *Id.*, s. 11(1).
7. Ministry of Economy, Trade and Industry (METI), “Personal Information Protection Guidelines,” available at <[https://www.meti.go.jp/policy/mono\\_info\\_service/mono/bio/Seimeirinnri/guideline\\_20170329.pdf](https://www.meti.go.jp/policy/mono_info_service/mono/bio/Seimeirinnri/guideline_20170329.pdf)> (last visited October 24, 2019) (in Japanese only).

8. Japanese Committee for Clinical Laboratory Standards (JCCLS), “Best Practice Guideline,” available at <[http://www.jccls.org/techreport/bestpractice\\_guideline.pdf](http://www.jccls.org/techreport/bestpractice_guideline.pdf)> (in Japanese only); Council for the Handling of Personal Genetic Information (CPGI), “Voluntary Standards that Companies Dealing with Personal Genetic Information Should Comply With (Voluntary Standards for Individual Genetic Information Handling Companies),” available at <[http://www.cpi.or.jp/jisyu/img/sin\\_jisyu.pdf](http://www.cpi.or.jp/jisyu/img/sin_jisyu.pdf)> (last visited October 24, 2019) (in Japanese only).
9. Japanese Association of Medical Sciences (JAMS), “Guidelines for Genetic Tests and Diagnoses in Medical Practice,” available at <[http://jams.med.or.jp/guideline/genetics-diagnosis\\_e.pdf](http://jams.med.or.jp/guideline/genetics-diagnosis_e.pdf)> (last visited October 24, 2019).

## Jordan

*Maysa Al-Hussaini and Amal Al-Tabba’*

Researchers in genomics are exploring novel ways to interact directly with prospective participants without utilizing physicians, hospitals, or biobanks as intermediaries. Many researchers are interested in using the internet to directly recruit and enroll research participants in genomic studies by posting information online about active or proposed studies. This direct-to-participant (DTP) approach could take place under three main scenarios:

- A researcher in your country wants to conduct DTP genomic research with participants in your country
- A researcher in your country wants to conduct DTP genomic research with participants in another country

**Maysa Al-Hussaini, M.D., FRCPath**, is a Consultant, Histopathologist/Neuropathologist, and Chair of the Institutional Review Board, King Hussein Cancer Center, Jordan. **Amal Al-Tabba’, M.Sc.**, is the Coordinator of the Human Research Protection Program, King Hussein Cancer Center, Jordan.

- A researcher from outside your country wants to conduct DTP genomic research with participants in your country

There is uncertainty about whether DTP recruitment, enrollment, and research are lawful under these scenarios.

### Part I — DTP-Specific Questions

#### 1. As far as you know, is DTP genomic research a topic of interest to researchers or other stakeholders in your country? [Multiple choice]

- There has been little, if any, discussion of the issue as of now**
- There has been discussion among researchers, but little discussion among policy makers
- There has been discussion among both researchers and policy makers
- I am not sure — or other answer

#### 2. Assume that a researcher in your country wants to conduct DTP genomic research with participants in your country and that such research is subject to IRB/REC review. Please describe the conditions for IRB/REC approval, if it could be approved at all.

The IRB may approve the research if adequate safeguards for the following are present:

- Privacy and confidentiality, e.g., sample coding/de-identification, who will have access to private data and test results, will the results be shared by other institutions or researchers, will such results be included in participants' medical records.
- Informed consent, e.g., how to make sure participants understand and comprehend information

provided including risks of participation, are participants able to make participation decisions autonomously.

- Participants' benefits and compensation, e.g., identifying harmful genetic mutations for certain diseases, where effective measures can be taken for better health outcomes (i.e., prophylaxis or treatment options).
- Returning results, whether individual or aggregated, and incidental findings, especially actionable ones e.g., the emotional, psychological, and social impact of returning such results on the individual and family, including stigmatization, family conflicts or genetic discrimination in insurance or employment.
- Genetic counseling services, e.g., how and who will interrupt results to the participant and its health impact for the individual and family, possible effective measures to reduce risk, clinical validity and uncertainty of some tests.
- Data and biospecimen ownership.
- Commercialization.
- Provision for data and biospecimens withdrawal, and biospecimens destruction.

#### 3. Assume that a researcher in your country wants to conduct DTP genomic research in another country. Please describe the conditions that must be satisfied for IRB/REC approval in your country, if it could be approved at all. Would your IRB/REC also require approval from a research ethics review body in the other country?

Same conditions as above in addition to the approval from the IRB/research ethics review body in the other country or institution.

#### 4. Assume that a researcher from outside your country wants to

#### conduct DTP genomic research in your country.

- Would it be lawful for the researcher to do so without IRB/REC approval in either the researcher's country or your country? [Yes/No]

Yes

No

- Not sure or other;** Since there is no governing official legislation or guidelines that regulate such research in Jordan, the issue is left to the local IRB/REC to determine whether such research can be approved as per the requirements described in question 2. If there was direct recruitment from the researcher to the participants without passing through an institution, then there are no publicly available guidelines that can be applied.

- Would it be lawful for the researcher to do so if the research were approved by an IRB/REC in the researcher's own country, but was not submitted for approval in your country? [Yes/No]

Yes

No

- Not sure or other;** There is no law or guideline that can be used to guide the researcher or the participants. So essentially this would be similar to part A.

- Would the external researcher be required to have a collaborator in your country? [Yes/No]

Yes

No

- Not sure or other**

At our institution we always ask for an internal "Site Principal Investigator" for all external research that is conducted within the premises of the institution. If our local IRB acts as the

“IRB of Record” where it reviews a study by an external PI that plans to recruit participants from the community, we always mandate the presence of a local collaborator from the country. However, in the absence of official legislation or guidelines that govern this type of research, it is left up to the external researcher to approach one of the local IRBs and act accordingly.

- d. Would it matter whether the external researcher is based at a commercial, governmental, or academic entity? [Yes/No]
- Yes
- No
- Not sure or other**

A survey study of 205 adult cancer patients in a cancer center in Amman reported that 81.0% accepted sending their surplus samples to research laboratories abroad, even without specific consent.<sup>1</sup> Additionally, an unpublished survey study of 400 adult cancer patients in the same center found that 60.6% believed that they should retain some ownership of donated samples, while 86.6% would not mind using their samples in research by “for-profit” third-parties if they were initially informed.

Although the public might find such acts acceptable as supported by the above studies, the situation might be different from a governmental point of view. For example, Article 9 of the *Jordanian Stem Cell Statute* prohibits the collection, procurement, storage or use of embryonic stem cells for research or therapy in any form unless by a specialized governmental institution or publicly funded academic institution.<sup>2</sup> Dajani (2014) commented that this is due to the expected higher levels of transparency of governmental organizations in addition to the supervision by the Ministry of Health and its specialized committee.<sup>3</sup>

From my own previous experience with transfer of biospecimens (saliva in the case encountered) for the purpose of an IRB-approved research activity, the Ministry of Internal Affairs in Jordan did not approve the transfer of the saliva outside of

the country. Therefore, such issues should be taken into consideration when dealing with DTP genomic research, even in the absence of official legalization that addresses this issue in particular.

5. **As far as you know, what are the perceived benefits and risks that could occur if a researcher from another country conducted IRB/REC-approved genomic research on samples or data obtained from your country? Please consider the perspectives of the public, research participants, socially-defined groups (e.g., indigenous or minority populations), researchers, and other professional or government entities.**

There are no clear obligations from governmental entities. Nonetheless, our IRB mandates the presence of a local collaborator from the original country, i.e., a site principal investigator. This is to ensure accountability of the biospecimens in the country of origin and integrity of the data. The IRB may request the site principal investigator to approve the way the results will be presented and disseminated to eliminate the risk of social stigmatization, especially in minority populations. This is very important considering the tribal nature of our community and high risk of social and psychological stigmatization and its serious consequences if such results were to be disclosed inappropriately. Again, this is the practice of our local IRB; other IRBs in the country might not mandate having a site principal investigator.

From the public perspective, people in this part of the world are very worried about potential misuse of their biospecimens and data in, for example, foreign political agendas affecting the safety and security of the nation, publicly known as the “Conspiracy Theory.” In the unpublished survey study, “Trust” in the custodian research organization and employees were the main driving forces for

participation in biobanking research (84.2% and 85.3%, respectively).

## Part II – General Questions

6. **Does your country have biohazard committees, data protection boards, export permit authorities, or other entities that regulate the exporting of biospecimens or the transferring of data across borders for research? If so, do these requirements apply to individual citizens as well as research and medical institutions?**

None.

7. **Does your country have laws, policies, or guidelines dealing with genetic or genomic research or genetic or genomic privacy that would apply to international DTP research? Do your national laws on these issues apply outside of your country when residents or citizens of your country enroll in a DTP study conducted abroad?**

None.

8. **Does your country have laws, policies, guidelines, or cultural expectations regarding the return of individual or aggregate research results? [Multiple choice]**

- a. The law requires the return of individual results unless the participant expressly declines to have results returned
- b. The law is silent on return of results; the expectation is that individual results will be returned unless the participant expressly declines to have the results returned
- c. **The law is silent on return of results; aggregate results are typically returned, but**

**individual results are not returned unless expressly stated in the research protocol**

d. I am not sure — or other answer

*Note:* In the previous published work, 84.9% were interested to know the results of that research, but with a specific opt-in consent.<sup>4</sup> Similarly, in the unpublished work, 74% respondents wanted to know results when donating biospecimens for biobanking.

**9. Does your country have laws, policies, or guidelines regarding “direct-to-consumer” genetic testing (e.g., 23andMe) and, if so, what do they provide? [Multiple choice]**

- a. Yes. Direct-to-consumer genetic testing is illegal
- b. Yes. Direct-to-consumer genetic testing is legal
- c. **No. Direct-to-consumer genetic testing is not an issue**
- d. I am not sure — or other answer

### Part III — Looking to the Future

**10. How, if at all, do you anticipate that your country’s laws, policies, or guidelines will change in the next 5-10 years in response to international DTP genomic research? [Multiple choice]**

- a. I do not think they will change at all
- b. I think they will restrict international DTP research
- c. I think they will allow international DTP research

**d. I am not sure — or other answer.** While this issue is becoming regulated in many countries, the local authorities, with the help of the scientists, should work to ensure the drafting and approval of legislation to regulate and govern “genomic research,” including international DTP research.

#### Note

The authors have no conflicts to disclose.

#### References

1. M. Al Hussaini and A. Abu Hmaidan, “Use of Human Surplus Biospecimens in Research: A Survey from a Cancer Centre,” *Eastern Mediterranean Health Journal* 20, no. 6 (2014): 378-384.
2. Statute No. 10 of 2014 on Stem Cells (Jordan).
3. R. Dajani, “Jordan’s Stem-Cell Law can Guide the Middle East,” *Nature* 510, no. 7504 (2014): 189-189.
4. See Al Hussaini and Abu Hmaidan, *supra* note 1.

## Mexico

*Lourdes Motta-Murgía and Laura Estela Torres Moran*

Researchers in genomics are exploring novel ways to interact directly with prospective participants without utilizing physicians, hospitals, or biobanks as intermediaries. Many researchers are interested in using the internet to directly recruit and enroll research participants in genomic studies by posting information online about active or proposed studies. This direct-to-participant (DTP) approach could take place under three main scenarios:

- A researcher in your country wants to conduct DTP genomic research with participants in your country
- A researcher in your country wants to conduct DTP genomic research with participants in another country
- A researcher from outside your country wants to conduct DTP genomic research with participants in your country

There is uncertainty about whether DTP recruitment, enrollment, and

research are lawful under these scenarios.

### Part I — DTP-Specific Questions

**1. As far as you know, is DTP genomic research a topic of interest to researchers or other stakeholders in your country? [Multiple choice]**

- a. **There has been little, if any, discussion of the issue as of now**
- b. There has been discussion among researchers, but little discussion among policy makers
- c. There has been discussion among both researchers and policy makers
- d. I am not sure — or other answer

From our perspective, the Mexican discussion about genomic research gravitates around the lack of funding. There is little discussion about the recruitment of participants for this type of study; mostly it revolves around the need for previous informed consent.<sup>1</sup>

**2. Assume that a researcher in your country wants to conduct DTP genomic research with participants in your country and that such research is subject to IRB/REC review. Please describe the conditions for IRB/REC approval, if it could be approved at all.**

According to the *General Health Law*, every institution that conducts medical research on human beings should establish a Research Ethics Committee (REC). This includes public, private, and social institutions. The REC is responsible for evaluating and accepting all protocols involving

**Lourdes Motta-Murgía, M.Sc, LL.B., Ph. D.,** is the CEO of PPAL Bureau de Asuntos Públicos y Comunicación (PPAL: Bureau of Public Affairs and Communication); **Laura Estela Torres Moran, LL.B., LL.M.,** is Director of Public Affairs of PPAL Bureau de Asuntos Públicos y Comunicación (PPAL: Bureau of Public Affairs and Communication).

research on human beings. The REC is also responsible for establishing research ethics guidelines and overseeing their implementation. The REC's activities must comply with the laws and guidelines set forth by the National Bioethics Commission. The statutory provisions also establish that RECs should be interdisciplinary organs, including the participation of people that have received training in bioethics, including: physicians with different specialties, nurses, social workers, and experts in psychology, sociology, anthropology, philosophy or law. RECs must include patients representing the affected community. The law also mandates that RECs should aim for gender equality. (See article 41 Bis of the *General Health Law*)

Article 100 of the *General Health Law* and its Regulations on Health Research establish the following requirements to conduct research on human beings:

- Respect for the scientific and ethical principles that justify the project.
- The project can be conducted only when the expected knowledge cannot be obtained by other means.
- Reasonably ensure that the project does not create unnecessary risks for the participant. The Regulations classify research on human beings according to the risks it might entail. Genomic studies using samples of blood or saliva are classified as minimal risk studies.
- Written informed consent letter signed by the participant or their legal guardian. According to the Regulations, the project's research leader should draft the document and ask for the approval of the institution's REC. The participant must be informed on the research objectives and justification, as well as its possible positive or negative outcomes for their health. The document must be signed by two witnesses. Two copies of the informed consent document must be signed: one for the participant and one for

the institution. The participants can withdraw their consent at all times.

- Research on human beings can only be conducted within medical institutions, acting under the surveillance of health authorities. Such institutions must have the capacity to secure the participants' integrity.
- Population genomics studies must be part of a research project.
- The health professional responsible for the project is bound to stop activities if they could cause serious injury, disability or death.
- The responsible institution must secure medical care for the participants in case they suffer any collateral injuries related to the research activities performed on them. This does not exclude other types of liability.
- The responsible parties (institutions and individuals) must protect the participant's privacy, identifying the subject only when the research activities require it and the participant has granted permission to do so.

RECs must assess that protocols comply with the aforementioned requirements and shall be registered before the National Bioethics Commission. It is important to clarify that Mexican law does not create barriers on a DTP approach. In fact, Regulations contemplate both individual and group approaches.<sup>2</sup>

**3. Assume that a researcher in your country wants to conduct DTP genomic research in another country. Please describe the conditions that must be satisfied for IRB/REC approval in your country, if it could be approved at all. Would your IRB/REC also require approval from a research ethics review body in the other country?**

Mexican law does not contemplate the hypothesis of a researcher based in Mexico wanting to conduct research in another country. Thus, the foreign country's requirements would apply. If the project involves any activities within Mexico, then the project would need a Mexican institution to sponsor it, through the approval of its REC and the fulfillment of all the requirements listed in the answer to question 2.

Historically, the Federal Government has allocated funds to Mexican scientists to conduct studies through grants administered by the Ministry of Foreign Affairs and the National Council of Science and Technology. However, these calls for proposals focus on establishing criteria for the allocation of funds to Mexican scientists affiliated with foreign institutions, but do not contemplate the approval of a research protocol in Mexico. Thus, the rules that apply are those that govern the foreign institution.

**4. Assume that a researcher from outside your country wants to conduct DTP genomic research in your country.**

- a. Would it be lawful for the researcher to do so without IRB/REC approval in either the researcher's country or your country? [Yes/No]
- Yes
- No
- Not sure or other

The foreign researcher would need to partner with a Mexican institution to conduct research in Mexico. Mexican law does not require the approval of an REC in the researcher's country. However, the REC housed by the Mexican institution would likely ask for such approval from the foreign IRB/REC.

- b. Would it be lawful for the researcher to do so if the research were approved by an IRB/REC in the researcher's own country, but was not sub-



mitted for approval in your country? [Yes/No]

- Yes  
 No  
 Not sure or other

Since Mexican law does not contemplate this hypothesis, the lawful way to handle this situation is to partner with a Mexican institution.

- c. Would the external researcher be required to have a collaborator in your country? [Yes/No]  
 Yes  
 No  
 Not sure or other

The external researcher would most likely be required to have a collaborator in Mexico. The researcher's institution might apply for authorization for the research protocol before Mexican Health Authorities; however, such a permit might be denied without the collaboration of a Mexican institution.

- d. Would it matter whether the external researcher is based at a commercial, governmental, or academic entity? [Yes/No]  
 Yes  
 No  
 Not sure or other

According to Mexican legislation, whether the researcher is based at a commercial, governmental, or academic entity should not be a relevant factor as long as the foreign institution collaborates with a Mexican institution that houses a validly installed REC. Research on human beings can be carried out by public, private and social institutions.

5. **As far as you know, what are the perceived benefits and risks that could occur if a researcher from another country conducted IRB/REC-approved genomic research on samples or data obtained from your country? Please consider the perspectives of the public, research partici-**

**pants, socially-defined groups (e.g., indigenous or minority populations), researchers, and other professional or government entities.**

If a researcher from another country conducted IRB/REC-approved genomic research on samples or data obtained from Mexico, there is a risk that the public could misinterpret the work as "experimenting" with the Mexican population, especially if the project involves members of a socially-defined group. Partnering with a well-renowned Mexican public institution could limit such risk. However, it is recommended to handle the research process with transparency and in compliance with the Mexican legal framework, especially with the provisions on informed consent for research purposes and for the protection of personal data.

## Part II — General Questions

6. **Does your country have biohazard committees, data protection boards, export permit authorities, or other entities that regulate the exporting of biospecimens or the transferring of data across borders for research? If so, do these requirements apply to individual citizens as well as research and medical institutions?**

Mexican laws and regulations expressly allow for exporting human tissues that may be a source of genetic material outside the national territory with the purpose of conducting population genomic studies. According to the *General Health Law* (articles 317 Bis y 317 Bis 1) such activity is subject to the following requirements:

- I. The material is used solely for the purposes approved by a Mexican institution devoted to scientific research and pursuant to article 100 of the Law (requirements for research on human beings) as well as to the Regulations on research and other applicable provisions, and

II. A permit from the Federal Ministry of Health, through the national regulatory authority (Federal Commission for the Protection against Sanitary Risks), is obtained.

These articles of the *General Health Law* also indicate that the Federal Ministry of Health, in coordination with the National Institute of Genomic Medicine, in its capacity as advisory body to the Federal Government and national reference center in the field, shall keep a record of the permits granted for the transfer of the aforementioned tissues.

Such provisions are applicable to individual citizens as well as research and medical institutions. It is important to reiterate that exportation of samples requires the intervention of a Mexican scientific institution.<sup>3</sup>

7. **Does your country have laws, policies, or guidelines dealing with genetic or genomic research or genetic or genomic privacy that would apply to international DTP research? Do your national laws on these issues apply outside of your country when residents or citizens of your country enroll in a DTP study conducted abroad?**

Concerning data protection, the following laws exist in Mexico: *Federal Law on Protection of Personal Data*, *Federal Law of Transparency and Access to Public Government Information*, and *Federal Law on the Protection of Personal Data held by Private Parties*. These laws, along with their associated regulations, provide for the protection of health information and personal data, defining them as confidential data. The aforementioned laws establish that genetic information is sensitive personal data and mandate its protection.

In addition to laws on the matter, the National Institute for Transparency, Access to Information and Data Protection (before Federal Institute for Transparency, Access to Information and Data Protection) has issued a series of recommendations for the management of public and private information and data protection. For

example, the *Recommendations on Personal Data Safety* were issued to implement administrative, technical, and physical safety measures aimed to protect personal data against damage, loss, alteration, destruction, or unauthorized use, access, or treatment. One of the main challenges, not only in Mexico but worldwide, is the establishment of technological measures for database protection, both for storage in physical locations and in virtual spaces, like clouds. The protection of participant information in research studies is not just guaranteed by anonymity or by the biological sample data dissociation anymore; it has become a more complex process.

Mexico has taken part in international efforts to harmonize data protection laws such as the Global Alliance for Genomics and Health. The National Institute of Genomic Medicine is part of such an effort. However, there is still a long way to go in order to harmonize different standards from countries allowing information exchange without affecting the privacy rights of participants on research studies.

Mexican legal standards have no means of applying outside of Mexican territory when Mexican residents or citizens enroll in a DTP study conducted entirely abroad. If a foreign researcher or institution partners with a Mexican institution to conduct the study partially in Mexico, the aforementioned data protections laws are applicable.<sup>4</sup>

**8. Does your country have laws, policies, guidelines, or cultural expectations regarding the return of individual or aggregate research results? [Multiple choice]**

- a. The law requires the return of individual results unless the participant expressly declines to have results returned
- b. The law is silent on return of results; the expectation is that individual results will be returned unless the par-**

**ticipant expressly declines to have the results returned**

- c. The law is silent on return of results; aggregate results are typically returned, but individual results are not returned unless expressly stated in the research protocol
- d. I am not sure — or other answer

The expectation of receiving results arises from the informed consent provisions. Mexican laws do not intend to govern acts performed in other countries.

**9. Does your country have laws, policies, or guidelines regarding “direct-to-consumer” genetic testing (e.g., 23andMe) and, if so, what do they provide? [Multiple choice]**

- a. Yes. Direct-to-consumer genetic testing is illegal
- b. Yes. Direct-to-consumer genetic testing is legal
- c. No. Direct-to-consumer genetic testing is not an issue**
- d. I am not sure — or other answer

Mexican law provisions are not specific on “direct-to-consumer” genetic testing. Regardless of the recruiting process, provisions on informed consent and personal data protection apply.

**Part III — Looking to the Future**

**10. How, if at all, do you anticipate that your country’s laws, policies, or guidelines will change in the next 5-10 years in response to international DTP genomic research? [Multiple choice]**

- a. I do not think they will change at all
- b. I think they will restrict international DTP research
- c. I think they will allow international DTP research
- d. I am not sure — or other answer**

I do not think that the Mexican legal framework will change in the short term because science does not seem to be a priority of the current administration. The only scenario in which I foresee an interest to regulate DTP genomic research specifically would be if such type of research would generate a noteworthy crisis that would call for a direct response from the government.

**Note**

The authors have no conflicts to disclose.

**References**

1. M. Ruiz de Chávez and R. Piña Jiménez, eds., *Bioética y Nuevas Fronteras de la Genética*, (Mexico: Fontamara/Conbioética, 2018); G. Jiménez Sánchez, et al., “La Medicina Genómica en México: Los Primeros Pasos y el Camino por Recorrer,” *Genome Research* 18, no. 8 (2008): 1191-1198.; P.F. Oliva Sánchez, et al., “La Medicina Genómica en las Políticas de Salud Pública: Una Perspectiva de Investigadores Mexicanos del área Biomédica,” *Salud Pública de México* 55, no. 1 (2013): 16-25.
2. Ley General de Salud [LGS] Diario Oficial de la Federación [DOF] 07-02-1984, últimas reformas DOF 07-12-2018 (General Health Law) (Mex.); Reglamento de la Ley General de Salud en materia de Investigación para la Salud [RLGS-mIS], Diario Oficial de la Federación [DOF] 04-02-2014, últimas reformas DOF 07-12-2018 (Regulations of the General Health Law on Health Research); Acuerdo por el que se Emiten las Disposiciones Generales para la Integración y Funcionamiento de los Comités de Ética en Investigación y se Establecen las Unidades Hospitalarias que Deben Contar con Ellos, de Conformidad con los Criterios Establecidos por la Comisión Nacional de Bioética, Diario Oficial de la Federación [DOF] 10-31-2012 (General Rules for the Integration and Operation of Research Ethics Committees and the Health Care Units that must Establish Them, According to the Criteria of the National Bioethics Commission) (Mex.); National Bioethics Commission Mexico, *Guía Nacional para la Integración y el Funcionamiento de los Comités de Ética en Investigación*, [National Guidelines for the Integration and Operation of Research Ethics Committees] 5th edition, 2016.
3. Ley General de Salud [LGS], Diario Oficial de la Federación [DOF] 07-02-1984, últimas reformas DOF 07-12-2018 (General Health Law); Reglamento de la Ley General de Salud en materia de Investigación para la Salud [RLGS-mIS], Diario Oficial de la Fed-

eración [DOF] 04-02-2014, últimas reformas DOF 07-12-2018 (Regulations of the General Health Law on Health Research) (Mex.).

4. Ley General de Protección de Datos Personales en Posesión de Sujetos Obligados [LGPDPPO], Diario Oficial de la Federación [DOF] 01-26-2017; Ley Federal de Transparencia y Acceso a la Información Pública [LFTAIP], Diario Oficial de la Federación [DOF] 05-09-2016, últimas reformas DOF 01-27-2017 (Federal Law of Transparency and Access to Public Government Information) (Mex.); Ley Federal de Protección de Datos Personales en Posesión de los Particulares [LFPDPPP] Diario Oficial de la Federación [DOF] 07-05-2010 (Federal Law on the Protection of Personal Data held by Private Parties)(Mex.).

## The Netherlands

Aart Hendriks

Researchers in genomics are exploring novel ways to interact directly with prospective participants without utilizing physicians, hospitals, or biobanks as intermediaries. Many researchers are interested in using the internet to directly recruit and enroll research participants in genomic studies by posting information online about active or proposed studies. This direct-to-participant (DTP) approach could take place under three main scenarios:

- A researcher in your country wants to conduct DTP genomic research with participants in your country
- A researcher in your country wants to conduct DTP genomic research with participants in another country
- A researcher from outside your country wants to conduct DTP genomic research with participants in your country

There is uncertainty about whether DTP recruitment, enrollment, and research are lawful under these scenarios.

### Part I — DTP-Specific Questions

#### 1. As far as you know, is DTP genomic research a topic of interest to researchers or other stakeholders in your country? [Multiple choice]

- a. There has been little, if any, discussion of the issue as of now
- b. There has been discussion among researchers, but little discussion among policy makers**

In the Netherlands, there has been discussion among researchers, notably about the “obstacles” they feel they encounter as a result of the implementation of the *General Data Protection Regulation*.<sup>1</sup> One of the problems researchers encounter concerns the extent to which, if at all, further use can be made of data from human beings in health research. The so-called (Dutch) Council of the Federation of Medical Scientific Societies, an initiative by health researchers, has developed, and in 2013/2014 revised a code of conduct for medical research.<sup>2</sup> The Dutch Privacy Authority<sup>3</sup> (“Autoriteit Persoonsgegevens”) has, however, not endorsed the code given that permission from the research subject for use of data is, according to the code, not always required, something the Privacy Authority considers as an encroachment of privacy standards.<sup>4</sup>

So far, policy makers have hardly addressed the legal and ethical aspects of genomic research. It should be added that the application of knowledge on genomics in the area of public health is still relatively scarce in the Netherlands.<sup>5</sup> Neither have many legal issues been resolved. This holds true, for example, about the issue of property/control over donated bodily materials in the course of a study.<sup>6</sup> In April 2017, the government started a public consultation on a draft bill on control over bodily materials,<sup>7</sup> but since the end of the consultation (June 2017) no further action has been taken. In the absence of normative clarity about a

number of issues relevant to genomic research, the government stimulates, through the Dutch *Innovatiegerichte Onderzoeksprogramma Genomics* (IOP Genomics) programme,<sup>8</sup> fundamental genomics research within public-private partnerships. The government also encourages — mostly indirectly — genomic research, for example, by making funds available to do research in the area of personalized medicine.<sup>9</sup> These funds are tacitly only available to researchers that adhere to quality standards and not to those who address prospective research participants without involving a health care provider.

In general, it should be mentioned that the Netherlands is bound by EU law. In this respect, reference should be made to *Directive 98/79/EC of the European Parliament and of the Council of October 27, 1998 on in vitro diagnostic medical devices*,<sup>10</sup> being replaced by *Regulation (EU) 2017/746 of the European Parliament and of the Council of April 5, 2017 on in vitro diagnostic medical devices*.<sup>11</sup> The latter directive/regulation contains safety and security standards for companion diagnostics, laboratory tests and home brews that should be applied in the Netherlands (and all other Member States of the European Union). This directive/regulation is indirectly relevant to DTP genomic research.

It follows that an IRB/REC review is generally not required.

- c. There has been discussion among both researchers and policy makers
- d. I am not sure — or other answer

#### 2. Assume that a researcher in your country wants to conduct DTP genomic research with participants in your country and that such research is subject to IRB/REC review. Please describe the conditions for IRB/REC approval, if it could be approved at all.

Aart Hendriks, Ph.D., is a Professor of Health Law, Leiden University, Netherlands.

Researchers based in the Netherlands considering genomic research with human beings/research participants in the Netherlands need to obtain a permit to perform this kind of research. This follows from the *Medical Research Involving Human Subjects Act*.<sup>12</sup> If the study falls under the realm of this *Act*, a prior review needs to be carried out by a State acknowledged medical research ethics committee (MREC) or, on appeal, by the Central Committee on Research Involving Human Subjects (CCMO).<sup>13</sup> Positive advice from an MREC (IRB/REC), on the basis of a research design, is required before medical research involving human beings is allowed to start. The MREC thoroughly analyzes whether a proposed study meets the scientific and quality standards laid down in Article 3 of the WMO. Another requirement laid down in the WMO is that the researcher has insurance for research participants, that is to say insurance that will financially compensate research participants in case of harm to their health or life due to the study.<sup>14</sup> Given these requirements and the fact that almost all MRECs are attached to hospitals or other health care providers it is very unlikely that a researcher who wants to conduct DTP genomic research with participants in the Netherlands will get a license.

It should be added that not all studies fall under the scope of this Act. In practice, most hospitals and health care providers will only allow a researcher to conduct a study with human beings after a positive advice from a MREC — even though this is not a legal requirement.

I am not aware of DTP genomic studies taking place in the Netherlands that obtained a permit on the basis of the WMO.

**3. Assume that a researcher in your country wants to conduct DTP genomic research in another country. Please describe the conditions that must be satisfied for IRB/REC approval in your country, if it could be approved at all. Would your IRB/REC also require approval from a research eth-**

**ics review body in the other country?**

A Dutch researcher planning to conduct DTP genomic research in another country is required to abide by Dutch law, failure of which may result in legal and disciplinary action. This means that he or she needs a permit (see question 2).

It follows that an IRB/REC review is generally not required.

**4. Assume that a researcher from outside your country wants to conduct DTP genomic research in your country.**

a. Would it be lawful for the researcher to do so without IRB/REC approval in either the researcher's country or your country? [Yes/No]

Yes  
 No

Dutch law does not foresee the possibilities of prohibiting/regulating DTP genomic research conducted in other countries by using internet as a means to address and involve prospective research participants. Dutch authorities may inform persons based in the Netherlands about the risks of participating in DTP genomic research. This would be different in the case of a researcher based outside the Netherlands who seeks to “regularly” address prospective research participants, for example, by having an office/postal address in the Netherlands and carrying out research in the Netherlands. These researchers are bound by Dutch law and therefore need a permit and IRB/REC review.

Not sure or other

b. Would it be lawful for the researcher to do so if the research were approved by an IRB/REC in the researcher's own country, but was not submitted for approval in your country? [Yes/No]

Yes  
 No

No. Despite the fact that quite some laws in Europe are harmonized, a Dutch permit — based on positive advice by an IRB/REC — is required to start research with human beings in the Netherlands. European (EU) laws on research in this respect differ from European (EU) laws on medicinal products for human use.<sup>15</sup>

Not sure or other

c. Would the external researcher be required to have a collaborator in your country? [Yes/No]

Yes  
 No

Dutch law does not require the involvement of a Netherlands-based collaborator. The main requirement is that the research design has been approved by an MREC and has consequently received a permit. This would only be different if prospective research participants are only addressed via the internet.

Not sure or other

d. Would it matter whether the external researcher is based at a commercial, governmental, or academic entity? [Yes/No]

Yes  
 No

This does not matter, neither for the GDPR nor its privacy principles.

Not sure or other

**5. As far as you know, what are the perceived benefits and risks that could occur if a researcher from another country conducted IRB/REC-approved genomic research on samples or data obtained from your country? Please consider the perspectives of the public, research participants, socially-defined groups (e.g., indigenous or minority populations), researchers, and other professional or government entities.**

A study conducted in another country above all seems to entail risks for

research participants in the Netherlands now that national/European/international standards are less self-evidently being adhered to. This not only raises privacy considerations (and the risk that personal data are being sold to third parties without the approval of the research participant), but also concerns such as informed consent, the right to withdraw consent, the rights of minors / persons not able to consent, and possibilities to enforce legal standards.

## Part II — General Questions

**6. Does your country have biohazard committees, data protection boards, export permit authorities, or other entities that regulate the exporting of biospecimens or the transferring of data across borders for research? If so, do these requirements apply to individual citizens as well as research and medical institutions?**

Such institutional bodies partially exist. The main means to protect the interests of research participants are the permit requirements under the WMO, the requirement for researchers to have insurance that can be applied in case of harm caused to the health or life of a research participant due to the research, and the privacy requirements laid down in the GDPR and the Act implementing the GDPR<sup>16</sup> — which also apply to the transfer of data across borders. In addition, researchers have their own professional standards with respect to quality, integrity, and privacy.

**7. Does your country have laws, policies, or guidelines dealing with genetic or genomic research or genetic or genomic privacy that would apply to international DTP research? Do your national laws on these issues apply outside of your country when residents or citizens of your country enroll in a DTP study conducted abroad?**

There are no laws, policies or guidelines specifically dealing with genetic/genomic research or genetic/genomic privacy. When it comes to the assessment of a research protocol concerning genetic/genomic research in view of a permit, the risks/privacy implications are considered. In the Netherlands, unlike e.g., Germany, the right to informational privacy has not been recognized under law. This is not to suggest that the risks/privacy implications of a research proposal do not receive special attention. This already follows from the GDPR, the *European Convention on Human Rights and Biomedicine*<sup>17</sup> and its Protocols, notably the *Additional Protocol to the Convention on Human Rights and Biomedicine concerning Genetic Testing for Health Purposes*.<sup>18</sup>

**8. Does your country have laws, policies, guidelines, or cultural expectations regarding the return of individual or aggregate research results? [Multiple choice]**

- The law requires the return of individual results unless the participant expressly declines to have results returned
  - The law is silent on return of results; the expectation is that individual results will be returned unless the participant expressly declines to have the results returned
  - The law is silent on return of results; aggregate results are typically returned, but individual results are not returned unless expressly stated in the research protocol
- d. I am not sure — or other answer**

We do not have such laws as yet, even though scientific journals and media regularly report on research participants in developing countries who contribute to studies but who — as well as others from their country — will probably not get access to the positive outcomes of a study. The

*Additional Protocol to the Convention on Human Rights and Biomedicine, concerning Biomedical Research*<sup>19</sup> partially addresses this issue by stipulating that:

(Article 28 — Availability of results) para. 2: “The conclusions of the research shall be made available to participants in reasonable time, on request” and (Article 29 — Research in States not parties to this Protocol): “Sponsors or researchers within the jurisdiction of a Party to this Protocol that plan to undertake or direct a research project in a State not party to this Protocol shall ensure that, without prejudice to the provisions applicable in that State, the research project complies with the principles on which the provisions of this Protocol are based. Where necessary, the Party shall take appropriate measures to that end.”

The Netherlands is, however, not a party to the Convention and its Protocols. The *Medical Research Involving Human Subjects Act*<sup>20</sup> explicitly prohibits financially compensating research participants to such an extent that this would influence their decision to participate in the study or not (Article 3 under f).

**9. Does your country have laws, policies, or guidelines regarding “direct-to-consumer” genetic testing (e.g., 23andMe) and, if so, what do they provide? [Multiple choice]**

- Yes. Direct-to-consumer genetic testing is illegal**
- Yes. Direct-to-consumer genetic testing is legal
- No. Direct-to-consumer genetic testing is not an issue
- I am not sure — or other answer

Direct-to-consumer genetic testing is illegal, unless the organization is offering DTC genetic testing with a permit. A request for a permit should be submitted to the Minister of Health on the basis of the *Population Screening Act*.<sup>21</sup> However, this act does **not apply to all** forms of population screening. The absence of a permit does not

imply that it is forbidden to **advertise** for genetic testing (e.g., for DTC genetic testing abroad or online).

Over the course of the last ten years the government commissioned three reports:<sup>22</sup>

- Council for Public Health & Care (Raad voor de Volksgezondheid & Zorg): Screening en de rol van de overheid (2008) (no longer available online)
- Health Council (Gezondheidsraad): Screening: tussen hoop en hype (2008), *available at* <<https://www.gezondheidsraad.nl/documenten/adviezen/2008/04/01/screening-tussen-hoop-en-hype>>
- Health Council (Gezondheidsraad): Doorlichten doorgelicht (2015), *available at* <<https://www.rijksoverheid.nl/documenten/rapporten/2015/03/05/doorlichten-doorgelicht-gepast-gebruik-van-health-checks>>

The basis of these reports and the discussion in society have resulted in the announcement by the government that it wants to change the WBO. The government has the intention to broaden the scope of the WBO, so that all health checks fall within the realm of this act. According to the draft amendments, the WBO will in the future distinguish between (1) health checks without medical risks — no permit required, (2) health checks with some medical risks — with professional standards applying, and (3) health checks that may uncover serious diseases or abnormalities for which no prevention or treatment exists — need a permit. The government held a public consultation on these proposals from June 26, 2018 — August 8, 2018.<sup>23</sup> Since then the government did not undertake any further action, the current WBO and other applicable laws still apply in the same way.

The discussion among researchers, doctors, patients, and various advisory bodies on direct-to-consumer genetic testing mostly centers on:

- What are the benefits and risks for individuals and society at large when individuals can freely decide to undergo a genetic test without the involvement/approval/reference of a health care provider?
- Should we protect individuals (prohibit participation, unless...) or allow individuals to enjoy their right of individual autonomy (allow individuals to participate, unless...)?
- Who should guarantee that the individual participant is adequately informed prior to undergoing a genetic test?
- How can we guarantee the validity of genomic tests?
- How can we protect the privacy of individuals?
- Do we need to pay special attention to the rights and interests of children/persons unable to consent?
- How can we guarantee that national standards are respected given the European/international context in which DTC genomic testing takes place?

### Part III — Looking to the Future

#### 10. How, if at all, do you anticipate that your country's laws, policies, or guidelines will change in the next 5-10 years in response to international DTP genomic research? [Multiple choice]

- I do not think they will change at all
- I think they will restrict international DTP research
- I think they will allow international DTP research

#### d. I am not sure — or other answer

I foresee/hope that these issues will be addressed on a European level (and, if possible, an international level).

#### Note

The author has no conflict to disclose.

### References

1. Regulation (EU) 2016/679 of the European Parliament and of the Council of April 27, 2016 on the protection of natural persons with regard to the processing of personal data and on the free movement of such data, and repealing Directive 95/46/EC (General Data Protection Regulation), 2016 O.J. (L 119), 1
2. The Council of the Federation of Medical Scientific Societies, FMWV Code of Conduct for Health Research, *available at* <[https://www.federa.org/sites/default/files/bijlagen/coreon/code\\_of\\_conduct\\_for\\_medical\\_research\\_1.pdf](https://www.federa.org/sites/default/files/bijlagen/coreon/code_of_conduct_for_medical_research_1.pdf)> (last visited October 28, 2019).
3. Autoriteit Persoonsgegevens, *available at* <<https://www.autoriteitpersoonsgegevens.nl/en>> (last visited October 28, 2019).
4. Federation of Dutch Medical Scientific Societies, code Goed Gedrag, *available at* <<https://www.federa.org/code-goed-gedrag>> (last visited October 28, 2019), English version, *available at* <<https://www.federa.org/codes-conduct>> (last visited October 28, 2019).
5. M. van den Berg and H.J. van Kranen, "Public Health Genomics: Wat Zijn de Kansen voor Preventie?," Rijksinstituut voor Volksgezondheid en Milieu (RIVM) Report 270524001/2013, *available at* <<https://www.rivm.nl/bibliotheek/rapporten/270524001.pdf>> (last visited August 2, 2019).
6. B. Jansen and R.I.C. Baart, "Van wie is mijn geamputeerde been?" *Nederlands Tijdschrift voor Geneeskunde* 162 (2018): D2301, *available at* <<https://www.ntvg.nl/artikelen/van-wie-mijn-geamputeerde-been/artikelinfo>> (last visited October 28, 2019).
7. Wet zeggenschap lichaamsmateriaal, Ministerie van Volksgezondheid, Welzijn en Sport, April 24, 2017, *available at* <<https://www.internetconsultatie.nl/zeggenschaplichaamsmateriaal>> (last visited October 28, 2019).
8. Rijksdienst voor Ondernemend Nederland, "Projects IOP Genomics (English)," *available at* <<https://www.rvo.nl/subsidies-regelingen/iops/iop-genomics/projects-english>> (last visited October 28, 2019).
9. Netherlands Organisation for Health Research and Development (ZonMw), "Personalised Medicine Program," *available at* <<https://www.zonmw.nl/nl/onderzoek-resultaten/genesmidelen/programmas/programma-detail/personalised-medicine/>> (last visited August 2, 2019).
10. Directive 98/79/EC of the European Parliament and of the Council of October 27, 1998 on in vitro diagnostic medical devices, 1998 O.J. (L 331), 1.
11. Regulation (EU) 2017/746 of the European Parliament and of the Council of April 5, 2017 on in vitro diagnostic medical devices and repealing Directive 98/79/EC and Commission Decision 2010/227/EU, 2017 O.J. (L 117), 176.

12. Wet medisch-wetenschappelijk onderzoek met mensen februari 26, 1998, Stb. 1998.
13. See Centrale Commissie Mensgebonden Onderzoek (CCMO), Erkende METC's, *available at* <<https://www.ccmo.nl/metcs/erkende-mets>> (last visited October 28, 2019); Committee Finder, *available at* <[https://pauljanssenfuturelab.eu/tools/clinical\\_research\\_in\\_the\\_netherlands/committee\\_finder/?user\\_id=0&token](https://pauljanssenfuturelab.eu/tools/clinical_research_in_the_netherlands/committee_finder/?user_id=0&token)> (last visited October 28, 2019).
14. Besluit verplichte verzekering bij medisch-wetenschappelijk onderzoek met mensen 2015 November 24, 2014, Stb. 2014, 477.
15. Directive 2001/83/EC of the European Parliament and of the Council of November 6, 2001 on the Community code relating to medicinal products for human use, 2001 O.J. (L 31), 28, 67.
16. Uitvoeringswet Algemene verordening gegevensbescherming Mei 25, 2018, Stb. 2018, 145.
17. Convention for the Protection of Human Rights and Dignity of the Human Being with regard to the Application of Biology and Medicine: Convention on Human Rights Biomedicine, C.E.T.S. no. 164 (April 4, 1997).
18. Additional Protocol to the Convention on Human Rights and Biomedicine concerning Genetic Testing for Health Purposes, C.E.T.S. No. 203 (November 27, 2008).
19. Additional Protocol to the Convention on Human Rights and Biomedicine, concerning Biomedical Research, C.E.T.S. no. 195 (January 1, 2005).
20. Wet medisch-wetenschappelijk onderzoek met mensen Februari 26, 1998, Stb. 1998.
21. Wet op het bevolkingsonderzoek Oktober 29, 1992, Stb. 1992, 611.
22. Raad voor de Volksgezondheid and Zorg (Council for Public Health & Care), Screening en de rol van de overheid (2008) (no longer available online); Health Council (Gezondheidsraad): Screening: tussen hoop en hype (2008), *available at* <<https://www.gezondheidsraad.nl/documenten/adviezen/2008/04/01/screening-tussen-hoop-en-hype>> (last visited October 28, 2019); Health Council (Gezondheidsraad): Doorlichten doorlicht (2015), *available at* <<https://www.rijksoverheid.nl/documenten/rapporten/2015/03/05/doorlichten-doorlicht-gepast-gebruik-van-health-checks>> (last visited October 28, 2019).
23. Wet op het bevolkingsonderzoek, Oktober 29, 1992, Stb. 1992, 611.

## Nigeria

### Obiajulu Nnamuchi

Researchers in genomics are exploring novel ways to interact directly

with prospective participants without utilizing physicians, hospitals, or biobanks as intermediaries. Many researchers are interested in using the internet to directly recruit and enroll research participants in genomic studies by posting information online about active or proposed studies. This direct-to-participant (DTP) approach could take place under three main scenarios:

- A researcher in your country wants to conduct DTP genomic research with participants in your country
- A researcher in your country wants to conduct DTP genomic research with participants in another country
- A researcher from outside your country wants to conduct DTP genomic research with participants in your country

There is uncertainty about whether DTP recruitment, enrollment, and research are lawful under these scenarios.

#### Part I — DTP-Specific Questions

##### 1. As far as you know, is DTP genomic research a topic of interest to researchers or other stakeholders in your country? [Multiple choice]

- a. There has been little, if any, discussion of the issue as of now
- b. There has been discussion among researchers, but little discussion among policy makers
- c. There has been discussion among both researchers and policy makers
- d. I am not sure — or other answer

##### 2. Assume that a researcher in your country wants to conduct DTP genomic research with

**participants in your country and that such research is subject to IRB/REC review. Please describe the conditions for IRB/REC approval, if it could be approved at all.**

There is no clear statement on DTP genomic research in Nigeria; nonetheless, it seems such research could be approved if the researcher can demonstrate adequate protection of research subjects, for instance, by protecting privacy and confidentiality of health information;<sup>1</sup> and complying with the requirements regarding consent.<sup>2</sup>

##### 3. Assume that a researcher in your country wants to conduct DTP genomic research in another country. Please describe the conditions that must be satisfied for IRB/REC approval in your country, if it could be approved at all. Would your IRB/REC also require approval from a research ethics review body in the other country?

The conditions stipulated above (see response to previous question) must be satisfied, and approval from a research ethics committee in the other country will be required.

##### 4. Assume that a researcher from outside your country wants to conduct DTP genomic research in your country.

- a. Would it be lawful for the researcher to do so without IRB/REC approval in either the researcher's country or your country? [Yes/No]
  - Yes
  - No
  - Not sure or other

Obiajulu Nnamuchi, LL.B., LL.M., M.A., S.J.D., is an Associate Professor of Law, University of Nigeria (Enugu Campus) Enugu, Nigeria.

b. Would it be lawful for the researcher to do so if the research were approved by an IRB/REC in the researcher's own country, but was not submitted for approval in your country? [Yes/No]

Yes

No

Not sure or other

c. Would the external researcher be required to have a collaborator in your country? [Yes/No]

Yes

No

Not sure or other

d. Would it matter whether the external researcher is based at a commercial, governmental, or academic entity? [Yes/No]

Yes

No

Not sure or other

5. As far as you know, what are the perceived benefits and risks that could occur if a researcher from another country conducted IRB/REC-approved genomic research on samples or data obtained from your country? Please consider the perspectives of the public, research participants, socially-defined groups (e.g., indigenous or minority populations), researchers, and other professional or government entities.

Benefits that could result from conducting IRB/REC-approved genomic research by a researcher from another country on samples or data obtained from Nigeria include (a) enrichment of or new knowledge regarding etiology, diagnosis, and treatment of diseases/adverse health conditions; (b) building capacity on the part of local scientists that would be recruited as collaborators; and (c) discovery of improved techniques of responding to or treatment of illnesses.

Risks consist of (a) abuse of research subjects, especially the poor and uneducated, most of whom are inadequately informed about the processes involved in their participation or the result,<sup>3</sup> and also considering the novelty of genomic research in Nigeria; and (b) inadequate attention to the rights and liberties of the research participants,<sup>4</sup> such as breach of confidentiality obligation regarding samples procured from a particular population group or community, which, in turn, could expose them to harm — discrimination/stigmatization.

## Part II — General Questions

6. Does your country have biohazard committees, data protection boards, export permit authorities, or other entities that regulate the exporting of biospecimens or the transferring of data across borders for research? If so, do these requirements apply to individual citizens as well as research and medical institutions?

Yes, Nigeria has an entity which regulates the exporting of biospecimens or the transferring of data across borders for research, namely, the Health Research Ethics Committee. This body is authorized to grant provisional approval pending the submission of a Material Transfer Agreement (MTA) to the National Health Research Ethics Committee (NHREC) and receipt of acknowledgment from the NHREC.<sup>5</sup> The requirement applies to all parties involved in the research including local and international principal investigators, heads of local institutions, research sponsors, and other relevant parties, all of whom must sign the MTA.<sup>6</sup>

7. Does your country have laws, policies, or guidelines dealing with genetic or genomic research or genetic or genomic privacy that would apply to international DTP research? Do your national laws on these

issues apply outside of your country when residents or citizens of your country enroll in a DTP study conducted abroad?

There is no law, policy or guideline specifically designed to apply to international DTP. Nonetheless, extant legal and policy frameworks — that is, National Code of Health Research Ethics;<sup>7</sup> Policy Statement on Storage of Human Samples in Biobanks and Biorepositories in Nigeria;<sup>8</sup> and *National Health Act*<sup>9</sup> — could be adopted to apply to international DTP research in the realm of genetic or genomic research or genetic or genomic privacy. There is no clear stipulation as to the applicability of these regimes outside of Nigeria when residents or citizens of the country enroll in a DTP study conducted abroad, but it would seem that they could be interpreted to apply.

8. Does your country have laws, policies, guidelines, or cultural expectations regarding the return of individual or aggregate research results? [Multiple choice]

a. The law requires the return of individual results unless the participant expressly declines to have results returned

b. The law is silent on return of results; the expectation is that individual results will be returned unless the participant expressly declines to have the results returned<sup>10</sup>

c. The law is silent on return of results; aggregate results are typically returned, but individual results are not returned unless expressly stated in the research protocol

d. I am not sure — or other answer

9. Does your country have laws, policies, or guidelines regarding “direct-to-consumer” genetic testing (e.g., 23andMe) and,



**if so, what do they provide?**  
**[Multiple choice]**

- a. Yes. Direct-to-consumer genetic testing is illegal
- b. Yes. Direct-to-consumer genetic testing is legal
- c. No. Direct-to-consumer genetic testing is not an issue**
- d. I am not sure — or other answer

**Part III — Looking to the Future**

**10. How, if at all, do you anticipate that your country's laws, policies, or guidelines will change in the next 5-10 years in response to international DTP genomic research? [Multiple choice]**

- a. I do not think they will change at all
- b. I think they will restrict international DTP research
- c. I think they will allow international DTP research
- d. I am not sure — or other answer**

**Note**

The author has no conflicts to disclose.

**References**

1. National Health Act (2014) SB. 215, § 26, available at <<http://www.ilo.org/dyn/natlex/docs/ELECTRONIC/104157/126947/F-693610255/NGA104157.pdf>> (last visited October 29, 2019).
2. Federal Ministry of Health (FMoH), National Code of Health Research Ethics, August 13, 2007, at 28 — 31, 37 — 40, [hereinafter cited as National Code of Health Research Ethics].
3. O. Nnamuchi, "Biobank/Genomic Research in Nigeria: Examining Relevant Privacy and Confidentiality Frameworks," *Journal of Law, Medicine & Ethics*, 43, no. 4 (2015): 776-786, at 776.
4. *Id.* at 776.
5. See National Code of Health Research Ethics, *supra*, note 2 at 24.
6. *Id.*
7. *Id.* at 37 — 42.
8. FMoH/ NHREC, Policy Statement on Storage of Human Samples in Biobanks and Biorepositories in Nigeria (PS1.02013), Nov. 1, 2013, available at <[http://nhrec.net/nhrec/NHREC\\_Policy\\_Statement\\_on\\_Biobanks\\_FINAL.pdf](http://nhrec.net/nhrec/NHREC_Policy_Statement_on_Biobanks_FINAL.pdf)> (last visited October 29, 2019).

9. See National Health Act, (2014) SB. 215, §§ 31 — 34 (Nigeria).
10. See FMoH/ NHREC, *supra*, note 8, at ¶ D(i).

## Peru

### *Rosario Isasi*

Researchers in genomics are exploring novel ways to interact directly with prospective participants without utilizing physicians, hospitals, or biobanks as intermediaries. Many researchers are interested in using the internet to directly recruit and enroll research participants in genomic studies by posting information online about active or proposed studies. This direct-to-participant (DTP) approach could take place under three main scenarios:

- A researcher in your country wants to conduct DTP genomic research with participants in your country
- A researcher in your country wants to conduct DTP genomic research with participants in another country
- A researcher from outside your country wants to conduct DTP genomic research with participants in your country

There is uncertainty about whether DTP recruitment, enrollment, and research are lawful under these scenarios.

### **Part I — DTP-Specific Questions**

**1. As far as you know, is DTP genomic research a topic of interest to researchers or other stakeholders in your country? [Multiple choice]**

- a. There has been little, if any, discussion of the issue as of now**

- b. There has been discussion among researchers, but little discussion among policy makers
- c. There has been discussion among both researchers and policy makers
- d. I am not sure — or other answer

Since 2015, the Peruvian government has adopted legislation and other norms to provide incentives to foster scientific research and innovation in the country. However, none of these efforts has been tailored to capture the nuances of genomic studies, creating loopholes, and legal uncertainty with respect to the scope and application of the current regulatory framework. Importantly, in Peru there are no specific norms (legislation, guidelines, etc.) applicable to direct-to-consumer genetic testing or genetic research.<sup>1</sup>

**2. Assume that a researcher in your country wants to conduct DTP genomic research with participants in your country and that such research is subject to IRB/REC review. Please describe the conditions for IRB/REC approval, if it could be approved at all.**

The Peruvian regulatory framework governing scientific research has been developed following the traditional clinical (interventional, pharmaceutical) research/trial paradigm which solely focuses on pharmacological products, devices, and similar products. As such, DTP does not fit into the existing legal categories, thereby creating significant uncertainty with respect to the legal framework and requirements applicable to DTP.<sup>2</sup>

Under the norms governing the promotion of scientific research and innovation (based on the above cited regulations) there are strict requirements pertaining to ethical licensing and oversight of research projects and adherence to ethical safeguards. How-

**Rosario Isasi, J.D., M.P.H.,** is Research Assistant Professor at the University of Miami Miller School of Medicine.

ever, as stated above, those norms are directed specifically to clinical trials, seemingly leaving DTP outside of their scope.<sup>3</sup>

The cited policies mandate prior approval by an Institutional Ethics Research Committee (“Comite Institucional de Etica en Investigacion” or CIEI) as an essential requirement for investigational studies. Furthermore, the decree regulating clinical trials<sup>4</sup> establishes the accreditation, mission, organizational structure and functions of the CIEI (articles 58 to 66). It further stipulates the ethical principles and safeguards that are necessary conditions to obtain all governmental licensing and accreditations, including CIEI approval, which are based on the following principles:

- Respect for human dignity and protection of rights and interests of research participants (art. 9)
- Favorable benefit/risk ratio for the participant or for society as a whole (art. 10)
- Informed consent (art. 11, art 33-34)
- Limiting financial compensation for participants (art. 35)

Finally, it is important to mention that the government, by a Supreme Decree on Bioethics, has established binding bioethical guidelines governing scientific research, and hence, they are applicable as mandatory requirements for obtaining CIEI approval. The guidelines follow a human rights model and surround:

- Respect for human dignity
- Primacy of the human being and defense of physical integrity
- Autonomy and personal responsibility
- Principle of integrity and therapeutic principle
- Principle of sociability and subsidiarity
- Principle of beneficence and non-maleficence
- Equality, justice, and equity
- Protection of the environment, biosphere and diversity.<sup>5</sup>

**3. Assume that a researcher in your country wants to conduct DTP genomic research in another country. Please describe the conditions that must be satisfied for IRB/REC approval in your country, if it could be approved at all. Would your IRB/REC also require approval from a research ethics review body in the other country?**

The Peruvian regulatory regime does not contemplate such circumstances, unless part of the research activities will be conducted under Peruvian jurisdiction. If such is the case, the regulatory gaps (and loopholes) and normative requirements described above (including legal uncertainty pertaining to the regulation of DTP) equally apply. If any component of the research project is going to be conducted in Peru (regardless of whether other parts such as recruitment occur in another country), the ICEI (IRB/REC) will require proof of approval by an IRB/REC or equivalent from the foreign country.<sup>6</sup>

**4. Assume that a researcher from outside your country wants to conduct DTP genomic research in your country.**

- a. Would it be lawful for the researcher to do so without IRB/REC approval in either the researcher’s country or your country? [Yes/No]
- Yes
- No
- Not sure or other**

As illustrated in the preceding questions, there is significant uncertainty regarding the legal framework applicable to DTP in Peru. Having said that, it is clear that the spirit of the current Peruvian regulatory system is to require IRB/REC (or similar) approval as an essential prerequisite for conducting all types of scientific research in the country. Despite the loopholes, IRB/REC

approval is deemed mandatory, particularly considering other legal requirements for investigators and their institutions which are mandated to obtain licensing and registering in government bodies as a pre-condition to carry out research in the country (e.g. approval by the National Institute of Health (INS), CONCYTEC, etc.). Finally, the Peruvian regulatory system applies to all research carried out in the country regardless of the researcher’s nationality or residence.

- b. Would it be lawful for the researcher to do so if the research were approved by an IRB/REC in the researcher’s own country, but was not submitted for approval in your country? [Yes/No]
- Yes
- No
- Not sure or other**

In this scenario, all the issues and answers given above remain.

- c. Would the external researcher be required to have a collaborator in your country? [Yes/No]
- Yes
- No**
- Not sure or other

Considering legal uncertainty pertaining to the regulation of DTP in Peru as stated in the previous questions, and extrapolating the requirements applicable to other types of research (e.g., clinical trials), the external researcher is not required to have a collaborator in the country, but other conditions are imposed.<sup>7</sup>

- d. Would it matter whether the external researcher is based at a commercial, governmental, or academic entity? [Yes/No]
- Yes
- No**
- Not sure or other

Keeping in mind uncertainties regarding the regulation of DTP in Peru as described above, the overall

regulatory framework governing scientific research in the country does not distinguish whether the research is carried out or sponsored by an individual (foreign or national), a private/commercial company, an academic institution (Peruvian or foreign), or a government entity.<sup>8</sup>

**5. As far as you know, what are the perceived benefits and risks that could occur if a researcher from another country conducted IRB/REC-approved genomic research on samples or data obtained from your country? Please consider the perspectives of the public, research participants, socially-defined groups (e.g., indigenous or minority populations), researchers, and other professional or government entities.**

Once more, as stated in the previous questions, there is significant legal uncertainty pertaining to the regulation of DTP and genetic research in Peru. Overall, the legal framework governing scientific research and the *General Health Law* (umbrella legislation covering, amongst other issues, health services and research in the country) contains several provisions to ensure equitable benefit sharing which reflect the concerns and interests of a wide range of stakeholders (e.g., researchers, professional organizations, patient groups, government, and the public at large). Benefit sharing is conceptualized here as, for instance: supporting local capacity training, access to medical/health care, access to new diagnostic tools, services and products, support health services; support for infrastructure, training, and services for scientific research; preferential access to new or advanced therapies, etc.). Similar provisions are in place for the protection of vulnerable populations, including indigenous communities over concerns of potential discrimination and stigmatization, revealing prevailing societal concerns.

Given existing national and international policies protecting bio-

diversity in the country (flora and fauna) and safeguarding against biopiracy, we can speculate that similar concerns over unique heritage and bioprospecting would also be quite prevalent.<sup>9</sup>

## Part II — General Questions

**6. Does your country have biohazard committees, data protection boards, export permit authorities, or other entities that regulate the exporting of biospecimens or the transferring of data across borders for research? If so, do these requirements apply to individual citizens as well as research and medical institutions?**

There are no specific committees or legislation. The general rules governing scientific research, medical products and other export control regulations would apply.<sup>10</sup>

**7. Does your country have laws, policies, or guidelines dealing with genetic or genomic research or genetic or genomic privacy that would apply to international DTP research? Do your national laws on these issues apply outside of your country when residents or citizens of your country enroll in a DTP study conducted abroad?**

There are no specific policies (laws, guidelines, directives, etc.) regulating human genetics or genomics research in Peru. The policies described above (which refer to other types of research such as clinical trials) do contain several provisions for the protection of the privacy of individuals (data protections, particularly for medical information). Respect for privacy is one of the fundamental principles adopted in the country's *Bioethical Guidelines* cited above.

The only exception is a provision in the directive governing clinical trials with biological samples which, in the context of addressing the issue of

benefit sharing, states, as an example of concrete benefits to the community, measures directed at "increasing and strengthening developing countries capacity to obtain and manage human genetic data."<sup>11</sup>

Finally, there is no extraterritorial application of Peruvian law in this context.

**8. Does your country have laws, policies, guidelines, or cultural expectations regarding the return of individual or aggregate research results? [Multiple choice]**

- The law requires the return of individual results unless the participant expressly declines to have results returned
- The law is silent on return of results; the expectation is that individual results will be returned unless the participant expressly declines to have the results returned
- The law is silent on return of results; aggregate results are typically returned, but individual results are not returned unless expressly stated in the research protocol
- I am not sure — or other answer

With the caveats regarding the limited scope of the Peruvian regulatory framework and uncertainties regarding how DTP is governed in the country as stated above, there are requirements for return of individual and aggregate results as well as for community benefit sharing.<sup>12</sup>

**9. Does your country have laws, policies, or guidelines regarding "direct-to-consumer" genetic testing (e.g., 23andMe) and, if so, what do they provide? [Multiple choice]**

- Yes. Direct-to-consumer genetic testing is illegal
- Yes. Direct-to-consumer genetic testing is legal

- c. No. Direct-to-consumer genetic testing is not an issue**  
 d. I am not sure — or other answer

### Part III — Looking to the Future

#### 10. How, if at all, do you anticipate that your country's laws, policies, or guidelines will change in the next 5-10 years in response to international DTP genomic research? [Multiple choice]

- a. I do not think they will change at all  
 b. I think they will restrict international DTP research  
**c. I think they will allow international DTP research**  
 d. I am not sure — or other answer

#### Note

The author has no conflicts to disclose.

#### References

- Ley N° 30309 — Ley Que Promueve La Investigación Científica, Desarrollo Tecnológico E Innovación Tecnológica (2015); Reglamento de la Ley N° 30309, Ley que promueve la investigación científica, desarrollo tecnológico e innovación tecnológica — Decreto Supremo N° 188-2015-EF (2015); Ley N° 26842 — Ley General De Salud (1997) y sus modificaciones (2017).
- Reglamento de Ensayos Clínicos Decreto Supremo N° 021-2017-SA; Ley N° 26842, Ley General de Salud (2017).
- Ley N° 30309 — Ley Que Promueve La Investigación Científica, *supra* note 1.
- Reglamento de Ensayos Clínicos Decreto Supremo N° 021-2017-SA; Ley, Ley General de Salud (2017)
- Lineamientos Para Garantizar El Ejercicio De La Bioética Desde El Reconocimiento De Los Derechos Humanos Decreto Supremo N° 011-2011-JUS
- Reglamento de Ensayos Clínicos Decreto Supremo N° 021-2017-SA; Ley N° 26842, Ley General de Salud, (2017); Lineamientos Para Garantizar El Ejercicio De La Bioética Desde El Reconocimiento De Los Derechos Humanos Decreto Supremo N° 011-2011-JUS; Ley N° 30309 — Ley Que Promueve La Investigación Científica, Desarrollo Tecnológico E Innovación Tecnológica (2015); Reglamento de la Ley N° 30309, Ley que promueve la investigación científica, desarrollo tecnológico e innovación tecnológica — Decreto Supremo N° 188-2015-EF (2015); Ley N° 26842 — Ley General

- De Salud (1997) y sus modificaciones (2017).
- Reglamento de la Ley N° 30309, Ley que promueve la investigación científica, desarrollo tecnológico e innovación tecnológica — Decreto Supremo N° 188-2015-EF (2015), art. 8; Ley que promueve la investigación científica, desarrollo tecnológico e innovación tecnológica — Decreto Supremo N° 188-2015-EF (2015).
  - Reglamento de Ensayos Clínicos Decreto Supremo N° 021-2017-SA; Ley N° 26842, Ley General de Salud (2017); Lineamientos Para Garantizar El Ejercicio De La Bioética Desde El Reconocimiento De Los Derechos Humanos Decreto Supremo N° 011-2011-JUS; Ley N° 30309 — Ley Que Promueve La Investigación Científica, Desarrollo Tecnológico E Innovación Tecnológica (2015); Reglamento de la Ley N° 30309, Ley que promueve la investigación científica, desarrollo tecnológico e innovación tecnológica — Decreto Supremo N° 188-2015-EF (2015); Ley N° 26842 — Ley General De Salud (1997) y sus modificaciones (2017); Directiva para Muestras Biológicas en Ensayos Clínicos Directiva N° INS/OGAT-V.01.
  - Ley N° 26821 Ley Orgánica para el aprovechamiento sostenible de los recursos naturales (1997).
  - Directiva para Muestras Biológicas en Ensayos Clínicos Directiva N° INS/OGAT-V.01.
  - Directiva para Muestras Biológicas en Ensayos Clínicos Directiva N° INS/OGAT-V.01, art. 5.7.f.
  - Directiva para Muestras Biológicas en Ensayos Clínicos Directiva N° INS/OGAT-V.01., art. 5.6.6.-5.7.

## Poland

*Dorota Krekora-Zajac*

Researchers in genomics are exploring novel ways to interact directly with prospective participants without utilizing physicians, hospitals, or biobanks as intermediaries. Many researchers are interested in using the internet to directly recruit and enroll research participants in genomic studies by posting information online about active or proposed studies. This direct-to-participant (DTP) approach could take place under three main scenarios:

- A researcher in your country wants to conduct DTP genomic research with participants in your country
- A researcher in your country wants to conduct DTP genomic research with participants in another country
- A researcher from outside your country wants to conduct DTP genomic research with participants in your country

There is uncertainty about whether DTP recruitment, enrollment, and research are lawful under these scenarios.

### Part I — DTP-Specific Questions

- As far as you know, is DTP genomic research a topic of interest to researchers or other stakeholders in your country? [Multiple choice]**
  - There has been little, if any, discussion of the issue as of now
  - There has been discussion among researchers, but little discussion among policy makers
**c. There has been discussion among both researchers and policy makers**

d. I am not sure — or other answer
- Assume that a researcher in your country wants to conduct DTP genomic research with participants in your country and that such research is subject to IRB/REC review. Please describe the conditions for IRB/REC approval, if it could be approved at all.**

The obligation to obtain an opinion of the bioethics commission in Poland is derived either from the law or from the regulations of the institution

*Dorota Krekora-Zajac, J.D., is an Assistant Professor in the Department of Comparative Civil Law, Faculty of Law and Administration at the University of Warsaw.*

where research is to be conducted (e.g., from the resolution of the senate or a dean of a medical university). Such opinion is necessary in the case of conducting a clinical trial<sup>1</sup> and conducting a medical experiment.<sup>2</sup> If, on the other hand, the basis for issuing opinions by the bioethics committee results from an internal act of the university or the research institute, which is more common, bioethical commissions give opinions on all research projects conducted on people, human biological samples, or personal data. This means, therefore, that if the DTP genomic test was not a part of a clinical trial or a scientific research, it is not required to obtain the opinion of the bioethics commission.

**3. Assume that a researcher in your country wants to conduct DTP genomic research in another country. Please describe the conditions that must be satisfied for IRB/REC approval in your country, if it could be approved at all. Would your IRB/REC also require approval from a research ethics review body in the other country?**

In the event that the tests are not part of a clinical trial, the opinion will only be required if it results from the internal legal regulations of the institution in which the researcher is conducting research. The rules for obtaining such an opinion are not regulated by acts of law commonly binding so that the conditions for obtaining them will depend on the regulations of individual bioethics commissions.

**4. Assume that a researcher from outside your country wants to conduct DTP genomic research in your country.**

- a. Would it be lawful for the researcher to do so without IRB/REC approval in either the researcher's country or your country? [Yes/No]
- Yes  
 No

**X Not sure or other**

- b. Would it be lawful for the researcher to do so if the research were approved by an IRB/REC in the researcher's own country, but was not submitted for approval in your country? [Yes/No]
- Yes  
 No  
**X Not sure or other**
- c. Would the external researcher be required to have a collaborator in your country? [Yes/No]
- Yes  
**X No**  
 Not sure or other
- d. Would it matter whether the external researcher is based at a commercial, governmental, or academic entity? [Yes/No]
- X Yes**  
 No  
 Not sure or other

**5. As far as you know, what are the perceived benefits and risks that could occur if a researcher from another country conducted IRB/REC-approved genomic research on samples or data obtained from your country? Please consider the perspectives of the public, research participants, socially-defined groups (e.g., indigenous or minority populations), researchers, and other professional or government entities.**

There are no specific regulations in Poland regarding the conduct of genetic tests. In practice, many tests are carried out, many of which have never been proven clinically. There are also no entities that could control the conduct of such tests in practice. This means that foreign entities may offer DTP genetic tests.

For many years, geneticists and bioethicists have been postulating that legislation needs to restrict the

conduct of genetic tests. One breakthrough point in this respect was the publication of the Polish Supreme Audit Office (NIK)<sup>3</sup> report on genetic testing on May 10, 2018. It found that there is a lack of specific legal regulation in Poland and that there is no proper registration of entities conducting genetic tests. The report also shows that the Minister of Health did not carry out proper control over the laboratories. The report concluded that laboratories carrying out tests did not follow an adequate procedure to protect the personal data of donors, participants, or patients. One of the threats resulting from the report was also conducting the DTP genetic test outside of Poland or sending results outside Poland. It was considered that in such situations, there are no proper mechanisms to control data and samples.

After the publication of the report, the Minister of Health appointed a group whose function is to prepare a law regulating the conduct of genetic tests, including DTP. A draft bill was created, but until the time of preparation this analysis was not published or forwarded to public consultations.

Summing up, it should be pointed out that conducting genetic tests in Poland may involve significant risks. First of all, there is a lack of legal regulations in Polish law protecting the rights of students of genetic research and guaranteeing the reliability of conducted research. Pointing to benefits, genetic tests are popular and enjoy favorable public opinion and it is difficult to point to clear restrictions on their performance.

**Part II — General Questions**

**6. Does your country have biohazard committees, data protection boards, export permit authorities, or other entities that regulate the exporting of biospecimens or the transferring of data across borders for research? If so, do these requirements apply to individual citizens as well as research and medical institutions?**

The rules for the transfer of personal data in Poland are regulated by *General Data Protection Regulations 2016/679*.<sup>4</sup>

According to article 37 Act of 1 July 2005 on the collection, storage, and transplantation of cells, tissues, and organs,<sup>5</sup> removal of bone marrow, hematopoietic blood cells, and umbilical cord blood from Poland is possible only after obtaining the consent of the director of the Organizing and Coordination Center for Transplantation Poltransplant and the export of other regenerating cells and tissues is possible after obtaining the consent of the director of the National Center for Tissue and Cell Banking. Those requirements apply equally to all.

- 7. Does your country have laws, policies, or guidelines dealing with genetic or genomic research or genetic or genomic privacy that would apply to international DTP research? Do your national laws on these issues apply outside of your country when residents or citizens of your country enroll in a DTP study conducted abroad?**

There are many general regulations in Polish law regarding patient rights, personal data protection, etc. However, there are no specific regulations regarding DTP.

- 8. Does your country have laws, policies, guidelines, or cultural expectations regarding the return of individual or aggregate research results? [Multiple choice]**

- The law requires the return of individual results unless the participant expressly declines to have results returned
- The law is silent on return of results; the expectation is that individual results will be returned unless the participant expressly declines to have the results returned

- c. The law is silent on return of results; aggregate results are typically returned, but individual results are not returned unless expressly stated in the research protocol**

d. I am not sure — or other answer

- 9. Does your country have laws, policies, or guidelines regarding “direct-to-consumer” genetic testing (e.g., 23andMe) and, if so, what do they provide? [Multiple choice]**

- Yes. Direct-to-consumer genetic testing is illegal
- Yes. Direct-to-consumer genetic testing is legal
- No. Direct-to-consumer genetic testing is not an issue**
- I am not sure — or other answer

### Part III — Looking to the Future

- 10. How, if at all, do you anticipate that your country’s laws, policies, or guidelines will change in the next 5-10 years in response to international DTP genomic research? [Multiple choice]**

- I do not think they will change at all
- I think they will restrict international DTP research**
- I think they will allow international DTP research
- I am not sure — or other answer

#### Note

The author has no conflicts to disclose.

#### References

- Ustawa o Wyrobach Medycznych [Act on medical devices], Dz. U. 2010, nr 107, poz. 679, art. 45; According to art. 2(4), a clinical trial is designed and planned for a systematic human research, undertaken to verify the safety or performance of a specific medical device, medical device or active medical device for implantation.
- Ustawa o o Zawodach Lekarza i Lekarza Dentysty [Act on the Professions of Physician and Dentist], Dz.U. 1997, nr 28, poz. 152, art. 29. According to

art. 21, a medical experiment conducted on people may be a therapeutic or research experiment. The therapeutic experiment is the introduction by the doctor of new or only partially tested diagnostic, therapeutic or prophylactic methods in order to achieve a direct benefit for the health of the person being treated. It can be carried out if the previously used medical methods are not effective or if their effectiveness is not sufficient. The research experiment is aimed primarily at expanding medical knowledge. It can be carried out both on sick and healthy people. Conducting a research experiment is permissible if participation in it is not associated with risk or the risk is small and does not remain in disproportion to the possible positive results of such an experiment. There for genetic testing cannot be treated as medical experiment.

- Najwyższa Izba Kontroli [Supreme Audit Office], available at <<https://www.nik.gov.pl/en/>> (last visited October 29, 2019).
- Regulation (EU) 2016/679 of the European Parliament and of the Council of 27 April 2016 on the protection of natural persons with regard to the processing of personal data and on the free movement of such data, and repealing Directive 95/46/EC (General Data Protection Regulation), 2016 O.J. (L 119), at 1.
- Ustawa o Pobieraniu, Przechowywaniu i Przeszczepianiu Komórek, Tkanki i Narządów [Act on the collection, storage and transplantation of cells, tissues and organs], Dz.U. 2005, nr 169, poz. 1411

## Qatar

*Eman Sadoun*

Researchers in genomics are exploring novel ways to interact directly with prospective participants without utilizing physicians, hospitals, or biobanks as intermediaries. Many researchers are interested in using the internet to directly recruit and enroll research participants in genomic studies by posting information online about active or proposed studies. This direct-to-participant (DTP) approach could take place under three main scenarios:

- A researcher in your country wants to conduct DTP genomic research with participants in your country
- A researcher in your country wants to conduct DTP genomic research with participants in another country
- A researcher from outside your country wants to conduct DTP genomic research with participants in your country

There is uncertainty about whether DTP recruitment, enrollment, and research are lawful under these scenarios.

### Part I — DTP-Specific Questions

#### 1. As far as you know, is DTP genomic research a topic of interest to researchers or other stakeholders in your country? [Multiple choice]

- a. There has been little, if any, discussion of the issue as of now
- b. There has been discussion among researchers, but little discussion among policy makers
- c. There has been discussion among both researchers and policy makers
- d. I am not sure — or other answer

#### 2. Assume that a researcher in your country wants to conduct DTP genomic research with participants in your country and that such research is subject to IRB/REC review. Please describe the conditions for IRB/REC approval, if it could be approved at all.

The IRB would review the researcher's application, guided by the Qatar Ministry of Public Health (QMOPH) Genomic Policy. As stated in the policy, the IRB would ensure that the

seven criteria of IRB approval are fulfilled as follows:

Criterion 1 requires that risks to subjects be minimized by using procedures which are consistent with sound research design and which do not unnecessarily expose subjects to risk.

Criterion 2 requires that the risks to subjects must be balanced against the sum of two benefits: the anticipated benefit to individual subjects and the anticipated benefit to society.

Criterion 3 requires the selection of subjects to be equitable.

Criterion 4 Informed consent should be obtained in every circumstance in which a patient/participant's data or bodily samples are used in genomics practices. Documented procedures by which they plan to carry out consent processes. This procedure should have the person obtaining consent take steps to verify that:

- The person providing consent has been given sufficient information.
- The person providing consent understands the information.
- The person providing consent does not feel coerced or unduly influenced.
- The person providing consent has sufficient time to make a decision.
- The individual providing consent understands the consequences of a decision.
- The individual providing consent can communicate a choice.
- The investigator stops the consent process if the person providing consent indicates that he or she does not want to consent.

Criterion 5 requires, when appropriate, that the research plan must include adequate provisions for monitoring collected data to ensure subject safety.

Criterion 6 requires, when appropriate, that there be adequate provisions to protect the privacy of subjects and

to maintain the confidentiality of data.

Criterion 7 requires that, when some or all subjects are likely to be vulnerable to coercion or undue influence, additional safeguards are included in the study to protect the rights and welfare of these subjects.

In addition to the review and approval criteria, the IRB would ensure that there are mechanisms for mitigation of risks associated with genomic research. The policy explains how the researchers and IRB can mitigate the risks (legal, social, privacy, economic, psychological, etc.) associated with genomic research. The policy requires researchers to establish a plan on how to communicate genomic results with participants.

The IRB would address the issue of data sharing with a third party. If there is a plan for sharing, the explicit consent of participants should be obtained. Information that is identifiably linked to participants should never be shared.

#### 3. Assume that a researcher in your country wants to conduct DTP genomic research in another country. Please describe the conditions that must be satisfied for IRB/REC approval in your country. Would your IRB/REC also require approval from a research ethics review body in the other country.

Same conditions as in question 2. Signed informed consent would be required.

#### 4. Assume that a researcher from outside your country wants to conduct DTP genomic research in your country.

- a. Would it be lawful for the researcher to do so without IRB/REC approval in either

Eman Sadoun, Ph.D., is Manager of the Research Division at the Ministry of Public Health, Qatar.

the researcher's country or your country? [Yes/No]

Yes

No

Not sure or other

b. Would it be lawful for the researcher to do so if the research were approved by an IRB/REC in the researcher's own country, but was not submitted for approval in your country? [Yes/No]

Yes

No

Not sure or other

c. Would the external researcher be required to have a collaborator in your country? [Yes/No]

Yes

No

Not sure or other

d. Would it matter whether the external researcher is based at a commercial, governmental, or academic entity? [Yes/No]

Yes

No

Not sure or other

5. As far as you know, what are the perceived benefits and risks that could occur if a researcher from another country conducted IRB/REC-approved genomic research on samples or data obtained from your country? Please consider the perspectives of the public, research participants, socially-defined groups (e.g., indigenous or minority populations), researchers, and other professional or government entities.

**Public perspective:** Scientific data and knowledge are common goods and should be shared within an appropriate framework. To this end, QMOPH promotes greater access to data in a responsible, equitable, ethical and efficient manner. In the practice of data sharing, there is a need to

balance between investigators who could contribute to new discoveries and research subjects who have a reasonable expectation of privacy and confidentiality. QMOPH recognizes the importance of making data available to investigators engaged in public health care research. Additionally, QMOPH affirms the principle that researchers involved in data sharing are credible investigators, and institutions sharing data should obtain proof of academic or other peer reviewed standing of investigators applying to receive data. When engaging in data sharing, QMOPH requires institutions to follow regulation, policy, and guidance published by QMOPH, including, but not limited to the "Guidance for the Use of Stored Data and Biological Specimens in Human Research" and the Genomic Research Policy.

#### **Data sharing and research participants:**

The QMOPH is committed to sharing its research data and/or bio samples and knowledge with both the national and international scientific communities in conformity with the informed consent provided by its research participants. In genomic research, participants should have an opportunity to consider risks and benefits of the research, including whether incidental findings will be shared post-test, and accept or deny participation in the research. Participants should be informed should the data be shared with a third party. The possibility of breaching the privacy of data should be shared with research participants.

#### **Data sharing and socially defined groups:**

considering the small Qatari population in Qatar, the following related risks are required to be discussed with participants by the researcher/research institution.

#### **Privacy Risks**

When genomic and phenotypic data are broadly shared in a database or repository, privacy risks may arise. Coded data can be released to the public. Data may be susceptible to computer or physical security breach.

#### **Legal Risks**

Genomic data may result in legal harms due to disputed claims of paternity. In some countries, genomic data may demonstrate familial or social relationships that raise citizenship questions or complicate access to goods or inheritance.

#### **Social Risks**

Genomic research may cause stigmatization or discrimination against an individual, family, or group of people with a particular genetic trait. Genomic data can raise issues that a person's biological father is not the person considered to be their father. Genomic data can uncover unexpected issues of family heritage.

### **Part II – General Questions**

6. Does your country have biohazard committees, data protection boards, export permit authorities, or other entities that regulate the exporting of bio specimens or the transferring of data across borders for research? If so, do these requirements apply to individual citizens as well as research and medical institutions?

The Qatar Biobank has an Access Committee; they apply both to individual citizens as well as research and medical institutions.

7. Does your country have laws, policies, or guidelines dealing with genetic or genomic research or genetic or genomic privacy that would apply to international DTP research?

Policy is in process.

Do your national laws on these issues apply outside of your country when residents or citizens of your country enroll in a DTP study conducted abroad?

Not sure yet.



**8. Does your country have laws, policies, guidelines, or cultural expectations regarding the return of individual or aggregate research results? [Multiple choice]**

- a. The law (policy) requires the return of individual results unless the participant expressly declines to have results returned, assuming the results are accurate, valid, and actionable.
- b. The law is silent on return of results; the expectation is that individual results will be returned unless the participant expressly declines to have the results returned
- c. The law is silent on return of results; aggregate results are typically returned, but individual results are not returned unless expressly stated in the research protocol
- d. I am not sure — or other answer

**9. Does your country have laws, policies, or guidelines regarding “direct-to-consumer” genetic testing (e.g., 23andMe) and, if so, what do they provide? [Multiple choice]**

- a. Yes. Direct-to-consumer genetic testing is illegal
- b. Yes. Direct-to-consumer genetic testing is legal
- c. No. Direct-to-consumer genetic testing is not an issue
- d. I am not sure — **or other answer** (A policy that deals with DTC is in process)

**Part III — Looking to the Future**

**10. How, if at all, do you anticipate that your country’s laws, policies, or guidelines will change in the next 5-10 years in response to international DTP genomic research? [Multiple choice]**

- a. I do not think they will change at all
- b. I think they will restrict international DTP research
- c. I think they will allow international DTP research**
- d. I am not sure — or other answer

**Note**

The author has no conflicts to disclose.

**References**

1. Ministry of Public Health, Department of Research, State of Qatar, *Guidance for the Design, Ethical Review, and Conduct of Genomic Research in Qatar*, POLICY, 2017-2018, available at <<https://www.moph.gov.qa/about-us/Documents/research/Guidance%20for%20the%20Design,%20Ethical%20Review,%20and%20Conduct%20of%20Genomic%20Research%20in%20Qatar.pdf>> (last visited October 29, 2019).

## Singapore

*Calvin Ho*

Researchers in genomics are exploring novel ways to interact directly with prospective participants without utilizing physicians, hospitals, or biobanks as intermediaries. Many researchers are interested in using the internet to directly recruit and enroll research participants in genomic studies by posting information online about active or proposed studies. This direct-to-participant (DTP) approach could take place under three main scenarios:

- A researcher in your country wants to conduct DTP genomic research with participants in your country
- A researcher in your country wants to conduct DTP genomic research with participants in another country
- A researcher from outside your country wants to conduct DTP genomic research with participants in your country

There is uncertainty about whether DTP recruitment, enrollment, and research are lawful under these scenarios.

**Part I — DTP-Specific Questions**

**1. As far as you know, is DTP genomic research a topic of interest to researchers or other stakeholders in your country? [Multiple choice]**

- a. There has been little, if any, discussion of the issue as of now
- b. There has been discussion among researchers, but little discussion among policy makers
- c. There has been discussion among both researchers and policy makers
- d. I am not sure — or other answer

**2. Assume that a researcher in your country wants to conduct DTP genomic research with participants in your country and that such research is subject to IRB/REC review. Please describe the conditions for IRB/REC approval, if it could be approved at all.**

The *Human Biomedical Research Act* (HBRA), enacted by Parliament on August 18, 2015, established a legislative framework for human biomedical research.<sup>1</sup> The explanatory statement describes the goals of the HBRA as: (a) regulating the conduct of human biomedical research, regulating tissue banks and tissue banking activities; (b) prohibiting certain types of human biomedical research; and (c) prohibiting the commercial trading of human tissue. Most of the legislative provisions are concerned with goals (a) and (b).<sup>2</sup>

**Calvin Ho, B.Sc., LL.B., M.Sc., LL.M., J.S.D.**, is an Assistant Professor at the Centre for Biomedical Ethics at the Yong Loo Lin School of Medicine, National University of Singapore (NUS).

The human biomedical research activities that are prohibited under the HBRA are those that involve:<sup>3</sup>

1. Development of cytoplasmic hybrid embryos or human-animal combination embryos created in vitro beyond 14 days or the appearance of the primitive streak, whichever is earlier;
2. Implantation of any human-animal combination embryo into the uterus of an animal or a human;
3. Introduction of human stem cells (including induced pluripotent stem cells (iPSC)) or human neural cells into the brain of living great apes whether prenatal or postnatal; and
4. Breeding of animals that have had any kind of human pluripotent stem cells (including iPSCs) introduced into them.

#### *IRB Review*

Essentially all human biomedical research that is not explicitly prohibited and that falls within the scope of the HBRA must be approved (unless exempted) by an appropriate IRB before it is carried out. To determine whether research falls within the scope of the legislation, the HBRA applies an “inclusion-exclusion” two-stage test. The first test is the “inclusion.” It assesses the nature of the research to determine whether it involves biological material deemed ethically, culturally or religiously sensitive,<sup>4</sup> or that has the intention to:

- a) Prevent, prognosticate, diagnose or alleviate any disease, disorder or injury affecting the human body;
- b) Restore, maintain or promote the aesthetic appearance of human individuals through clinical procedures or techniques; or
- c) Enhance the performance or endurance of human individuals.<sup>5</sup>

If it turns out the research has one of these goals, a second step is required

to ascertain if it is “excluded.” Does the research:

- a) have a temporary or permanent physical, mental or physiological effect on the research participant?
- b) use any individually identifiable human biological material? or
- c) use any individually identifiable health information?<sup>6</sup>

Thus, for instance, clinical trials of medicinal products will satisfy the inclusion criteria, but fall within the exclusion criteria (since clinical trials fall under different regulatory regimes, depending on whether they relate to medicinal products or health products).<sup>7</sup>

While the HBRA did not significantly modify the existing ethics review infrastructure, it has been broadened to apply uniformly to all human biomedical researchers and research institutions.<sup>8</sup> The HBRA also defines a “research institution” as an entity composed of two or more persons and that has managerial control over human biomedical research that is conducted in Singapore. In order to be legally recognized, a “research institution” is required to notify the Ministry of Health (MOH) and submit a declaration of compliance before it commences operation. Once recognized, it must appoint an IRB to review all research under its supervision and control, and to report any serious adverse events as defined in the legislation. The HBRA further requires a close relationship between the research institution and its IRB, primarily because the research institution assumes responsibility for research that is reviewed and approved by its IRB. The legal responsibilities of an IRB are essentially: the protection of the safety, dignity and welfare of human research participants.

In 2015, the national Bioethics Advisory Committee (BAC) consolidated the ethical principles, recommendations and guidelines published since 2002, including those that relate to IRB functions and genetic research.<sup>9</sup> Five ethical principles were identified as foundational to the eth-

ics governance of human biomedical research in Singapore. They are: (1) respect for persons; (2) solidarity; (3) justice; (4) proportionality; and (5) and sustainability. In addition, the BAC highlighted that research institutions have a responsibility to ensure that research integrity (that is to say the integrity and validity of the research process are observed) is maintained, and IRBs have a responsibility to check that it has been considered.<sup>10</sup> It is on the basis of this ethical premise that the BAC sets out the substantive responsibilities of research institutions, IRBs, and researchers. Their ethical responsibilities have been codified in subsequent regulations and are binding and enforceable under the HBRA.<sup>11</sup>

[See Appendix for further detail.]

3. **Assume that a researcher in your country wants to conduct DTP genomic research in another country. Please describe the conditions that must be satisfied for IRB/REC approval in your country, if it could be approved at all. Would your IRB/REC also require approval from a research ethics review body in the other country?**

Legal requirements under the HBRA do not apply to human biomedical research that is conducted outside of Singapore. However, the ethical requirements specified by the BAC are applicable, and research institutions in Singapore will require Singapore IRB approval to be obtained even though DTP genomic research is conducted in another country. It is at the discretion of the Singapore IRB to decide if approval from a research ethics review body in the other country is also necessary. Where research participants overseas are exposed to a significant risk of harm (including loss of privacy), research ethics review and approval in the other country is usually required.

4. **Assume that a researcher from outside your country wants to**

**conduct DTP genomic research in your country.**

- a. Would it be lawful for the researcher to do so without IRB/REC approval in either the researcher's country or your country? [Yes/No]

Yes

No

- Other (There is no specific law that prohibits this unless the extent of research involvement in Singapore substantively renders the foreign researcher a "research institution" or "tissue bank," and thereby falling within the scope of the HBRA.)**

- b. Would it be lawful for the researcher to do so if the research were approved by an IRB/REC in the researcher's own country, but was not submitted for approval in your country? [Yes/No]

Yes

No

- Other (Similar response to Question 4A above, since it would not matter if the research was approved by an IRB in the researcher's own country.)**

- c. Would the external researcher be required to have a collaborator in your country? [Yes/No]

Yes

No

- Other (While an external researcher is not legally required to have a collaborator in Singapore, it is unlikely that the researcher will have reliable access to biological materials and related data as a practical matter.)**

- d. Would it matter whether the external researcher is based at

a commercial, governmental, or academic entity? [Yes/No]

Yes

- No (It should be noted that commercial trading in tissue is prohibited under Section 32 of the HBRA.)**

Not sure or other

5. As far as you know, what are the perceived benefits and risks that could occur if a researcher from another country conducted IRB/REC-approved genomic research on samples or data obtained from your country? Please consider the perspectives of the public, research participants, socially-defined groups (e.g., indigenous or minority populations), researchers, and other professional or government entities.

A community-based survey in Singapore explored the willingness to donate blood samples for genetic research in 2002.<sup>12</sup> It found that one of the reasons given by those who were unwilling to donate blood specimens was the fear of discrimination by employers and insurance companies (18.7%). At a regulatory and policy level, there is a concern that genetic testing and test results will not be correctly understood and/or applied. For this reason, the BAC has emphasised pre- and post-test counseling in its report on genetic testing and genetic research.<sup>13</sup> Other concerns, including those relating to loss of privacy, are also set out in this report by the BAC. As for the collection of samples for research, there may be religious or cultural significance to the provision and use of such samples. For this reason, the BAC indicates that the collection and use of human biological materials must be respectful of cultural and religious sensitivities.<sup>14</sup>

Another study conducted in the Singaporean context suggests that participants are more likely to donate biological samples for research if they are confident that there is proper governance in place so that they will not suffer any harm as a consequence of

research participation.<sup>15</sup> A challenge with contributing to foreign research is that there is no assurance that proper governance is in place and that either the foreign researcher or the foreign IRB could be called to account for any problems, should they arise.

[See Appendix for further detail.]

## Part II – General Questions

6. Does your country have biohazard committees, data protection boards, export permit authorities, or other entities that regulate the exporting of biospecimens or the transferring of data across borders for research? If so, do these requirements apply to individual citizens as well as research and medical institutions?

The *Biological Agents and Toxins Act* was enacted in 2006 to regulate the possession, use, import, transfer, and transportation of biological agents (i.e., specified list of microorganisms) and toxins that are known to be hazardous to human health.<sup>16</sup> The legislation provides safe practices and security requirements in the handling of such agents and toxins. Facilities that possess or work with specified biological agents and toxins are required to have their facilities listed as a protected place under the *Protected Areas and Protected Places Act*.<sup>17</sup> Institutionally, handling of biological agents and toxins are to be managed by a Biosafety Committee, which has the responsibility to:

- Conduct risk assessments in relation to the activity proposed to be carried out;
- Devise such measures for the management of the risks that may arise from the proposed activity; and
- Formulate such other policies, programs and codes of practice as may be necessary for:
  - the proposed activity to be carried out safely at the facility; and

- the training of staff who will be involved in the carrying out of the proposed activity
- Review every 2 years or earlier, as may be appropriate, all measures, policies, programmes or codes of practice devised or formulated by it and shall immediately inform the operator of the facility of any change to such measures, policies, programmes and codes of practice as the biosafety committee thinks necessary.

Apart from these provisions and arrangements, the MOH has issued regulations relating to the transportation of these biological agents and toxins.

[See Appendix for further detail.]

**7. Does your country have laws, policies, or guidelines dealing with genetic or genomic research or genetic or genomic privacy that would apply to international DTP research? Do your national laws on these issues apply outside of your country when residents or citizens of your country enroll in a DTP study conducted abroad?**

Singapore has no law that is specific to genetics, genomic research, or genetic privacy, but the collection and use of genetic information may be subject to regulation, depending on the context to which such information relates. In the context of medical practice, genetic testing and the handling of genetic information are governed by a set of guidelines issued by the Bioethics Advisory Committee (BAC) in 2005.<sup>18</sup> These guidelines have regulatory effect on medical practitioners in Singapore. More recently, the Ministry of Health has issued a Code of Practice for the provision of clinical and laboratory genetic services.<sup>19</sup> Requirements in the Code of Practice are currently set out as good practices only, but they are expected to have regulatory effect from 2020 onwards.

In the context of biomedical research, the use of genetic technologies and information may be governed under the HBRA (as discussed above) or otherwise under legal requirements that apply to clinical trials. Statutory requirements under the HBRA are supplemented by guidelines issued by the BAC in 2015, which also incorporate those issued in 2005.<sup>20</sup> The legal and ethical requirements broadly reflect international standards, such as the restrictions that are set for genetic testing of children. Physicians and parents should decide together “where compelling interests of other family members or public health interests exist” for carrier tests on children (Rec 5). For certain types of tests, genetic counseling should be offered before and after clinical genetic testing to all individuals with sufficient information and support for the individual and his or her family members (Rec 19 & 20). More generally, genetic information that identifies an individual on its own or in combination with other information may be regulated as “personal data” under the PDPA, as noted above. The PDPA sets out requirements governing the collection, use, disclosure and care of personal data, and it recognizes both the rights of individuals to protect their personal data and the needs of organizations to collect, use, or disclose such data for legitimate and reasonable purposes. For sensitive data (such as medical information), the PDPA sets out the need for greater care in the processing of data. The national laws of Singapore on these issues are unlikely to apply outside of Singapore when residents or citizens enroll in a DTP study conducted abroad.

**8. Does your country have laws, policies, guidelines, or cultural expectations regarding the return of individual or aggregate research results? [Multiple choice]**

- a. The law requires the return of individual results unless the participant expressly declines to have results returned

- b. The law is silent on return of results; the expectation is that individual results will be returned unless the participant expressly declines to have the results returned
- c. The law is silent on return of results; aggregate results are typically returned, but individual results are not returned unless expressly stated in the research protocol
- d. **Other answer (Under the HBRA and the ethical guidelines of the BAC, researchers need to indicate whether or to what extent results will be returned to research participants.)**

**9. Does your country have laws, policies, or guidelines regarding “direct-to-consumer” genetic testing (e.g., 23andMe) and, if so, what do they provide? [Multiple choice]**

- a. Yes. Direct-to-consumer genetic testing is illegal
- b. Yes. Direct-to-consumer genetic testing is legal
- c. No. Direct-to-consumer genetic testing is not an issue
- d. **Other answer (Direct-to-consumer genetic testing is not explicitly prohibited, but Recommendation 22 of the BAC’s report on Genetic Testing and Genetic Research (on page 49) states: “Genetic testing should generally be conducted through a qualified healthcare professional. Tests that provide predictive health information should not be offered directly to the public. The advertising of direct genetic tests to the public should be strongly discouraged. The relevant authority should develop an oversight framework for the supply of direct genetic tests, services and information**

to the public.” The MOH is expected to develop such an oversight framework in the foreseeable future.)

### Part III — Looking to the Future

#### 10. How, if at all, do you anticipate that your country’s laws, policies, or guidelines will change in the next 5-10 years in response to international DTP genomic research? [Multiple choice]

- a. I do not think they will change at all
- b. I think they will restrict international DTP research**
- c. I think they will allow international DTP research
- d. I am not sure — or other answer

## Appendix

### Question 2

#### *Appropriate Consent*

In giving effect to the ethical principle of respect of persons, the HBRA places considerable emphasis on obtaining appropriate consent from research participants. For consent to be appropriate, it must be in writing, obtained from the research participant after certain prescribed information has been provided, and it must have been obtained in the presence of a witness.<sup>21</sup> Where the research involves a minor (defined as a person under the age of 21) or an adult without decision-making capacity, additional requirements and procedures have been set out.<sup>22</sup> The information to be provided to the participant for the purposes of consent taking includes all of the following:<sup>23</sup>

- a) nature of the research;
- b) purpose of the research;
- c) reasonably foreseeable risks, discomforts or inconveniences to a living research subject arising from the research;

- d) benefits that the research participant may reasonably expect from the research;
- e) where applicable, whether there are any alternative procedures or treatments available, and the potential benefits and risks of such alternatives;
- f) any compensation and treatment available in the event of injury;
- g) any anticipated expenses the research participant is likely to incur;
- h) the extent to which information identifying the research participant will be kept confidential;
- i) whether individually-identifiable information obtained from the research participant will be used for future research;
- j) whether any biological material taken from the research participant will be destroyed, discarded or stored for future research;
- k) whether the research involves information in individually identifiable form;
- l) the circumstances, if any, under which, the research participant will be contacted for further consent, including but not limited to changes in the proposed research, and serious adverse events that would lead to a change in the proposed research;
- m) whether the research participant would wish to be reidentified in the case of an incidental finding if the proposed research expressly provides for such reidentification;
- n) the right to withdraw consent and the limitations to such withdrawal;
- o) the person or persons to contact to obtain further information on the research and to provide feedback; and
- p) any other information that the Institutional Review Board may require.
- q) apart from appropriate consent, the HBRA further requires participation to be voluntary (i.e. free from coercion or intimidation, or deception or misrepresentation),<sup>24</sup>

and for privacy and confidentiality to be respected or safeguarded, as the case may be.<sup>25</sup>

#### *Human Tissue*

As noted above, another important component of the HBRA is the regulation of the collection and use of human tissue. These provisions are set out in Part 6, entitled “Regulation of Human Tissues Activities and Tissue Banking.” The definition of ‘human tissue’ is broad.<sup>26</sup> It encompasses any human biological material except those specified in the First Schedule of the legislation (i.e. essentially those that have limited scientific value, such as hair shaft, nail plate and naturally excreted bodily fluids and waste products) or materials that have been substantially manipulated and rendered non-individually identifiable.

The provisions on human tissue give effect to three objectives that were articulated during the public consultation leading to the adoption of the HBRA: protect the safety and welfare of tissue donors; prohibit commercial trading of human tissue; and ensure human tissue used in biomedical research is obtained only through altruistic donations.<sup>27</sup> The second and third of these objectives are relatively straightforward, and take the form of prohibitions of commercial trading of human tissue,<sup>28</sup> advertisements relating to such trade,<sup>29</sup> and compelling a person to provide tissue by means of coercion or intimidation, or by deception or misrepresentation.<sup>30</sup> The first objective is more intricate, and entails consent requirements and restrictions on certain activities of the tissue banks or the IRB. A tissue banking activity includes the collection, storage, procurement, importation, supply, provision or export of human tissue for purposes that are not limited to research, but may be for reasons of public health or epidemiological.<sup>31</sup> For all of these purposes, ‘appropriate consent’ must be taken. Procedurally, the requirements are: obtaining consent in writing;<sup>32</sup> from the tissue donor personally or otherwise in accordance with additional requirements that apply to adults who lack mental capacity for decision-making

ing;<sup>33</sup> minors<sup>34</sup> and deceased persons;<sup>35</sup> after certain information has been provided and explained, including a list of possible concerns;<sup>36</sup> and in the presence of a witness.

Crucially, the legislation empowers an IRB to waive the requirement of 'appropriate consent' where research involving human biological material (or health information) is concerned. To grant a waiver, the IRB must be satisfied that: (a) the proposed research on the individually-identifiable human biological material may not practically be carried out unless there is a waiver; (b) the use of such material involves no more than minimal risk to the research subject or donor; (c) the waiver will not adversely affect the rights and welfare of the research subject or donor; and (d) the research would reasonably be considered to contribute to the greater public good.<sup>37</sup> This statutory provision addresses a long-standing legal lacuna relating to the research use of legacy tissue that was first highlighted within a public policy forum held by the BAC more than a decade ago.<sup>38</sup> More specific regulations are expected to be issued by MOH on tissue banking in Singapore, as public consultation was concluded at the end of 2018.<sup>39</sup>

#### *Additional Requirements for Restricted Research*

The Fourth Schedule addresses ethically contentious types of research such as those that involve human embryonic stem cells and human-animal combinations, and is particularly relevant for the purposes of this volume. The types of research for which additional regulatory requirements apply are those that involve:

- a) Human eggs or human embryos;
- b) Human-animal combination embryos, specifically cytoplasmic hybrid embryos, human-animal combination embryos created by the incorporation of human stem cells (including iPSC), and human-animal combination embryos created in vitro by using human gametes and animal gametes, or one human pro-nucleus and one animal pro-nucleus;

- c) Introduction of human stem cells (including iPSC) into a prenatal animal fetus or animal embryo;
- d) Introduction of human pluripotent stem cells (including iPSC) into a living postnatal animal;
- e) Introduction of human stem cells (including iPSC) or human neural cells into the brain of a living postnatal animal; and
- f) Any entity created as a result of the process referred to in subparagraphs (c), (d) and (e) above.

To be sure, 'restricted research' may only be conducted after the requirements that apply to all human biomedical research under the HBRA are satisfied, as well as the additional provisions that are specific to this category of research. These include notification to be provided to MOH; IRB review; appropriate consent having been obtained from the research subject; and conduct of the research only by certain specific persons, at certain specific premises and in a specific manner.<sup>40</sup>

#### **Question 5**

For local healthcare and research institutions, it is relatively common practice to specify in the consent-taking document that samples or data obtained may be shared, whether within or outside of that specific institution, for use in future medical research and development, medical education, training, publication, diagnosis and possibly the treatment of medical conditions on a commercial basis or otherwise. Assurance will also be provided that any release of samples or data will be in accordance with the relevant laws and regulations.

The consent document will usually indicate that the samples or data may also be exported or transmitted (as the case may be) to researchers outside of Singapore. A typical explanation is that the researchers who use the samples or data may be part of a large group working in collaboration with institutions or commercial companies. Permission would therefore be obtained in advance for samples to be exported or removed from Sin-

gapore (or for data to be transmitted) to a place outside Singapore for research. The assurance provided to research participants is that any sample or data to be exported or transmitted overseas may only be released in accordance with legal and regulatory requirements and subject to IRB approval. Specific consent will be obtained to this effect.

Contribution of samples and data for research is expected to be on an altruistic basis, although fair compensation is permissible for time and effort. Whether for research in Singapore or outside of Singapore, the BAC has indicated that there is an ethical responsibility for everyone to contribute to responsible research, based on the principle of reciprocity or solidarity, more broadly.<sup>41</sup>

#### **Question 6**

Unless biological samples are specified biological agents or toxins, or are biological materials that have been affected by such agents or toxins, the transfer of such samples are not subject to control or regulation. However, where such biological samples are provided for medical or research purposes by a person, appropriate consent must have been provided by the sample donor. If the sample is provided by a medical or research institution as a tissue bank, then the requirements under the HBRA (discussed above) must be satisfied. As noted, these requirements relate mainly to consent, but detailed regulatory requirements are expected to be issued by the MOH in the foreseeable future.

Transfer of personal data across borders for research is regulated under the *Personal Data Protection Act* (PDPA). Personal data refers to data, whether true or not, about an individual who can be identified from that data; or from that data and other information to which the organization has or is likely to have access. Generally, a person is free to provide her or his personal data to an overseas entity for medical or research purposes, provided that this is done on a voluntary and informed basis. However, more onerous requirements apply to the transfer of personal data by an orga-

nization, which will include a medical or research institution.

Section 26 of the PDPA limits the ability of an organization to transfer personal data outside Singapore. In particular, section 26(1) provides that an organization must not transfer any personal data to a country or territory outside Singapore except in accordance with requirements prescribed under the PDPA to ensure that organizations provide a standard of protection to personal data so transferred that is comparable to the protection under the PDPA. This requirement not to transfer personal data unless in accordance with the prescribed requirements is referred to in the PDPA Guidelines as the Transfer Limitation Obligation.<sup>42</sup>

In essence, an organization may transfer personal data overseas if it has taken appropriate steps to ensure that it will comply with the Data Protection Provisions in respect of the transferred personal data while such personal data remains in its possession or under its control; and if the personal data is transferred to a recipient in a country or territory outside Singapore, that the recipient is bound by legally enforceable obligations to provide to the personal data transferred a standard of protection that is comparable to that under the PDPA. In this regard, legally enforceable obligations include obligations imposed on the recipient under:

- any law;
- any contract that requires the recipient to provide to the personal data transferred to the recipient a standard of protection that is at least comparable to the protection under the PDPA; and specifies the countries and territories to which the personal data may be transferred under the contract;
- any binding corporate rules that require every recipient of the transferred personal data to provide to the personal data transferred to the recipient a standard of protection that is at least comparable to the protection under the PDPA; and specify the recipients of the trans-

ferred personal data to which the binding corporate rules apply; the countries and territories to which the personal data may be transferred under the binding corporate rules; and the rights and obligations provided by the binding corporate rules;

- any other legally binding instrument.

#### Note

The author has no conflicts to disclose.

#### References

1. Human Biomedical Research Act 2015 (No. 29 of 2015), available at <<https://sso.agc.gov.sg/Act/HBRA2015>> (last visited October 29, 2019).
2. Ministry of Health Singapore, *Human Biomedical Research Act: Reflection on Transition*, March 2, 2018, available at <<https://www.moh.gov.sg/docs/librariesprovider5/legislation/reflection-on-transition.pdf>> (last visited October 29, 2019).
3. Human Biomedical Research Act 2015 (No. 29 of 2015) at 3<sup>rd</sup> sch.
4. *Id.*, § 3(3). This sub-section identifies these materials as human gametes or human embryos, cytoplasmic hybrid embryos, human-animal combination embryo and human stem cells or neural cells.
5. *Id.* § 3(2)(a)-(c).
6. *Id.* § 3(2)(i)-(iii).
7. *Id.*, 2<sup>nd</sup> sch, para. 1, 2, 6, 7. Other research excluded from the statutory definition of human biomedical research include minimal risk studies and tests that relate to normal human psychological responses and behaviours or measurement of human intelligence, as well as activities that are already governed under a different statutory regime.
8. *Id.* § 3(5).
9. Bioethics Advisory Committee Singapore, *Ethical Guidelines for Human Biomedical Research*, June 2015: at 28-29, available at <<https://www.bioethics-singapore.org/files/publications/reports/ethics-guidelines-for-human-biomedical-research-full-report.pdf>> (last visited October 29, 2019).
10. *Id.* para. 2.13. As the BAC explains, the principle of beneficence is not considered to be distinct from the principle of respect for persons for many research endeavors, and is hence not set apart as a standalone principle.
11. Human Biomedical Research (Restricted Research) Regulations 2017, S 621/2017, available at <<https://sso.agc.gov.sg/SL/HBRA2015-S621-2017?DocDate=20171030>> (last visited October 29, 2019).
12. M.L. Wong, K.S. Chia, W.M. Yam, G.R. Teodoro, and K.W. Lau, "Willingness to Donate Blood Samples for Genetic Research: A Survey from a Community in Singapore," *Clinical Genetics* 65, no. 1 (2004): 45-51.
13. Bioethics Advisory Committee Singapore, *Genetic Testing and Genetic Research*, November 2005, available at <<https://www.bioethics-singapore.org/files/publications/reports/genetic-testing-and-genetic-research-full-report.pdf>> (last visited October 29, 2019).
14. Bioethics Advisory Committee Singapore, *Human Tissue Research*, November 2002, para 9.6, available at <<https://www.bioethics-singapore.org/files/publications/reports/human-tissue-research-full-report.pdf>> (last visited October 29, 2019).
15. T.W. Chan and C.W.L. Ho, "A Ten-Year Retrospective Analysis of Consent for the Donation of Residual Human Tissue in Singapore Healthcare Institution: Reflections on Governance," *Asian Bioethics Review* 9, no. 4 (2017): 335-351.
16. See: Biological Agents and Toxins Act 2006, available at <<https://sso.agc.gov.sg/Act/BATA2005>> (last visited October 29, 2019).
17. See: Protected Areas and Protected Places Act (1987), available at <<https://sso.agc.gov.sg/Act-Rev/PAPPA1959/Published/20131231?DocDate=19870330>> (last visited October 29, 2019).
18. Bioethics Advisory Committee Singapore, *supra* note 13.
19. Ministry of Health Singapore, *Code of Practice: Standards for the Provision of Clinical Genetic/Genomic Testing Services; Standards for the Provision of Clinical Laboratory Genetic, Genomic Testing Services*, 2018, available at <<https://elis.moh.gov.sg/elis/publishInfo.do?task=download&pkId=295>> (last visited October 29, 2019).
20. Bioethics Advisory Committee Singapore, *supra* note 9.
21. Human Biomedical Research Act 2015 (No. 29 of 2015), § 6.
22. *Id.* § 7, 8.
23. *Id.* § 12(1).
24. *Id.* § 26.
25. *Id.* § 27-29.
26. *Id.* § 2.
27. Ministry of Health Singapore, *Human Biomedical Research Bill: Public Consultation Nov-Dec 2014 (2014)*, available at <[https://www.moh.gov.sg/content/dam/moh\\_web/e-Consultation/HBR%20Bill\\_Public%20Consultation\\_Slides.pdf](https://www.moh.gov.sg/content/dam/moh_web/e-Consultation/HBR%20Bill_Public%20Consultation_Slides.pdf)> (last visited October 29, 2019).
28. Human Biomedical Research Act 2015 (No. 29 of 2015), § 32.
29. *Id.* § 33.
30. *Id.* § 38.
31. *Id.* § 2.
32. *Id.* § 6.
33. *Id.* § 9.
34. *Id.* § 10.
35. *Id.* § 11.

36. *Id.* § 12(2).  
 37. *Id.* 5<sup>th</sup> sch, pt 2.  
 38. Bioethics Advisory Committee Singapore, *supra* note 14.  
 39. See: Ministry of Health Singapore, Singapore Government, *Online Consultation on Draft Subsidiary Legislation for Human Biomedical Research Act – Tissue Banking Regulations*, available at <<https://www.moh.gov.sg/e-consultation/online-consultation-on-draft-subsidiary-legislation-for-human-biomedical-research-act---tissue-banking-regulations>> (last visited October 29, 2019).  
 40. Human Biomedical Research Act 2015 (No. 29 of 2015) § 31.  
 41. Bioethics Advisory Committee Singapore, *supra* note 9.  
 42. Personal Data Protection Commission, *Advisory Guidelines on Key Concepts in the PDPA*, July 27, 2017, available at <[https://www.pdpc.gov.sg/-/media/Files/PDPC/PDF-Files/Advisory-Guidelines/the-transfer-limitation-obligation--ch-19-\(270717\).pdf](https://www.pdpc.gov.sg/-/media/Files/PDPC/PDF-Files/Advisory-Guidelines/the-transfer-limitation-obligation--ch-19-(270717).pdf)> (last visited October 29, 2019).

## South Africa

*Pamela Andanda*

Researchers in genomics are exploring novel ways to interact directly with prospective participants without utilizing physicians, hospitals, or biobanks as intermediaries. Many researchers are interested in using the internet to directly recruit and enroll research participants in genomic studies by posting information online about active or proposed studies. This direct-to-participant (DTP) approach could take place under three main scenarios:

- A researcher in your country wants to conduct DTP genomic research with participants in your country
- A researcher in your country wants to conduct DTP genomic research with participants in another country
- A researcher from outside your country wants to conduct DTP genomic research with participants in your country

There is uncertainty about whether DTP recruitment, enrollment, and research are lawful under these scenarios.

### Part I — DTP-Specific Questions

- 1. As far as you know, is DTP genomic research a topic of interest to researchers or other stakeholders in your country? [Multiple choice]**
  - a. There has been little, if any, discussion of the issue as of now
  - b. There has been discussion among researchers, but little discussion among policy makers**
  - c. There has been discussion among both researchers and policy makers
  - d. I am not sure — or other answer

The public, researchers, policymakers, ethics regulatory bodies, healthcare professionals, healthcare and pharmaceutical companies, and health insurance companies are all interested in genomic research.<sup>1</sup> However, it is mostly researchers who have expressed interest in DTP genomic research. Other stakeholders who are interested in direct-to-consumer (DTC) genetic testing are local and foreign DTC service providers, public consumers of DTC laboratory-based genetic testing and clinicians.<sup>2</sup>

- 2. Assume that a researcher in your country wants to conduct DTP genomic research with participants in your country and that such research is subject to IRB/REC review. Please describe the conditions for IRB/REC approval, if it could be approved at all.**

There are 46 research ethics committees (RECs) registered in South Africa. Although each of them establishes its own ethical and procedural requirements, they are expected to

comply with the guidelines issued by the National Department of Health<sup>3</sup> and the Department of Health's policy framework for ethical approval (2012).<sup>4</sup> For genomic research, the guidelines require researchers to ensure that the collection and storage of data and human biological materials balance the need for adequate participant safeguards with optimal advancement of research.<sup>5</sup> Depending on the affiliation of the researcher, they are also required to comply with the Health Professions Council of SA<sup>6</sup> or South African Medical Research Council Guidelines (2018)<sup>7</sup> as appropriate.

- 3. Assume that a researcher in your country wants to conduct DTP genomic research in another country. Please describe the conditions that must be satisfied for IRB/REC approval in your country, if it could be approved at all. Would your IRB/REC also require approval from a research ethics review body in the other country?**

RECs in South Africa have the mandate to approve research that is conducted in the country. The Human Science Research Council's guidelines explicitly state that its REC "cannot approve research conducted on human participants beyond our national jurisdiction. If the project involves countries other than South Africa, the applicant will need to seek concurrent ethics approval from RECs in the other host countries."<sup>8</sup> Although there is no specification about double ethics review in the local legislation or guidelines, the MRC Guidelines for ethics research, provide that "no research shall be performed in a host country without local research collaboration in the design and conduct of that research."<sup>9</sup>

- 4. Assume that a researcher from outside your country wants to**

**Pamela Andanda, LL.B., LL.M., Ph.D.,** *Professor of Law, University of the Witwatersrand, Johannesburg, South Africa.*



**conduct DTP genomic research in your country.**

- a. Would it be lawful for the researcher to do so without IRB/REC approval in either the researcher's country or your country? [Yes/No]  
 Yes  
 No  
 Not sure or other

See the explanation in 3 above regarding the need to seek concurrent ethics approval from RECs in the other host countries.

- b. Would it be lawful for the researcher to do so if the research were approved by an IRB/REC in the researcher's own country, but was not submitted for approval in your country? [Yes/No]  
 Yes  
 No  
 Not sure or other

See Department of Health Guidelines,<sup>10</sup> which require researchers to ensure that the collection and storage of data and human biological materials balance the need for adequate participant safeguards with optimal advancement of research. Such safeguards are ensured through ethics review in the South Africa.

- c. Would the external researcher be required to have a collaborator in your country? [Yes/No]  
 Yes  
 No  
 Not sure or other

The Department of health guidelines specifies that for international multi-center research, at least one (co-) PI must be based in South Africa.<sup>11</sup>

- d. Would it matter whether the external researcher is based at a commercial, governmental, or academic entity? [Yes/No]  
 Yes  
 No

Not sure or other

There are few specifications regarding this issue in the guidelines. For example, the Human Sciences Research Council guidance document requires the research to have a scholarly intent. But in general, the regulation applies equally to all research conducted with human participants in South Africa regardless of its commercial, governmental, or academic purpose.

**5. The perceived benefits and risks that could occur if a researcher from another country conducted IRB/REC-approved genomic research on samples or data obtained from South Africa.**

The various stakeholders both overlap and differ in terms of their perceived benefits and risks of international genomic research on South African samples and data. These include the benefits and risks of genomic research in general but extend to issues relating to export of samples and data.

*Some Benefits:*

- South African samples and data can provide insight into the diverse ancestries of our people.
- Research on South African samples and data can foster the development of precision medicine to serve South Africans and address the heavy burden of disease in the country.
- Disease screening can enable South Africans to respond to personal disease risk and take more appropriate care of their health (empowerment).
- International involvement can provide a helping hand while local capacity is still developing.

*Some Risks:*

- Valuable South African data and samples may not translate into local benefit or benefit for the participating community group.

- Removal of South African data and samples can stifle the development of local genomics capacity.
- South African data and samples could escape South African oversight and control if removed, even compromising original ethics commitments made if these are not respected by the foreign regulations, e.g. regarding secondary use of samples.
- If exported, South African samples could be subject to different cultural beliefs about blood etc.
- There are unresolved complexities involved in obtaining consent for this type of research, for example, South Africans who consent to DTP/DTC may not fully understand what they are consenting to because of the absence of a health professional in "recruitment."
- Disease screening conclusions may be premature because of dearth of knowledge of African genome and lack of scientific justification for claims of tests, especially regarding diseases in which genetics is only one of the many factors.
- Results could be a source of confusion, or even trauma and offense, especially where no genetic counselling (likely in SA where there is a shortage of capacity) and could have these implications for family and community who didn't consent to participate.
- Even if anonymized, misuse of data could lead to invasion of privacy, especially since genetic information can be used to identify people, which can then result in discrimination, for example, by insurance companies or employers.

**Part II – General Questions**

- 6. A few institutions have biohazard committees and data protection boards. Export permits are required, and the following entities have issued regulations and guidelines that regulate**

### the import/export of biological samples and data.

A permit is required for the import/export of biospecimens and the authority responsible for issuing such permits is the Director General of the National Department of Health.<sup>12</sup> Other relevant regulations are the *Material Transfer Agreement of Human Biological Materials*,<sup>13</sup> which establishes the contractual form of agreement required to transfer material between institutions (cf Question 7 below); and the *Protection of Personal Information Act 4 of 2013*,<sup>14</sup> which regulates the transfers of personal information outside South Africa and applies to any responsible party in the Republic.

#### Other Entities

The Information Regulator is, among others, empowered to monitor and enforce compliance by public and private bodies with the provisions of the *Promotion of Access to Information Act*,<sup>15</sup> and the *Protection of Personal Information Act*.<sup>16</sup>

### 7. Laws and guidelines dealing with genetic or genomic research or genetic or genomic privacy that would apply to international DTP research and their application outside the country when residents or citizens of SA enroll in a DTP study conducted abroad.

The position regarding these issues is unclear. See the guidelines and policies that are referred to in question 6 above. See the Academy of Science of South Africa report, which confirms that “legislation in South Africa that deals with genetics and genomics is very limited” and “no specific legislation on genetics and genomics exists in South Africa.”<sup>17</sup>

### 8. Does your country have laws, policies, guidelines, or cultural expectations regarding the return of individual or aggregate research results? [Multiple choice]

#### a. The law requires the return of individual results unless the participant expressly declines to have results returned

- b. The law is silent on return of results; the expectation is that individual results will be returned unless the participant expressly declines to have the results returned
- c. The law is silent on return of results; aggregate results are typically returned, but individual results are not returned unless expressly stated in the research protocol
- d. I am not sure — or other answer

DoH guidelines<sup>18</sup> and SAMRC guidelines<sup>19</sup> both require return of results. However, there are concerns regarding lack of regulation to ensure the return of research results to benefit the community that provided the samples and data.<sup>20</sup>

### 9. Does your country have laws, policies, or guidelines regarding “direct-to-consumer” genetic testing (e.g., 23andMe) and, if so, what do they provide? [Multiple choice]

- a. Yes. Direct-to-consumer genetic testing is illegal
- b. Yes. Direct-to-consumer genetic testing is legal
- c. No. Direct-to-consumer genetic testing is not an issue
- d. I am not sure — or other answer

There are no regulations or guidelines regarding DTC. The Academy of Science of SA has expressed concerns about this issue and given specific recommendations for suitable legislation.

The objective of the consensus report is “to inform the drafting of policy documents, regulations and guidelines under the auspices of the DoH [Department of Health], the Department of Science and Technology (DST) and other relevant departments.”<sup>21</sup> It calls for the regulation of

direct to consumer genetic marketing and testing<sup>22</sup> and makes the following specific recommendations:

1. Regulation of genetics and genomics in South Africa.<sup>23</sup>
2. Development of code of conduct and best practice for professionals working in the field of genetics and genomics in South Africa as well as policy and guidelines.<sup>24</sup>
3. See other overarching recommendations that are normative in nature.<sup>25</sup>

### Part III — Looking to the Future

### 10. How, if at all, do you anticipate that your country’s laws, policies, or guidelines will change in the next 5-10 years in response to international DTP genomic research? [Multiple choice]

- a. I do not think they will change at all
- b. I think they will restrict international DTP research
- c. I think they will allow international DTP research
- d. I am not sure — or other answer

Concerns have been raised regarding the inadequacy of laws, policies, and guidelines in dealing with DTP genomic research, especially where it crosses international borders. A few recommendations have been made on what ought to change, such as transparency in handling of genetic data collected from people in South Africa and the establishment of clear policies.<sup>26</sup>

#### Note

The author has no conflicts to disclose.

#### References

1. C. Staunton and K. Moodley, “Data Mining and Biological Sample Exportation from South Africa: A New Wave of Bioexploitation under the Guise of Clinical Care?” *South African Medical Journal* 106, no. 2 (2016): 136-138; M.S. Pepper et al., “ASSAf Consensus Study on the Ethical, Legal and Social

- Implications of Genetics and Genomics in South Africa,” *South African Journal of Science* 114, no. 11/12 (2018): 1-3.
2. C. Dandara et al., “Direct-to-Consumer Genetic Testing: To Test or Not to Test, That is the Question,” *South African Medical Journal* 103, no. 2 (2013): 510-512.
  3. National Department of Health, “Ethics in Health Research: Principles, Processes and Structures,” March 1, 2015, available at <<http://nhrec.health.gov.za/index.php/grids-preview>> (last visited October 30, 2019).
  4. National Department of Health (DoH), “Policy Framework for Ethics Approval and Endorsement of Health Research,” available at <<http://www.health.gov.za/index.php/2014-03-17-09-09-38/policies-and-guidelines/category/90-2012p>> (last visited October 30, 2019).
  5. DoH, *supra* note 3, para 3.3.9.
  6. Health Professions Council of South Africa HPCSA, *Guidelines for Good Practice in the Health Care Professions, Booklet 13* (2016).
  7. South African Medical Research Council (MRC), “Guideline Documents,” available at <<http://www.mrc.ac.za/research/ethics/guideline-documents>> (last visited October 30, 2019).
  8. Human Sciences Research Council, “Guidance For External Applicants Applying For Ethical Review by the HRSC Research Ethics Committee (REC),” January 2018, para. 7, available at <<http://www.hsrc.ac.za/uploads/pageContent/5498/Guidance%20for%20external%20applicants%20applying%20for%20ethical%20review%20by%20the%20HSRC%20REC%2020182.pdf>> (last visited October 30, 2019).
  9. MRC, “Guidelines on Ethics for Medical Research: Ethical Principles,” Book 1, par. 11.4.2, available at <<http://www.mrc.ac.za/sites/default/files/attachments/2016-06-29/ethicsbook1.pdf>> (last visited October 30, 2019).
  10. DoH, *supra* note 3, para. 3.3.9.
  11. DoH, *supra* note 3; para. 2.3.8.
  12. National Department of Health, National Health Act: Regulations Relating to Import and export of human tissue, blood, blood products, cultured cells, embryos, foetal tissue, zygotes and gametes, March 2, 2012.
  13. Material transfer agreement of human biological materials to be used by providers and recipients of biological material for use in research or clinical trials under the auspices of the Health Research Ethics Committees, GN 719 of GG 41781, July 20, 2018.
  14. Protection of Personal Information Act 4 of 2013 § 72 (S. Afr.).
  15. Promotion of Access to Information Act 2 of 2000 (S. Afr.).
  16. Protection of Personal Information Act 4 of 2013 (S. Afr.).
  17. Academy of Science of South Africa (ASSAF), “Human Genetics and Genom-

- ics in South Africa: Ethical, Legal and Social Implications. Consensus Study,” November, 2018, p. 20, available at <[http://research.assaf.org.za/bitstream/handle/20.500.11911/106/2018\\_assaf\\_ethical\\_genetics\\_genomics\\_consensus.pdf?sequence=1&isAllowed=y](http://research.assaf.org.za/bitstream/handle/20.500.11911/106/2018_assaf_ethical_genetics_genomics_consensus.pdf?sequence=1&isAllowed=y)> (last visited October 30, 2019).
18. DoH, *supra* note 3, para. 3.3.8.
  19. MRC, *supra* note 7, s. 11.
  20. A. Nienaber, “Consent to and Authorization of the Export and use of Human Biological Specimens for Future Research — Perspectives from Three African Countries,” *Comparative and International Law Journal of Southern Africa* 44, no. 2 (2011): 225-254.
  21. ASSAF, *supra* note 17, p. 20. s. 2.1.
  22. *Id.*, p. 38, R3.
  23. *Id.*, p. 90, para 5.6.
  24. *Id.*, p. 91, para 5.7.
  25. *Id.*, pp. 93-94.
  26. ASSAF, *supra* note 17.

## South Korea

Won Bok Lee

Researchers in genomics are exploring novel ways to interact directly with prospective participants without utilizing physicians, hospitals, or biobanks as intermediaries. Many researchers are interested in using the internet to directly recruit and enroll research participants in genomic studies by posting information online about active or proposed studies. This direct-to-participant (DTP) approach could take place under three main scenarios:

- A researcher in your country wants to conduct DTP genomic research with participants in your country
- A researcher in your country wants to conduct DTP genomic research with participants in another country
- A researcher from outside your country wants to conduct DTP genomic research with participants in your country

There is uncertainty about whether DTP recruitment, enrollment, and research are lawful under these scenarios.

## Part I — DTP-Specific Questions

1. **As far as you know, is DTP genomic research a topic of interest to researchers or other stakeholders in your country? [Multiple choice]**
  - a. There has been little, if any, discussion of the issue as of now
  - b. There has been discussion among researchers, but little discussion among policy makers
  - c. There has been discussion among both researchers and policy makers
  - d. I am not sure — or other answer
2. **Assume that a researcher in your country wants to conduct DTP genomic research with participants in your country and that such research is subject to IRB/REC review. Please describe the conditions for IRB/REC approval, if it could be approved at all.**

Substantively, the research must meet the requirements of the *Bioethics and Biosafety Act of Korea*, which includes measures to protect research subjects in a manner similar to the Common Rule. While the latest iteration of the US Common Rule stopped short of introducing a new provision that would deem a biospecimen to be personally identifiable information, Korea’s *Bioethics and Biosafety Act* has a separate set of rules governing research involving biospecimens,<sup>1</sup> in addition to provisions applicable to human subject research.

Under the *Bioethics and Biosafety Act*, a researcher must obtain approval from an IRB/REC before commencing any research on biospecimens,<sup>2</sup> unless one of the exemption criteria is met.<sup>3</sup> The principal investigator is usually required to submit the following documents for review by IRB/

Won Bok Lee, M.D., LL.M., S.J.D., is a Professor, Ewha Law School, Korea.

REC: a research proposal, a letter of commitment to abide by research ethics, a declaration of absence of conflict of interest, a resume, the informed consent template, and a certificate of completion of research ethics education.

In addition, the researcher must acquire informed consent from the donor before obtaining a biospecimen,<sup>4</sup> unless one of the exemption criteria is met.<sup>5</sup> Informed consent documents must include the following information: the purpose of the research, protective measures for personal information, procedures for preservation and disposal of the biospecimen, third-party sharing of the biospecimen and/or genetic information extracted from the biospecimen, withdrawal of informed consent, availability period of research results, and access to the information from the research. The law provides an informed consent template.<sup>6</sup>

**3. Assume that a researcher in your country wants to conduct DTP genomic research in another country. Please describe the conditions that must be satisfied for IRB/REC approval in your country, if it could be approved at all.**

It is debatable whether the *Korean Bioethics and Biosafety Act* will apply in this scenario. One argument is that the statute is applicable because the researcher resides in Korea and is subject to Korean jurisdiction. The counterargument is that the statute was legislated with the purpose of protecting research subjects in Korea and, thus, becomes inapplicable if research subjects are not Korean citizens or residents.

In practice, the Korea National Institute for Bioethics Policy (“KNIBP”)<sup>7</sup> is of the position that a Korean researcher conducting overseas research will trigger the IRB/REC approval under the *Korean Bioethics and Biosafety Act*. Under that view, the same conditions that must be satisfied for IRB/REC approval for purely domestic DTP genomic

research under Question 2 must be met in this case too.

**Would your IRB/REC also require approval from a research ethics review body in the other country?**

The *Bioethics and Biosafety Act* of Korea does not explicitly require approval from a research ethics review body in the other country under this scenario.

However, KNIBP recommends that research involving overseas human subjects with an overseas collaborator clear review by IRB/REC of that foreign country, in addition to an IRB/REC review in Korea. KNIBP leaves room for the possibility that the domestic (Korean) IRB/REC may defer to the overseas IRB/REC review, rather than going through a full-scale review in Korea again.

Under such a view, a researcher wanting to conduct DTP genomic research in another country would also be required to seek approval from an IRB/REC in that other country.

**4. Assume that a researcher from outside your country wants to conduct DTP genomic research in your country.**

a. Would it be lawful for the researcher to do so without IRB/REC approval in either the researcher’s country or your country? [Yes/No]

- Yes  
 No  
 Not sure or other

The *Bioethics and Biosafety Act* is silent as to whether a foreign researcher will be required to seek IRB/REC approval in this scenario, and it is debatable whether the law is applicable along the similar lines of argument as offered in Answer 3. Nevertheless, it will be very difficult for a foreign researcher to present a legal defense if no IRB/REC approval was obtained in either country, because the debate is about whether IRB/REC review is required in Korea,

not about whether IRB/REC review is required at all.

b. Would it be lawful for the researcher to do so if the research were approved by an IRB/REC in the researcher’s own country, but was not submitted for approval in your country? [Yes/No]

- Yes  
 No  
 Not sure or other

As in the previous question, this is debatable. KNIBP is of the view that approval by an IRB/REC in Korea is required, as long as research subjects are citizens or residents of Korea.

c. Would the external researcher be required to have a collaborator in your country? [Yes/No]

- Yes  
 No  
 Not sure or other

The *Bioethics and Biosafety Act* of Korea does not require a domestic collaborator for a foreign researcher to be able to pass review by an IRB/REC in Korea. In light of the usually conservative approach that IRBs/RECs in Korea tend to take, the possibility of IRB/REC requiring a Korean collaborator cannot be ruled out.

d. Would it matter whether the external researcher is based at a commercial, governmental, or academic entity? [Yes/No]

- Yes  
 No  
 Not sure or other

The *Bioethics and Biosafety Act* of Korea does not discriminate against any particular type of researcher. However, the IRB/REC in Korea reviewing the research proposal may exercise extra rigor if the applicant is a commercial entity rather than an academic or government entity.

**5. As far as you know, what are the perceived benefits and risks that could occur if a researcher from another country conducted**

**IRB/REC-approved genomic research on samples or data obtained from your country? Please consider the perspectives of the public, research participants, socially-defined groups (e.g., indigenous or minority populations), researchers, and other professional or government entities.**

The perceived benefits would be along the lines of possibly better analysis by a more able, foreign research institution, attention to rare diseases that may be neglected by the Korean academia, interracial comparison, and contribution to science.

As to the risks, data privacy would be the biggest issue, since the Korean government will no longer be able to have governance over foreign researchers and hold the foreign researcher to the Korean data privacy regulation. Another risk that is sometimes mentioned is losing “genomic sovereignty,” if foreign entities succeed in gaining more accurate insight into the genomic constitution of the Korean people than Korea’s own academia or industry.

## Part II — General Questions

**6. Does your country have biohazard committees, data protection boards, export permit authorities, or other entities that regulate the exporting of biospecimens or the transferring of data across borders for research? If so, do these requirements apply to individual citizens as well as research and medical institutions?**

While importing of biospecimens or disposal of human tissue is tightly regulated, exporting of biospecimens per se is not regulated. Therefore, individual citizens will not face any issue in sending their samples abroad. In fact, many individual Korean citizens have been able to purchase services of US-based DTC genetic testing companies, such as 23andMe, by

sending their sample to the US without any restriction.

As to data transfer across borders, the *Personal Information Protection Act* of Korea sets forth meticulous duties on a “data processor” who gathers personal information and utilizes it. However, the statute will not apply if the recipient of data resides outside of Korea and passively receives information from a willing Korean citizen. Thus, individual citizens can freely transfer their data without the overseas recipient having to comply with the *Personal Information Protection Act*.

**7. Does your country have laws, policies, or guidelines dealing with genetic or genomic research or genetic or genomic privacy that would apply to international DTP research? Do your national laws on these issues apply outside of your country when residents or citizens of your country enroll in a DTP study conducted abroad?**

Korea does not have laws, policies, or guidelines dealing with genetic/genomic research or genetic/genomic privacy, other than the requirement that the donor be informed about third-party sharing of genetic information in the consent document, as explained in Answer 2.

Whether this piece of informed consent requirement will apply when residents or citizens of Korea enroll in a DTP study conducted abroad will probably depend on the nature of the recruitment that took place in Korea. Korea’s national laws are, in principle, territorial; they will apply if relevant action takes place in Korea or if the actor is in Korea. Therefore, if residents or citizens of Korea willingly and independently enroll in a DTP study conducted abroad, Korean law should not apply. As mentioned in Answer 6, Korean citizens’ use of US-based DTC genetic testing companies has not triggered any regulatory response, since 23andMe never marketed its business in Korea.

However, if the investigators of the DTP research conduct what can be

characterized as “active recruitment” of research subjects in Korea, rather than remaining a “passive recipient” of biospecimens, the Korean regulator will more likely than not bring the Korean law to bear on the DTP research, including informed consent and IRB/REC review requirements as explained in Answer 4.

**8. Does your country have laws, policies, guidelines, or cultural expectations regarding the return of individual or aggregate research results? [Multiple choice]**

- a. The law requires the return of individual results unless the participant expressly declines to have results returned
- b. The law is silent on return of results; the expectation is that individual results will be returned unless the participant expressly declines to have the results returned
- c. The law is silent on return of results; aggregate results are typically returned, but individual results are not returned unless expressly stated in the research protocol
- d. I am not sure — or other answer**

The Bioethics and Biosafety Act requires that the informed consent document describe the availability period of research results and the details on the access to the information,<sup>8</sup> as explained in Answer 2. This provides the ground for individual participants’ access to the results, while return of results is not mandatory.

The expectation is probably that the individual results will be returned, since past genomic projects returned individual results, which I believe was one of the incentives to participating in genomic research to begin with. For example, the Ulsan 10,000 Genome Project, which launched in 2015, returns individual reports that include genetic variations, ethnicity

analysis, haplotype analysis, the “biological age” based on telomere length, and genotypes related to diseases or physical traits.<sup>9</sup>

**9. Does your country have laws, policies, or guidelines regarding “direct-to-consumer” genetic testing (e.g., 23andMe) and, if so, what do they provide? [Multiple choice]**

- Yes. Direct-to-consumer genetic testing is illegal
- Yes. Direct-to-consumer genetic testing is legal**
- No. Direct-to-consumer genetic testing is not an issue
- I am not sure — or other answer

While direct-to-consumer genetic testing is legal, its scope is closely regulated. Currently, the regulation allows only 12 genotyping tests that can be characterized as “wellness-related” — i.e., not disease-related. The list is attached at the end of this questionnaire. Disease-related genetic testing — e.g., BRCA genes — or pharmacogenetic testing must be ordered by a clinician.

**Part III — Looking to the Future**

**10. How, if at all, do you anticipate that your country’s laws, policies, or guidelines will change in the next 5-10 years in response to international DTP genomic research? [Multiple choice]**

- I do not think they will change at all
- I think they will restrict international DTP research
- I think they will allow international DTP research
- I am not sure — or other answer**

While it is very difficult to predict one way or another, the Korean government definitely is aware of the privacy issues that genomic research can create and will want to assert some type of governance over international DTP

research that reaches Korean citizens. However, I do not think the Korean government will go so far as restricting it outright.

**Genotypes Permitted for Direct-to-Consumer Genetic Testing Service in Korea**

- body mass index based on FTO, MC4R & BDNF genes
- triglyceride level based on GCKR, DOCK7, ANGPTL3, BAZ1B, TBL2, MLXIPL, LOC105375745 & TRIB1 genes
- cholesterol level based on CELSR2, SORT1, HMGCR, ABO, ABCA1, MYL2, LIPG & CETP
- blood glucose level based on CDKN2A/B, G6PC2, GCK, GSKR, GLIS3, MTNR1B, DGKB-TMEM195 & SLC30A8 genes
- hypertension based on NPR3, ATP2B1, NT5C2, CSK, HECTD4, GUCY1A3, CYP17A1 & FGF5 genes
- hyperpigmentation based on OCA2 & MC1R genes
- baldness based on chr20p11(rs1160312, rs2180439), IL2RA & HLA-DQB1 genes
- hair thickness based on EDAR gene
- skin aging based on AGER gene
- skin tone based on MMP1 gene
- vitamin c level based on SLC23A1(SVCT1) gene
- caffeine metabolism based on AHR & CYP1A1-CYP1A2 genes

**Note**

The author has no conflicts to disclose.

**References**

- Bioethics and Biosafety Act, Act No. 9100, Jan. 1, 2005, art. 36-40 (S. Kor.), *translated in* Ministry of Government Legislation, *available at* <<http://moleg.go.kr/english/korLawEng?pstSeq=47518>> (last visited October 30, 2019).
- Id.* art 36, para 1.
- Id.* art 36, para 2. However, a DTP genomic research will not be able to meet any of the exemption criteria.
- Id.* art 37, para 1-3.
- Id.* art 37, para 4. However, a DTP genomic research will not be able to meet any of the exemption criteria.
- Minister’s Decree under the Bioethics and Biosafety Act of Korea, Schedule 34, art. 34, para. 2. This form was men-

tioned in my previous article “Biobank Regulation in South Korea,” *Journal of Law, Medicine & Ethics* 44, no. 2 (2016): 342-351. Regardless of whether the researcher preserves the biospecimens in a repository or simply discards them after sequencing, the Regulatory Framework for “Non-Bank” Repositories will apply to DTP genomic research, as the framework is geared towards biospecimens research. I refer to Figure 1 of the article that contains word-for-word translation of the informed consent template.

- The Korea National Institute for Bioethics Policy is a policy research institute that is funded by the Ministry of Health and Welfare, the equivalent to the Department of Health and Human Services of the U.S. As such, although the institute does not have any legal authority to issue interpretive guidance, many researchers turn to the institute for guidance and its guidance often becomes *de facto* standards.
- Minister’s Decree under the Bioethics and Biosafety Act of Korea, *supra* note 6, art 34, para 1.
- Ulsan Metropolitan City, Ulsan National Institute of Science and Technology, Ulsan University Hospital, “Ulsan 10k Genome Project,” *available at* <<http://www.10000genomes.org/>> (last visited July 30, 2019).

## Spain

*Pilar Nicolás*

Researchers in genomics are exploring novel ways to interact directly with prospective participants without utilizing physicians, hospitals, or biobanks as intermediaries. Many researchers are interested in using the internet to directly recruit and enroll research participants in genomic studies by posting information online about active or proposed studies. This direct-to-participant (DTP) approach could take place under three main scenarios:

- A researcher in your country wants to conduct DTP genomic research with participants in your country
- A researcher in your country wants to conduct DTP genomic research with

participants in another country

- A researcher from outside your country wants to conduct DTP genomic research with participants in your country

There is uncertainty about whether DTP recruitment, enrollment, and research are lawful under these scenarios.

### Part I — DTP-Specific Questions

#### 1. As far as you know, is DTP genomic research a topic of interest to researchers or other stakeholders in your country? [Multiple choice]

- There has been little, if any, discussion of the issue as of now
- There has been discussion among researchers, but little discussion among policy makers
- There has been discussion among both researchers and policy makers
- I am not sure — or other answer

#### 2. Assume that a researcher in your country wants to conduct DTP genomic research with participants in your country and that such research is subject to IRB/REC review. Please describe the conditions for IRB/REC approval, if it could be approved at all.

The REC will review the same conditions as in any genomic research:

- The interest and quality of the research.
- If the participants have been informed about: objectives, duration and relevance of the research; right to access the results, right to return of results and right to with-

draw consent; possible relevance of the results for family members; identity of the principal researcher and the data controller; possibility and how to contact the data protection officer.

- The consent has to be written.
- Special requirements if there are minors or vulnerable populations involved.
- There is no economic benefit for the participant.
- Guarantee of confidentiality and data protection according to European and Spanish law.
- Guarantee of return of results relevant for health unless the participant expressly declines to have results returned.
- Availability of genetic counseling in case it could be appropriate.

These conditions apply for cases in which the participant gives his/her data. If samples were to be required, guarantees would have to be added regarding their collection and traceability so physicians, hospitals, or biobanks would be needed as intermediaries (unless there is no risk and the quality of the samples is guaranteed).

#### 3. Assume that a researcher in your country wants to conduct DTP genomic research in another country. Please describe the conditions that must be satisfied for IRB/REC approval in your country, if it could be approved at all. Would your IRB/REC also require approval from a research ethics review body in the other country?

If data are to be processed and analyzed in Spain, the Spanish IRB/REC will be competent to evaluate the study. The same guarantees will apply as in the previous case. No other evaluation would be required.

If samples are required, article 31 of the *Royal Decree 1716/2011*, November 18th, which establishes the basic requirements for authorization and operation of biobanks for the purpose of biomedical research and the treatment of biological samples of human origin and regulates the operation and organization of the National Registry of Biobanks for biomedical research, shall be applicable: “Biological samples of human origin from other countries may only be used for biomedical research purposes when, in addition to the requirements laid down in the regulations relating to the entry and exit of samples in Spanish territory, the guarantees laid down in this royal decree and other applicable regulations have been observed as a minimum, in addition to their collection, storage or conservation and transfer, which will be assessed by the Research Ethics Committee evaluating the research project and, where appropriate, by the biobank’s external committees.”<sup>1</sup> In addition, the regulations governing the import of samples should be respected (in case of countries outside the customs territory of the Community).

#### 4. Assume that a researcher from outside your country wants to conduct DTP genomic research in your country.

- Would it be lawful for the researcher to do so without IRB/REC approval in either the researcher’s country or your country? [Yes/No]
  - Yes
  - No
  - Not sure or other
- Would it be lawful for the researcher to do so if the research were approved by an IRB/REC in the researcher’s own country, but was not submitted for approval in your country? [Yes/No]
  - Yes

**Pilar Nicolás, Ph.D.**, Senior Permanent Researcher, Faculty of Law, Research Group Chair in Law and the Human Genome, University of the Basque Country, Spain.

- No  
 Not sure or other

c. Would the external researcher be required to have a collaborator in your country? [Yes/No]  
 Yes  
 No  
 Not sure or other

d. Would it matter whether the external researcher is based at a commercial, governmental, or academic entity? [Yes/No]  
 Yes  
 No  
 Not sure or other

5. As far as you know, what are the perceived benefits and risks that could occur if a researcher from another country conducted IRB/REC-approved genomic research on samples or data obtained from your country? Please consider the perspectives of the public, research participants, socially-defined groups (e.g., indigenous or minority populations), researchers, and other professional or government entities.

The perception is rather negative if there is no collaboration with a Spanish researcher, in particular:

- Perception of the use of Spanish resources especially in the case of biological samples.
- Perception that remoteness from the researcher may make it difficult for the participant to exercise rights.

## Part II – General Questions

6. Does your country have biohazard committees, data protection boards, export permit authorities, or other entities that regulate the exporting of biospecimens or the transferring of data across borders for research?

### If so, do these requirements apply to individual citizens as well as research and medical institutions?

Concerning samples, the Spanish import/export authority is the Public Health, Quality and Innovation General Director in the Ministry of Health.

The regulation applies to individual citizens as well as research and medical institutions: *Royal Decree 65/2006*, January 30th, which establishes the requirements for the import and export of biological samples for diagnosis or research in humans;<sup>2</sup> *Royal Decree-Law 9/2014*, July 4th, which establishes the quality and safety standards for the donation, collection, evaluation, processing, preservation, storage and distribution of human tissues and cells and which approves the coordination and operation standards for human use.<sup>3</sup>

There are rules concerning international data transfers that could involve the Data Protection Authority in some circumstances, but are applicable when the data are transferred by data controllers or processors.<sup>4</sup> As a matter of fact, the “transfer of data” is an operation related to controllers or processors but not to the data subject.

7. Does your country have laws, policies, or guidelines dealing with genetic or genomic research or genetic or genomic privacy that would apply to international DTP research? Do your national laws on these issues apply outside of your country when residents or citizens of your country enroll in a DTP study conducted abroad?

According to article 31 of the Royal Decree 1716/2011, November 18th, establishing the basic requirements for the authorization and operation of biobanks for the purposes of biomedical research and the treatment of biological samples of human origin, for biomedical Research: “Biological samples of human origin from other countries may only be used for

biomedical research purposes when, in addition to the requirements laid down in the regulations relating to the entry and exit of samples in Spanish territory, the guarantees provided for in this royal decree and other applicable regulations have been observed as a minimum, in addition to their collection, storage or conservation and transfer, which will be assessed by the Research Ethics Committee evaluating the research project and, where appropriate, by the Biobank’s external committees.”<sup>5</sup>

Our national law on genetic tests applies only in Spain.<sup>6</sup> If the donation of a sample for research purposes is done in Spain, this law should be applied. There are no specific rules establishing when it is considered that the donation is done in Spain. It could be said that the applicable law is the one of the donor’s residence.

In addition, the regulations governing the export of samples should be respected (in case of countries outside the customs territory of the Community).

It is expressly established that data protection regulation is also applicable in those aspects not covered by the *Biomedical Research Law*. In the case that Spanish residents or citizens enroll in a DTP study conducted abroad, it seems this regulation is not applicable, as scientific research does not fall into the cases described in article 3 of the GDPR.<sup>7</sup>

8. Does your country have laws, policies, guidelines, or cultural expectations regarding the return of individual or aggregate research results? [Multiple choice]

- The law requires the return of individual results unless the participant expressly declines to have results returned
- The law is silent on return of results; the expectation is that individual results will be returned unless the participant expressly declines to have the results returned



- c. The law is silent on return of results; aggregate results are typically returned, but individual results are not returned unless expressly stated in the research protocol
- d. I am not sure — or other answer

**Law 14/2007:**

**49.1.** The subject shall be informed of the genetic data of a personal nature obtained from the genetic analysis according to the terms in which he expressed his will, without prejudice to the right of access recognized in the legislation on the protection of personal data, which may entail the revocation of the prior manifestation of the free will granted.

**59. 1.** Without prejudice to the provisions of legislation on the protection of personal data, and in particular Article 45 of this Law, before issuing consent for the use of a biological sample for biomedical research purposes that will not be subject to a process of anonymization, the source subject shall receive the following information in writing: (...) g) The right to know the genetic data obtained from the analysis of donated samples. (...) i) Warning about the possibility of obtaining information relating to his/her health derived from the genetic analyses carried out on the biological sample, as well as about the right to take a position in relation to the communication.

**9. Does your country have laws, policies, or guidelines regarding “direct-to-consumer” genetic testing (e.g., 23andMe) and, if so, what do they provide? [Multiple choice]**

- a. Yes. Direct-to-consumer genetic testing is illegal
- b. Yes. Direct-to-consumer genetic testing is legal
- c. No. Direct-to-consumer genetic testing is not an issue
- d. I am not sure — **or other answer**

Not specifically, but they should comply with the requirements established

by law for the practice of genetic analysis. A health-related genetic analysis can only be performed if there is a clinical indication or approved research purpose. The analysis must be carried out within the framework of a genetic counseling process. There must be quality guarantees regarding professionals, centres and procedures.<sup>8</sup>

**Part III — Looking to the Future**

**10. How, if at all, do you anticipate that your country’s laws, policies, or guidelines will change in the next 5-10 years in response to international DTP genomic research? [Multiple choice]**

- a. I do not think they will change at all
- b. I think they will restrict international DTP research
- c. I think they will allow international DTP research
- d. I am not sure — or other answer

I’m not sure about any change in the next few years. There has been no debate on this issue. Data protection legislation has recently been adopted, including a new regime on the processing of data for research purposes, and this issue was not discussed in the process. Nor is it being discussed in academic literature. Furthermore, I believe that it is very difficult to regulate this matter with a national approach.

**Note**

The author has no conflicts to disclose.

**References**

1. Real Decreto 1716/2011, de 18 de noviembre, por el que se establecen los requisitos básicos de autorización y funcionamiento de los biobancos con fines de investigación biomédica y del tratamiento de las muestras biológicas de origen humano, y se regula el funcionamiento y organización del Registro Nacional de Biobancos para investigación biomédica art. 31 (B.O.E. 2011, 290) (Spain).
2. Real Decreto 65/2006, de 30 de enero, por el que se establecen requisitos para la importación y exportación de

muestras biológicas (B.O.E. 2006, 32) (Spain).

3. Real Decreto-ley 9/2014, de 4 de julio, por el que se establecen las normas de calidad y seguridad para la donación, la obtención, la evaluación, el procesamiento, la preservación, el almacenamiento y la distribución de células y tejidos humanos y se aprueban las normas de coordinación y funcionamiento para su uso en humanos (B.O.E. 2014, 163) (Spain).
4. Regulation (EU) 2016/679 of the European Parliament and of the Council of April 27, 2016 on the protection of natural persons with regard to the processing of personal data and on the free movement of such data, and repealing Directive 95/46/EC (General Data Protection Regulation), 2016 O.J. (L 119), 1, art. 46, 47 and 49.
5. Real Decreto 1716/2011, *supra* note 1, art. 31.
6. Ley 14/2007, de 3 de julio, de Investigación biomédica (B.O.E. 2007, 159) (Spain).
7. Regulation (EU) 2016/679 of the European Parliament and of the Council of April 27, 2016 on the protection of natural persons with regard to the processing of personal data and on the free movement of such data, and repealing Directive 95/46/EC (General Data Protection Regulation), 2016 O.J. (L 119), 1.
8. Ley 14/2007, de 3 de julio, de Investigación biomédica (B.O.E. 2007, 159), art. 46-57 (Spain).

**Sweden**

*Titti Mattsson*

Researchers in genomics are exploring novel ways to interact directly with prospective participants without utilizing physicians, hospitals, or biobanks as intermediaries. Many researchers are interested in using the internet to directly recruit and enroll research participants in genomic studies by posting information online about active or proposed studies. This direct-to-participant (DTP) approach could take place under three main scenarios:

- A researcher in your country wants to conduct DTP genomic research with participants in your country
- A researcher in your country wants to conduct DTP genomic research

with participants in another country

- A researcher from outside your country wants to conduct DTP genomic research with participants in your country

There is uncertainty about whether DTP recruitment, enrollment, and research are lawful under these scenarios.

## Part I — DTP-Specific Questions

### 1. As far as you know, is DTP genomic research a topic of interest to researchers or other stakeholders in your country? [Multiple choice]

- There has been little, if any, discussion of the issue as of now
- There has been discussion among researchers, but little discussion among policy makers**
- There has been discussion among both researchers and policy makers
- I am not sure — or other answer

There has been discussion among legal researchers, but little as yet among policy makers.

Unlike DTP testing, DTP research has not been discussed much in Sweden. Scholarly discussion on legal issues related to the field has started to emerge,<sup>1</sup> but there is still little discussion of such matters among policymakers.<sup>2</sup> It bears noting, however, that biobanking *per se* and biobank research have attracted strong interest in Sweden among researchers, policymakers, and practitioners of law.<sup>3</sup>

### 2. Assume that a researcher in your country wants to conduct DTP genomic research with participants in your country and that such research is subject to IRB/REC review. Please describe the conditions for IRB/

### REC approval, if it could be approved at all.

Genome research meets the criteria stated in the general act on the conduct of research in Sweden: the *Lag (2003:460) om etikprövning av forskning som avser människor* [Swedish Code on Ethical Review Concerning Research Involving Human Beings (SCER)]. This legislation applies to research that includes the processing of personal data according to Article 9.1 of the EU *Data Protection Ordinance* (Sec. 3). The Code must also be applied to research that implies physical intervention on a study participant, to research conducted using a method intended to influence the study participant either physically or mentally, to research which implies a blatant risk of physical or mental injury to the study participant, and to research conducted on biological material that has been taken from a living person and which can be traced to that person (Sec. 4).

As of January 1, 2019, applications for permission to conduct research involving humans are examined by the Swedish Ethical Review Authority.<sup>4</sup> The ethical review is conducted by one of six regional sections of the Ethics Examination Authority. Each of these sections consists of one chairman (a former judge) and fifteen other members, who possess scientific competence or who represent public interests. There is also a supervisory Ethics Review Appeals Board (Sec 31).<sup>5</sup> A rejection by a committee can be appealed to this Board (Sec 36).

The fee is approximately €500 for an application that concerns one main research group and €1600 for other research constellations.

Research may only be approved if the risks it entails for the subject's health, safety, and personal integrity do not outweigh its scientific value (Sec. 9). Approval is also withheld if the expected outcome can be achieved by other means that involve less risk to the health, safety, and personal integrity of the subject (Sec. 10). Research that is conducted on biological mate-

rial taken from a living person and which can be traced back to that person demands formal consent from said person. Consent must be freely given, formally specified, and precisely tailored to the research in question. Approval by the Ethical Review Authority must be granted before any research can be started.

### 3. Assume that a researcher in your country wants to conduct DTP genomic research in another country. Please describe the conditions that must be satisfied for IRB/REC approval in your country, if it could be approved at all. Would your IRB/REC also require approval from a research ethics review body in the other country?

The national legislation on ethical review has jurisdiction only within Sweden (SCER Sec. 5). Generally speaking, Swedish law does not follow the researcher, but rather the sample/data and the establishment of the research. Research that takes place outside Sweden must be approved according to the rules pertaining in the country in question.

For research within the EU, the *Regulation (EU) No 536/2014 of the European Parliament and of the Council of April 16, 2014 on clinical trials on medicinal products for human use and repealing Directive 2001/20/EC* may be applicable to a particular project. In general, EU law requirements apply where relevant, as in connection with the clinical trials legal framework and tissue and cells legal framework as well as in connection with the *in vitro* diagnostic medical devices framework.

### 4. Assume that a researcher from outside your country wants to conduct DTP genomic research in your country.

Titti Mattsson, Ph.D., is Professor of Public Law, Director of Health Law Centre, Faculty of Law, Lund University, Sweden.

- a. Would it be lawful for the researcher to do so without IRB/REC approval in either the researcher's country or your country? [Yes/No]  
 Yes  
 No  
 Not sure or other

- b. Would it be lawful for the researcher to do so if the research were approved by an IRB/REC in the researcher's own country, but was not submitted for approval in your country? [Yes/No]  
 Yes  
 No<sup>6</sup>  
 Not sure or other

- c. Would the external researcher be required to have a collaborator in your country? [Yes/No]  
 Yes  
 No<sup>7</sup>  
 Not sure or other

- d. Would it matter whether the external researcher is based at a commercial, governmental, or academic entity? [Yes/No]  
 Yes  
 No<sup>8</sup>  
 Not sure or other

5. **As far as you know, what are the perceived benefits and risks that could occur if a researcher from another country conducted IRB/REC-approved genomic research on samples or data obtained from your country? Please consider the perspectives of the public, research participants, socially-defined groups (e.g., indigenous or minority populations), researchers, and other professional or government entities.**

If the matter pertains to research approved in another country but conducted in Sweden by a researcher from another country, then lawful-

ness is undermined and the public trust vested in research betrayed.

If the matter pertains to research approved by the Swedish authorities and conducted in Sweden by a researcher from another country, then there is no problem — i.e., the non-Swedish background of the researcher poses no additional risk.

One possible risk factor when it comes to cross-border genomic research has to do with the handling of personal data. The *General Data Protection Regulation* (GDPR) protects personal information within the EU, and several other agreements protect personal data outside the EU; however, there is always a risk that the personal details of research subjects will be wrongfully revealed. Issues of privacy protection are perceived as increasingly problematic in relation to the release of genomic data.<sup>9</sup> Swedish rules on public access to information make it easy to obtain official documents from public agencies and certain private bodies.<sup>10</sup> Provisions of this kind may increase the risk for wrongful use of data.

In cases where research results are returned to a study participant, a general risk factor arises in connection with the impact that such results may have on the person in question — especially in view of the relative uncertainty and/or evaluative difficulty associated with this type of research.<sup>11</sup> A mistaken interpretation of research results may have serious repercussions for the individual in question.<sup>12</sup> Moreover, increased geographical distance between researcher and subject can make communicating results to the latter harder.

In general, the Swedish population seems to be well-disposed to participating in research; however, any wrongdoing risks betraying the trust which the public has placed in research.

## Part II — General Questions

6. **Does your country have biohazard committees, data protection boards, export permit authorities, or other entities that regulate the exporting of biospeci-**

**mens or the transferring of data across borders for research? If so, do these requirements apply to individual citizens as well as research and medical institutions?**

Sweden has all of the stated governmental entities. However, not all of them are involved with exports.

### *Biohazards Committee*

There are two governmental entities that deal with matters connected with biological materials: the *Kemikalieinspektion* (Swedish Chemicals Agency) and the *Läkemedelsverk* (Swedish Medical Products Agency). Only the latter handles export permits.<sup>13</sup>

### *Data Protection Board*

The *Datainspektion* (Swedish Data Protection Authority) works with the transfer of data within and outside Sweden. As the general national agency for supervising the rules regarding data protection, it is responsible for ensuring that personal data is handled in accordance with EU regulations and for supervising the processes whereby personal data is transferred to countries outside the EU/EEA. The processes for transferring data to locations outside the EU/EEA may differ from those applying within it, depending on the nature of the data and the location of the receiver.

### *Swedish Export Permit Authorities*

The Swedish export permit authority, the *Kommerskollegium* (National Board of Trade Sweden) is responsible for Swedish policy on trade and the EU's internal market. The *EU Regulation for accreditation and market surveillance relating to the marketing of products and repealing regulation (762/2008)* is part of an EU mandate to improve trade with industrial products. It aims to strengthen the common rules that require member states to ensure that products do not threaten human health or security. The Swedish law which applies in this area (and which is harmonized with EU law) is the *Lag (2004:451) om produktsäkerhet* (Swedish Code

of Product Safety). Its purpose is to guarantee the safety of goods and services provided by either private companies or the state (Sec. 2). The Swedish Medical Products Agency is responsible for export permits (or Free Sales Certificates, as the Agency calls them) for biospecimen-specific exports for use in medicine and clinical trials. Once a product is cleared by the Medical Products Agency, it can be distributed throughout the EU/EEA market. Sometimes a Free Sales Certificate can facilitate export to countries outside the EU/EEA, through the verification it provides of the product's quality.

#### *Export of Biospecimens*

The procedures that apply when goods are exported to other EU/EEA member states are different from those that apply when goods are exported to a country outside that area. The *Tullverk* (Swedish Customs Agency) only labels goods transported to destinations outside of the EU's internal market as exports. When products that fall under the supervision of the Swedish Medical Products Agency are exported to a country outside the EU/EEA, a Certificate of Origin issued by the proper authorities in the recipient country is required.

#### *Data Transfer for Research Purposes*

The transfer of data within the EU/EEA enjoys uniform protection under the GDPR.<sup>14</sup> Personal data includes any information of a genetic nature (including data from analysis of a biological sample) and biometric data for the purpose of uniquely identifying a natural person. It can be transferred outside the EU/EEA if the European Commission has judged the receiving country to uphold an adequate level of data protection, and if the receiving party has taken appropriate protection measures: e.g., Binding Corporate Rules (BCR) or Standard Contractual Clauses (SCC). In exceptional situations, Article 49 GDPR also applies.

The rules and regulations mentioned above apply to all concerned parties equally, whether they be major corporations or individual citizens.

**7. Does your country have laws, policies, or guidelines dealing with genetic or genomic research or genetic or genomic privacy that would apply to international DTP research? Do your national laws on these issues apply outside of your country when residents or citizens of your country enroll in a DTP study conducted abroad?**

The Swedish state regulates how research in Sweden is to be conducted, monitored, and subsequently evaluated (see questions 1-5 above). Yet, however extensive they are on the national level, these laws do not apply beyond Sweden's borders. Where the protection of personal data is concerned, the Swedish Data Protection Agency enforces the provisions of the GDPR, which cover personal data stemming from genetic and genomic research in other EU/EEA countries.

Except in the case of the GDPR, our national laws on genetic or genomic research and genetic or genomic privacy do not apply to research applied abroad.

**8. Does your country have laws, policies, guidelines, or cultural expectations regarding the return of individual or aggregate research results? [Multiple choice]**

- The law requires the return of individual results unless the participant expressly declines to have results returned
- The law is silent on return of results; the expectation is that individual results will be returned unless the participant expressly declines to have the results returned
- The law is silent on return of results; aggregate results are typically returned, but individual results are not returned unless expressly stated in the research protocol

**d. I am not sure — or other answer**<sup>15</sup>

**9. Does your country have laws, policies, or guidelines regarding “direct-to-consumer” genetic testing (e.g., 23andMe) and, if so, what do they provide? [Multiple choice]**

- Yes. Direct-to-consumer genetic testing is illegal
- Yes. Direct-to-consumer genetic testing is legal
- No. Direct-to-consumer genetic testing is not an issue**
- I am not sure — or other answer

There is no specific law addressing direct-to-consumer genetic testing. The approach taken varies according to whether the test in question falls under the health-care regulatory framework or not.

When the test does fall under this framework, all medicinal DNA-analysis is to be registered with the Swedish Medical Products Agency (MPA). This does not mean, however, that the test has been subjected to any quality-validation procedure prior to being rolled out to consumers. In 2018, the Swedish Data Protection Agency proposed that products used for genetic self-testing be made subject to its regulations; however, no such legislation exists yet.<sup>16</sup>

When a test does not fall under the health-care regulatory framework, the consumer-protection framework would appear to apply.

### **Part III — Looking to the Future**

**10. How, if at all, do you anticipate that your country's laws, policies, or guidelines will change in the next 5-10 years in response to international DTP genomic research? [Multiple choice]**

- I do not think they will change at all
- I think they will restrict international DTP research
- I think they will allow international DTP research

### d. I am not sure — or other answer

Sweden has generally been liberal in regulating research. Moreover, the country's overall approach to the governance of new technology appears to be affected by a "we want to be first" attitude. The question is how research is to be regulated and whether current laws in the area have deficiencies. In regard to research relating to children, for example, there are some unresolved issues. It does not seem that Sweden has mapped out all of the problems that arise in connection with DTP research governance. Sweden can expect its provisions in this area to be reviewed, but new legislation *per se* is more uncertain. In general, the GDPR pre-empts regulatory initiatives on Sweden's part to a considerable extent.

#### Note

The author has no conflicts to disclose.

#### References

1. H.C. Howard et al., "The Convergence of Direct-to-Consumer Genetic Testing Companies and Biobanking Activities: The Case of 23andme," in M. Weinroth and E. Rodrigues, eds., *Knowing New Biotechnologies: Social Aspects of Technical Convergence* (London: Routledge, 2015): 59-74; S. Slokenberga and H.C. Howard, "The Right to Science and Human Germline Editing. Sweden, its External Commitments and the Ambiguous National Responses under the Genetic Integrity Act," *Förvaltningsrättslig tidskrift* 2 (2019): 199-222
2. Swedish Government Official Report 2018: 4 (SOU 2018:4).
3. At the Centre for Research Ethics and Bioethics, at Uppsala University, Heidi C. Howard and her team are working on ELSI issues, including direct-to-participant research/testing. Howard is a leading ELSI expert on genetics and genomics. The team's publications are not generally focused on Swedish law. See Uppsala University Publications, "Howard, Heidi Carmen," available at <<http://uu.diva-portal.org/smash/person.jsf?pid=authority-person%3A19956&dsid=827>> (last visited August 2, 2019).
4. See "Ethikprövnings myndigheten," Swedish Ethical Review Authority, available at <<https://etikprovningmyndigheten.se>> (last visited August 2, 2019).
5. See "Överklagandenämnden för etikprövning," (Ethics Review Appeals Board), available at <<https://www.onep.se/en/start/>> (last visited August 2, 2019).
6. According to the SCER, all planned research that meets legal requirements according to Sec 3-4 is subject to ethical review, as long as that research is to take place within Sweden's geographical boundaries (Sec. 5). Thus, a research project must undergo ethical review in Sweden even if it has been approved elsewhere.
7. The Head of Research can be either a physical or a legal person who runs the organization within which the research is to be performed. The Head of Research is the person with the formal responsibility for the research, and thus the one who must apply for ethical review.
8. The research may be based at a commercial, governmental, or academic entity. A research project is generally subject to Swedish ethical review based on its content, not on how it is funded or otherwise set up logistically. A project involving DTP genome research is handled the same way regardless of organizational form, as long as the content of the research is the same.
9. C. Heeney, N. Hawkins, J. de Vries, P. Boddington, and J. Kaye, "Assessing the Privacy Risks of Data Sharing in Genomics," *Public Health Genomics* 14, no. 1 (2011): 17–25.
10. The Press Act and the Public Access to Information and the Secrecy Act (both of which are part of the constitutional framework in Sweden).
11. Centre for Research Ethics & Bioethics, Uppsala University, "Mind the Risk: Managing Genetic Risk Information," available at <<https://www.crb.uu.se/mind-the-risk/>> (last visited August 2, 2019).
12. Centre for Research Ethics & Bioethics, Uppsala University, "Welcome to CRB," available at <<https://www.crb.uu.se/>> (last visited August 2, 2019).
13. Läkemedelsverket (Swedish Medicinal Products Agency), "Certificate of a Pharmaceutical Product (CPP)," available at <<https://lakemedelsverket.se/malgrupp/Foretag/Lakemedel/Exportcertifikat-CPP/>> (last visited August 2, 2019).
14. Datainspektionen (Swedish Data Protection Authority), "Transfer of Data to a Third Country: When Personal Data is Made Available Outside the EU/EEA," available at <<https://www.datainspektionen.se/other-lang/in-english/the-general-data-protection-regulation-gdpr/transfer-of-data-to-a-third-country/>> (last visited August 2, 2019).
15. On the topic on return of genetic risk information, see J. Stjernschantz Forsberg, *Biobank Research — Individual Rights and Public Benefit*, Uppsala University Dissertation, 2012.
16. On the EU level as well, there is currently a lack of legislation specifically

targeting DTC genetic testing. Genetic self-testing kits are usually classified as "in vitro diagnostic medical devices," and they are considered to fall under Directive 98/79/EC of the European Parliament and of the Council of October 27, 1998 on *in vitro* diagnostic medical devices, 1998 O.J. (L 331) 1.

## Switzerland

Vladislava Talanova,  
Alexandre Dosch, and  
Dominique Sprumont

Researchers in genomics are exploring novel ways to interact directly with prospective participants without utilizing physicians, hospitals, or biobanks as intermediaries. Many researchers are interested in using the internet to directly recruit and enroll research participants in genomic studies by posting information online about active or proposed studies. This direct-to-participant (DTP) approach could take place under three main scenarios:

- A researcher in your country wants to conduct DTP genomic research with participants in your country
- A researcher in your country wants to conduct DTP genomic research with participants in another country
- A researcher from outside your country wants to conduct DTP genomic research with participants in your country

There is uncertainty about whether DTP recruitment, enrollment, and research are lawful under these scenarios.

### Part I — DTP-Specific Questions

1. As far as you know, is DTP genomic research a topic of interest to researchers or other stakeholders in your country? [Multiple choice]

- a. There has been little, if any, discussion of the issue as of now
- b. There has been discussion among researchers, but little discussion among policy makers
- c. There has been discussion among both researchers and policy makers
- d. I am not sure — or other answer

To the best of our knowledge, DTP genomic research is not (yet) a topic of interest for researchers or other stakeholders in Switzerland. This type of research raises complex legal questions under Swiss law that makes them difficult to conduct. This may discourage researchers to engage in such projects.

**2. Assume that a researcher in your country wants to conduct DTP genomic research with participants in your country and that such research is subject to IRB/REC review. Please describe the conditions for IRB/REC approval, if it could be approved at all.**

Article 45 (2) of the *Federal Act on Research Involving Human Beings* of September 30, 2011 (HRA) provides that an authorization is granted by the responsible ethics committee if the ethical, legal, and scientific requirements of the HRA are met.<sup>1</sup> As DTP genomic research is not likely to be considered a clinical trial, it would fall under the *Ordinance on Human Research with the Exception of Clinical Trials* of September 20, 2013 (HRO).<sup>2</sup>

Besides the general requirements of research ethics and regulation, DTP genomic research raises specific questions linked to the HRA and the *Federal Act on Human Genetic Testing* of October 8, 2004 (HGTA).<sup>3</sup> A first difficulty is the limitation of genomic research to the biomedical field under the current HRA and

HGTA. Research that would not aim at establishing or developing generalizable knowledge concerning human health is not likely to obtain an authorization from the competent research ethics committee. This would exclude research for so-called recreational purposes. The Federal Parliament has adopted a revision of the HGTA on June 15, 2018 that expands its scope to genetic testing beyond the domain of medicine.<sup>4</sup> Yet concerning research, it does not seem to modify the current situation. To the contrary, the new HGTA includes a revision of the HRA that reinforces the links between the two Acts and does not facilitate research beyond the biomedical field. This revision is not yet in force and without specific cases, it remains unclear how it will impact the current situation.

A second difficulty is linked to informed consent and genetic counseling. In view of both the HRA and HGTA, a genetic test, especially as a part of research, can only be performed if the participant has given his or her written consent. This would require that the participant has received the necessary information concerning the nature and scope of the specific genetic testing to be performed. For instance, it is becoming common practice in oncology to look for specific biomarkers influencing the outcome of treatment. The participant has to be informed about the test and his or her consent is limited to that test. The researcher would not be allowed to conduct different genetic testing than the one for which he or she has obtained the participant's consent. Even more, according to article 14 HGTA, "Presymptomatic and prenatal genetic tests and tests for the purpose of family planning must be preceded and followed by non-directive genetic counselling provided by a qualified person. The counselling session must be documented."<sup>5</sup> This imposes an additional burden for the researcher if the test falls under such a category. If there are some uncertainties whether this provision applies

also in case of research, the revision of the HGTA and HRA clarifies that element: genetic counselling will be required also in case of research.

The responsible research ethics committee could only accept a DTP genomic research project with participants located in Switzerland if the conditions listed above are met. Under the current law, this seems rather challenging.

In addition, according to the *Declaration of Helsinki*<sup>6</sup> and the *Declaration of Taipei* of the World Medical Association,<sup>7</sup> it seems rather obvious that research involving human biological samples are subject to an ethical review by the competent research ethics committee at the national/local level. The question seems therefore misleading as it may assume that in some countries both declarations would not apply as professional and ethical standards. Even if there is no specific regulation on this issue in a given country, it would seem reasonable to argue that those standards would be recognized as binding for a professional, especially the healthcare providers. A researcher that would assume otherwise would have first to demonstrate the opposite, especially in North-South projects where some researchers from the North sometimes tend to ignore the laws in developing countries.

**3. Assume that a researcher in your country wants to conduct DTP genomic research in another country. Please describe the conditions that must be satisfied for IRB/REC approval in your country, if it could be approved at all. Would your IRB/REC also require approval from a research ethics review body in the other country?**

When the sponsor of the project is based in Switzerland, it must be considered whether the research project includes the sampling of biological

Vladislava Talanova, MLaw, is affiliated with University of Neuchâtel, Switzerland. Alexandre Dosch, MLaw, is a Lawyer and affiliated with University of Neuchâtel, Switzerland. Dominique Sprumont, Ph.D., is a Professor, Institute of Health Law, University of Neuchâtel, Switzerland.

cal material and/or the collection of personal data related to health, and is therefore subject to the provisions of Chapter 2 of the HRO,<sup>8</sup> even if the sampling and/or collection of the material and/or data is conducted outside of Switzerland.

The research project is then submitted to the responsible Swiss ethics committee for approval before any sampling or collection takes place.<sup>9</sup> The conditions set out in question 2 apply.

Whether the research also requires approval of a foreign ethics committee is first a question of foreign law. But, even if not explicitly required by the HRA, Swiss research ethics committees would make it a requirement as the researcher must provide the decision of all research ethics committees involved in case of multi-center studies. As mentioned above, this is already the current practice to request such positive opinion in case of research based on questionnaire where the targeted participants are not in Switzerland. In such case, it is also common to ask for the decision from the data protection authorities when requested by the local legislation.

**4. Assume that a researcher from outside your country wants to conduct DTP genomic research in your country.**

- a. Would it be lawful for the researcher to do so without IRB/REC approval in either the researcher's country or your country? [Yes/No]
- Yes  
 **No**  
 Not sure or other

Research projects are subject to the HRA when they take place abroad but research participants are recruited in Switzerland to participate in the research.

In this case, an authorization from the responsible Swiss ethics committee is therefore required. Otherwise, the research would not be lawful. Conditions set out in question 2 also apply in this case.

- b. Would it be lawful for the researcher to do so if the research were approved by an IRB/REC in the researcher's own country, but was not submitted for approval in your country? [Yes/No]
- Yes  
 **No**  
 Not sure or other

No. As expressed in question 4A, the research project requires the approval of the responsible ethics committee in Switzerland. Otherwise, the research is not lawful. An authorization issued abroad does not replace the one required in Switzerland.

- c. Would the external researcher be required to have a collaborator in your country? [Yes/No]
- Yes  
 No  
 Not sure or **Other**

It depends. Sponsors are requested to have a local representative that will bear the liability in case of damages related to participation in a project. For the investigators, a research agreement describing the sharing of tasks and responsibilities is required. In case of exchanges of data or biological material, a Data or Material Transfer Agreement (DTA or MTA) are also required. The competent research ethics committee will assess the validity of those documents according to the HRA<sup>10</sup> and the *Data Protection Act*.<sup>11</sup>

- d. Would it matter whether the external researcher is based at a commercial, governmental, or academic entity? [Yes/No]
- Yes  
 **No**  
 Not sure or other

Whether the researcher is based in a commercial, governmental, or academic entity, does not pose a problem and the conditions listed above for authorization are identical. Yet, the research ethics committees will pay attention that the will of the par-

ticipants as expressed in the Informed Consent Form is respected concerning such issue as in some cases participants are given the choice not to participate in a research funded by the industry.

**5. As far as you know, what are the perceived benefits and risks that could occur if a researcher from another country conducted IRB/REC-approved genomic research on samples or data obtained from your country? Please consider the perspectives of the public, research participants, socially-defined groups (e.g., indigenous or minority populations), researchers, and other professional or government entities.**

With regard to the risks, the sponsor located abroad might not be subject to Article 19 HRA<sup>12</sup> relating to liability for any damage suffered in relation with the research project. However, the victim may sue the sponsor in Switzerland for compensation for the damage by means of Article 97 of the *Swiss Code of Obligations* (CO)<sup>13</sup> if there is a contractual relationship and, failing that, on the basis of Article 41 CO.<sup>14</sup> There is also an issue concerning the level of data protection granted by law in the country of destination of the samples. The Swiss *Federal Act on Data Protection* (FADP) of 19 June 1992,<sup>15</sup> as the *European General Regulation on Data Protection* (GDPR),<sup>16</sup> requires that this level should be at least equivalent to the Swiss.<sup>17</sup> For US based studies, such guarantee is not granted and would require extra measure from the researcher to meet the Swiss requirements. Such guarantees will be requested by the competent Swiss research ethics committee.

The sponsor might also be sued in Switzerland if, for example, it carries out a research project without the authorization of the responsible ethics commission.<sup>18</sup>

Concerning the benefits, pursuant in particular to Article 5 (1) of the *Nagoya Protocol on Access to Genetic Resources* and the fair and equitable

sharing of benefits arising from their utilization (Nagoya Protocol),<sup>19</sup> benefits arising from the use of genetic resources as well as subsequent applications and commercialization shall be shared in a fair and equitable way between Switzerland and the country of the sponsor.

Finally, the persons concerned by a research project are entitled to be informed of results relating to their health. The information is to be communicated in an appropriate manner. The persons concerned may choose to forgo such information.<sup>20</sup>

## Part II — General Questions

### 6. Does your country have biohazard committees, data protection boards, export permit authorities, or other entities that regulate the exporting of biospecimens or the transferring of data across borders for research? If so, do these requirements apply to individual citizens as well as research and medical institutions?

According to the Article 42 HRA, biospecimens and genetic data could be transferred abroad only with the informed consent of the concerned person. Non-genetic data could be transferred abroad if the destination country has legislation that guarantees adequate protection.<sup>21</sup>

The aim of the Article 6 FADP is that no personal data can be communicated abroad if this communication constitutes a serious infringement of personality, in particular because of the absence of an adequate level of protection. The Federal Data Protection and Information Commissioner (the Commissioner) establish a list of countries with legislation to ensure an adequate level of protection.<sup>22</sup>

If the level of the legislation in the destination country is not considered adequate, personal data may be communicated abroad only if sufficient guarantees, including contractual guarantees, ensure an adequate level of protection.

The requirements of the HRA apply to both individual citizens as well as research and medical institutions. Data processing carried out by cantonal public bodies, such as universities (with the exception of the Federal Institutes of Technology) and cantonal hospitals, fall under the competence of the cantonal data protection laws, but on the matter of data protection the cantonal laws on data protection provide the same requirements as the federal law.

Concerning pathogenic organisms and genetically modified organisms (GMO), their dissemination for research purposes is subject to authorization by the Federal Office for the Environment (FOEN) according to Article 27 of the *Epidemics Act* (EpidA) of September 28, 2012.<sup>23</sup> Furthermore, it should be noted that the *Ordinance on the Transboundary Movements of Genetically Modified Organisms* (CartO) regulates the transboundary movements of genetically modified organisms.<sup>24</sup> Anyone intending to export genetically modified organisms must comply with this duty of care<sup>25</sup> and, if they are intended for handling in the environment, must first obtain the consent of the competent national authority of the country in question.<sup>26</sup> The applicant must submit a copy of the application and of the decision of the importing country to the FOEN.<sup>27</sup>

### 7. Does your country have laws, policies, or guidelines dealing with genetic or genomic research or genetic or genomic privacy that would apply to international DTP research? Do your national laws on these issues apply outside of your country when residents or citizens of your country enroll in a DTP study conducted abroad?

Research projects are submitted to the HRA when they take place abroad but the participants are recruited in Switzerland. When the sponsor/investigator or project initiative is based in Switzerland, it should be considered that the research project includes the collection of biological

material and/or personal health data, and thus the Swiss legislation (*e.g.*, HRA) is applicable, even if the collection of samples and/or data takes place outside Switzerland.

### 8. Does your country have laws, policies, guidelines, or cultural expectations regarding the return of individual or aggregate research results? [Multiple choice]

- The law requires the return of individual results unless the participant expressly declines to have results returned
- The law is silent on return of results; the expectation is that individual results will be returned unless the participant expressly declines to have the results returned
- The law is silent on return of results; aggregate results are typically returned, but individual results are not returned unless expressly stated in the research protocol
- I am not sure — or other answer

Article 8 HRA states that “The persons concerned are entitled to be informed of results relating to their health. The information is to be communicated in an appropriate manner. The persons concerned may choose to forgo such information.”<sup>28</sup> This right has a primary goal of helping the concerned person to take a decision on preventive measures and on treatment. If, as part of a research project, a clear result reveals the presence of a disease, the person participating in the project must be kept informed, unless he/she has given up his/her right of being informed. However, it matters in all cases that this result is reliable. As a general rule, the more the disease (existing or likely to develop) is serious and the results are reliable, the more important it is to inform the person.



**9. Does your country have laws, policies, or guidelines regarding “direct-to-consumer” genetic testing (e.g., 23andMe) and, if so, what do they provide? [Multiple choice]**

- a. Yes. Direct-to-consumer genetic testing is illegal
- b. Yes. Direct-to-consumer genetic testing is legal
- c. No. Direct-to-consumer genetic testing is not an issue
- d. I am not sure — or other answer

In Switzerland, the direct-to-consumer genetic tests are currently not authorized in the medical field, nor for establishing a DNA profile. The current HGTA states that a genetic test may only be performed for a medical purpose with respect of the right to self-determination of the patient<sup>29</sup> and they may only be prescribed by medical doctors who are authorized to practice their profession independently or under supervision.<sup>30</sup> Genetic laboratories cannot accept direct demands from patients.

However, the HGTA was recently revised and will come into force in 2021. The regime for genetic analysis for medical purposes and the establishment of a DNA profile remain the same as today, the same regime will be applicable for non-medical genetic analysis to identify sensitive characteristics of personality (i.e., physiological characteristics that can influence on the lifestyle, personal characteristics such as character, behavior, intelligence, preferences or abilities, or those relating to ethnic origin etc.). Other genetic analyses for non-medical purposes could be delivered directly to the consumer (e.g., the ready-to-use genetic tests). The reason for such limitations is that the three categories of tests protected by law could have severe consequences for the concerned person and his family and, therefore, the quality of the analysis must be ensured and controlled by the authorities.

**Part III — Looking to the Future**

**10. How, if at all, do you anticipate that your country’s laws, policies, or guidelines will change in the next 5-10 years in response to international DTP genomic research? [Multiple choice]**

- a. I do not think they will change at all
- b. I think they will restrict international DTP research
- c. I think they will allow international DTP research
- d. I am not sure — or other answer**

To our best knowledge, DTP genomic research is not a topic of interest for researchers or other stakeholders in Switzerland now, therefore we cannot anticipate further developments. Depending on the pressure that may come from the international scientific community, this may change. Yet, we do not see a legal and ethical necessity to facilitate such type of research in Switzerland or elsewhere.

**Note**

The authors have no conflicts to disclose.

**References**

1. Loi fédérale relative à la recherche sur l'être humain (LRH), Federal Act on Research involving Human Beings (HRA), September 30, 2011, RS 810.30, art. 45(2) (Switz.).
2. Ordonnance relative à la recherche sur l'être humain à l'exception des essais cliniques (ORH), Ordinance on Human Research with the Exception of Clinical Trials [HRO], September 20, 2013, RS 810.301 (Switz.).
3. Loi fédérale sur l'analyse génétique humaine [LAGH], Federal Act on Human Genetic Testing [HGTA], October 8, 2004, RS 810.12 (Switz.).
4. Loi fédérale sur l'analyse génétique humaine [LAGH], entrera en vigueur en 2021 (FF 2018 3627), Federal Act on Human Genetic Testing [HGTA], will come into force in 2021 (FF 2018 3627).
5. Loi fédérale sur l'analyse génétique humaine (LAGH), Federal Act on Human Genetic Testing [HGTA], October 8, 2004, RS 810.12, art. 14(1) (Switz.).
6. World Medical Association [WMA], “Declaration of Helsinki,” June 1964, available at <<https://www.wma.net/policies-post/wma-declaration-of-hel-sinki-ethical-principles-for-medical-research-involving-human-subjects/>> (last visited October 31, 2019).
7. World Medical Association [WMA], “Declaration of Taipei,” October 2002, available at <<https://www.wma.net/policies-post/wma-declaration-of-taipei-on-ethical-considerations-regarding-health-databases-and-biobanks/>> (last visited October 31, 2019).
8. Ordonnance relative à la recherche sur l'être humain à l'exception des essais cliniques (ORH), Ordinance on Human Research with the Exception of Clinical Trials (HRO), September 20, 2013, RS 810.301, art. 6-23 (Switz.).
9. *Id.* art 14 et seq.; HRA, *supra* note 1, art. 45(1) ff; HRO, *supra* note 2, art. 14 ff.
10. HRA, *supra* note 1, art. 45; HRO, *supra* note 2, art. 14 ff.
11. Loi fédérale sur la protection des données (LPD), Federal Act on Data Protection (FADP), June 19, 1992, RS 235.1.
12. HRA, *supra* note 1, art. 19.
13. OBLIGATIONENRECHT (OR), CODE DES OBLIGATIONS (CO), CODICE DELLE OBLIGAZIONI (CO) (Code of Obligations), March 30, 1991, SR 220, RS 220, art. 97.
14. *Id.*, art. 41.
15. FADP, *supra* note 11.
16. Regulation (EU) 2016/679 of the European Parliament and of the Council of April 27, 2016 on the protection of natural persons with regard to the processing of personal data and on the free movement of such data, and repealing Directive 95/46/EC (General Data Protection Regulation). EUR-Lex Access to Eur. Union law, available at <<https://eur-lex.europa.eu/eli/reg/2016/679/2016-05-04>> (last visited October 31, 2019).
17. FADP, *supra* note 15, art. 6(1).
18. HRA, *supra* note 2, art. 62 ff.
19. Convention on Biological Diversity (CBD), “Nagoya Protocol on Access to Genetic Resources and the Fair and Equitable Sharing of Benefits Arising from their Utilization to the Convention on Biological Diversity,” October 29, 2010, available at <<https://www.cbd.int/abs/doc/protocol/nagoya-protocol-en.pdf>> (last visited October 31, 2019).
20. HRA, *supra* note 2, art. 8.1.
21. *Id.*, art. 42(2); FADP, *supra* note 15, art. 6.
22. FADP, *supra* note 15, art. 6.
23. Loi fédérale sur la lutte contre les maladies transmissibles de l'homme (LEp), Epidemics Act (EpidA), September 28, 2012, RS 818.101, art. 27 (Switz.).
24. Ordonnance sur les mouvements transfrontières des organismes génétiquement modifiés (OCart), Ordinance on the Transboundary Movements of Genetically Modified Organisms (CartO), November 3, 2004, RS 814.912.21, art. 1 (Switz.).
25. *Id.*, art. 3.
26. *Id.*, art. 6(1).
27. *Id.*, art. 6(3).
28. HRA, *supra* note 2, art. 8.

29. HGTA, *supra* note 3, art. 10(1).  
30. *Id.*, art. 13.

## Taiwan

Chien-Te Fan and  
Tzu-Hsun Hung

Researchers in genomics are exploring novel ways to interact directly with prospective participants without utilizing physicians, hospitals, or biobanks as intermediaries. Many researchers are interested in using the internet to directly recruit and enroll research participants in genomic studies by posting information online about active or proposed studies. This direct-to-participant (DTP) approach could take place under three main scenarios:

- A researcher in your country wants to conduct DTP genomic research with participants in your country
- A researcher in your country wants to conduct DTP genomic research with participants in another country
- A researcher from outside your country wants to conduct DTP genomic research with participants in your country

There is uncertainty about whether DTP recruitment, enrollment, and research are lawful under these scenarios.

### Part I — DTP-Specific Questions

1. **As far as you know, is DTP genomic research a topic of interest to researchers or other stakeholders in your country? [Multiple choice]**
  - a. There has been little, if any, discussion of the issue as of now
  - b. There has been discussion among researchers, but little discussion among policy makers

- c. **There has been discussion among both researchers and policy makers**
- d. I am not sure — or other answer

2. **Assume that a researcher in your country wants to conduct DTP genomic research with participants in your country and that such research is subject to IRB/REC review. Please describe the conditions for IRB/REC approval, if it could be approved at all.**

DTP genomic research refers to research involving obtaining, investigating, analyzing, or using human specimens or an individual person's physiological, genetic, or medical information, which should be subject to Taiwan's *Human Subjects Research Act* (HSRA). According to Regulations for Organization and Operation of Human Research Ethics Review Board, which are set forth pursuant to Para. 3, Article 7 of HSRA, the review of research project shall at least include the following: (1) qualifications of the principal investigator, (2) eligibility criteria for the research subjects and the way of recruitment, (3) content of the project and way and place of execution, (4) items of agreement of be informed, the subjects to be informed, the way and procedure of indicating agreement as provided in Article 14 of HSRA, and (5) protections for the research subjects, including the channel of enquiry and complaint, etc.<sup>1</sup>

3. **Assume that a researcher in your country wants to conduct DTP genomic research in another country. Please describe the conditions that must be satisfied for IRB/REC approval in your country, if it could be approved at all. Would your IRB/REC also require approval from a research ethics review body in the other country?**

### ics review body in the other country?

In addition to the conditions mentioned above, if the DTP genomic research involves provision of non-delinked research materials overseas, a certification of guarantee to follow our domestic regulations and research material scope of permitted uses signed by the overseas research entity is required by IRB/REC according to Article 19 of HRSA.<sup>2</sup> However, an approval from a research ethics review body in the other country is not necessary for review by our IRB/REC.

4. **Assume that a researcher from outside your country wants to conduct DTP genomic research in your country.**

- a. Would it be lawful for the researcher to do so without IRB/REC approval in either the researcher's country or your country? [Yes/No]
  - Yes
  - No
  - Not sure or other
- b. Would it be lawful for the researcher to do so if the research were approved by an IRB/REC in the researcher's own country, but was not submitted for approval in your country? [Yes/No]
  - Yes
  - No
  - Not sure or other
- c. Would the external researcher be required to have a collaborator in your country? [Yes/No]
  - Yes
  - No
  - Not sure or other
- d. Would it matter whether the external researcher is based at

Chien-Te Fan, J.D., LL.M., is a Professor, Institute of Law for Science & Technology, National Tsing Hua University, Taiwan. Tzu-Hsun Hung, LL.M., is an Attorney-at-Law, Taiwan.

- a commercial, governmental, or academic entity? [Yes/No]  
 Yes  
 No  
 Not sure or other

Per Article 9 of HRSA, where research personnel are unaffiliated with a research entity or not engaged in cooperative research with a research entity in Taiwan, e.g., the external researchers, they shall nevertheless be required to obtain IRB approval from one research entity or approval from a non-research entity affiliated independent IRB in Taiwan, prior to engaging in a protocol.<sup>3</sup> It would not matter whether the external researcher is based at a commercial, governmental, or academic entity if the IRB/REC determines that the research project satisfies the conditions in accordance with the regulations and HRSA.

- 5. As far as you know, what are the perceived benefits and risks that could occur if a researcher from another country conducted IRB/REC-approved genomic research on samples or data obtained from your country? Please consider the perspectives of the public, research participants, socially-defined groups (e.g., indigenous or minority populations), researchers, and other professional or government entities.**

The perceived benefits might be as follows:

- 1) Accelerating the development of science and technology through the collaboration with local researchers;
- 2) Increasing the diversity of research projects and areas;
- 3) Sharing of hardware and software resources, etc.

The perceived risks might be as follows:

- 1) The difficulty in confirming whether the informed consent is appropriate;

- 2) The uncertainty of the follow-up use of specimens and materials;
- 3) The diversity of ethical regulations or guidelines and the practices thereof, etc.

## Part II – General Questions

- 6. Does your country have biohazard committees, data protection boards, export permit authorities, or other entities that regulate the exporting of biospecimens or the transferring of data across borders for research? If so, do these requirements apply to individual citizens as well as research and medical institutions?**

Yes, the exporting of biospecimens for research must be approved in advance by the Taiwan Food and Drug Administration per the *Biospecimen Input and Output Guidelines*,<sup>4</sup> and the transferring of data across borders for research must follow the *Personal Information Protection Act*.<sup>5</sup> Furthermore, if the exporting of biospecimens or the transferring of data across borders for research is relevant to the biospecimens or data collected and stored in a biobank, the approval from National Institute of Health is required in accordance with the guidelines for reviewing the international transfer of biospecimens or data from a biobank. However, those guidelines are mainly for biobanks, organizations, and research institutes but not for individual citizens.

- 7. Does your country have laws, policies, or guidelines dealing with genetic or genomic research or genetic or genomic privacy that would apply to international DTP research? Do your national laws on these issues apply outside of your country when residents or citizens of your country enroll in a DTP study conducted abroad?**

Since international DTP research will certainly involve research relating to human subjects in Taiwan, HRSA will apply to international DTP research when residents or citizens of Taiwan enroll in a DTP study conducted abroad. Also, the *Personal Information Protection Act* of Taiwan applies to international DTP research as it is related to collection and use of highly sensitive personal information of residents or citizens of Taiwan.

- 8. Does your country have laws, policies, guidelines, or cultural expectations regarding the return of individual or aggregate research results? [Multiple choice]**

- a. The law requires the return of individual results unless the participant expressly declines to have results returned
- b. The law is silent on return of results; the expectation is that individual results will be returned unless the participant expressly declines to have the results returned
- c. The law is silent on return of results; aggregate results are typically returned, but individual results are not returned unless expressly stated in the research protocol
- d. I am not sure — or other answer**

The issues relating to “incidental findings” have been discussed in Taiwan since the World Medical Association adopted and revised the WMA Declaration of Taipei on Ethical Considerations Regarding Health Databases and Biobanks. However, laws, regulations, or practices in Taiwan currently do not directly address these issues. Although the HSRA requires the principal investigator to provide the research protocol, including attribution of research results and uses thereof, said research results and uses are more related to the return of aggregate research results than individual results.

**9. Does your country have laws, policies, or guidelines regarding “direct-to-consumer” genetic testing (e.g., 2 and, if so, what do they provide? [Multiple choice]**

- Yes. Direct-to-consumer genetic testing is illegal
- Yes. Direct-to-consumer genetic testing is legal
- No. Direct-to-consumer genetic testing is not an issue

**d. I am not sure — or other answer**

For now, there are no specific laws, policies, or guidelines regarding “direct-to-consumer” genetic testing in Taiwan, but whether to introduce legislation or not has been a long-discussed issue in Taiwan. It is worth mentioning that the biospecimens or health information of the consumer shall be collected in accordance with Article 6 of *Personal Information Protection Act*, which stipulates the limitations of collection, processing, or use of sensitive personal information.<sup>6</sup>

**Part III — Looking to the Future**

**10. How, if at all, do you anticipate that your country’s laws, policies, or guidelines will change in the next 5-10 years in response to international DTP genomic research? [Multiple choice]**

- I do not think they will change at all
- I think they will restrict international DTP research
- I think they will allow international DTP research

**d. I am not sure — or other answer**

The issues relating to DTP genomic research have been discussed among both researchers and policy makers, but it is hard to anticipate what direction the law, policies, or guidelines will go.

**Note**

The authors have no conflicts to disclose.

**References**

- Regulations for Organization and Operation of Human Research Ethics Review Board, Fawubu Quanguo Fagui Ziliaoku, *available at* <<https://law.moj.gov.tw/Eng/LawClass/LawAll.aspx?PCode=L0020179>> (last visited November 1, 2019).
- Human Subjects Research Act, Fawubu Quanguo Fagui Ziliaoku, art. 19, *available at* <<https://law.moj.gov.tw/ENG/LawClass/LawAll.aspx?pcode=L0020176>> (last visited December 11, 2019).
- Id.*, art. 9.
- Taiwan Food and Drug Administration, “Biospecimen Input and Output,” *available at* <<https://www.fda.gov.tw/TC/siteListContent.aspx?sid=1245&id=5705>> (last visited November 1, 2019).
- Personal Information Protection Act, Fawubu Quanguo Fagui Ziliaoku, *available at* <<https://law.moj.gov.tw/ENG/LawClass/LawAll.aspx?pcode=I0050021>> (last visited November 1, 2019).
- Id.*, art. 6.

## Uganda

### Obiajulu Nnamuchi

Researchers in genomics are exploring novel ways to interact directly with prospective participants without utilizing physicians, hospitals, or biobanks as intermediaries. Many researchers are interested in using the internet to directly recruit and enroll research participants in genomic studies by posting information online about active or proposed studies. This direct-to-participant (DTP) approach could take place under three main scenarios:

- A researcher in your country wants to conduct DTP genomic research with participants in your country
- A researcher in your country wants to conduct DTP genomic research with participants in another country
- A researcher from outside your country wants to conduct DTP genomic research with participants in your country

There is uncertainty about whether DTP recruitment, enrollment, and research are lawful under these scenarios.

### Part I — DTP-Specific Questions

**1. As far as you know, is DTP genomic research a topic of interest to researchers or other stakeholders in your country? [Multiple choice]**

- There has been little, if any, discussion of the issue as of now
- There has been discussion among researchers, but little discussion among policy makers
- There has been discussion among both researchers and policy makers
- I am not sure — or other answer

**2. Assume that a researcher in your country wants to conduct DTP genomic research with participants in your country and that such research is subject to IRB/REC review. Please describe the conditions for IRB/REC approval, if it could be approved at all.**

Although there is no explicit provision on DTP genomic research in Uganda, it seems such research could be approved if the researcher can demonstrate adequate respect for the rights and welfare of research participants, and comply with the regulatory regime on health research in the country.<sup>1</sup>

**3. Assume that a researcher in your country wants to conduct DTP genomic research in another country. Please describe the conditions that must be satisfied for IRB/REC approval in your country, if it could be approved at all. Would your IRB/REC also require approval**

**from a research ethics review body in the other country?**

The conditions stipulated above (see response to previous question) must be satisfied, and approval from a research ethics committee in the other country will be required.

**4. Assume that a researcher from outside your country wants to conduct DTP genomic research in your country.**

a. Would it be lawful for the researcher to do so without IRB/REC approval in either the researcher's country or your country? [Yes/No]

- Yes  
 No  
 Not sure or other

b. Would it be lawful for the researcher to do so if the research were approved by an IRB/REC in the researcher's own country, but was not submitted for approval in your country? [Yes/No]

- Yes  
 No  
 Not sure or other

c. Would the external researcher be required to have a collaborator in your country? [Yes/No]

- Yes<sup>2</sup>  
 No  
 Not sure or other

d. Would it matter whether the external researcher is based at a commercial, governmental, or academic entity? [Yes/No]

- Yes  
 No  
 Not sure or other

**5. As far as you know, what are the perceived benefits and risks that could occur if a researcher from**

**another country conducted IRB/REC-approved genomic research on samples or data obtained from your country? Please consider the perspectives of the public, research participants, socially-defined groups (e.g., indigenous or minority populations), researchers, and other professional or government entities.**

There are several benefits that could inure from conducting IRB/REC-approved genomic research by a researcher from another country on samples or data obtained from Uganda including (a) enrichment of or new knowledge regarding etiology, diagnosis, and treatment of diseases/adverse health conditions; (b) building capacity on the part of local scientists that would be recruited as collaborators; and (c) discovery of improved techniques of responding to or treatment of illnesses.

Similarly, a number of risks could result from such research, such as abuse of research participants, and inadequate attention to the rights and welfare of the research participants,<sup>3</sup> particularly in the realm of confidentiality obligation regarding samples procured from a particular population group or community, which, in turn, could expose them to harm — discrimination/stigmatization.

**Part II — General Questions**

**6. Does your country have biohazard committees, data protection boards, export permit authorities, or other entities that regulate the exporting of biospecimens or the transferring of data across borders for research? If so, do these requirements apply to individual citizens as well as research and medical institutions?**

Yes, Uganda has an entity which regulates the exporting of biospecimens or the transferring of data across borders for research, namely, the Uganda National Council for Science and Technology (UNCST).<sup>4</sup> Importation and exportation of biospecimens for research purposes shall require clearance from UNCST, which is authorized to maintain a depository of all Material Transfer Agreements (MTAs).<sup>5</sup> The requirement applies to all parties involved in the research although the MTA is required to be signed by only the authorized representative of the party seeking the transfer.<sup>6</sup>

**7. Does your country have laws, policies, or guidelines dealing with genetic or genomic research or genetic or genomic privacy that would apply to international DTP research? Do your national laws on these issues apply outside of your country when residents or citizens of your country enroll in a DTP study conducted abroad?**

Uganda does not have a law, policy, or guideline specifically designed to apply to international DTP. However, the extant policy regime — that is, *National Guidelines for Research Involving Humans as Research Participants* — could be modified to apply to international DTP research in the realm of genetic or genomic research or genetic or genomic privacy. There is no clear stipulation as to the applicability of this framework outside Uganda when residents or citizens of the country enroll in a DTP study conducted abroad, but it would seem that they could be interpreted to apply.

**8. Does your country have laws, policies, guidelines, or cultural expectations regarding the return of individual or aggregate research results? [Multiple choice]**

Obiajulu Nnamuchi, LL.B., LL.M., M.A., S.J.D., is an Associate Professor of Law, University of Nigeria (Enugu Campus) Enugu, Nigeria.

- a. The law requires the return of individual results unless the participant expressly declines to have results returned
- b. The law is silent on return of results; the expectation is that individual results will be returned unless the participant expressly declines to have the results returned<sup>7</sup>**
- c. The law is silent on return of results; aggregate results are typically returned, but individual results are not returned unless expressly stated in the research protocol
- d. I am not sure — or other answer

**9. Does your country have laws, policies, or guidelines regarding “direct-to-consumer” genetic testing (e.g., 23andMe) and, if so, what do they provide? [Multiple choice]**

- a. Yes. Direct-to-consumer genetic testing is illegal
- b. Yes. Direct-to-consumer genetic testing is legal
- c. No. Direct-to-consumer genetic testing is not an issue**
- d. I am not sure — or other answer

**Part III — Looking to the Future**

**10. How, if at all, do you anticipate that your country’s laws, policies, or guidelines will change in the next 5-10 years in response to international DTP genomic research? [Multiple choice]**

- a. I do not think they will change at all
- b. I think they will restrict international DTP research
- c. I think they will allow international DTP research
- d. I am not sure — or other answer**

**Note**

The author has no conflicts to disclose.

**References**

1. Uganda National Council for Science and Technology (UNCST), National Guidelines for Research Involving Humana as Research Participants, July 2014, at 2-8, *available at* <[https://www.swarthmore.edu/sites/default/files/assets/documents/institutional-review-board/Human\\_Subjects\\_Protection\\_Guidelines\\_July\\_2014.pdf](https://www.swarthmore.edu/sites/default/files/assets/documents/institutional-review-board/Human_Subjects_Protection_Guidelines_July_2014.pdf)> (last visited November 1, 2019).
2. *Id.* at 28.
3. *Id.* at 2-3.
4. *Id.* at 29.
5. *Id.*
6. *Id.*
7. *Id.* at 29-30.

**The United Kingdom**

*Jane Kaye, Andelka Phillips, Heather Gowans, and Nisha Shah*

Researchers in genomics are exploring novel ways to interact directly with prospective participants without utilizing physicians, hospitals, or biobanks as intermediaries. Many researchers are interested in using the internet to directly recruit and enroll research participants in genomic studies by posting information online about active or proposed studies. This direct-to-participant (DTP) approach could take place under three main scenarios:

- A researcher in your country wants to conduct DTP genomic research with participants in your country
- A researcher in your country wants to conduct DTP genomic research with participants in another country
- A researcher from outside your country wants to conduct DTP genomic research with participants in your country

There is uncertainty about whether DTP recruitment, enrollment, and research are lawful under these scenarios.

**Part I — DTP-Specific Questions**

**1. As far as you know, is DTP genomic research a topic of interest to researchers or other stakeholders in your country? [Multiple choice]**

- a. There has been little, if any, discussion of the issue as of now
- b. There has been discussion among researchers, but little discussion among policy makers
- c. There has been discussion among both researchers and policy makers**
- d. I am not sure — or other answer

As far as we are aware, when UK researchers based in universities and publicly-funded institutions wish to recruit participants in other countries for medical research, this is usually done as partners to a funding collaboration. Recruitment is usually carried out through clinical leads, biobanks, cohort studies, or hospitals to reach patients in other countries and increase the power and scope of a study. There are studies that advertise online in patient forums, but it is not clear how many of those studies are able to recruit patients outside of their jurisdiction in this way. This would be subject to research ethics approval and would depend upon the type and nature of the study. However, there are a number of projects, particularly in rare diseases that are being approached by patients in other countries who have discovered the project online. For example, patients from Japan have enrolled in the online UK-based, University of Oxford RUDY project (<https://research.ndorms.ox.ac.uk/rudy/>). Further research would need to be done to understand the numbers of projects in the UK recruiting online or being approached by patients and to establish the countries where participants are based.

While the UK is active in genomics research with a number of projects in this field, these projects do not tend to recruit online and do not recruit from other countries

into their studies. For example, the 100,000 Genomes Project<sup>1</sup> is a significant project in world terms and recruits patients through the clinic. UK Biobank<sup>2</sup> recruited patients via the National Health Service clinical services with a section 251 exemption and sent invitations by post. However, these projects increasingly use digital technologies alongside more traditional methods for interactions with participants.

The difference is with commercial DTC companies, as they recruit online and are not always based in the country where they are recruiting. A number of these operate in the UK and research is the “back end” of their business model. Legal requirements may in fact be more restrictive for DTC testing companies that also engage in secondary research, rather than specific research projects that recruit participants, but do not charge for their services. Consent requirements may be more stringent as applied to DTC companies engaging in health research than for other types of research conducted by public research institutions.

There has also been much discussion of issues raised by genomics research. The work of the now disbanded Human Genetics Commission (HGC) has been influential in this area. This was an independent advisory body to the government. It released a number of reports on various matters related to genetics, including: DTC genetic testing; genetic discrimination; genetics in insurance; and genetic databases. In relation to DTC they released two reports and a Framework of Principles, which could be drawn upon in improving industry governance, but as yet have not been.<sup>3</sup> The HGC was replaced by the Emerging Science and Bioethics Advisory Committee (ESBAC),<sup>4</sup> but this has also been disbanded. The Human Tissue Authority, which enforces the

*Human Tissue Act 2004* has also released various guidance documents, including a Code of Practice on Consent. There are a number of versions of this document, the most recent was released in 2017.<sup>5</sup>

**2. Assume that a researcher in your country wants to conduct DTP genomic research with participants in your country and that such research is subject to IRB/REC review. Please describe the conditions for IRB/REC approval, if it could be approved at all.**

When considering conditions for granting research approval, RECs seek to balance the advancement of science against the protection of participants’ welfare and rights. As such, an REC should perform an ethical and scientific review of the research in question.<sup>6</sup> Conditions attached to any REC approval granted, might include:<sup>7</sup>

- patient and clinical benefits of the research;
- the scientific and transformational objectives of the research;
- the implementation strategy;
- the ethical and governance frameworks required (both including the policy for data access, to ensure that all necessary safeguards are in place).

Conditions considered by an ethics committee are listed in the *Medicines for Human Use (Clinical Trials) Regulations (2004)*; and the remit of RECs is laid out in the “Governance arrangements for research ethics committees” document. The initial process involves contacting the clinical governance or research development office who advises whether the project is research and whether HRA

approval and/or ethical approval is required. For non-research, if patient data is to be used without consent, a recommendation from the Confidentiality Advisory Group (CAG) and advice from the Caldicott Guardian will be required.<sup>8</sup> Where necessary, applications need to go to a flagged REC which is designated for review of particular types of application, and flagging of RECs is based on legal or regulatory authority for review of particular types of application.

**3. Assume that a researcher in your country wants to conduct DTP genomic research in another country. Please describe the conditions that must be satisfied for IRB/REC approval in your country, if it could be approved at all. Would your IRB/REC also require approval from a research ethics review body in the other country?**

To conduct genomic research in another country, a UK researcher would have to fulfill the regulatory requirements for ethics approval in that country. This would be the same if an external researcher conducted research in the jurisdiction of the UK. For example, RECs outside the UK are not recognized for the purposes of the *Human Tissue Act 2004*.<sup>9</sup> There is currently no system that recognizes the equivalency of REC decisions across Europe and so researchers have to apply in each jurisdiction for approval.

Where UK NHS patients or their data will be used, in addition to patient or non-patient studies outside of the UK, HRA approval is required for the UK NHS portion. University research ethics approval and local ethics approval or organizational approval will be required if a REC

**Jane Kaye, B.A., Grad Dip Leg, LL.B., D.Phil.**, is Director of the HeLEX Centre for Health, Law and Emerging Technologies, University of Oxford, Oxford, United Kingdom. **Andelka Phillips, B.A., LL.B., B.A., LL.M., D.Phil.**, is a Senior Lecturer at Te Piringa Faculty of Law, University of Waikato, New Zealand. **Heather Gowans, Ph.D.**, is a Researcher in Law at the HeLEX Centre for Health, Law and Emerging Technologies, University of Oxford, Oxford, United Kingdom. **Nisha Shah, M.Sc., B.Sc.**, is a Researcher in Social Science at the HeLEX Centre for Health, Law and Emerging Technologies, University of Oxford, Oxford, United Kingdom.

does not exist in the location where research will be conducted or data collected from.

**4. Assume that a researcher from outside your country wants to conduct DTP genomic research in your country.**

a. Would it be lawful for the researcher to do so without IRB/REC approval in either the researcher's country or your country? [Yes/No]

Yes

No

Not sure or other

While there has been much international collaborative research conducted in the UK, due to the ongoing Brexit negotiations, there is now some level of uncertainty regarding the conditions for when it will be permitted for researchers from outside the UK to conduct genomic research within the UK.<sup>10</sup>

b. Would it be lawful for the researcher to do so if the research were approved by an IRB/REC in the researcher's own country, but was not submitted for approval in your country? [Yes/No]

Yes

No

Not sure or other

c. Would the external researcher be required to have a collaborator in your country? [Yes/No]

Yes

No

Not sure or other

There would not necessarily be a requirement for a collaborator, though this would make things much easier logistically.

d. Would it matter whether the external researcher is based at a commercial, governmental, or academic entity? [Yes/No]

Yes

No

Not sure or other

The managing organization (which subsequently becomes the sponsor) can be commercial, governmental, or academic, and so can the external researcher. If the project is determined to be research, then the relevant approvals apply. If a project is a research tissue bank, research database, or takes place outside the NHS setting, then HRA approval is not required, but REC approval is. It does not matter for the purposes of submitting an application to a research ethics committee where researchers are based, and all researchers will undergo the same process of review if they are using the NHS to recruit patients or are using NHS data, facilities, or staff. However, for the purposes of data protection, it does matter. According to the Health Research Authority and the Information Commissioners Office Guidance, research for health and social care should rely on other grounds for processing data, such as the public interest,<sup>11</sup> whereas organizations that are not public entities, especially DTC companies, are unlikely to be able to rely on these same grounds, given that they are typically conducting research on consumer data, which is originally collected for the purposes of a commercial genetic testing service.

**5. As far as you know, what are the perceived benefits and risks that could occur if a researcher from another country conducted IRB/REC-approved genomic research on samples or data obtained from your country? Please consider the perspectives of the public, research participants, socially-defined groups (e.g., indigenous or minority populations), researchers, and other professional or government entities.**

In the UK, any research on samples from NHS patients or other research will have to have relevant approvals as outlined above. The risks and benefits would be considered by HRA and the

appropriate REC accordingly. There are specific governance mechanisms that researchers have to adhere to, including providing assurances for the handling of data. Risks might include that ethical standards and regulations may differ between countries, ethical review may not be required in the country of the researcher, research participants may not receive feedback of results, particularly of incidental findings if applicable, and different levels of choice are given to participants regarding the collection, use, and sharing of their samples.

**Part II – General Questions**

**6. Does your country have biohazard committees, data protection boards, export permit authorities, or other entities that regulate the exporting of biospecimens or the transferring of data across borders for research? If so, do these requirements apply to individual citizens as well as research and medical institutions?**

Yes. The relevant data protection regulator is the ICO (Information Commissioner's Office). Current legislation on data protection is the *Data Protection Act 2018* together with the *General Data Protection Regulation*. There is some level of uncertainty regarding how the UK will be treated by other European member states post-Brexit, but the *Data Protection Act* has incorporated the GDPR into the UK's domestic law, as well as making derogations from it.

The Human Tissue Authority enforces the *Human Tissue Act 2004* and regulates "organizations that remove, store, and use human tissue for research, medical treatment, post-mortem examination, education and training, and display in public."<sup>12</sup>

The Health Research Authority (HRA) was established in accordance with the *Care Act 2014*, "as an executive non-departmental public body (NDPB) sponsored by the Department of Health on 1 January 2015."<sup>13</sup>



The HRA's primary purpose "is to protect and promote the interests of patients and the public in health and social care research." In order to achieve this, it seeks to:

- make sure research is ethically reviewed and approved
- promote transparency in research
- oversee a range of committees and services
- provide independent recommendations on the processing of identifiable patient information where it is not always practical to obtain consent, for research and non-research projects.<sup>14</sup>

Both the ICO and the Health Research Authority have released guidance indicating that consent should not be the basis for processing in the context of health and social care research.<sup>15</sup> However, in the context of DTC testing companies conducting health research, all companies will still need appropriate consent for the initial test and are likely to need additional consent for secondary research in accordance with both data protection legislation and the *Human Tissue Act*.

The *Human Fertilisation and Embryology Act 1990*, which is enforced by the Human Fertilisation and Embryology Authority, also is relevant here. It "approves and licences research projects which use human tissue. The Act prohibits a number of acts including the creation of an embryo, except when holding a licence issued by the Authority. Generally speaking, without authorisation, there cannot be any genetic alterations of eggs and sperm and no person shall use modified germ cells to provide fertility services."<sup>16</sup>

- 7. Does your country have laws, policies, or guidelines dealing with genetic or genomic research or genetic or genomic privacy that would apply to international DTP research? Do your national laws on these issues apply outside of your country when residents or citi-**

**zens of your country enroll in a DTP study conducted abroad?**

The UK has enacted the Data Protection Act 2018, which incorporates the GDPR into the UK's domestic law and also sits alongside the GDPR, while the UK remains part of the EU. Under both the *Data Protection Act* and the GDPR, genomic data is categorized as sensitive information, and the standard of consent required for processing this data is quite high. For organizations conducting health and social care research within the UK, in accordance with the HRA and ICO guidance, consent may not be the main legal basis for processing, but where a DTC company is conducting health research on consumers' data they should be complying with data protection requirements and should be obtaining appropriate consent for all processing of genetic data.

- 8. Does your country have laws, policies, guidelines, or cultural expectations regarding the return of individual or aggregate research results? [Multiple choice]**

- The law requires the return of individual results unless the participant expressly declines to have results returned
- The law is silent on return of results; the expectation is that individual results will be returned unless the participant expressly declines to have the results returned
- The law is silent on return of results; aggregate results are typically returned, but individual results are not returned unless expressly stated in the research protocol
- I am not sure — or other answer**

- 9. Does your country have laws, policies, or guidelines regarding "direct-to-consumer" genetic testing (e.g., 23andMe) and,**

**if so, what do they provide? [Multiple choice]**

- Yes. Direct-to-consumer genetic testing is illegal
- Yes. Direct-to-consumer genetic testing is legal**
- No. Direct-to-consumer genetic testing is not an issue
- I am not sure — or other answer

At present, DTC genetic testing is technically legal. That being said, all organizations conducting genetic tests are supposed to be complying with the provisions of the *Human Tissue Act*, as enforced by the Human Tissue Authority. The *Human Tissue Act* (HTA) governs the use of human tissue and organs in the UK. The Act sets requirements for consent and makes it a criminal offence under section 45 to analyze DNA without appropriate consent. It would appear that the Act has direct application to the DTC industry.<sup>17</sup> The Human Tissue Authority's "Analysis of DNA under the HT Act FAQs" states that:

All companies providing DNA testing kits or DNA testing services must comply with the provisions of the *Human Tissue Act 2004* relating to consent and the holding of bodily material with the intent to analyze DNA.<sup>18</sup>

However, 23andMe has been allowed to market through Superdrug in the UK because it obtained a Conformité Européene (CE) mark for its test kit, which means essentially that the kit has been approved as safe for the purposes of collecting saliva.<sup>19</sup> This also means that the kit can be marketed throughout the EU, as CE certification is recognized reciprocally, so that if a company receives a CE mark in one Member State the mark will be recognized by others.<sup>20</sup>

An inquiry was launched in March 2019 into the commercial genomics industry by the Science and Technology Committee (Commons). We are still awaiting the recommendations from this consultation.<sup>21</sup>

In October 2018 the Association of British Insurers released a Code of Practice On Genetic Testing And

Insurance.<sup>22</sup> This is a voluntary code and does not apply to all insurers, but it is a positive step in relation to providing some level of protection for people in this context.

### Part III — Looking to the Future

#### 10. How, if at all, do you anticipate that your country's laws, policies, or guidelines will change in the next 5-10 years in response to international DTP genomic research? [Multiple choice]

- I do not think they will change at all
  - I think they will restrict international DTP research
  - I think they will allow international DTP research
- d. I am not sure — or other answer**

How the laws on this change are likely to be connected with the form that Brexit ultimately takes and how other countries, both within the EU and those outside the EU, treat the UK for data protection and other purposes.

#### Note

The authors have no conflicts to disclose.

#### References

- Genomics England, "The 100,000 Genomes Project," available at <<https://www.genomicsengland.co.uk/about-genomics-england/the-100000-genomes-project/>> (last visited November 1, 2019).
- Biobank UK*, available at <<https://www.ukbiobank.ac.uk>> (last visited November 1, 2019).
- Human Genetics Commission, *Genes Direct: Ensuring The Effective Oversight Of Genetic Tests Supplied Directly To The Public* (Department of Health, 2003), available at <<http://webarchive.nationalarchives.gov.uk/20120504102222/http://www.hgc.gov.uk/Client/document.asp?DocId=34&CategoryId=10>> (last visited October 30, 2018); Human Genetics Commission, *More Genes Direct* (Department of Health, 2007), available at <[http://sites.nationalacademies.org/cs/groups/pgasite/documents/webpage/pgs\\_053238.pdf](http://sites.nationalacademies.org/cs/groups/pgasite/documents/webpage/pgs_053238.pdf)> (last visited October 22, 2018); Human Genetics Commission, *A Common Framework of Principles for Direct-to-Consumer Genetic Testing Services* (Department of Health, 2010), available at <<https://ukgtn.nhs.uk/resources/library/article/human-genetics-commission-a-common-framework-of-principles-for-direct-to-consumer-genetic-testing-services-70/>> (last visited October 22, 2018).
- Government of the United Kingdom, "Emerging Science and Bioethics Advisory Committee," available at <<https://www.gov.uk/government/groups/emerging-science-and-bioethics-advisory-committee>> (last visited November 1, 2019).
- Human Tissue Authority, *Code A: Guiding Principles and The Fundamental Principle of Consent* (version updated 3 April 2017), para 40, available at <<https://www.hta.gov.uk/hta-codes-practice-and-standards-0>> (last visited October 25, 2018). The previous version of this code was substantially similar. Please see Human Tissue Authority, *Code of Practice 1 — Consent* (Version 14.0, updated July 2014), para. 33 and 35, available at <[https://www.hta.gov.uk/sites/default/files/Code\\_of\\_practice\\_1\\_-\\_Consent.pdf](https://www.hta.gov.uk/sites/default/files/Code_of_practice_1_-_Consent.pdf)> (last visited May 12, 2016).
- In accordance with World Medical Association [WMA], "Declaration of Helsinki," June 1964, available at <<https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/>> (last visited November 1, 2019).
- See for example, Genomics England, "Ethical Approval for 100,000 Genomes Project," available at <<https://www.genomicsengland.co.uk/100k-genomes-project-p-gains-ethical-approval-to-offer-nhs-patients-further-information-about-their-genomic-results/>> (last visited November 1, 2019); Genomics England, "Protocol and Related Policies," available at <[www.genomicsengland.co.uk](http://www.genomicsengland.co.uk)> (last visited November 1, 2019).
- See Health Research Authority, "Governance Arrangements for Research Ethics Committees," available at <<https://www.hra.nhs.uk/planning-and-improving-research/policies-standards-legislation/governance-arrangement-research-ethics-committees/>> (last visited November 1, 2019).
- See Health Research Authority, "What Approvals and Decisions do I Need?" available at <<https://www.hra.nhs.uk/approvals-amendments/what-approvals-do-i-need/>> (last visited November 1, 2019).
- Please see the forthcoming chapter A.M. Phillips and T.K. Hervey, "Brexit and Biobanking: GDPR Perspectives," in *Individual Rights, Public Interest and Biobank Research. Article 89 GDPR and European Legal Responses*, edited by S. Slokenberga, O. Tzortzatou, and J. Reichel (Springer, forthcoming).
- Health Research Authority, "Legal Basis for Processing Data," available at <<https://www.hra.nhs.uk/planning-and-improving-research/policies-standards-legislation/data-protection-and-information-governance/gdpr-detailed-guidance/legal-basis-processing-data/>> (last visited Apr. 24, 2019).
- Human Tissue Authority, "About Us," available at <<https://www.hta.gov.uk/about-us>> (last visited November 1, 2019).
- Health Research Authority, "About Us," available at <<https://www.hra.nhs.uk/about-us/>> (last visited November 1, 2019).
- Health Research Authority, "What We Do," available at <<https://www.hra.nhs.uk/about-us/what-we-do/>> (last visited November 1, 2019).
- See A.M. Phillips and T.K. Hervey, *supra* note 10, citing Health Research Authority, "Consent in Research," available at <<https://www.hra.nhs.uk/planning-and-improving-research/policies-standards-legislation/data-protection-and-information-governance/gdpr-guidance/what-law-says/consent-research/>> (last visited Apr. 24, 2019).
- Joint Research Centre, *Overview of EU National Legislation on Genomics* (JRC Science for Policy Report 2018), at 71.
- Id.*, ch. 1.
- A.M. Phillips, *Buying Your Self on the Internet: Wrap Contracts and Personal Genomics* (Edinburgh: Edinburgh University Press, 2019), ch. 3, citing Human Tissue Authority, "Analysis of DNA under the HT Act FAQs," available at <<https://www.hta.gov.uk/faqs/analysis-dna-under-ht-act-faqs/>> (last visited October 27, 2018). Note: The Human Tissue Authority has not altered its stance on this.
- T. Ray, "23andMe Gets CE Mark, Launches PGS Offering in UK for £125," GenomeWeb, December 1, 2014, available at <<https://www.genomeweb.com/microarrays-multiplexing/23andme-gets-ce-mark-launches-pgs-offering-uk-1255>> (last visited Oct. 22, 2018); S. Gibbs, "DNA-Screening Test 23andMe Launches in UK after US Ban," *The Guardian*, December 2, 2014, available at <<https://www.theguardian.com/technology/2014/dec/02/google-genetic-testing-23andme-uk-launch>> (last visited Oct. 22, 2018).
- A.M. Phillips, *supra* note 18, ch. 1.
- UK Parliament, *Science and Technology Committee (Commons)*, at <<https://www.parliament.uk/business/committees/committees-a-z/commons-select/science-and-technology-committee/inquiries/parliament-2017/commercial-genomics-17-19/>> (last visited November 1, 2019).
- HM Government & Association of British Insurers, *Code on Genetic Testing and Insurance*, available at <<https://www.hra.nhs.uk/planning-and-improving-research/policies-standards-legislation/data-protection-and-information-governance/gdpr-detailed-guidance/legal-basis-processing-data/>>

www.abi.org.uk/globalassets/files/publications/public/genetics/code-on-genetic-testing-and-insurance\_embargoed.pdf> (last visited November 1, 2019).

## United States

*James W. Hazel*

Researchers in genomics are exploring novel ways to interact directly with prospective participants without utilizing physicians, hospitals, or biobanks as intermediaries. Many researchers are interested in using the internet to directly recruit and enroll research participants in genomic studies by posting information online about active or proposed studies. This direct-to-participant (DTP) approach could take place under three main scenarios:

- A researcher in your country wants to conduct DTP genomic research with participants in your country
- A researcher in your country wants to conduct DTP genomic research with participants in another country
- A researcher from outside your country wants to conduct DTP genomic research with participants in your country

There is uncertainty about whether DTP recruitment, enrollment, and research are lawful under these scenarios.

### Part I — DTP-Specific Questions

1. **As far as you know, is DTP genomic research a topic of interest to researchers or other stakeholders in your country?**  
[Multiple choice]
  - a. There has been little, if any, discussion of the issue as of now
  - b. There has been discussion among researchers, but little

### discussion among policy makers

- c. There has been discussion among both researchers and policy makers
- d. I am not sure — or other answer

DTP research is increasingly seen as a valuable tool for researchers seeking to study rare genetic disorders or populations that are historically underrepresented in genetic datasets. DTP research studies are already underway in the United States. For example, the Metastatic Breast Cancer Project at the Broad Institute (MIT/Harvard) recruits participants directly with the help of breast cancer advocacy organizations and has successfully done so in all 50 states.<sup>1</sup> DTP research efforts are also underway in the private sector. The National Geographic Genographic Project has recruited nearly 1 million individuals in over 140 countries in an attempt to gain insights into human migration patterns.<sup>2</sup> 23andMe has utilized the DTP model to recruit participants for their Global Genetics<sup>3</sup> and African Genetics projects<sup>4</sup> in an effort to increase the diversity of samples in genetic and genomic datasets (although enrollment in these projects is currently limited to individuals who reside in the U.S.). 23andMe is expanding these efforts internationally with its Populations Collaborations Program, which provides monetary support and test kits to “researchers working with understudied populations from locations as wide-ranging as the Democratic Republic of Congo, Angola, and Honduras.”<sup>5</sup>

There has been limited formal discussion among policy makers regarding DTP genomic research. Instead, policymakers have generally limited their involvement to providing guidance on subjects directly relevant to DTP research more broadly (e.g., recruiting participants via the internet or obtaining consent online; both of which are discussed below).

2. **Assume that a researcher in your country wants to conduct DTP genomic research with participants in your country and that such research is subject to IRB/REC review. Please describe the conditions for IRB/REC approval, if it could be approved at all.**

Since this question assumes that the DTP genomic research is subject to IRB review, the research most likely falls under the Federal Policy for the Protection of Human Subjects (i.e., the Common Rule).<sup>6</sup> However, it may also fall under the analogous FDA Policy for the Protection of Human Subjects<sup>7</sup> and/or state laws that impose a requirement of IRB review. This section will focus on conditions for approval under the Common Rule, while FDA and state law regulations are discussed in greater detail in the context of Question 7.

### *The Common Rule*

The Common Rule “applies to all research involving human subjects conducted, supported, or otherwise subject to regulation by any Federal department or agency that takes appropriate administrative action to make the policy applicable to such research,”<sup>8</sup> including “research conducted, supported, or otherwise subject to regulation by the Federal Government outside the United States.”<sup>9</sup> Although the revised Common Rule eliminated the option for institutions to formally apply the Common Rule to non-federally funded research through a Federalwide Assurance (FWA; i.e., “checking the box”), implementation of this provision has been delayed<sup>10</sup> and institutions that previously “checked the box” and have an active FWA on file will still continue to be subject to federal oversight for the time being. Even if eliminated, institutional policy may still require compliance with the Common Rule and IRB review of research, although

**James W. Hazel, Ph.D., J.D.,** is a Post-Doctoral Fellow at the Center for Biomedical Ethics and Society, Vanderbilt University Medical Center.

such research would not be subject to federal oversight.

Under the revised Common Rule, “human subject” is now defined as “a living individual about whom an investigator [...] conducting research: (i) Obtains information or biospecimens through intervention or interaction with the individual, and uses, studies, or analyzes the information or biospecimens; or (ii) Obtains, uses, studies, analyzes, or generates identifiable private information or identifiable biospecimens.”<sup>11</sup> The regulations define “intervention” to include “both physical procedures by which information or biospecimens are gathered (e.g., venipuncture) and manipulations of the subject or the subject’s environment that are performed for research purposes.”<sup>12</sup> An “identifiable biospecimen” is defined as “a biospecimen for which the identity of the subject is or may readily be ascertained by the investigator or associated with the biospecimen.”<sup>13</sup>

#### EXPEDITED REVIEW PROCEDURES RELEVANT TO DTP GENOMIC RESEARCH

The revised Common Rule provides for “expedited review procedures for certain kinds of research involving no more than minimal risk, and for minor changes in approved research.”<sup>14</sup> The Common Rule defines “minimal risk” to mean “that the probability and magnitude of harm or discomfort anticipated in the research are not greater in and of themselves than those ordinarily encountered in daily life or during the performance of routine physical or psychological examinations or tests.”<sup>15</sup> Therefore, many types of DTP genomic research would likely fall under these expedited review provisions.

Expedited review does not require review by a full IRB board, but instead “may be carried out by the IRB chairperson or by one or more experienced reviewers designated by the chairperson from among members of the IRB.”<sup>16</sup> When conducting such a review, “the reviewers may exercise all of the authorities of the IRB except that the reviewers may not disapprove the research. A research activity may be disapproved only after review in

accordance with the nonexpedited procedure set forth in §46.108(b).<sup>17</sup> It is important to note that “[l]ike review by the convened IRB, expedited review must fulfill all the requirements of review found at 45 C.F.R. 46.111 and subparts B, C, and D, if applicable. IRBs are reminded that the requirements for informed consent (or for altering or waiving the requirement for informed consent) apply regardless of whether research is reviewed by the convened IRB or under an expedited procedure.”<sup>18</sup>

The 1998 Expedited Review List remains in effect under the revised Common Rule. The Department of Health and Human Services (HHS) must publish proposed revisions to the 1998 list in the Federal Register and solicit public comment prior to adopting a revised Expedited Review List.<sup>19</sup> Categories two and three of the Expedited Review List<sup>20</sup> are likely to be the most directly relevant to DTP genomic research:

- **Expedited 2:** “The collection of blood specimens for research purposes using techniques consistent with routine clinical practice to minimize pain and risk of infection and within the following limits for volume.”<sup>21</sup> The List includes “finger stick[s]” and “venipuncture” as examples that may be directly relevant to a DTP research effort. Therefore, with the exception of certain populations where a finger stick would pose an increased risk of injury (e.g., hemophiliacs), at-home blood collection by a participant may be deemed permissible by an IRB under Category 2 if appropriate safeguards were in place (e.g., detailed collection instructions, sterilization equipment and other necessary supplies are provided to the participant).<sup>22</sup> In contrast, venipuncture would likely not be permissible in an at-home setting; and indeed, the Metastatic Breast Cancer (MBC) Project at The Broad Institute (discussed above) requires participants providing blood samples to do so

in coordination with a healthcare provider.<sup>23</sup>

- **Expedited 3:** “Prospective collection of biological specimens, excluding blood, for research purposes by noninvasive or minimally invasive means.”<sup>24</sup> The List includes several examples that may be directly relevant to DTP research, including: “[t]issues and fluids that the body produces continuously or sheds as a normal process, which are collected in a non-disfiguring manner,” “specimens collected in adults by curettage, urethral, vaginal or rectal swabs,” and “[s]pecimens collected from the external auditory canal or nares.” Therefore, DTP research relying on participants to provide a saliva sample or buccal swab would likely fall under Expedited Category 3, even if not carried out in coordination with a healthcare provider.

In addition to these expedited review categories, DTP research efforts that obtain biospecimens or other data in coordination with a healthcare provider might fall under expedited categories four<sup>25</sup> or five<sup>26</sup> (depending on the nature of the research).

#### EXEMPTIONS POTENTIALLY RELEVANT TO DTP GENOMIC RESEARCH

Certain DTP research activities may fall under an exemption to the Common Rule and therefore would require limited IRB review. The following new (or modified) exemptions may be relevant to the secondary use of biospecimens and genetic data in DTP research. For example, these exemptions may apply to specimens or data initially obtained in the course of a DTP research project, or research involving data or specimens contributed by individuals to a public resource or subject to the regulations of HIPAA.

- **Exemption 4:** “Secondary research for which consent is not required: Secondary research uses of identifiable private information or identifiable biospecimens,”

if certain criteria are met (see footnote).<sup>27</sup>

- **Exemption 7:** “Storage or maintenance for secondary research for which broad consent is required: Storage or maintenance of identifiable private information or identifiable biospecimens for potential secondary research use if an IRB conducts a limited IRB review and makes the determinations required by §46.111(a)(8).”<sup>28</sup>
- **Exemption 8:** “Secondary research for which broad consent is required: Research involving the use of identifiable private information or identifiable biospecimens for secondary research use, if the following criteria are met: (i) Broad consent for the storage, maintenance, and secondary research use of the identifiable private information or identifiable biospecimens was obtained in accordance with §46.116(a)(1) through (4), (a)(6), and (d); (ii) Documentation of informed consent or waiver of documentation of consent was obtained in accordance with §46.117.”<sup>29</sup>

#### INFORMED CONSENT AND DTP RESEARCH

According to the Office for Human Research Protections (OHRP), participant recruitment is considered part of the informed consent process and is therefore subject to IRB review.<sup>30</sup> OHRP has provided guidance on “Internet Research,”<sup>31</sup> which includes direct recruitment of study participants online. The guidelines contemplate recruiting participants directly using tools such as “Web ads, Twitter streams, blog postings, YouTube videos, and ‘push’ methods, such as email solicitations and texts [...] and [...] inks to online recruitment sites [...] provided in other media (television, newspaper, classified, public transit posters, robo-calls, etc.).”<sup>32</sup> In addition, OHRP and the FDA have also issued guidance to IRBs, investigators, and sponsors on instituting an electronic informed consent process for HHS and FDA regulated research.

The guidance includes a discussion of informed consent requirements, use of electronic signatures, and verification of identity.<sup>33</sup> Both sets of guidance indicate that what constitutes “informed consent” of participants recruited online may vary depending on the nature of the study and the level of risk.

The revised Common Rule contains several changes to the informed consent requirements, including one new general requirement,<sup>34</sup> one new basic element, and three new additional elements of informed consent. The new basic element and three new additional elements of informed consent are likely to be most directly relevant to DTP genomic research.

The new basic element requires “[o]ne of the following statements about any research that involves the collection of identifiable private information or identifiable biospecimens: (i) “[a] statement that identifiers might be removed from the identifiable private information or identifiable biospecimens and that, after such removal, the information or biospecimens could be used for future research studies or distributed to another investigator for future research studies without additional informed consent from the subject or the legally authorized representative, if this might be a possibility;” or (ii) “[a] statement that the subject’s information or biospecimens collected as part of the research, even if identifiers are removed, will not be used or distributed for future research studies.”<sup>35</sup>

The new additional elements of informed consent include: (1) “[a] statement that the subject’s biospecimens (even if identifiers are removed) may be used for commercial profit and whether the subject will or will not share in this commercial profit;”<sup>36</sup> (2) “[a] statement regarding whether clinically relevant research results, including individual research results, will be disclosed to subjects, and if so, under what conditions;”<sup>37</sup> and (3) “[f]or research involving biospecimens, whether the research will (if known) or might include whole genome sequencing (i.e., sequencing of a human germline or somatic

specimen with the intent to generate the genome or exome sequence of that specimen).”<sup>38</sup>

Finally, it is worth noting that under the revised Common Rule, “[a]n IRB may approve a research proposal in which an investigator will obtain information or biospecimens for the purpose of screening, recruiting, or determining the eligibility of prospective subjects without the informed consent of the prospective subject or the subject’s legally authorized representative, if [...] [t]he investigator will obtain information through oral or written communication with the prospective subject or legally authorized representative.”<sup>39</sup>

### 3. Assume that a researcher in your country wants to conduct DTP genomic research in another country. Please describe the conditions that must be satisfied for IRB/REC approval in your country, if it could be approved at all. Would your IRB/REC also require approval from a research ethics review body in the other country?

Again, because this question assumes IRB approval is necessary, the research is likely subject to the Common Rule, which applies to federally-funded human subjects research regardless of whether the participants are located in another country.<sup>40</sup> The OHRP International Program “works to ensure that human subjects outside of the United States who participate in research projects conducted or funded by HHS receive an equal level of protection as research participants inside the United States”<sup>41</sup> and publishes a list of international laws, regulations, and guidelines relevant to human subjects research.<sup>42</sup>

U.S. IRBs would require approval from an IRB/REC (or equivalent) in another country if that country’s laws or policies required that the proposed research be approved locally. Researchers would therefore need to research the specific country’s policies and/or coordinate with an individual

knowledgeable in the applicable regulations. For example, in Europe the approval of both a U.S. IRB and the country's data protection board would be required. However, even where the country's laws do not specifically require local IRB/REC approval, U.S. IRBs would likely impose additional requirements on investigators (e.g., a local collaborator or consultation with a local expert or community leader as a condition of approval). These requirements are likely to vary by IRB and may depend on the nature of the study and the level of risk involved.

Below are two examples of IRB policies pertaining to the question of whether international research requires local IRB/REC approval that appear to be representative:

- “Where appropriate, research projects [conducted internationally] must have been approved by the local equivalent of an IRB before they are presented to the University IRB. Where there is no equivalent board or group, investigators are expected to consult with local experts or community leaders about the project and to secure their support for the conduct of the research. The IRB does require that there be good faith effort applied to secure local cooperation for the research and to document those efforts as part of the application.”<sup>43</sup>
- “If a study [conducted internationally] involves more than minimal risk, investigators will be required to obtain approval from a Research Ethics Board, an IRB equivalent, or a ministry of health. Local collaborators and local IRBs can provide insight on local laws, such as privacy or other laws that may restrict the export from other countries of personally identifiable data. As determined by the IRB, an expert in the culture of the other country may be used in lieu of the IRB equivalent. [...] If a study involves minimal risk, the IRB equivalent to an approval letter or permission letter from the research

site may be acceptable. The [...] IRB will review these on a case-by-case basis.”<sup>44</sup>

Less clear is the extent to which state laws might implicate researchers engaged in international DTP research, such as those that impose restrictions on researchers conducting research within the jurisdiction (e.g., a requirement of IRB approval for all human subjects research) or convey protections to research participants in a given jurisdiction (e.g., informed consent requirements). Such determinations would depend on the state law at hand as well as the specific details surrounding the research project (e.g. the location of the researcher as well as the participants, the method of recruitment or nature of the research, etc.). State law is discussed in greater detail in Question 7.

**4. Assume that a researcher from outside your country wants to conduct DTP genomic research in your country.**

- a. Would it be lawful for the researcher to do so without IRB/REC approval in either the researcher's country or your country? [Yes/No]
- Yes**
- No**
- Not sure or other**

Yes/Other. Unless the researcher was subject to the Common Rule, FDA Policy for the Protection of Human Subjects and/or state laws that impose a requirement of IRB review, whether the international researcher would require IRB/REC approval in their country would depend on the laws and policies in place in that country. If an international institution is federally funded (by a U.S. Common Rule agency) or is “engaged” in federally funded research, the institution would be required to file an International FWA that describes the foreign research protections in place as well as adhere to the Common Rule regulations (including IRB approval).<sup>45</sup> According to OHRP guidance, “an institution is considered *engaged* in

a particular non-exempt human subjects research project when its employees or agents for the purposes of the research project obtain: (1) data about the subjects of the research through intervention or interaction with them; (2) identifiable private information about the subjects of the research; or (3) the informed consent of human subjects for the research.”<sup>46</sup> If no international or U.S. researcher that falls under the Common Rule/FDA regulations is “engaged” in the research, then no approval from an IRB would be necessary in either country (although, as noted above, foreign laws or regulations may require it).

- b. Would it be lawful for the researcher to do so if the research were approved by an IRB/REC in the researcher's own country, but was not submitted for approval in your country? [Yes/No]
- Yes**
- No**
- Not sure or other**

Yes/Other. Again, if no researcher that falls under the Common Rule, FDA Policy for the Protection of Human Subjects and/or state laws that impose a requirement of IRB is “engaged” in the research, then no approval from a U.S. IRB would be necessary. Whether an international researcher would require IRB/REC approval in the U.S. as a condition of approval in their own country would largely depend on the laws and policies in place in the researcher's country.

There are few mechanisms to stop a researcher from recruiting citizens in the U.S. without any form of local approval *if* the researcher is not subject to the Common Rule or analogous FDA or state regulations. For example, the NIH's Office for Human Research Protections (OHRP) only has oversight authority over research “conducted or supported” by the Department of Health and Human Services (HHS).<sup>47</sup> Similarly, the FDA and its Office of Good Clinical Practice (OGCP) would only exercise

jurisdiction over research regulated or sponsored by the FDA.<sup>48</sup> As discussed above, state laws that place restrictions on researchers conducting research within the state or convey additional protections to research participants could result in local restrictions on the foreign researcher (state laws are discussed below in the context of Question 7). In addition, if the foreign researcher was engaging in nefarious conduct (e.g., data practices at odds with their privacy policy or agreement with the participant), then the Federal Trade Commission or analogous state consumer protection agencies may be able to exercise jurisdiction (FTC authority is discussed below in Question 9).

- c. Would the external researcher be required to have a collaborator in your country? [Yes/No]  
 Yes  
 No  
 Not sure or other

No/Other. Whether an external researcher would be required to have a collaborator in the United States would largely depend on the laws and policies in place in the researcher's country. However, if the foreign researcher sought out a collaborator in the United States that was subject to the Common Rule (or analogous FDA or state regulations) and deemed to be "engaged" in the research, then the researcher in the United States would be required to obtain IRB approval.

- d. Would it matter whether the external researcher is based at a commercial, governmental, or academic entity? [Yes/No]  
 Yes  
 No  
 Not sure or other

No. The central question of whether there would be restrictions on the research or the resulting data would be whether the research is subject to the Common Rule or FDA regulations based on the funding source or nature of the research, respectively, or whether the researcher/entity is a

"covered entity" under HIPAA due to qualifying operations in the United States (HIPAA is discussed in greater detail below). It is worth noting that state law may also regulate research in certain jurisdictions within the U.S. and that the applicability of such laws could depend on the entity conducting the research.<sup>49</sup>

5. **As far as you know, what are the perceived benefits and risks that could occur if a researcher from another country conducted IRB/REC-approved genomic research on samples or data obtained from your country? Please consider the perspectives of the public, research participants, socially-defined groups (e.g., indigenous or minority populations), researchers, and other professional or government entities.**

*Potential Benefits of DTP Research*

International research projects have the ability to make meaningful scientific contributions (e.g., advancing general knowledge and improving healthcare outcomes) that could provide downstream benefit to the U.S. public (and domestic researchers). Allowing international research to be conducted without overly burdensome restrictions benefits researchers by providing them access to a larger, more diverse pool of research participants. Existing biomedical datasets tend to be skewed heavily toward participants of European descent.<sup>50</sup> Similarly, it would provide prospective participants the ability to exercise individual autonomy and participate in a broader range of scientific research that may be meaningful to them. Both of these aspects would be particularly important in the context of rare disease research and research involving populations that have been historically underrepresented in genetic datasets.

*Potential Risks of DTP Research*

There may be a concern that without U.S. oversight, the protections afforded by international laws, regula-

tions, and/or policies of the researcher's country would not provide sufficient protection to U.S. subjects. This may include a lack of informed consent requirements or regulations governing privacy and confidentiality of the data. Relatedly, there is a risk that the samples or data could be put to uses that were not anticipated by the individuals and may be contrary to societal beliefs or values. In contrast, there may be a fear that international laws or regulations create an undue risk of liability on the part of the researcher or research participant.

There is also a concern that the benefits derived from such data might not translate into benefits for the individuals whose data are being used or may not be readily available to domestic researchers. All of these concerns may be heightened with respect to indigenous, disadvantaged, or minority populations. DTP research efforts should involve a bi-directional flow of data and resulting benefits (whether economic in nature, such as intellectual property rights, or social). Finally, there is a risk that poorly implemented DTP research efforts (which may be subject to little or no regulation) may lead to abuses that could negatively influence public opinion and create a general reluctance to participate in biomedical research.<sup>51</sup>

**Part II — General Questions**

6. **Does your country have biohazard committees, data protection boards, export permit authorities, or other entities that regulate the exporting of biospecimens or the transferring of data across borders for research? If so, do these requirements apply to individual citizens as well as research and medical institutions?**

Given the paucity of regulations surrounding DTP research carried out by entities that do not fall within the Common Rule, FDA regulations, or HIPAA, export and import regulations may be one of the more complicated issues for individuals and

entities wishing to engage in DTP research. In the United States, the *export* of biospecimens (e.g., DNA, saliva, blood) is regulated primarily by the Department of Commerce (DOC). The *import* of biospecimens may be regulated by several federal agencies and organizations, including: US Customs and Border Protection (CBP), Food and Drug Administration (FDA), and the Centers for Disease Control and Prevention (CDC). Finally, both import and export would likely require compliance with Department of Transportation (DOT), United States Postal Service (USPS; or similar carrier), and International Air Transport Association (IATA) regulations. The applicability of import/export regulations depends largely on the type of biospecimen at issue (as opposed to the entity importing/exporting the biospecimen), so they would generally apply equally to citizen scientists, research and medical institutions, and commercial entities.

#### *Exporting Biospecimens From the United States*

Export of biospecimens from the United States is regulated primarily by the Department of Commerce. However, export may also implicate Department of Transportation, United States Postal Service, and International Air Transport Association (IATA) regulations, depending on the nature of the shipment and biospecimen.

#### DEPARTMENT OF COMMERCE

The Department of Commerce may require a license for the export of certain biospecimens utilized in DTP research. According to the Export Administration Regulations,<sup>52</sup> licenses are generally required if such specimens are classified as “restricted biologicals” (e.g., known to contain biological agents that are pathogenic to humans, plants, or animals, including genetic material that codes for a pathogen). A list of human pathogens and toxins is found in Export Classification Control Number (ECCN) 1C351.

If the biospecimen does not fall within one of the control list catego-

ries, it will generally be deemed to fall outside of the jurisdiction of the Department of Commerce (i.e., category EAR99 – material not listed). Therefore, a permit would not be required unless the biospecimen was destined for a country under embargo or the subject of U.S. sanctions.

#### DEPARTMENT OF TRANSPORTATION

Export/import of biospecimens would likely require shipment on public highways, waterways, or through the airspace of the United States and fall under the jurisdiction of the Department of Transportation (DOT). The DOT regulates transportation of certain categories of biospecimens,<sup>53</sup> including those “known or reasonably expected to contain a pathogen,” as well as certain shipping materials that may accompany them (e.g. preservatives, dry ice, etc.).<sup>54</sup> Biospecimens not known or reasonably expected to contain a pathogen would generally be considered “exempt human specimens” not subject to the DOT regulations (although it is recommended that they be labeled as such during shipment), but would still be subject to the packaging requirements of USPS (or private carrier) and the IATA (discussed below).

Infectious substances subject to regulation would generally fall into one of two categories (Category A or Category B). Depending on the classification, the biospecimen may be subject to various packaging, labeling, and shipping requirements, including documentation and/or safety plans:

- **Category A:** “An infectious substance in a form capable of causing permanent disability or life-threatening or fatal disease in otherwise healthy humans or animals when exposure to it occurs. [...] Classification must be based on the known medical history or symptoms of the source patient [...], endemic local conditions, or professional judgment concerning the individual circumstances of the source human [...]”<sup>55</sup> Category A infectious substances cannot be mailed via the

USPS (but may be mailed by private carriers, with restrictions).<sup>56</sup>

- **Category B:** “An infectious substance that is not in a form generally capable of causing permanent disability or life-threatening or fatal disease in otherwise healthy humans or animals when exposure to it occurs. This includes Category B infectious substances transported for diagnostic or investigational purposes.”<sup>57</sup> Category B may be mailed domestically “when they are intended for medical or veterinary use, research, or laboratory certification related to public health” and internationally to an authorized<sup>58</sup> laboratory.

#### UNITED STATES POSTAL SERVICE (USPS) AND INTERNATIONAL AIR TRANSPORT ASSOCIATION (IATA)

Even if the biospecimens are considered “exempt” under Department of Transportation regulations, researchers importing or exporting biospecimens may still be required to comply with packaging requirements of the USPS (or private carrier) and/or the IATA. Since international shipment of biospecimens would likely require international air travel, DTP researchers must also comply with IATA “Dangerous Goods Regulations” that impose packaging and labeling requirements that vary depending on the category of specimen in question (see above discussion regarding DOT regulations).<sup>59</sup> Both USPS and IATA require that all biospecimens, including those considered “exempt” (i.e., not likely to contain an infectious agent), be triple packaged and should be labeled as “exempt human specimens.”<sup>60</sup>

#### *Importing Biospecimens into the United States*

In addition to DOT, USPS, and IATA regulations, DTP researchers importing biospecimens into the U.S. must also comply with CBP regulations, and may fall under the jurisdiction of the FDA or CDC depending on the nature of the biospecimen or research.



#### U.S. CUSTOMS AND BORDER PROTECTION (CBP)

DTP researchers wishing to *import* biospecimens obtained internationally would need to comply with CBP regulations. The CBP provides examples of biospecimens, many of which would implicate DTP research, including: “[u]rine, feces, saliva,” “cell or tissue culture,” “cell/tissue culture product” (including nucleic acids), “test kits,” tissue organ/extracts and samples,” “blood, plasma, blood cells, clotting factors.”<sup>61</sup>

According to CBP, “[a] formal entry may be required at the port of arrival if *any* of the following conditions apply: “[o]ne or more Partner Government Agencies (U.S. Food and Drug Administration, USDA, CDC, etc.) require information to fulfill their regulatory requirements; or Commercial shipments of biological materials that exceed \$2,500 in value; or Port Director at the arrival port otherwise requires it.”<sup>62</sup> Importers are required to complete an Importer Identity Form [Form 5106] and Entry Summary [Form 7501]. In addition, the biospecimens should be accompanied with any applicable documentation required by other federal agencies (e.g., FDA, CDC; discussed below), including a permit, disclaimer of jurisdiction, or certification letter, depending on the nature of the sample. If the biospecimens are hand carried or imported via checked baggage, “they must be declared in accordance with CBP regulations, using CBP Form 6059B, and an oral declaration to a CBP officer or at an Automated Passport Control kiosk or Global Entry Kiosk.”<sup>63</sup>

#### FOOD AND DRUG ADMINISTRATION

DTP research involving biological specimens that are used in conjunction with FDA regulated biological products, drugs, or devices may require an import permit from the agency. The FDA would not require a permit for biospecimens intended for basic scientific research or for testing in a clinical laboratory under most circumstances:

If the biological specimens [imported] are intended for

use only for testing in a clinical laboratory or for basic scientific research and are not articles intended for the prevention, treatment, diagnosis, or cure of diseases, injuries, or conditions in human beings, the specimens are not considered to be biological products subject to licensure by FDA in accordance with Section 351(a) [42 USC 262(a)] of the Public Health Service Act (PHS Act), nor would they appear to be a drug or device as defined in sections 201(g) and (h), respectively, of the Federal Food, Drug, and Cosmetic Act [21 USC 321(g) and (h)], nor an HCT/P [human cells or tissues intended for implantation, transplantation, infusion or transfer into a human recipient] as defined in 21 C.F.R. 1271.3, which was promulgated under Section 361 of the PHS Act [42 USC 264].<sup>64</sup>

DTP researchers may be required to enter the appropriate tariff code for their biospecimen and disclaim FDA jurisdiction to CBP upon importing the sample (labeling to that effect is recommended, but not required).<sup>65</sup>

#### CENTERS FOR DISEASE CONTROL AND PREVENTION (CDC)/HEALTH AND HUMAN SERVICES (HHS)

The *Public Service Health Act* requires that individuals or entities wishing to import “diagnostic specimens”<sup>66</sup> or “genomic material”<sup>67</sup> accompany the sample with “an importer [defined as sender *or* recipient<sup>68</sup>] certification statement<sup>69</sup> confirming that the material is not known to contain or suspected of containing an infectious biological agent, or has been rendered noninfectious.”<sup>70</sup> If the biospecimens were collected from an individual or population at risk of an infectious disease or known to have an infectious disease (including instances where the researcher intends to test for an infectious disease), a permit would be acquired from the HHS/CDC Import Permit Program.<sup>71</sup> In cases where a

permit is required, additional CDC permits would likely be required to transfer the specimens across state lines following clearance of customs. In contrast, *export* of analogous biospecimens would not fall under CDC regulations, but may require a permit from the Department of Commerce (discussed above).

#### State Law

State and local laws may also impose additional requirements depending on the origin or destination of the biospecimen.<sup>72</sup>

### 7. Does your country have laws, policies, or guidelines dealing with genetic or genomic research or genetic or genomic privacy that would apply to international DTP research? Do your national laws on these issues apply outside of your country when residents or citizens of your country enroll in a DTP study conducted abroad?

#### The Common Rule

The revised Common Rule and possible implications for DTP research are discussed in detail in the context of Question 2.

#### The Food and Drug Administration

FDA regulations analogous to Common Rule protections may apply to DTP research if such research involves an FDA-regulated investigational drug or medical device, regardless of whether the research was conducted by an entity or individual subject to the Common Rule. Specifically, these regulations would apply to “clinical investigations regulated by the Food and Drug Administration under sections 505(i) and 520(g) of the *Federal Food, Drug, and Cosmetic Act*, as well as clinical investigations that support applications for research or marketing permits for products regulated by the Food and Drug Administration, including foods, including dietary supplements, that bear a nutrient content claim or a health claim, infant formulas, food and color additives, drugs for human use, medical devices for human use,

biological products for human use, and electronic products.<sup>73</sup> “Subject” is defined as “a human who participates in an investigation, either as an individual on whom or on whose specimen an investigational device is used or as a control.”<sup>74</sup>

FDA regulations set forth requirements for, among other things, electronic records and electronic signatures,<sup>75</sup> informed consent,<sup>76</sup> and IRB review.<sup>77</sup> If the research is also subject to the Common Rule,<sup>78</sup> then both sets of regulations would apply (in event of conflict between policies, the stricter regulations would need to be followed).

#### *Informed Consent Guidance*

As discussed above in the context of the Common Rule, the FDA has issued guidance with OHRP on obtaining consent electronically, including information consent requirements, use of electronic signatures, and verification of identity.<sup>79</sup> The FDA has also issued guidance on recruiting study participants online and the role of IRBs in the process. The guidelines indicate that IRB review and approval of online clinical trial listings is not required if the listing is limited to “basic trial information, such as: the title; purpose of the study; protocol summary; basic eligibility criteria; study site location(s); and how to contact the site for further information.”<sup>80</sup> However, recruitment plans that provide any additional information (including proposed advertisements) “should be reviewed and approved by the IRB as part of the package for initial review” in order to “assure that the additional information does not promise or imply a certainty of cure or other benefit beyond what is contained in the protocol and the informed consent document.”<sup>81</sup>

#### *Health Insurance Portability and Accountability Act (HIPAA)*

HIPAA and its Privacy Rule require patient authorization for uses and disclosures of protected health information in contexts other than treatment, payment, and healthcare operations.<sup>82</sup> However, the rule contains numerous exceptions,<sup>83</sup> including for research in cases where an IRB or

privacy review board has waived or altered the consent requirement.<sup>84</sup> In addition, HIPAA would only apply to DTP research conducted by one of four types of “covered entities:” “healthcare providers that transmit any health information in electronic form in connection with a covered transaction; health plans, including a health insurer, HMO, Medicare or Medicaid program, or other entity that provides or pays the costs of medical care; health clearinghouses, public or private entities, including a billing service or health information management system, that process health information into a standard format for billing purposes; and business associates of these entities, including individuals or entities that perform or assist in billing, management, administration, or other functions regulated by the Privacy Rule.”<sup>85</sup>

In addition, HIPAA does not place restrictions on the use or disclosure of de-identified health information, including genetic information, as it is not considered protected health information;<sup>86</sup> such data can be de-identified either by the Safe Harbor Method (which specifies personal identifiers that must be removed) or through the Expert Determination Method (in which a qualified expert determines that the data has been sufficiently de-identified).<sup>87</sup>

#### *Genetic Information Nondiscrimination Act (GINA) and Other Federal Anti-Discrimination Laws*

GINA prohibits discrimination based on genetic information in the context of health insurance (Title I) and employment (Title II).<sup>88</sup> In addition, GINA designates “genetic information” as protected “health information” under HIPAA and its Privacy Rule.<sup>89</sup> Therefore, GINA may indirectly implicate the genetic information generated by DTP research by placing restrictions on uses of such information in specific contexts. Genetic information may also be subject to other federal anti-discrimination laws such as the *Americans with Disabilities Act (ADA)*<sup>90</sup> and the *Affordable Care Act (ACA)*.<sup>91</sup>

#### *U.S.-EU/Swiss Privacy Shield Framework*

The recently updated EU-US Privacy Shield is a regulatory framework governing the exchange of personal information, including genetic data, between the United States and European Union. The framework was “designed by the U.S. Department of Commerce and the European Commission and Swiss Administration to provide companies on both sides of the Atlantic with a mechanism to comply with data protection requirements when transferring personal data from the European Union and Switzerland to the United States in support of transatlantic commerce.”<sup>92</sup>

The framework allows any U.S. organization that falls under the jurisdiction of the Federal Trade Commission or Department of Transportation to participate in the program. The U.S. Department of Commerce maintains a list of companies that have self-certified that they have a privacy policy that is compliant with the principles outlined in the framework (including Notice, Choice, Accountability for Onward Transfer, Security, Data Integrity and Purpose Limitation, Access, and Recourse, Enforcement and Liability).<sup>93</sup> Organizations must also certify that they have established an independent mechanism for consumer recourse in the event of a dispute.<sup>94</sup> Organizations participating in the program “are deemed to provide ‘adequate’ privacy protection, a requirement (subject to limited derogations) for the transfer of personal data outside of the European Union under the EU *General Data Protection Regulation (GDPR)* and outside of Switzerland under the Swiss *Federal Act on Data Protection*.”<sup>95</sup> In addition, “EU Member State requirements for prior approval of data transfers either are waived or approval will be automatically granted.”<sup>96</sup>

#### *The Privacy Act of 1974*

The *Privacy Act of 1974*<sup>97</sup> “establishes a code of fair information practices that governs the collection, maintenance, use, and dissemination of information about individuals that is maintained in systems of records by federal agencies.”<sup>98</sup> The *Act* defines

“system of records” as “a group of any records under the control of any agency from which information is retrieved by the name of the individual or by some identifying number, symbol, or other identifying particular assigned to the individual.”<sup>99</sup> The *Act* may therefore implicate DTP research if such research was conducted by a federal agency and the agency stored participants’ data in a qualifying “system of records.” If this were the case, the federal agency would be required to provide public notice of such a system in the Federal Register as well as provide participants within the system the right to access and amend their information.<sup>100</sup> The *Act* would also prohibit the agency from disclosing a participant’s information without written authorization unless such disclosure fell under an exception.<sup>101</sup>

#### *Health Information Technology for Economic and Clinical Health (HITECH) Act*

The HITECH *Act* was enacted to facilitate the implementation of electronic medical records (EHRs) in the United States.<sup>102</sup> The *Act* not only provided financial incentives to healthcare providers to adopt intraoperative EHRs (Subtitle B) but also enhanced security and privacy protections under HIPAA (Subtitle D), such as instituting accounting and data breach notification requirements and harsher penalties for non-compliance. Given that DTP researchers may request authorization to access a participant’s EHR as part of the informed consent process, the HITECH *Act* may indirectly facilitate DTP research efforts by increasing access to data contained in EHRs and enhancing security and privacy protections.

#### *State Law*

DTP researchers will also have to navigate a complex array of state laws. The National Human Genome Research Institute (NHGRI) maintains a database of state laws that implicate genetics and genomics in a variety of contexts, including ownership of genetic data, employment and insurance discrimination, health insurance coverage, privacy, research, and the use of residual newborn

screening specimens.<sup>103</sup> As of January 2019, the database contained over 200 statutes in effect in 49 states and the District of Columbia. Only Mississippi does not appear to have laws that implicate genetics or genomics in any of the above contexts. Although state laws that conflict with federal law may be preempted in certain circumstances, HIPAA, GINA, and CLIA generally do not preempt state laws that are more stringent in their protections.

State law has the potential to implicate DTP research in a number of different contexts:

- *Ownership of Genetic Information:* Although courts have been reluctant to recognize a property interest in biospecimens that have been surrendered to researchers,<sup>104</sup> several states have enacted laws providing that genetic information is the property of the individual being tested.<sup>105</sup>
- *Informed Consent Requirements:* Several states impose informed consent requirements that may implicate DTP research. These laws generally require informed consent in order to either obtain or disclose genetic information about an individual.<sup>106</sup> Many such laws contain exemptions for data that is de-identified and used for research.<sup>107</sup>
- *Security and Retention of Data and/or Biospecimens:* States may also impose security requirements for genetic data (generally via laws governing health information and medical records more broadly) or deem such information to be confidential.<sup>108</sup> A few states grant individuals the right to request destruction of biospecimens or place restrictions on the retention of biospecimens following genetic analysis or the completion of a research study.<sup>109</sup>
- *Research Protections:* State law may also enhance protections for individuals participating in DTP who reside in the state or

impose additional requirements on researchers conducting research within the state. For example, state law may require that all human subjects research within the state comply with Common Rule regulations, convey additional protections to participants (e.g., regulating informed consent and permissible uses/disclosures of data in the context of research), or place additional restrictions on researchers.<sup>110</sup>

However, the extent to which state laws such as these would implicate researchers engaged in international DTP research is unclear. Such determinations would depend on the state law at hand as well as the specific details surrounding the research project (e.g., the location of the researcher as well as the participants, the method of recruitment or nature of the research, etc.). For example, an international researcher actively soliciting participation from residents of a given state *may* be more likely to be deemed to be conducting research “within the state” (and thus subject to local regulations) than a researcher who was simply sought out by a participant that happened to reside in the state.

#### **8. Does your country have laws, policies, guidelines, or cultural expectations regarding the return of individual or aggregate research results? [Multiple choice]**

- a. The law requires the return of individual results unless the participant expressly declines to have results returned
- b. The law is silent on return of results; the expectation is that individual results will be returned unless the participant expressly declines to have the results returned
- c. The law is silent on return of results; aggregate results are typically returned, but indi-

vidual results are not returned unless expressly stated in the research protocol

**d. I am not sure — or other answer**

There is currently an active, ongoing debate about the extent to which individual research results should be returned to participants and uncertainty regarding the effect of existing laws on such disclosures (e.g., whether they are prohibited by CLIA or required under HIPAA). Return of results may fall into several categories: public release of study data, return of general (aggregate) study results to subjects, return of individual results to subjects, and return of incidental/secondary findings to subjects. The extent to which results are returned varies depending on the study. Historically, the return of results to participants was generally limited, but there is currently a trend toward the increased return of individual results. For example, the NIH All of Us Research Program in the U.S.<sup>111</sup> and the U.K. 100,000 Genomes Project<sup>112</sup> will provide individuals access to their research data. This is in line with recent studies showing that participants are generally in favor of receiving individual results.<sup>113</sup> Scholars and researchers opposed to a broader return of individual results often cite increased costs and logistical issues, concerns about validity of the results and potential liability, and a lack of clear protocols for doing so.

Currently, individual or incidental/secondary research results are generally returned to individuals via one of three mechanisms:

The first is to perform research analyses in laboratories that comply with the *Clinical Laboratory Improvement Amendments* of 1988 (CLIA) — a federal statute that aims to ensure the safety and analytic quality of laboratory tests conducted for health care purposes—so that research results can be freely used in clinical care. A second pathway,

for results from non-CLIA research laboratories, is for researchers to confirm results that raise clinical concerns in a CLIA laboratory before return. A third option for results from non-CLIA research laboratories is a clinical hand-off: return research results while advising the participant that clinical confirmation and follow-up are needed before clinical use. In this option, researchers maintain the line between research and clinical care by making a referral for clinical workup rather than venturing a diagnosis based on potentially uncertain research results.<sup>114</sup>

*Law*

CLINICAL LABORATORY IMPROVEMENT AMENDMENTS OF 1988 (CLIA)

CLIA prohibits non-CLIA certified laboratories from providing results “for the diagnosis, prevention, or treatment of any disease or impairment of, or the assessment of the health of, human beings.”<sup>115</sup> The Centers for Medicare and Medicaid Services (CMS) and others have taken the position that “reporting an individual’s research results for any reason is doing so for clinical use and thus needs CLIA certification,”<sup>116</sup> an interpretation that would preclude the return of results from many research laboratories (the majority of which are not CLIA certified).<sup>117</sup> Other scholars disagree, arguing instead that “[w]hen the purpose for return of results is to recommend that the participant seek clinical confirmation and evaluation, rather than for direct use in clinical care, CLIA does not apply [...] Nor does it apply when the goal of returning results is to respect the many nonclinical reasons why participants want their results and data.”<sup>118</sup> These scholars question the authority of CMS to apply such restrictions in the absence of a clear congressional mandate.<sup>119</sup>

THE HEALTH INSURANCE PORTABILITY AND ACCOUNTABILITY ACT (HIPAA)

Scholars also disagree about the extent to which HIPAA gives patients a right of access to individual research results. Some argue that “[u]nder the [...] Privacy Rule, research participants have a legally protected right of access to their data and results in the “designated record set” (DRS) at HIPAA-covered clinical and research laboratories,” even if those laboratories are not CLIA certified.<sup>120</sup> Further, since GINA designates “genetic information” as “health information” under HIPAA, it has been argued that “Congress made clear that these HIPAA access rights include genetic information.”<sup>121</sup>

REVISED COMMON RULE

Although the Revised Common Rule does not directly address the question of whether individual research results should be returned to participants, recent revisions regarding additional elements of informed consent,<sup>122</sup> including broad consent,<sup>123</sup> require researchers to disclose to participants whether results will be returned.

The Revised Common Rule also addresses return of results in the context of a new exemption for secondary research using identifiable biospecimens (or identifiable private information) for which broad consent was initially obtained. The Rule states that this exemption is only available if “[t]he investigator does not include returning individual research results to subjects as part of the study plan.”<sup>124</sup> However, the “provision does not prevent an investigator from abiding by any legal requirements to return individual research results.”<sup>125</sup>

*Guidelines*

Several organizations have issued guidelines pertaining to return of individual research results:

AMERICAN COLLEGE OF MEDICAL GENETICS AND GENOMICS (ACMG)

The American College of Medical Genetics and Genomics (ACMG) has published a minimum list of 59 genes that should be screened for in clinical exome and genome sequencing and returned to participants, with their

consent, due to their high penetrance and medical actionability.<sup>126</sup> Although the recommendations are primarily directed at clinicians, they have also been adopted by some researchers.

Other organizations have also released recommendations and guidance regarding return of results, including the National Heart, Lung, and Blood Institute (NHLBI)<sup>127</sup> and the Presidential Commission for the Study of Biomedical Issues.<sup>128</sup>

REPORT BY THE NATIONAL  
ACADEMIES OF SCIENCES,  
ENGINEERING, AND MEDICINE

A recent report by the National Academies of Sciences, Engineering, and Medicine recommends that the decision about whether to return results (and the extent of return) should be made on a study-by-study basis and be clearly described in the research protocol and informed consent process.<sup>129</sup> The report calls for the use of CLIA certified laboratories for results intended to be utilized for clinical decision making. For results not intended to be utilized for clinical decision making, the report allows for the use of non-CLIA certified laboratories, approved research laboratories under a proposed NIH “quality management system” (yet to be established), or after an extensive case-by-case determination about the quality of the results by an IRB.<sup>130</sup>

**9. Does your country have laws, policies, or guidelines regarding “direct-to-consumer” genetic testing (e.g., 23andMe) and, if so, what do they provide? [Multiple choice]**

- Yes. Direct-to-consumer genetic testing is illegal
- Yes. Direct-to-consumer genetic testing is legal**
- No. Direct-to-consumer genetic testing is not an issue
- I am not sure — or other answer

DTC-GT is generally legal in the United States, but is regulated, to differing degrees, by three federal agencies: Food and Drug Administration, Centers for Medicare and Medicaid

Services, and Federal Trade Commission. State laws may also place varying restrictions on DTC-GT.

*Centers for Medicare and Medicaid Services (CMS)*

Under the Clinical Laboratory Improvements Amendments (CLIA),<sup>131</sup> CMS regulates DTC-GT through its authority to establish quality guidelines for clinical laboratories. CLIA regulations are concerned primarily with ensuring the analytical validity of certain tests, including genetic tests, performed by a laboratory<sup>132</sup> that analyzes “materials derived from the human body for the purpose of providing information for the *diagnosis, prevention, or treatment of any disease or impairment of, or the assessment of the health of, human beings.*”<sup>133</sup> This relatively narrow statutory definition excludes many categories of DTC genetic tests (e.g., ancestry, non-health related physical traits) from the mandates of CLIA, although there has been a recent trend among some leading DTC-GT companies to transition to CLIA-certified labs (e.g., 23andMe and FamilyTreeDNA).<sup>134</sup> In addition, CLIA does not grant CMS the authority to assess the clinical validity or utility of the tests being performed, nor does it regulate the privacy-related disclosures that companies must convey to consumers regarding those tests.<sup>135</sup>

Although CMS has been relatively hands-off to date in the context of DTC-GT, the agency recently issued a warning letter to Orig3n, a company offering free health-related genetic testing at Baltimore Ravens football games without obtaining CLIA certification for their laboratory.<sup>136</sup> Although the Orig3n disputed the fact that it was performing health-related testing subject to CLIA, the company subsequently acquired a CLIA-certified lab through their acquisition of Interleukin Genetics.<sup>137</sup>

*Food and Drug Administration (FDA)*

The Food and Drug Administration (FDA) has the authority to regulate certain health-related DTC genetic tests under the *Federal Food, Drug, and Cosmetic Act* (FDCA).<sup>138</sup> Recent

regulatory developments have been driven largely by the FDA and 23andMe.

To date, 23andMe has received separate de novo FDA authorizations to market DTC-GTs on four occasions: carrier tests (Bloom Syndrome; 2015),<sup>139</sup> genetic health risk reports for 10 conditions (including Parkinson’s and early-onset Alzheimer’s; 2017),<sup>140</sup> genetic health risk reports for selected variants of BRCA1/BRCA2 (2018),<sup>141</sup> and pharmacogenetic (PGx) reports for 33 variants associated with medication metabolism (including response to certain antidepressants and cardiac medications; 2018).<sup>142</sup> Most recently, 23andMe has received FDA clearance to market a genetic health risk report for colorectal cancer syndrome (MUTYH-Associated Polyposis; 2018) through the agency’s Section 510(k) pathway<sup>143</sup> by demonstrating substantial equivalence to a predicate device (23andMe’s BRCA1/BRCA2 Genetic Health Risk report).<sup>144</sup> For certain tests the FDA has imposed “special controls” as part of its authorization, such as a warning label requirement for PGx reports designed to inform consumers that they should not make any changes to their medications based on the results.<sup>145</sup>

Under this regulatory approach, the FDA “intends to exempt additional 23andMe GHR tests from the FDA’s premarket review, and GHR tests from other makers may be exempt after submitting their first premarket notification [...] allow[ing] other, similar tests to enter the market as quickly as possible and in the least burdensome way, after a one-time FDA review.”<sup>146</sup>

*Federal Trade Commission (FTC)*

Under the Federal Trade Commission Act,<sup>147</sup> the FTC has broad authority to regulate the privacy practices of companies offering DTC-GT, including the associated research activities involving DTC data. The bipartisan<sup>148</sup> Commission is tasked with protecting consumers and promoting competition by policing “unfair or deceptive acts or practices in or affecting commerce” (Section 5)<sup>149</sup> and the dissemination of “any false advertisement” surrounding “food, drugs, devices, ser-

vices, or cosmetics” (Section 12-15).<sup>150</sup> The agency has the authority to conduct investigations and bring enforcement actions, as well as issue adjudications and engage in rulemaking. It is also empowered to shape policy in the form of official reports and legislative recommendations to Congress and the public (Section 6).<sup>151</sup>

Aside from an enforcement action in 2014,<sup>152</sup> the agency has largely limited its action to releasing consumer-facing bulletins regarding the implications and limitations of DTC-GT<sup>153</sup> and a blog containing “tips” to help keep companies “in line with the FTC Act.”<sup>154</sup> However, the agency has not gone so far as it has in the context of mobile health apps, where the agency has developed formal Best Practices and an interactive web-based tool for developers.<sup>155</sup> But the agency may be poised to take a more active role; reporting in the summer of 2018 suggests that “[p]opular DNA testing companies like 23andMe and Ancestry.com are being investigated by the FTC over their policies for handling personal information and genetic data, and how they share that information with third parties.”<sup>156</sup> It remains to be seen whether these reports are accurate, as they are based solely on the agency’s cryptic response to a *Freedom of Information Act* request.

#### State Regulation

State laws that may implicate DTP research are discussed above in the context of Question 7. Many of these same laws may also implicate DTC-GT (directly or indirectly), such as those relating to informed consent, ownership of genetic information, and disclosure of genetic information. A 2012 50-state survey found that the majority of states either had no laws that appeared to directly implicate DTC-GT (23 states) or explicitly permitted such testing (8 states). Fifteen states had laws that appeared to place restrictions on DTC-GT.<sup>157</sup> These laws directly or indirectly restrict DTC genetic testing primarily through four main mechanisms: informed consent requirements, legislating who is legally authorized to order medical tests, imposing laboratory licensing

requirements, or by defining the practice of medicine to encompass certain DTC tests.<sup>158</sup>

### Part III — Looking to the Future

#### 10. How, if at all, do you anticipate that your country’s laws, policies, or guidelines will change in the next 5-10 years in response to international DTP genomic research? [Multiple choice]

- a. I do not think they will change at all
- b. I think they will restrict international DTP research
- c. I think they will allow international DTP research
- d. I am not sure — or other answer

Given the relatively hands-off approach that federal agencies and legislators have taken toward issues like DTC-GT and research conducted by individuals and entities outside the scope of the Common Rule, the United States does not appear likely to place significant restrictions on international DTP research in the next five to ten years. In addition, the Common Rule was recently revised (and the revisions do not directly address DTP research), so it does not appear likely that revisions that would affect international DTP research are imminent. Instead, policy changes in the next 5-10 years will likely come in the form of guidance from federal agencies or the implementation of IRB policies as opposed to formal rulemaking or legislation.

It remains to be seen what effect state and federal data privacy legislation will have on DTP research efforts. There are currently numerous federal bills relating to data privacy currently pending in the Congress that, if enacted, would likely have an impact on DTP research efforts and the collection, use, and sharing of genetic information more broadly.<sup>159</sup> These bills vary in their scope and whether they explicitly address research or genetic information, but, like the GDPR, commonly grant access and correction rights to individuals and

impose restrictions on the use and sharing of personal information without informed consent.<sup>160</sup> While Congress debates federal legislation, sweeping data privacy laws are being enacted and implemented at the state level; the *California Consumer Privacy Act* of 2018 (CCPA),<sup>161</sup> effective January 1, 2020, and New York is currently considering similar, even more stringent legislation in the *New York Privacy Act*.<sup>162</sup> Other states seem poised to follow.

Given the unique promise of DTP research to increase the diversity of genomic datasets and to further the study of rare diseases, there would likely be public (and possibly political) support in the U.S. to clarify the present law surrounding DTP research. The American public would likely be receptive to efforts to clarify the law surrounding DTP genomic research. A 2018 NPR/Truven Health poll found that 77% of the Americans surveyed would be willing to share their genetic test results for health-care research and indeed, millions of Americans have already undergone direct-to-consumer genetic testing and agreed to participate in the associated research activities.<sup>163</sup> Resolving the uncertainty created by a patchwork of state and federal laws could help facilitate the largescale precision medicine initiatives already underway in the country (e.g., NIH’s All of Us Research Program). In addition, various stakeholders (e.g., academic researchers, pharmaceutical companies, direct-to-consumer genetic testing companies) stand to benefit from additional clarity and may have the political influence to shape the debate.

#### Note

The author has no conflicts to disclose.

#### References

1. The Broad Institute and Dana-Farber Cancer Institute, “About Us,” Metastatic Breast Cancer Project website, available at <<https://www.mbcproject.org/about>> (last visited June 5, 2019).
2. National Geographic, “The Genographic Project,” available at <<https://genographic.nationalgeographic.com/about/>> (last visited June 5, 2019).
3. 23andMe, Global Genetics Project website, available at <<https://>

- www.23andme.com/global-genetics/> (last visited June 5, 2019).
4. 23andMe, African Genetics Project website, *available at* <<https://www.23andme.com/africa-project/>> (last visited June 5, 2019).
  5. 23andMe, “23andMe Populations Collaborations Program,” 23andMe website, *available at* <<https://research.23andme.com/populations-collaborations/#howitworks>> (last visited August 31, 2019).
  6. 45 C.F.R. § 46.
  7. 21 C.F.R. pts. 50, 56.
  8. 45 C.F.R. § 46.101(a).
  9. 45 C.F.R. § 46.101(a).
  10. Department of Health and Human Services, “Revised Common Rule Q&As,” *available at* <<https://www.hhs.gov/ohrp/education-and-outreach/revised-common-rule/revised-common-rule-q-and-a/index.html>> (last visited June 6, 2019).
  11. 45 C.F.R. § 46.102(e)(1).
  12. 45 C.F.R. § 46.102(e)(2).
  13. 45 C.F.R. § 46.102(e)(6).
  14. 45 C.F.R. § 46.110(b)(2).
  15. 45 C.F.R. § 46.102(j).
  16. 45 C.F.R. § 46.110(b)(2).
  17. *Id.*
  18. HHS Office of Human Research Protections, “Expedited Review Procedures Guidance (2003),” *available at* <<https://www.hhs.gov/ohrp/regulations-and-policy/guidance/guidance-on-expedited-review-procedures/index.html/>> (last visited June 4, 2019).
  19. *Id.*
  20. HHS Office of Human Research Protections, “OHRP Expedited Review Categories (1998),” *available at* <<https://www.hhs.gov/ohrp/regulations-and-policy/guidance/categories-of-research-expedited-review-procedure-1998/index.html>> (last visited June 4, 2019).
  21. *Id.*
  22. Personal correspondence from representatives from the Vanderbilt IRB, OHRP to author.
  23. The Broad Institute and Dana-Farber Cancer Institute, *supra* note 1.
  24. HHS Office of Human Research Protections, *supra* note 19.
  25. *Id.* Expedited category four provides for “[c]ollection of additional data and biological specimens, excluding blood specimens, for research purposes during procedures already being performed for clinical purposes, provided the additional collection does not entail more than a minimal increase in risk, pain or discomfort.”
  26. *Id.* Expedited category five provides for “[c]ollection of data through noninvasive or minimally invasive procedures (not requiring the addition of general anesthesia or sedation for research purposes) routinely employed in clinical practice.”
  27. 45 C.F.R. § 46.104(4). “Secondary research for which consent is not required: Secondary research uses of identifiable private information or identifiable biospecimens, if at least one of the following criteria is met: (i) The identifiable private information or identifiable biospecimens are publicly available; (ii) Information, which may include information about biospecimens, is recorded by the investigator in such a manner that the identity of the human subjects cannot readily be ascertained directly or through identifiers linked to the subjects, the investigator does not contact the subjects, and the investigator will not re-identify subjects; (iii) The research involves only information collection and analysis involving the investigator’s use of identifiable health information when that use is regulated under 45 C.F.R. pts. 160 and 164, sub pts. A and E, for the purposes of “health care operations” or “research” as those terms are defined at 45 C.F.R. 164.501 or for “public health activities and purposes” as described under 45 C.F.R. 164.512(b); or (iv) The research is conducted by, or on behalf of, a Federal department or agency using government-generated or government-collected information obtained for nonresearch activities, if the research generates identifiable private information that is or will be maintained on information technology that is subject to and in compliance with section 208(b) of the E-Government Act of 2002, 44 U.S.C. 3501 note, if all of the identifiable private information collected, used, or generated as part of the activity will be maintained in systems of records subject to the Privacy Act of 1974, 5 U.S.C. 552a, and, if applicable, the information used in the research was collected subject to the Paperwork Reduction Act of 1995, 44 U.S.C. 3501 *et seq.*” 45 C.F.R. § 46.104(7).
  28. 45 C.F.R. § 46.104 (8).
  29. According to the informed consent requirements found in 45 C.F.R. § 46.116(2), “[a]n investigator shall seek informed consent only under circumstances that provide the prospective subject or the legally authorized representative sufficient opportunity to discuss and consider whether or not to participate and that minimize the possibility of coercion or undue influence.” *See also* Department of Health and Human Services, Office of the Inspector General, “Recruiting Human Subjects: Pressures in Industry-Sponsored Clinical Research (June 2000),” *available at* <<https://oig.hhs.gov/oei/reports/oei-01-97-00195.pdf>> (last visited June 5, 2019).
  30. Department of Health and Human Services, Secretary’s Advisory Committee on Human Research Protections, *Considerations and Recommendations Concerning Internet Research and Human Subjects Research Regulations, with Revision* (March 2013), *available at* <<https://www.hhs.gov/ohrp/sachrp-committee/recommendations/2013-may-20-letter-attachment-b/index.html>> (last visited June 6, 2019).
  31. Food and Drug Administration and HHS Office for Human Research Protections, *Use of Electronic Informed Consent, Questions and Answers, Guidance for Institutional Review Boards, Investigators, and Sponsors* (December 2016), *available at* <<http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/guidances/UCM436811.pdf>> (last visited June 4, 2019).
  32. *Id.*
  33. Under 45 C.F.R. § 46.116(a)(5)(i), “[i]nformed consent [forms] must begin with a concise and focused presentation of the key information that is most likely to assist a prospective subject or legally authorized representative in understanding the reasons why one might or might not want to participate in the research. This part of the informed consent must be organized and presented in a way that facilitates comprehension.”
  34. 45 C.F.R. § 46.116(b)(9)(i-ii).
  35. 45 C.F.R. § 46.116(c)(7).
  36. 45 C.F.R. § 46.116(c)(8).
  37. 45 C.F.R. § 46.116(c)(9).
  38. 45 C.F.R. § 46.116(g).
  39. 45 C.F.R. § 46.
  40. HHS Office for Human Research Protections, “International,” *available at* <<https://www.hhs.gov/ohrp/international/index.html>> (last visited June 4, 2019).
  41. HHS Office for Human Research Protections, “International Compilation of Human Research Standards,” *available at* <<https://www.hhs.gov/ohrp/international/compilation-human-research-standards/index.html>> (last visited June 4, 2019).
  42. Food and Drug Administration, *Human Subject Protection; Acceptance of Data from Clinical Investigations for Medical Devices* (Feb. 21, 2018), 83 Federal Register 7366-7388, *available at* <<https://www.federalregister.gov/documents/2018/02/21/2018-03244/human-subject-protection-acceptance-of-data-from-clinical-investigations-for-medical-devices>> (last visited June 5, 2019).
  43. Northwestern Institutional Review Board Office, “IRB Review of International Research,” *available at* <<https://irb.northwestern.edu/sbs/review-international/>> (last visited June 4, 2019).
  44. University of Southern California, Office for the Protection of Research Subjects, “International Research,” *available at* <<https://oprs.usc.edu/irb-review/international-research/>> (last visited June 4, 2019).

45. Department of Health and Human Services, *Protection of Human Subjects: Interpretation of Assurance Requirements* (July 7, 2006), 71 Federal Register 130, available at <<https://www.govinfo.gov/content/pkg/FR-2006-07-07/pdf/E6-10511.pdf>> (last visited June 5, 2019).
46. Department of Health and Human Services, Office for Human Research Protections, Engagement of Institutions in Human Subjects Research, October 2008, available at <<https://www.hhs.gov/ohrp/regulations-and-policy/guidance/guidance-on-engagement-of-institutions/index.html>> (last visited June 5, 2019). See also Department of Health and Human Services, Office for Human Research Protections, “Determining When Institutions are Engaged in Research,” January 2009, available at <<https://www.hhs.gov/ohrp/regulations-and-policy/guidance/determining-when-institutions-are-engaged-in-research/index.html>> (last visited June 5, 2019).
47. National Institutes of Health, “Compliance and Reporting,” February 11, 2016, available at <<https://www.hhs.gov/ohrp/compliance-and-reporting/index.html>> (last visited August 1, 2019). See 45 C.F.R. § 46.
48. Food and Drug Administration, “Reporting Complaints Related to FDA-Regulated Clinical Trials,” July 31, 2018, available at <<https://www.fda.gov/science-research/clinical-trials-and-human-subject-protection/reporting-complaints-related-fda-regulated-clinical-trials>> (last visited August 1, 2019). See 21 C.F.R. pts. 50, 56 (2018).
49. See National Human Genome Research Institute, “Genome Statute and Legislation Database,” available at <<https://www.genome.gov/about-genomics/policy-issues/Genome-Statute-Legislation-Database>> (last visited June 5, 2019).
50. A.B. Popejoy and S.M. Fullerton, “Genomics Is Failing on Diversity,” *Nature* 538, no. 7624 (2016): 161-164.
51. See, e.g., M. Sleeboom, “The Harvard Case of Xiu Xiping: Exploitation of the People, Scientific Advance, or Genetic Theft?” *New Genetics and Society* 24, no. 1 (2005): 57-78.
52. 15 C.F.R. § 730 et seq.
53. Under 49 C.F.R. § 173.134(4), “patient specimen” is defined as “human or animal material collected directly from humans or animals and transported for research, diagnosis, investigational activities, or disease treatment or prevention. Patient specimen includes excreta, secreta, blood and its components, tissue and tissue swabs, body parts, and specimens in transport media.”
54. 49 C.F.R. § 173.134(1) (2018); 49 C.F.R. pts. 171-177.
55. 49 C.F.R. § 173.134(1)(i).
56. United States Postal Service, “Publication 52 — Hazardous, Restricted, and Perishable Mail,” June 2018, available at <[https://pe.usps.com/text/pub52/pub52apxc\\_019.htm](https://pe.usps.com/text/pub52/pub52apxc_019.htm)> (last visited June 5, 2019).
57. 49 C.F.R. § 173.134(1)(ii).
58. United States Postal Service, “USPS Packaging Instruction 6H,” June 2018, available at <[https://pe.usps.com/text/pub52/pub52apxc\\_024.htm](https://pe.usps.com/text/pub52/pub52apxc_024.htm)> (last visited June 5, 2019); IATA Dangerous Good Regulation, *supra* note 55, at 3.6.2.2.3.8.
59. International Air Transport Association, “Dangerous Good Regulation,” January 2017, available at <<https://www.iata.org/whatwedo/cargo/dgr/Documents/infectious-substance-classification-DGR56-en.pdf>> (last visited June 5, 2019).
60. United States Postal Service, *supra* note 57; IATA Dangerous Good Regulation, *supra* note 55, at 3.6.2.2.3.8.
61. Customs and Border Patrol, Info Center, “Importing Biological Materials into the United States”, Customs and Border Patrol website, available at <[https://help.cbp.gov/app/answers/detail/a\\_id/3681/kw/non%20commercial%20shipment](https://help.cbp.gov/app/answers/detail/a_id/3681/kw/non%20commercial%20shipment)> (last visited June 5, 2019).
62. *Id.*
63. *Id.*
64. Food and Drug Administration, *Importing CBER-Regulated Products: Clinical Laboratories and Basic Scientific Research*, available at <<https://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/ComplianceActivities/BiologicsImportingExporting/ucm390716.htm>> (last visited June 4, 2019).
65. *Id.* “In addition, to avoid possible delays with importation of specimens for testing or research, it is recommended that the labeling of each specimen container include the following information to make clear that the specimens do not fall under FDA regulation: An accurate description of the biological specimens. For example: human blood specimen, human tissue specimen, human DNA specimen. [2] A statement regarding the intended use of the specimen. For example: “Human Blood For Testing in a Clinical Laboratory,” or “Human DNA Specimen for Basic Scientific Research.” [3] If the biological specimen has been tested for infectious agents such as the hepatitis B surface antigen (HBsAg) and/or the antibody to human immunodeficiency virus (anti-HIV), a statement relative to the test results should be included.”
66. Under 42 C.F.R. § 71.54(a), “Diagnostic specimen” is broadly defined as “[s]pecimens of human and animal matter (including tissue, blood, body discharges, fluids, excretions or similar material), or environmental samples.”
67. Under 42 C.F.R. § 71.54(a), “Genomic material” is defined as “Deoxyribonucleic acid (DNA) or Ribonucleic acid (RNA) comprising the genome or organism’s hereditary information, that may be single-stranded or double-stranded, and in a linear, circular, or segmented configuration and may be positive sense (same polarity as mRNA), negative sense, or ambisense (mixture of the two).”
68. Centers for Disease Control and Prevention, “FAQ,” available at <<https://www.cdc.gov/cpr/ipp/faq.htm>> (last visited June 4, 2019) (indicating that the certification may be included by either the importer or the sender).
69. *Id.* According to CDC policy, “To facilitate clearance of materials that do not require a CDC import permit, each shipment must be accompanied by a certification statement, on an official letterhead, from the sender or the recipient of this material. The certification statement must include: A detailed description of the material and Statements affirming: 1. The material is not known or suspected to contain an infectious biological agent, and 2: One of the following: How the person knows that the material does not contain an infectious biological agent, or Why there is no reason to suspect that the material contains an infectious biological agent, or A detailed description of how the material was rendered noninfectious.”
70. 42 C.F.R. § 71.54(f).
71. 42 C.F.R. § 71.54; see Centers for Disease Control and Prevention, “Import Permit Program,” available at <<https://eipp.cdc.gov>> (last visited June 5, 2019).
72. National Research Council, Panel on Collecting, Storing, Accessing, and Protecting Biological Specimens and Biodata in Social Surveys, *Conducting Biosocial Surveys: Collecting, Storing, Accessing, and Protecting Biospecimens and Biodata* (2010), available at <<https://www.ncbi.nlm.nih.gov/books/NBK50729/>> (last visited June 5, 2019).
73. 21 C.F.R. § 50.1.
74. 21 C.F.R. § 812.3(p).
75. 21 C.F.R. § 11.
76. 21 C.F.R. § 50.
77. 21 C.F.R. § 56.
78. 45 C.F.R. § 46.
79. Food and Drug Administration and HHS Office for Human Research Protections, *supra* note 31.
80. Food and Drug Administration, Office of Good Clinical Practice, *Recruiting Study Subjects: Guidance for Institutional Review Boards and Clinical Investigators* (January 1998), available at <<https://www.fda.gov/regulatory-information/search-fda-guidance-documents/recruiting-study-subjects>> (last visited June 4, 2019).
81. *Id.*



82. 45 C.F.R. § 164.506.
83. 45 C.F.R. § 164.512(a-1).
84. 45 C.F.R. § 164.512(i)(1)(i).
85. E.W. Clayton et al., "The Law of Genetic Privacy: Applications, Implications, Limitations," *Journal of Law and Biosciences* 6, no. 1 (2019): 1-36, doi.org/10.1093/jlb/lz007; see 45 C.F.R. § 160.103.
86. 45 C.F.R. §§ 164.502(d)(2), 164.514(a-b).
87. *Id.*
88. The Genetic Information Non-discrimination Act of 2008, Pub. L. 110-233, 122 Stat. 881 (2008), available at <<https://www.gpo.gov/fdsys/pkg/PLAW-110publ233/html/PLAW-110publ233.htm>> (last visited June 5, 2019).
89. *Id.* at §§ 102, 105.
90. 42 U.S.C. § 12101 et seq.; see E. W. Clayton, "Why the Americans with Disabilities Act Matters for Genetics," *Journal of the American Medical Association* 313, no. 22 (2014): 2225–2226, at 2225.
91. 42 U.S.C. §§ 18001-18122.
92. U.S. Department of Commerce, "Privacy Shield Framework," available at <<https://www.privacyshield.gov/eu-us-framework>> (last visited June 5, 2019).
93. *Id.*
94. *Id.*
95. Department of Commerce, International Trade Administration, *The EU-U.S. and Swiss-U.S. Privacy Shield Frameworks*, available at <<https://www.privacyshield.gov/ps-overview-businesses>> (last visited June 5, 2019).
96. *Id.*
97. The Privacy Act of 1974, Pub.L. 93-579, 88 Stat. 1896 (1974), available at <<https://www.gpo.gov/fdsys/pkg/STATUTE-88/pdf/STATUTE-88-Pg1896.pdf>> (last visited June 5, 2019).
98. Department of Justice, Office of Privacy and Civil Liberties, *Privacy Act of 1974*, available at <<https://www.justice.gov/opcl/privacy-act-1974>> (last visited June 5, 2019).
99. 5 U.S.C. § 552a(a).
100. 5 U.S.C. § 552a(d).
101. 5 U.S.C. § 552a(b).
102. Health Information Technology for Economic and Clinical Health Act, The American Recovery and Reinvestment Act of 2009, Pub.L. 111–5, 123 Stat. 115 (2009), available at <<https://www.govinfo.gov/content/pkg/PLAW-110publ233/pdf/PLAW-110publ233.pdf>> (last visited June 5, 2019).
103. A comprehensive list of state statutes and bills is maintained by the National Human Genome Research Institute (NHGRI). See National Human Genome Research Institute, *Genome Statute and Legislation Database*, available at <<https://www.genome.gov/about-genomics/policy-issues/Genome-Statute-Legislation-Database>> (last visited June 5, 2019).
104. See, e.g., *Moore v. Regents of the University of California*, 51 Cal. 3d. 120 (Cal. 1990); *Greenberg v. Miami Children's Hospital Research Institute, Inc.*, 264 F. Supp. 1064 (S.D. Fla. 2003); *Washington University v. Catalona*, 490 F.3d 667 (8<sup>th</sup> Cir. 2007). See A.L. McGuire, "Who Owns the Data in a Medical Information Commons," *Journal of Law, Medicine, and Ethics* 47, no. 1 (2019): 62-69.
105. See, e.g., Alaska Stat. § 18.13.010(a)(2); Colo. Rev. Stat. § 10-3-1104.7(1)(a); Fla. Stat. § 760.40(2)(a); Ga. Code Ann. § 33-54-1(1); La. Rev. Stat. Ann. § 22:213.7(E).
106. See, e.g., Alaska Stat. Ann. § 18.13.010(a)(2); Ariz. Rev. Stat. § 20-448.02; Del. Code tit. 16, §1201 et seq.; Fla. State. Ann. § 760.40(2)(a).
107. See, e.g., Ark. Code §§20-35-101 et seq.; Colo. Rev. Stat. § 10-3-1104.6); Ga. Code § 33-54-1 et seq.; Me. Stat. tit. 22, § 1711C; N.M. Stat. § 24-21-1 et seq.
108. See, e.g., Fla Stat. §7 60.40); Ky. Rev. Stat. §61.931 et seq.; Me. Stat. tit. 22, § 1711C.
109. See e.g. Del. Code tit. 16, §1201 et seq.; Nev. Rev. Stat. §629.101 et seq.; N.J. Rev. Stat. §10:5-43 et seq.; Tex. Bus. & Com. Code § 546.001 et seq.; Wyo. Stat. § 35-31-101 et seq.
110. See, e.g., Cal. Health and Safety Code § 24170 et seq.; Md. Health Code §13-2001 et seq.; NY Public Health Code §2440 et seq.; Code of Va. § 32.1-162.16. See also *supra* notes 93, 97, 98.
111. National Institutes of Health, All of Us Research Program, available at <<https://www.nih.gov/research-training/allofus-research-program>> (last visited June 4, 2019).
112. Genomics England, available at <<https://www.genomicsengland.co.uk>> (last visited June 5, 2019).
113. See, e.g., C.R. Long et al., "Health Research Participants' Preferences for Receiving Research Results," *Clinical Trials* 13, no. 6 (2016): 582-591; A. Thorogood et al., "APPLaUD: Access for Patients and Participants to Individual Level Uninterpreted Genomic Data," *Human Genomics* 12, no. 1 (2018): 1-7.
114. S.M. Wolf and B. J. Evans, "Return of Results and Data to Study Participants," *Science* 362, no. 6411 (2018): 159-160, 159. See 45 C.F.R. §§ 164.501, 164.524.
115. 42 U.S.C. § 263a(a).
116. Wolf and Evans, *supra* note 114, at 160.
117. National Human Genome Research Institute (NHGRI), *Return of Research Results*, available at <<https://www.genome.gov/27569049/return-of-research-results/>> (last visited June 5, 2019). The NHGRI notes that "[a]lthough some scientists have obtained CLIA certification for their laboratories, most research laboratories are not CLIA-certified, and not all research laboratories have the resources to enable re-testing in a CLIA-certified laboratory"
118. Wolf and Evans, *supra* note 114, at 159-160. See also W. Burke, B.J. Evans, and G.P. Jarvik, "Return of Results: Ethical and Legal Distinctions Between Research and Clinical Care," *American Journal of Medical Genetics* 166, no. 1 (2014): 105-111.
119. Wolf and Evans, *supra* note 114, at 159-160; W. Burke et al., *supra* note 118.
120. Wolf and Evans, *supra* note 114, at 160.
121. *Id.*; See GINA §§ 102, 105.
122. 45 C.F.R. § 46.116(c)(8) requires additional elements of informed consent including "[a] statement regarding whether clinically relevant research results, including individual research results, will be disclosed to subjects, and if so, under what conditions."
123. 45 C.F.R. § 46.116(d)(6) requires that "[u]nless it is known that clinically relevant research results, including individual research results, will be disclosed to the subject in all circumstances, a statement that such results may not be disclosed to the subject."
124. 45 C.F.R. § 46.104(d)(8)(iii); See Department of Health and Human Services, Office for Human Research Protections, "Revised Common Rule Q&As," available at <<https://www.hhs.gov/ohrp/education-and-outreach/revised-common-rule/revised-common-rule-q-and-a/index.html>> (last visited June 5, 2019).
125. *Id.*
126. R.C. Green et al., "ACMG Recommendations for Reporting of Incidental Findings in Clinical Exome and Genome Sequencing," *Genetics in Medicine* 15, no. 7 (2013): 565-574; S.S. Kalia et al., "Recommendations for Reporting of Secondary Findings in Clinical Exome and Genome Sequencing, 2016 Update (*ACMG SFv.2.0*): A Policy Statement of the American College of Medical Genetics and Genomics," *Genetics in Medicine* 19, no. 2 (2017): 249-255.
127. R.R. Fabsitz et al., "Ethical and Practical Guidelines for Reporting Genetic Research Results to Study Participants: Updated Guidelines from a National Heart, Lung, and Blood Institute Working Group," *Circulation: Cardiovascular Genetics* 3, no. 6 (2010): 574-580.
128. C. Weiner, "Anticipate and Communicate: Ethical Management of Incidental and Secondary Findings in the Clinical, Research, and Direct-to-Consumer Contexts (December 2013 report of the Presidential Commission for the Study of Bioethical Issues)," *American Journal of Epidemiology* 180, no. 6 (2014): 562-564.
129. National Academies of Sciences, Engineering, and Medicine, *Returning Individual Research Results to Participants: Guidance for a New Research*

- Paradigm* (Washington, DC: The National Academies Press, 2018), doi.org/10.17226/25094.
130. *Id.*
  131. Clinical Laboratory Improvement Amendments of 1988, Pub. L. No. 100-578, 102 Stat. 2903 (1988) (codified at 42 U.S.C. § 263a).
  132. Under CLIA, a laboratory is defined as “a facility for the biological, microbiological, serological, chemical, immunohematological, hematological, biophysical, cytological, pathological, or other examination of materials derived from the human body for the purposes of providing information for the diagnosis, prevention, or treatment of any disease or impairment of, or the assessment of the health of, human beings.” 42 C.F.R. § 493.2.
  133. 42 U.S.C. § 263a(a).
  134. See, e.g., 23andMe, “Genetic Science,” available at <https://www.23andme.com/genetic-science/> (last visited June 5, 2019); FamilyTreeDNA, available at <https://www.familytreedna.com> (last visited June 5, 2019).
  135. 42 U.S.C. § 263a(a).
  136. See J. Barker, “DNA day’ Planned for Ravens’ Game Undergoes Federal and State Scrutiny,” *Baltimore Sun*, September 18, 2017, available at <http://www.baltimoresun.com/business/bs-bz-ravens-dna-day-20170918-story.html> (last visited June 5, 2019); J. Stone, “Federal Regulators Issue Notice to DTC Test Company Orig3n That Its Purchase of Interleukin Genetics Could Involve CLIA Compliance Issues,” *Dark Daily*, January 10, 2018, available at <https://www.darkdaily.com/federal-regulators-issue-notice-to-dtc-test-company-orig3n-that-its-purchase-of-interleukin-genetics-could-involve-clia-compliance-issues/> (last visited June 5, 2019).
  137. *Id.*
  138. The Federal Food, Drug, and Cosmetic Act, Pub. L. No. 75-717, 52 Stat. 1040 (1939) (codified at 21 U.S.C. ch. 9 § 301); Medical Device Amendments of 1976, Pub. L. No. 94-295, 90 Stat. 539 (1976) (codified at U.S.C. §360c-360k).
  139. Food and Drug Administration, “Press Announcements,” “FDA Permits Marketing of First Direct-to-Consumer Genetic Carrier Test for Bloom Syndrome” (Feb. 19, 2015), Food and Drug Administration website, available at <https://wayback.archiveit.org/7993/20170111191740/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm435003.htm> (last visited June 5, 2019).
  140. Food and Drug Administration, “Press Announcements,” “FDA Allows Marketing of First Direct-to-Consumer Tests that Provide Genetic Risk Information for Certain Conditions,” April 6, 2017, Food and Drug Administration website, available at <https://www.fda.gov/news-events/press-announcements/fda-allows-marketing-first-direct-consumer-tests-provide-genetic-risk-information-certain-conditions> (last visited June 5, 2019).
  141. Food and Drug Administration, “FDA Authorizes, with Special Controls, Direct-to-Consumer Test that Reports Three Mutations in the BRCA Breast Cancer Genes,” Press Announcements, March 6, 2018, available at <https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm599560.htm> (last visited June 5, 2019).
  142. Food and Drug Administration, *Press Announcements*, “FDA Authorizes First Direct-to-Consumer Test for Detecting Genetic Variants that May Be Associated with Medication Metabolism,” Oct. 31, 2018, Food and Drug Administration website, available at <https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm624753.htm> (last visited June 5, 2019).
  143. Food and Drug Administration, “501(k) Clearances,” Food and Drug Administration website, available at <https://www.fda.gov/medical-devices/device-approvals-denials-and-clearances/510k-clearances> (last visited June 5, 2019).
  144. 23andMe, “23andMe Receives FDA Clearance for Direct-to-Consumer Genetic Test on a Hereditary Colorectal Cancer Syndrome,” Press Release, Jan. 22, 2019, 23andMe website, available at <https://mediacenter.23andme.com/press-releases/23andme-receives-fda-clearance-for-direct-to-consumer-genetic-test-on-a-hereditary-colorectal-cancer-syndrome/> (last visited June 5, 2019).
  145. FDA Press Release, *supra* note 141.
  146. Food and Drug Administration, *Press Announcements*, “Statement from FDA Commissioner Scott Gottlieb, M.D. on Implementation of Agency’s Streamlined Development and Review Pathway for Consumer Tests that Evaluate Genetic Health Risks” (Nov. 6, 2017), Food and Drug Administration website, available at <https://www.fda.gov/news-events/press-announcements/statement-fda-commissioner-scott-gottlieb-md-implementation-agencys-streamlined-development-and> (last visited June 4, 2019).
  147. 15 U.S.C. §§ 41-58 (2018).
  148. See Federal Trade Commission, “Commissioners,” Federal Trade Commission website, available at <https://www.ftc.gov/about-ftc/commissioners> (last visited June 5, 2019) (describing that “[t]he Commission is headed by five Commissioners, nominated by the President and confirmed by the Senate, each serving a seven-year term. No more than three Commissioners can be of the same political party. The President chooses one Commissioner to act as Chairman.”).
  149. 15 U.S.C. § 45.
  150. 15 U.S.C. §§ 52-55.
  151. 15 U.S.C. § 45.
  152. See J. W. Hazel and C. Slobogin, “Who Knows What, and When?: A Survey of the Privacy Policies Proffered by U.S. Direct-to-Consumer Genetic Testing Companies,” *Cornell Journal of Law and Public Policy* 28, no. 1 (2018): 35-66, at 42. The most prominent example of FTC action against a DTC-GT company occurred in January 2014, when the agency filed an administrative complaint against Genelink, Inc. and its subsidiary, Foru International Corporation, makers of an at-home genetic test kit that purported to match consumers to products in its line of dietary and skincare supplements. The FTC took issue with Genelink’s representations “that genetic disadvantages identified through the companies’ DNA assessments [were] scientifically proven to be mitigated by or compensated for with the companies’ nutritional supplements.” The FTC also claimed that “the companies’ acts and practices related to data security were unfair and deceptive” because, in contradiction to the companies’ posted privacy policies, it had “failed to provide reasonable and appropriate security for consumers’ personal information,” including genetic information and social security, credit card, and bank account numbers. Genelink ultimately entered into a consent agreement with the FTC to settle the complaint, which required the company to “have at least 2 [randomized human clinical trials] before making disease prevention, treatment, and diagnosis claims,” “prohibited [the company] from misrepresenting [its] privacy and security practices,” and required the company to “establish and maintain comprehensive data security programs and submit to security audits by independent auditors every other year for twenty years” (citations omitted).
  153. Federal Trade Commission, *Consumer Information*, “Direct-to-Consumer Genetic Tests” (February 2018), Federal Trade Commission website, available at <https://www.consumer.ftc.gov/articles/0166-direct-consumer-genetic-tests> (last visited June 5, 2019); Federal Trade Commission, “DNA Test Kits: Consider the Privacy Implications,” Consumer Information, December 2017, Federal Trade Commission website, available at <https://www.consumer.ftc.gov/blog/2017/12/dna-test-kits-consider-privacy-implications> (last visited June 5, 2019).
  154. Elisa Jillson, Federal Trade Commission, *Business Blog*, “Selling genetic testing kits? Read on,” March 2019, available at <https://www.ftc.gov/news-events/blogs/business-blog/2019/03/selling-genetic-testing-kits-read> (last visited June 5, 2019).
  155. Federal Trade Commission, “Mobile Health App Developers: Best Practices,”

- April 2016, available at <<https://www.ftc.gov/slideshow-items/best-practices-mobile-health-app-developers>> (last visited June 5, 2019); Federal Trade Commission, "Mobile Health Apps Interactive Tool," available at <<https://www.ftc.gov/tips-advice/business-center/guidance/mobile-health-apps-interactive-tool>> (last visited June 5, 2019).
156. M. Baram, "The FTC is Investigating DNA Firms like 23andMe and Ancestry over Privacy," *Fast Company*, June 5, 2018, available at <<https://www.fastcompany.com/40580364/the-ftc-is-investigating-dna-firms-like-23andme-and-ancestry-over-privacy>> (last visited June 4, 2019).
157. H.C. Dick, "Risk and Responsibility: State Regulation and Enforcement of the Direct-to-Consumer Genetic Testing Industry," *Saint Louis University Journal of Health Law & Policy* 6, no. 2 (2012): 167-200, at 174-184.
158. *Id.*
159. See, e.g., Social Media Privacy Protection and Consumer Rights Act of 2018, available at <<https://www.congress.gov/bill/115th-congress/senate-bill/2728/text?format=txt>> (last visited August 31, 2019); Information Transparency & Personal Data Control Act, available at <<https://www.congress.gov/bill/116th-congress/house-bill/2013/text>> (last visited August 31, 2019); Algorithmic Accountability Act of 2019, available at <<https://www.congress.gov/bill/116th-congress/house-bill/2231/text>> (last visited August 31, 2019); Balancing the Rights of Web Surfers Equally and Responsibly Act of 2019, available at <<https://www.congress.gov/bill/116th-congress/senate-bill/1116/text>> (last visited Aug. 31, 2019); Protecting Personal Health Data Act, available at <<https://www.congress.gov/bill/116th-congress/senate-bill/1842/text>> (last visited August 31, 2019); Do Not Track Act, available at <<https://www.congress.gov/bill/116th-congress/senate-bill/1578/text>> (last visited August 31, 2019); Designing Accounting Safeguards to Help Broaden Oversight and Regulations on Data Act, available at <<https://www.scribd.com/document/414097245/Data-Value-Transparency-SIL19753>> (last visited August 31, 2019).
160. See *id.*
161. California Consumer Privacy Act of 2018, available at <[https://leginfo.ca.gov/faces/billTextClient.xhtml?bill\\_id=201720180SB1121](https://leginfo.ca.gov/faces/billTextClient.xhtml?bill_id=201720180SB1121)> (last visited August 31, 2019). See M.A. Rothstein and S.A. Tovino, "California Takes the Lead in Data Privacy Act," *Hastings Center Report* 49, no. 5 (2019).
162. New York Privacy Act, available at <<https://legislation.nysenate.gov/pdf/bills/2019/S5642>> (last visited August 31, 2019).
163. National Public Radio & Truven Health Analytics, *Health Poll: Genetic Testing* (March 2018), available at <[https://truvenhealth.com/Portals/0/Assets/NPR-Truven-Health-Poll/TRU\\_18842\\_0318\\_NPR\\_Poll\\_GeneticTesting.pdf](https://truvenhealth.com/Portals/0/Assets/NPR-Truven-Health-Poll/TRU_18842_0318_NPR_Poll_GeneticTesting.pdf)> (last visited August 1, 2019).